<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12012300</article-id><article-id pub-id-type="pmcid-ver">PMC12012300.1</article-id><article-id pub-id-type="pmcaid">12012300</article-id><article-id pub-id-type="pmcaiid">12012300</article-id><article-id pub-id-type="pmid">40264660</article-id><article-id pub-id-type="doi">10.3389/fphar.2025.1544956</article-id><article-id pub-id-type="publisher-id">1544956</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>
<italic toggle="yes">In vivo</italic> effects of bempedoic acid on microdosed CYP probe drugs</article-title><alt-title alt-title-type="left-running-head">Stoll et al.</alt-title><alt-title alt-title-type="right-running-head">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2025.1544956" ext-link-type="uri">10.3389/fphar.2025.1544956</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Stoll</surname><given-names initials="F">Felicitas</given-names></name><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1949824/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Amato</surname><given-names initials="S">Salvatore</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burhenne</surname><given-names initials="J">Jürgen</given-names></name><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blank</surname><given-names initials="A">Antje</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1946460/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib></contrib-group><aff>
<institution>Internal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology</institution>, <institution>Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital</institution>, <addr-line>Heidelberg</addr-line>, <country>Germany</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2318425/overview" ext-link-type="uri">Peter Swaan</ext-link>, University of Florida, United States</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/26647/overview" ext-link-type="uri">Melih O. Babaoglu</ext-link>, Hacettepe University, Türkiye</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/443090/overview" ext-link-type="uri">Federica Fogacci</ext-link>, University of Bologna, Italy</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1075189/overview" ext-link-type="uri">Weichieh Lee</ext-link>, Chi Mei Medical Center, Taiwan</p></fn><corresp id="c001">*Correspondence: Felicitas Stoll, <email>felicitas.stoll@med.uni-heidelberg.de</email>
</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480654</issue-id><elocation-id>1544956</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>22</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-23 09:25:14.567"><day>23</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2025 Stoll, Amato, Burhenne and Blank.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Stoll, Amato, Burhenne and Blank</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-16-1544956.pdf"/><abstract><sec><title>Background</title><p>Bempedoic acid (BA) is a novel oral cholesterol-lowering drug. So far, <italic toggle="yes">in vivo</italic> evidence on potential drug–drug interactions via the cytochrome P450 (CYP) enzymes is lacking.</p></sec><sec><title>Methods</title><p>In a clinical trial, we evaluated the effect of BA on microdosed probe drugs using a limited sampling strategy in healthy volunteers. The outcome measures were as follows: 1) the omeprazole AUC<sub>0–4h</sub> and hydroxylation index (HI) after a 100 µg dose to evaluate CYP2C19 activity, 2) the midazolam AUC<sub>2–4h</sub> after a 30 µg dose to evaluate CYP3A activity, and 3) the yohimbine AUC<sub>0–4h</sub> after a 50 µg dose to evaluate CYP2D6 activity. Partial areas under the curve (AUCs) were evaluated at baseline and under BA steady state. The endpoints were the geometric mean ratios (GMRs) with 95% confidence intervals (CI) of the partial AUCs.</p></sec><sec><title>Results</title><p>In 15 participants, the AUC<sub>0–4h</sub> of omeprazole and its HI significantly decreased (GMR: 0.75, 90% CI: 0.66–0.85; change in HI <italic toggle="yes">p</italic> &lt; 0.0001). There was no change in the AUC<sub>2–4h</sub> of midazolam (GMR: 1.18, 90% CI: 0.87–1.61) and AUC<sub>0–4h</sub> of yohimbine (GMR: 0.92, 90% CI: 0.75–1.14).</p></sec><sec><title>Conclusion</title><p>In healthy volunteers, BA was a mild inducer of CYP2C19 and did not affect CYP3A or CYP2D6 activity.</p></sec></abstract><kwd-group><kwd>microdosed probe drugs</kwd><kwd>CYP3A</kwd><kwd>CYP2D6</kwd><kwd>CYP2C19</kwd><kwd>bempedoic acid</kwd><kwd>limited sampling strategy</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. FS received a research scholarship by Heidelberg Medical Faculty. For the publication fee, we acknowledge financial support by Heidelberg University.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Drug Metabolism and Transport</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Bempedoic acid (BA) is a novel oral cholesterol-lowering drug that acts by inhibiting adenosine triphosphate citrate lyase, an enzyme involved in the hepatic cholesterol synthesis; this inhibition occurs upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which is targeted by the statins (<xref rid="B7" ref-type="bibr">EMA, 2024</xref>). Its positive effects on LDL cholesterol (LDL-C) and cardiovascular endpoints in patients with increased cardiovascular risk—including those with full or partial statin intolerance—have been demonstrated in large clinical trials (<xref rid="B17" ref-type="bibr">Nissen et al., 2023</xref>; <xref rid="B18" ref-type="bibr">Ray et al., 2019</xref>). BA can be administered in conjunction with statin therapy to achieve evidence-based LDL-C goals and as a monotherapy or in combination with other cholesterol-lowering drugs for patients who are statin-intolerant. It is available as a single-substance drug or as a combination pill with ezetimibe (<xref rid="B7" ref-type="bibr">EMA, 2024</xref>; <xref rid="B8" ref-type="bibr">EMA, 2020</xref>). Thus, it is a relevant new option to combine these oral drugs for the treatment of hypercholesterolemia.</p><p>The pharmacokinetics of BA have been described in detail elsewhere by us and other authors (<xref rid="B4" ref-type="bibr">Cicero et al., 2021</xref>; <xref rid="B23" ref-type="bibr">Stoll et al., 2022</xref>; <xref rid="B21" ref-type="bibr">Stoll et al., 2025</xref>; <xref rid="B1" ref-type="bibr">Amore et al., 2023</xref>). Importantly, BA is administered as a prodrug that is activated at the site of action; this is expected to reduce the risk for off-site adverse effects, particularly those related to muscle. After absorption, the maximum concentration is reached after 3.5 h. The volume of distribution is 18 L, and plasma binding is high (99%) (<xref rid="B7" ref-type="bibr">EMA, 2024</xref>; <xref rid="B4" ref-type="bibr">Cicero et al., 2021</xref>). BA has an active metabolite, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="ESP15228">ESP15228</ext-link>, with a plasma exposure of approximately 20% that of the parent substance (<xref rid="B21" ref-type="bibr">Stoll et al., 2025</xref>; <xref rid="B1" ref-type="bibr">Amore et al., 2023</xref>). Both are inactivated by glucuronidation and are mainly excreted in urine (70%) (<xref rid="B7" ref-type="bibr">EMA, 2024</xref>; <xref rid="B1" ref-type="bibr">Amore et al., 2023</xref>). The steady-state half-life of BA is 19 h (<xref rid="B7" ref-type="bibr">EMA, 2024</xref>).</p><p>
<italic toggle="yes">In vitro</italic> and clinical interaction studies revealed that BA inhibits the hepatic transporter OATP1B1 (<xref rid="B7" ref-type="bibr">EMA, 2024</xref>). In contrast, <italic toggle="yes">in vitro</italic> studies indicate that BA has no relevant effect on the cytochrome P450 (CYP) enzymes. Specifically, there was no significant direct inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 with BA concentrations up to approximately 100 μg/mL; furthermore, IC<sub>50</sub> values for these CYP isoenzymes did not change significantly after pre-incubation with BA, making time-dependent inhibition unlikely. Regarding the <italic toggle="yes">in vitro</italic> induction of CYP enzymes, there was no inducing effect on CYP1A2 or CYP2B6 enzyme activity. BA induced the activities of CYP2C8, CYP2C9, CYP2C19, and CYP3A4 at a high BA concentration of approximately 100 μg/mL. However, because this concentration is well above the human exposure at steady state (20 μg/mL), <italic toggle="yes">in vivo</italic> induction was deemed unlikely (<xref rid="B9" ref-type="bibr">FDA, 2019</xref>).</p><p>However, <italic toggle="yes">in vivo</italic> data on the interaction with CYP isoenzymes are lacking. The use of microdosed probe drugs is well-established for the phenotyping of CYP enzymes (<xref rid="B24" ref-type="bibr">van der Heijden et al., 2024</xref>), and we have proven the value of drug microdosing in many projects (<xref rid="B3" ref-type="bibr">Burhenne et al., 2012</xref>; <xref rid="B11" ref-type="bibr">Halama et al., 2013</xref>; <xref rid="B15" ref-type="bibr">Mahmoudi et al., 2021</xref>; <xref rid="B16" ref-type="bibr">Muhareb et al., 2023</xref>; <xref rid="B19" ref-type="bibr">Rohr et al., 2024</xref>; <xref rid="B22" ref-type="bibr">Stoll et al., 2024</xref>; <xref rid="B25" ref-type="bibr">Vay et al., 2020</xref>; <xref rid="B26" ref-type="bibr">Vay et al., 2019</xref>; <xref rid="B6" ref-type="bibr">Elbe et al., 2022</xref>). A significant advantage of this approach is that microdosed probe drugs, unlike standard doses, do not produce therapeutic effects while maintaining CYP specificity. We investigated the effect of BA on CYP3A, CYP2D6, and CYP2C19 using midazolam (<xref rid="B11" ref-type="bibr">Halama et al., 2013</xref>; <xref rid="B19" ref-type="bibr">Rohr et al., 2024</xref>; <xref rid="B22" ref-type="bibr">Stoll et al., 2024</xref>), yohimbine (<xref rid="B22" ref-type="bibr">Stoll et al., 2024</xref>; <xref rid="B25" ref-type="bibr">Vay et al., 2020</xref>), and omeprazole (<xref rid="B16" ref-type="bibr">Muhareb et al., 2023</xref>; <xref rid="B19" ref-type="bibr">Rohr et al., 2024</xref>; <xref rid="B6" ref-type="bibr">Elbe et al., 2022</xref>) as microdosed probe drugs.</p></sec><sec id="s2"><title>2 Participants and methods</title><sec id="s2-1"><title>2.1 Trial conduct</title><p>The trial design is described in detail by <xref rid="B21" ref-type="bibr">Stoll et al. (2025)</xref>. In brief, we conducted an open-label phase I drug interaction trial in healthy volunteers at the ISO-certified Pharmacological Early Clinical Trial Center (KliPS) at Heidelberg University Hospital, Department of Clinical Pharmacology and Pharmacoepidemiology (Internal Medicine IX), from July 2022 to June 2023. The trial was approved by the national authority and the responsible Ethics Committee of the Medical Faculty of Heidelberg University (27 June 2022, AFmo-366/2022), and it was conducted according to the guidelines of Good Clinical Practice, the ethical principles expressed in the Declaration of Helsinki, and all legal requirements for clinical trials in Germany and the European Union. The fully informed participants provided their written consent before any trial procedures.</p><p>Participants included were aged 18–45 years and in full physical and mental health. The intake of medications (with the exception of iodine, thyroxine, and oral contraception) was not allowed during the trial. Furthermore, all substances (e.g., food supplements) known to inhibit or induce CYP enzymes, grapefruit products, and cannabis were prohibited.</p><p>The influence of BA on CYP2D6, CYP2C19, and CYP3A4 was assessed through microdose phenotyping at BA steady state, conducted on at least the 5th day of BA intake (optional +2 days) in the evening (standard dose of 180 mg daily; Nilemdo Filmtabletten, Daiichi Sankyo Europe). This was an independent secondary endpoint. The primary objective was to evaluate the interaction between BA and pravastatin, which is reported separately (<xref rid="B21" ref-type="bibr">Stoll et al., 2025</xref>).</p></sec><sec id="s2-2"><title>2.2 Microdosed trial medication and blood sampling</title><p>For the evaluation of CYP3A activity, the area under the curve (AUC) or the clearance of microdosed midazolam is an established phenotyping strategy, with experience spanning doses from 0.1 to 75 µg (<xref rid="B24" ref-type="bibr">van der Heijden et al., 2024</xref>; <xref rid="B3" ref-type="bibr">Burhenne et al., 2012</xref>; <xref rid="B11" ref-type="bibr">Halama et al., 2013</xref>; <xref rid="B16" ref-type="bibr">Muhareb et al., 2023</xref>; <xref rid="B19" ref-type="bibr">Rohr et al., 2024</xref>; <xref rid="B22" ref-type="bibr">Stoll et al., 2024</xref>). CYP2C19 activity can be phenotyped using the AUC of microdosed omeprazole at a dose of 100 µg (<xref rid="B24" ref-type="bibr">van der Heijden et al., 2024</xref>; <xref rid="B15" ref-type="bibr">Mahmoudi et al., 2021</xref>; <xref rid="B16" ref-type="bibr">Muhareb et al., 2023</xref>; <xref rid="B19" ref-type="bibr">Rohr et al., 2024</xref>; <xref rid="B6" ref-type="bibr">Elbe et al., 2022</xref>). Similarly, CYP2D6 activity can be determined using the AUC of microdosed yohimbine at a dose of 50 µg (<xref rid="B24" ref-type="bibr">van der Heijden et al., 2024</xref>; <xref rid="B19" ref-type="bibr">Rohr et al., 2024</xref>; <xref rid="B22" ref-type="bibr">Stoll et al., 2024</xref>; <xref rid="B25" ref-type="bibr">Vay et al., 2020</xref>; <xref rid="B26" ref-type="bibr">Vay et al., 2019</xref>).</p><p>The microdosed drugs were administered as follows: midazolam as an oral solution at a dose of 30 µg (Dormicum V<sup>®</sup> 5 mg/5 mL Lösung, Roche Pharma AG) in 50 mL of water; yohimbine at a dose of 50 µg as tablets (Yohimbinum hydrochloricum D4 DHU Tabletten, DHU-Arzneimittel GmbH &amp; Co. KG); and omeprazole at a dose of 100 µg as an oral solution (OMEP<sup>®</sup> 40 mg, powder for the solution for infusion, HEXAL AG) in 100 mL of 4.2% sodium bicarbonate (Natriumhydrogencarbonat 4.2% B. Braun Infusionslösung) to prevent the gastric degradation of omeprazole.</p><p>All microdosed drugs (along with BA) were taken together. Ten minutes prior to the intake of medication, 50 mL of sodium bicarbonate (4.2%) was administered to buffer gastric acid.</p><p>The participants fasted (water was allowed) at least 6 h prior to the administration and 4 h thereafter.</p><p>Blood samples were collected in lithium heparin tubes. A limited sampling strategy (<xref rid="B14" ref-type="bibr">Katzenmaier et al., 2010</xref>) was undertaken with the following schedules: midazolam: predose, 2, 2.5, 3, and 4 h; yohimbine and omeprazole: predose, 0.5, 1, 1.5, 2, 2.5, 3, and 4 h.</p></sec><sec id="s2-3"><title>2.3 Quantification of CYP3A, CYP2D6, and CYP2C19 probe drugs</title><p>The plasma quantification of midazolam/1-OH-midazolam (<xref rid="B3" ref-type="bibr">Burhenne et al., 2012</xref>), yohimbine (<xref rid="B26" ref-type="bibr">Vay et al., 2019</xref>), and omeprazole/5-OH-omeprazole (<xref rid="B15" ref-type="bibr">Mahmoudi et al., 2021</xref>; <xref rid="B6" ref-type="bibr">Elbe et al., 2022</xref>) was performed using the already published UPLC–MS/MS methods. The lower limit of quantification was 1 pg/mL for all compounds, and the quality control was performed strictly according to the ICH M10 guideline (<xref rid="B13" ref-type="bibr">ICH, 2022</xref>) under GCLP conditions.</p></sec><sec id="s2-4"><title>2.4 Pharmacokinetic and statistical analysis</title><p>Outcome measures included the partial area under the concentration–time curve AUC<sub>2–4h</sub> for midazolam and its metabolite 1-OH-midazolam derived from the concentration–time curve, the AUC<sub>0–4h</sub> for yohimbine as well as for omeprazole and its metabolite 5-OH-omeprazole, and the hydroxylation index of omeprazole, defined as the molar ratio of omeprazole to 5-OH-omeprazole from the single 3 h-samples. Non-compartmental pharmacokinetic (PK) analysis (a standard pharmacokinetic assessment with one compartment) was performed using Phoenix WinNonlin Version 8.4 (Certara, Princeton, NJ, United States). PK data are presented as geometric means with 95% confidence intervals (CIs) and were compared using ratio-paired t-tests. The geometric mean ratios (GMRs) are shown with a 90% CI. The hydroxylation indices of omeprazole are presented as the arithmetic mean with a 95% CI and were compared using the Wilcoxon test. Demographic data are presented as the arithmetic mean ± standard deviation. The statistical analysis was conducted in GraphPad Prism Version 10 (La Jolla, CA, United States). A <italic toggle="yes">p</italic>-value &lt;0.05 was considered significant.</p></sec></sec><sec sec-type="results" id="s3"><title>3 Results</title><p>Fifteen participants (eight female individuals) were evaluated for microdose PK. They had a mean age of 26 y ± 4 and a body mass index of 23.3 kg/m<sup>2</sup> ± 2.6.</p><p>Under BA, the partial AUC of omeprazole significantly decreased by 25%, indicating the induction of CYP2C19. Concurrently, the partial AUC of 5-OH-omeprazole increased by 17%. Furthermore, the hydroxylation index of omeprazole decreased significantly. The partial AUC of midazolam as a marker for CYP3A activity and that of yohimbine as a marker for CYP2D6 activity remained unchanged (<xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F1" ref-type="fig">Figure 1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Pharmacokinetic parameters of microdosed cytochrome P450 probe drugs at baseline and with BA dosed to steady state in healthy volunteers (n = 15).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1"/><th colspan="2" align="left" rowspan="1">Baseline</th><th colspan="2" align="left" rowspan="1">Bempedoic acid</th><th colspan="3" align="left" rowspan="1">Comparison</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">GM</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">GM</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">GMR</th><th align="left" rowspan="1" colspan="1">90% CI</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>-value</th></tr><tr><th colspan="8" align="left" rowspan="1">Omeprazole</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">AUC<sub>0–4h</sub> (h * pg/mL)</td><td align="left" rowspan="1" colspan="1">1276</td><td align="left" rowspan="1" colspan="1">995–1636</td><td align="left" rowspan="1" colspan="1">955</td><td align="left" rowspan="1" colspan="1">688–1325</td><td align="left" rowspan="1" colspan="1">
<bold>0.75</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.66–0.85</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.0013</bold>
</td></tr><tr style="background-color:#BFBFBF"><td colspan="8" align="left" rowspan="1">5-OH-omeprazole</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>0–4h</sub> (h * pg/mL)</td><td align="left" rowspan="1" colspan="1">1660</td><td align="left" rowspan="1" colspan="1">1484–1858</td><td align="left" rowspan="1" colspan="1">1945</td><td align="left" rowspan="1" colspan="1">1677–2255</td><td align="left" rowspan="1" colspan="1">
<bold>1.17</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.08–1.28</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.0057</bold>
</td></tr><tr style="background-color:#BFBFBF"><td colspan="8" align="left" rowspan="1">Hydroxylation index (HI)</td></tr><tr><td align="left" rowspan="1" colspan="1">Molar ratio of omeprazole to 5-OH-omeprazole from single 3 h sample (mean)</td><td align="left" rowspan="1" colspan="1">0.4556</td><td align="left" rowspan="1" colspan="1">0.2370–0.6742</td><td align="left" rowspan="1" colspan="1">0.1517</td><td align="left" rowspan="1" colspan="1">0.09776–0.2057</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&lt; 0.0001</bold>
</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="top"><tr><th colspan="8" align="left" rowspan="1">Midazolam</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">AUC<sub>2–4h</sub> (h * pg/mL)</td><td align="left" rowspan="1" colspan="1">62.4</td><td align="left" rowspan="1" colspan="1">49.3–78.9</td><td align="left" rowspan="1" colspan="1">73.7</td><td align="left" rowspan="1" colspan="1">45.5–119</td><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">0.87–1.61</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr style="background-color:#BFBFBF"><td colspan="8" align="left" rowspan="1">1-OH-midazolam</td></tr><tr><td align="left" rowspan="1" colspan="1">AUC<sub>2–4h</sub> (h * pg/mL)</td><td align="left" rowspan="1" colspan="1">30.8</td><td align="left" rowspan="1" colspan="1">26.3–36.0</td><td align="left" rowspan="1" colspan="1">37.0</td><td align="left" rowspan="1" colspan="1">23.2–59.0</td><td align="left" rowspan="1" colspan="1">1.19</td><td align="left" rowspan="1" colspan="1">0.89–1.59</td><td align="left" rowspan="1" colspan="1">0.32</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="top"><tr><td colspan="8" align="left" rowspan="1">Yohimbine</td></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">AUC<sub>0–4h</sub> (h * pg/mL)</td><td align="left" rowspan="1" colspan="1">172</td><td align="left" rowspan="1" colspan="1">98.1–303</td><td align="left" rowspan="1" colspan="1">159</td><td align="left" rowspan="1" colspan="1">94.5–268</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.75–1.14</td><td align="left" rowspan="1" colspan="1">0.51</td></tr></tbody></table><table-wrap-foot><fn><p>AUC, area under the plasma concentration–time curve; CI, confidence interval; GM, geometric mean; GMR, geometric mean ratio. Bold values are statistically significant.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Concentration–time curves for microdosed omeprazole <bold>(A)</bold>, midazolam <bold>(B)</bold>, and yohimbine <bold>(C)</bold>, showing a limited sampling strategy. Geometric mean and 95% confidence interval.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-16-1544956-g001.jpg"/></fig></sec><sec sec-type="discussion" id="s4"><title>4 Discussion</title><p>This pharmacokinetic evaluation with microdosed CYP probe drugs indicated that BA does not affect CYP3A and CYP2D6 activity but induces CYP2C19. The inducing effect of 25% is mild according to the definition of the U.S. Food and Drug Administration (FDA) (<xref rid="B10" ref-type="bibr">FDA, 2024</xref>). An inducing effect of BA on CYP2C19 was also found <italic toggle="yes">in vitro</italic> but was considered unlikely to be relevant for humans due to the expected plasma concentrations of BA (<xref rid="B9" ref-type="bibr">FDA, 2019</xref>). Intrahepatic concentrations–in addition to the plasma concentration of BA–might be of primary importance.</p><p>A significant number of patients receiving cholesterol-lowering drugs also take other medications, like platelet inhibitors, antihypertensives, beta-blockers, glucose-lowering drugs, or drugs for the treatment of peptic ulcer (<xref rid="B5" ref-type="bibr">Corn et al., 2024</xref>); these potential drug interactions should be considered. Concomitant treatment with statins or other OATP substrates must now be taken into account for potential drug interactions (<xref rid="B7" ref-type="bibr">EMA, 2024</xref>). Based on our results, cardiovascular and non-cardiovascular CYP2C19 substrates—including clopidogrel and neuropsychiatric drugs, such as amitriptyline, citalopram, and phenytoin, in addition to proton pump inhibitors (<xref rid="B2" ref-type="bibr">Asiimwe and Pirmohamed, 2022</xref>)—may need further investigation in the future.</p><p>It should be advised to monitor the clinical effects and, in selected cases, the drug levels of CYP2C19 substrates that are co-administered with BA to detect a lack of efficacy. The quantification of drug levels could be useful for CYP2C19 substrates with a narrow therapeutic range or/and a strong recommendation for therapeutic drug monitoring, e.g., amitriptyline or phenytoin (<xref rid="B12" ref-type="bibr">Hiemke et al., 2018</xref>). In the case of clopidogrel, the induction of CYP2C19 is expected to increase the level of the active metabolite, which could be associated with an increased risk of bleeding. The SmPC of clopidogrel advises against the concomitant use of strong CYP2C19 inducers (<xref rid="B20" ref-type="bibr">SmPC, 2022</xref>). The relevance of BA with only mild inducing effects in this study remains unclear.</p><p>Although our findings–based on a microdosing approach after a limited time of BA intake–are supported by previous <italic toggle="yes">in vitro</italic> results on CYP2C19 induction, it should be pointed out that the magnitude of the effect might differ with the long-term BA administration or full therapeutic doses of the affected drug.</p><p>We chose the microdosing approach because of its minimized risk of undesired drug effects. Although microdosing for CYP phenotyping is widely established, evidence differs across CYPs, with some limitations remaining (<xref rid="B24" ref-type="bibr">van der Heijden et al., 2024</xref>). We used a limited sampling strategy, as developed and applied in previous studies (<xref rid="B19" ref-type="bibr">Rohr et al., 2024</xref>; <xref rid="B22" ref-type="bibr">Stoll et al., 2024</xref>; <xref rid="B14" ref-type="bibr">Katzenmaier et al., 2010</xref>). The use of microdosed omeprazole necessitates the administration of sodium bicarbonate to buffer gastric acid. It cannot be excluded that this affects the absorption of the other CYP probe drugs, although this was found to be unlikely in previous studies (<xref rid="B19" ref-type="bibr">Rohr et al., 2024</xref>; <xref rid="B6" ref-type="bibr">Elbe et al., 2022</xref>).</p><p>CYP2D6 activity is highly variable depending on the genotype, thus leading to substantial interindividual variability in yohimbine partial AUC (<xref rid="B22" ref-type="bibr">Stoll et al., 2024</xref>; <xref rid="B25" ref-type="bibr">Vay et al., 2020</xref>). We cannot entirely rule out an effect of BA on CYP2D6 due to the sample size of our trial. However, BA showed no inhibitory effect on CYP2D6 <italic toggle="yes">in vitro</italic>, and CYP2D6 is not inducible; so taken all together, it is unlikely that BA interacts with CYP2D6 in a clinically relevant manner.</p><p>In conclusion, our results indicate that BA possesses a mild CYP2C19-inducing effect, while there was no detectable effect on CYP3A4 and CYP2D6.</p></sec></body><back><ack><p>The authors would like to thank the team of the Early Clinical Trial Unit (KliPS) and the laboratory technicians for their excellent support.</p></ack><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>The studies involving humans were approved by the Ethics Committee of the Medical Faculty of Heidelberg University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>FS: conceptualization, formal analysis, investigation, and writing–original draft. SA: conceptualization, investigation, and writing–review and editing. JB: investigation, methodology, and writing–review and editing. AB: conceptualization, investigation, supervision, and writing–review and editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher’s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Amore</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>C.</given-names></name><name name-style="western"><surname>MacDougall</surname><given-names>D.</given-names></name><name name-style="western"><surname>Emery</surname><given-names>M. G.</given-names></name></person-group> (<year>2023</year>). <article-title>The disposition and metabolism of bempedoic acid, a potent inhibitor of ATP citrate lyase, in healthy human subjects</article-title>. <source>Drug Metab. Dispos.</source>
<volume>51</volume> (<issue>5</issue>), <fpage>599</fpage>–<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.122.001142</pub-id>
<pub-id pub-id-type="pmid">36878717</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Asiimwe</surname><given-names>I. G.</given-names></name><name name-style="western"><surname>Pirmohamed</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Drug-drug-gene interactions in cardiovascular medicine</article-title>. <source>Pharmgenomics Pers. Med.</source>
<volume>15</volume>, <fpage>879</fpage>–<lpage>911</lpage>. <pub-id pub-id-type="doi">10.2147/PGPM.S338601</pub-id>
<pub-id pub-id-type="pmid">36353710</pub-id>
<pub-id pub-id-type="pmcid">PMC9639705</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Halama</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry</article-title>. <source>Anal. Bioanal. Chem.</source>
<volume>402</volume> (<issue>7</issue>), <fpage>2439</fpage>–<lpage>2450</lpage>. <pub-id pub-id-type="doi">10.1007/s00216-011-5675-y</pub-id>
<pub-id pub-id-type="pmid">22252655</pub-id>
</mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cicero</surname><given-names>A. F. G.</given-names></name><name name-style="western"><surname>Fogacci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cincione</surname><given-names>I.</given-names></name></person-group> (<year>2021</year>). <article-title>Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia</article-title>. <source>Expert Opin. Drug Metab. Toxicol.</source>
<volume>17</volume> (<issue>9</issue>), <fpage>1031</fpage>–<lpage>1038</lpage>. <pub-id pub-id-type="doi">10.1080/17425255.2021.1951222</pub-id>
<pub-id pub-id-type="pmid">34197267</pub-id>
</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Corn</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>N. W.</given-names></name><name name-style="western"><surname>Dohlmann</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Hlatky</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Wohlfahrt</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Low-density lipoprotein cholesterol response to statins according to comorbidities and co-medications: a population-based study</article-title>. <source>Am. Heart J.</source>
<volume>274</volume>, <fpage>102</fpage>–<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2024.04.018</pub-id>
<pub-id pub-id-type="pmid">38710378</pub-id>
</mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Elbe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>K. I.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>P.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W. E.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans</article-title>. <source>Eur. J. Clin. Pharmacol.</source>
<volume>78</volume> (<issue>6</issue>), <fpage>975</fpage>–<lpage>987</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-022-03304-3</pub-id>
<pub-id pub-id-type="pmid">35238961</pub-id>
<pub-id pub-id-type="pmcid">PMC9107402</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<collab>EMA</collab>, (<year>2024</year>). <article-title>Nilemdo Summary of Product Characteristics. Daiichi Sankyo europe GmbH</article-title>.</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<collab>EMA</collab>, (<year>2020</year>). <article-title>Nustendi Summary of Product Characteristics. Daiichi Sankyo europe GmbH</article-title>.</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<collab>FDA</collab> (<year>2019</year>). <article-title>Integrated Review NDA211616 Nexletol (bempedoic acid) tablets</article-title>
</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="webpage">
<collab>FDA</collab> (<year>2024</year>). <article-title>FDA’s examples of drugs that interact with CYP enzymes and transporter systems</article-title>. <comment>Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems" ext-link-type="uri">https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems</ext-link>. (Accessed February 21, 2025)</comment>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Halama</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W. E.</given-names></name></person-group> (<year>2013</year>). <article-title>A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>93</volume> (<issue>6</issue>), <fpage>564</fpage>–<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2013.27</pub-id>
<pub-id pub-id-type="pmid">23511711</pub-id>
</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hiemke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bergemann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Conca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deckert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Domschke</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017</article-title>. <source>Pharmacopsychiatry</source>
<volume>51</volume> (<issue>1-02</issue>), <fpage>e1</fpage>. <pub-id pub-id-type="doi">10.1055/s-0037-1600991</pub-id>
<pub-id pub-id-type="pmid">29390205</pub-id>
</mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<collab>ICH</collab> (<year>2022</year>). <article-title>Bioanalytical method validation and sample analysis M10</article-title>
</mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Katzenmaier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Markert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name></person-group> (<year>2010</year>). <article-title>Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam</article-title>. <source>Eur. J. Clin. Pharmacol.</source>
<volume>66</volume> (<issue>11</issue>), <fpage>1137</fpage>–<lpage>1141</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-010-0878-2</pub-id>
<pub-id pub-id-type="pmid">20680253</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mahmoudi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>K. I.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W. E.</given-names></name></person-group> (<year>2021</year>). <article-title>Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity</article-title>. <source>J. Clin. Pharmacol.</source>
<volume>61</volume> (<issue>6</issue>), <fpage>789</fpage>–<lpage>798</lpage>. <pub-id pub-id-type="doi">10.1002/jcph.1789</pub-id>
<pub-id pub-id-type="pmid">33236774</pub-id>
</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Muhareb</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meid</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>K. I.</given-names></name><name name-style="western"><surname>Stoll</surname><given-names>F.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>CYP3A and CYP2C19 activity determined by microdosed probe drugs accurately predict voriconazole clearance in healthy adults</article-title>. <source>Clin. Pharmacokinet.</source>
<volume>62</volume> (<issue>9</issue>), <fpage>1305</fpage>–<lpage>1314</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-023-01287-7</pub-id>
<pub-id pub-id-type="pmid">37505445</pub-id>
<pub-id pub-id-type="pmcid">PMC10450012</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nissen</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Lincoff</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kastelein</surname><given-names>J. J. P.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Bempedoic acid and cardiovascular outcomes in statin-intolerant patients</article-title>. <source>N. Engl. J. Med.</source>
<volume>388</volume> (<issue>15</issue>), <fpage>1353</fpage>–<lpage>1364</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2215024</pub-id>
<pub-id pub-id-type="pmid">36876740</pub-id>
</mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Bays</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Catapano</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Lalwani</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Bloedon</surname><given-names>L. T.</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>L. R.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Safety and efficacy of bempedoic acid to reduce LDL cholesterol</article-title>. <source>N. Engl. J. Med.</source>
<volume>380</volume> (<issue>11</issue>), <fpage>1022</fpage>–<lpage>1032</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1803917</pub-id>
<pub-id pub-id-type="pmid">30865796</pub-id>
</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rohr</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Krohmer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>K. I.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Time course of the interaction between oral short-term ritonavir therapy with three factor xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers</article-title>. <source>Clin. Pharmacokinet.</source>
<volume>63</volume> (<issue>4</issue>), <fpage>469</fpage>–<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-024-01350-x</pub-id>
<pub-id pub-id-type="pmid">38393578</pub-id>
<pub-id pub-id-type="pmcid">PMC11052790</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="book">
<collab>SmPC</collab> (<year>2022</year>). “<article-title>Plavix® 75 mg Filmtabletten</article-title>,” <source>Sanofi-aventis Deutschland</source>.</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Stoll</surname><given-names>F.</given-names></name><name name-style="western"><surname>Amato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W. E.</given-names></name><etal/></person-group> (<year>2025</year>). <article-title>Effect of staggered vs. Simultaneous Co-administration of bempedoic acid on pharmacokinetics of pravastatin: randomized, cross-over clinical trial in healthy volunteers</article-title>. <source>Pharmaceutics</source>
<volume>17</volume> (<issue>1</issue>), <fpage>60</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics17010060</pub-id>
<pub-id pub-id-type="pmid">39861708</pub-id>
<pub-id pub-id-type="pmcid">PMC11768435</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Stoll</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Czock</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meyer-Tönnies</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2024</year>). <article-title>Evaluation of hydroxychloroquine as a perpetrator on cytochrome P450 (CYP) 3A and CYP2D6 activity with microdosed probe drugs in healthy volunteers</article-title>. <source>Eur. J. Drug Metab. Pharmacokinet.</source>
<volume>49</volume> (<issue>1</issue>), <fpage>101</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1007/s13318-023-00872-2</pub-id>
<pub-id pub-id-type="pmid">38114885</pub-id>
<pub-id pub-id-type="pmcid">PMC10781839</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Stoll</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eidam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W. E.</given-names></name></person-group> (<year>2022</year>). <article-title>Drug treatment of hypercholesterolemia in older adults: focus on newer agents</article-title>. <source>Drugs Aging</source>
<volume>39</volume> (<issue>4</issue>), <fpage>251</fpage>–<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1007/s40266-022-00928-z</pub-id>
<pub-id pub-id-type="pmid">35278206</pub-id>
<pub-id pub-id-type="pmcid">PMC8995260</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van der Heijden</surname><given-names>L. T.</given-names></name><name name-style="western"><surname>Opdam</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>A. D. R.</given-names></name></person-group> (<year>2024</year>). <article-title>The use of microdosing for <italic toggle="yes">in vivo</italic> phenotyping of cytochrome P450 enzymes: where do we stand? A narrative review</article-title>. <source>Eur. J. Drug Metab. Pharmacokinet.</source>
<volume>49</volume> (<issue>4</issue>), <fpage>407</fpage>–<lpage>418</lpage>. <pub-id pub-id-type="doi">10.1007/s13318-024-00896-2</pub-id>
<pub-id pub-id-type="pmid">38689161</pub-id>
<pub-id pub-id-type="pmcid">PMC11199305</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A.</given-names></name><name name-style="western"><surname>Skopp</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tzvetkov</surname><given-names>M. V.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial</article-title>. <source>Clin. Pharmacokinet.</source>
<volume>59</volume> (<issue>7</issue>), <fpage>927</fpage>–<lpage>939</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-020-00862-6</pub-id>
<pub-id pub-id-type="pmid">32060866</pub-id>
<pub-id pub-id-type="pmcid">PMC7329762</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range</article-title>. <source>Bioanalysis</source>
<volume>11</volume> (<issue>16</issue>), <fpage>1459</fpage>–<lpage>1467</lpage>. <pub-id pub-id-type="doi">10.4155/bio-2019-0129</pub-id>
<pub-id pub-id-type="pmid">31411489</pub-id>
</mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicina (Kaunas)</journal-id><journal-id journal-id-type="iso-abbrev">Medicina (Kaunas)</journal-id><journal-id journal-id-type="pmc-domain-id">3494</journal-id><journal-id journal-id-type="pmc-domain">medicina</journal-id><journal-id journal-id-type="publisher-id">medicina</journal-id><journal-title-group><journal-title>Medicina</journal-title></journal-title-group><issn pub-type="ppub">1010-660X</issn><issn pub-type="epub">1648-9144</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10972143</article-id><article-id pub-id-type="pmcid-ver">PMC10972143.1</article-id><article-id pub-id-type="pmcaid">10972143</article-id><article-id pub-id-type="pmcaiid">10972143</article-id><article-id pub-id-type="pmid">38541153</article-id><article-id pub-id-type="doi">10.3390/medicina60030427</article-id><article-id pub-id-type="publisher-id">medicina-60-00427</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development of a New Bioequivalent Omeprazole Product</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5355-7724</contrib-id><name name-style="western"><surname>Kumisbek</surname><given-names initials="G">Gulzina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><xref rid="af1-medicina-60-00427" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2476-9861</contrib-id><name name-style="western"><surname>Vetchý</surname><given-names initials="D">David</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-medicina-60-00427" ref-type="aff">1</xref><xref rid="c1-medicina-60-00427" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kadyrbay</surname><given-names initials="A">Arshyn</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-medicina-60-00427" ref-type="aff">2</xref></contrib></contrib-group><aff id="af1-medicina-60-00427"><label>1</label>Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 612 00 Brno, Czech Republic; <email>kgulzzina@gmail.com</email></aff><aff id="af2-medicina-60-00427"><label>2</label>Viva Pharm, Almaty 050060, Kazakhstan; <email>karshyn@internet.ru</email></aff><author-notes><corresp id="c1-medicina-60-00427"><label>*</label>Correspondence: <email>vetchy@email.cz</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2024</year></pub-date><volume>60</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">458690</issue-id><elocation-id>427</elocation-id><history><date date-type="received"><day>25</day><month>12</month><year>2023</year></date><date date-type="rev-recd"><day>27</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-29 18:25:14.503"><day>29</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>© 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medicina-60-00427.pdf"/><abstract><p><italic toggle="yes">Background and Objectives:</italic> The enteric form of omeprazole is one of the most commonly prescribed medications. Similarly to Europe, Kazakhstan relies on the localization of pharmaceutical drug production as one of its primary strategies to ensure that its population has access to affordable and good-quality medicines. This study comprehensively describes the technologically available development of bioequivalent delayed-release omeprazole. <italic toggle="yes">Materials and Methods:</italic> Various regimes and technological parameters were tested on laboratory- and production-scale equipment to establish a technical process where a functional and gastro-protective layer is essential. According to the ICH guidance on stability testing and Kazakhstan local rules, stability studies were conducted under conditions appropriate for climate zone II. The comparison of the rate and extent of absorption with subsequent assessment of the bioequivalence of the generic and reference drugs after a single dose of each drug at a dose of 40 mg was performed. <italic toggle="yes">Results:</italic> The quantitative and qualitative composition and technology of producing a new generic enteric form of omeprazole in capsules were developed and implemented at the manufacturing site of solid forms. Dissolution profiles in media with pH 1.2 and 6.8 were proven. During the accelerated six-month and long-term twelve-month studies, the developed formulation in both packaging materials at each control point passed the average weight and mass uniformity test, dissolution test, acid-resistance stage test, buffer stage test, impurity assay, and microbiological purity test and met all the specification criteria. A bioequivalence study in 24 healthy volunteers compared against the innovative drug showed the bioequivalency of the new generic system. The obtained values from the test and reference products were 1321 ± 249.0 ng/mL and 1274 ± 233 ng/mL for C<sub>max</sub>, 4521 ± 841 ng·h /mL and 4371 ± 695 ng·h /mL for AUC<sub>0-t</sub>, and 4636 ± 814 ng·h /mL and 4502 ± 640 ng·h /mL for AUC<sub>0-∞</sub>. <italic toggle="yes">Conclusions:</italic> Using affordable technologies, a bioequivalent generic delayed-release formulation of 20 and 40 mg omeprazole has been developed.</p></abstract><kwd-group><kwd>omeprazole</kwd><kwd>bioequivalence study</kwd><kwd>stability study</kwd><kwd>enteric coating</kwd><kwd>pellets</kwd><kwd>dissolution</kwd><kwd>industrial development</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this research.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-medicina-60-00427"><title>1. Introduction</title><p>Peptic ulcer disease (PU) is a chronic, recurrent acid-dependent disease characterized by alternating periods of exacerbation and remission. It is considered the most common disease of the digestive system, affecting 10–15% of the world’s population. The main component of gastric juice is hydrochloric acid. When secreted at levels above normal, it has a pathological effect and is the main factor in the pathogenesis of ulcers. This pathology shows defects (ulcers) in the wall of the stomach and duodenum. In contrast to erosive changes in the mucosa, an ulcer affects the mucous membrane as well as the submucosal layer [<xref rid="B1-medicina-60-00427" ref-type="bibr">1</xref>,<xref rid="B2-medicina-60-00427" ref-type="bibr">2</xref>,<xref rid="B3-medicina-60-00427" ref-type="bibr">3</xref>].</p><p>Currently, proton pump inhibitors (PPIs) are the primary drugs used to treat acid-related diseases of the upper gastrointestinal tract due to their highly selective inhibitory effect on the acid-forming function of the stomach. The primary drug from the PPI group is omeprazole, which was synthesized in 1979 after the discovery of a unique enzyme, K<sup>+</sup>-stimulated ATPase, in parietal cells during experiments on the gastric mucosa [<xref rid="B2-medicina-60-00427" ref-type="bibr">2</xref>,<xref rid="B4-medicina-60-00427" ref-type="bibr">4</xref>,<xref rid="B5-medicina-60-00427" ref-type="bibr">5</xref>]. Omeprazole, as an agent that reduces gastric acid secretion, is prescribed for the treatment of the following diseases: duodenal ulcer; gastric ulcer; NSAID-associated (non-steroidal anti-inflammatory drugs) gastric and duodenal ulcers; reflux esophagitis; symptomatic gastroesophageal reflux disease (GERD), i.e., heartburn and regurgitation; Zollinger–Ellison syndrome (pathological hypersecretory condition); Helicobacter pylori (H. pylori) [<xref rid="B3-medicina-60-00427" ref-type="bibr">3</xref>]. In 2022, omeprazole was found to be the second most commonly prescribed chemical substance in England, with the drug listed on approximately 35 million prescriptions [<xref rid="B6-medicina-60-00427" ref-type="bibr">6</xref>]. According to the Drug Usage Statistics for 2021 in the USA, omeprazole was ranked as the ninth top drug in the market, with an estimated number of 54.5 million prescriptions [<xref rid="B7-medicina-60-00427" ref-type="bibr">7</xref>].</p><p>In the Republic of Kazakhstan, drugs for patients with acidity disorders are the eighth most often prescribed according to the ATC (Anatomical Therapeutic Chemical) classification system. Omeprazole is among the top 15 main molecules (active ingredients) of the general prescription market and ranks 13th in terms of importance (Vi-ORTIS data). PPIs account for 75.3% in monetary terms and 89.6% in volume terms of the total market for medicines used to treat acid-related disorders. Omeprazole ranks first among the top ten PPI market leaders in terms of the number of packages sold, accounting for 71.66% of the total PPI market in volume terms, and in monetary terms, it comes to 43.56% of the total PPI market [<xref rid="B8-medicina-60-00427" ref-type="bibr">8</xref>].</p><p>The enteric form is the most common form of omeprazole oral dosage formulations. Since omeprazole is a pro-drug that accumulates in the acidic space of the parietal cell and is converted into an active state there, it has the characteristics of a weak base, so it remains stable in neutral pH but degrades rapidly in an acidic environment. Therefore, to reach the small intestine where it is absorbed, omeprazole must be protected from gastric acid when administered orally. These characteristics are a challenge for drug developers in the search for optimal delivery of the pharmacologically active substance to the desired site of absorption or activation [<xref rid="B8-medicina-60-00427" ref-type="bibr">8</xref>]. Ten products are marketed in Kazakhstan: a powder for suspension for oral administration (India), one lyophilizate for intravenous administration (India), and ten enteric capsules (Belarus, India, Spain, Slovenia, Russia). Only one of these is manufactured in Kazakhstan. The presented capsules contain enteric-coated micropellets, pellets, granules, and microgranules [<xref rid="B8-medicina-60-00427" ref-type="bibr">8</xref>,<xref rid="B9-medicina-60-00427" ref-type="bibr">9</xref>].</p><p>There have been several inventions aimed at producing enteric-coated pellets of PPIs. These pellets consist of an empty pellet core, a drug-loaded layer, isolating layers I and II, and an enteric-coated layer coated using a fluidized bed coater [<xref rid="B10-medicina-60-00427" ref-type="bibr">10</xref>,<xref rid="B11-medicina-60-00427" ref-type="bibr">11</xref>,<xref rid="B12-medicina-60-00427" ref-type="bibr">12</xref>]. Against this background, the development of an enteric form of omeprazole in Kazakhstan has been of great interest. However, the coating of pellets or granules is a complex process that requires a high level of technology. The technical capacity to produce such products on an industrial scale is not available in all manufacturing locations. This article describes the technologically feasible development of a bioequivalent extended-release generic product containing 20 mg and 40 mg of omeprazole, focusing on an in vivo bioequivalence study. </p></sec><sec id="sec2-medicina-60-00427"><title>2. Materials and Methods</title><sec id="sec2dot1-medicina-60-00427"><title>2.1. Materials</title><p>The following materials were used in the study: omeprazole (Hetero Labs, Hyderabad, India) Active Pharmaceutical Ingredient (API), lactose monohydrate Supertab 22AN (Glentnam Life Sciences Ltd., Corsham, UK), sodium lauryl sulfate (RNDr Kulich Pharma s.r.o., Hradec Králové, Czech Republic), disodium hydrogen phosphate dodecahydrate cryst. EMPROVE<sup>®</sup> (Merck KGaA, Darmstadt, Germany), hydroxypropylmethylcellulose (Tailopur 603), hydroxypropyl cellulose Klucel EF Pharm (Ashland Industries Europe GmbH, Schaffhausen, Switzerland), pellets from microcrystalline cellulose (MCC) Cellets<sup>®</sup>700 (Process center GmbH&amp;Co.Kg, Dresden, Germany), polyethylene glycol 400 (Applichem GmbH, Darmstadt, Germany), methacrylic acid–ethyl acrylate copolymer Eudragit<sup>®</sup> L30-D55 (Evonic Nutrition and Care GmbH, Darmstadt, Germany), hard gelatin capsules size 0 (Capsugel, Bornem, Belgium), PlasAcryl<sup>®</sup> HTP20 (Emerson Resources Ink., Norristown, PA, USA), titanium dioxide (Venator Germany GmbH, Krefeld, Germany), talc (Imerys Talc Italy S.p.A, Porte, Italy). All ingredients were of pharmaceutical production grade as described in the European Pharmacopoeia, and are widely used in preparations for oral use at concentrations not exceeding the recommended limits. Losec<sup>®</sup>, enteric capsules, 20 mg, AstraZeneca AB, Sweden, was used as the reference drug.</p></sec><sec id="sec2dot2-medicina-60-00427"><title>2.2. Preparation of Omeprazole Pellets</title><p>In order to define the drug’s qualitative and quantitative composition and production technology, several experimental batches were produced in laboratory and pilot sizes at the Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University Brno, Czech Republic (the University). Quality control analytical methods and dissolution profile tests were determined and performed accordingly during the experiments. The developed composition and production technology were tested and improved on a pharmaceutical production scale at Viva Pharm, Almaty, Kazakhstan (Viva Pharm). </p><p>The sizes of the laboratory and pilot batches produced at the University ranged from 0.210 kg to 2.1 kg. At Viva Pharm, the pilot batches were manufactured on a production scale with a batch size of approximately 10.9 kg. The batch intended for the bioequivalence study was 45.68 kg size/200,000 capsules (20 mg)/100,000 capsules (40 mg). The pellets containing omeprazole were prepared in three main steps: I, active coating; II, protective coating; and III, enteric coating. </p><sec id="sec2dot2dot1-medicina-60-00427"><title>2.2.1. Active Coating</title><p>In this step, omeprazole suspensions from two suspensions, IA and IB, were coated on inactive microcrystalline cellulose cores. </p><p>Suspension IA was prepared by mixing the following ingredients: omeprazole, lactose monohydrate, sodium lauryl sulfate, and di-sodium phosphate dodecahydrate in purified water.</p><p>The second, IB, a solution of hydroxypropylmethylcellulose (HPMC) and hydroxypropylcellulose (HPC), was prepared by dispersing the components in purified water heated to 80 °C followed by slow cooling at room temperature for 3 h. Parts IA and IB were then mixed and sprayed onto inactive cores in fluidized bed coaters: Medipore, Czech Republic, for laboratory-scale batches, and Aeromatic-Fielder AG, Switzerland, FBD Bosch pilotlab L, Germany, for pilot-scale batches. The following equipment was used at Viva Pharm for pilot- and production-scale batches: FBD Bosch pilotlab L; calibrator, Frewitt ConiWitt-150; shelf dryer, Hansung HS-DO-1.4; conical granulator, Keno KZ SKZ-180; moisture analyzer, KERN DS8K0.5; overhead mixer Jeio Tech Lab MSD 0420; mixers, Hansung HS-DM 200 and UPT HLS-50H.</p></sec><sec id="sec2dot2dot2-medicina-60-00427"><title>2.2.2. Protective Coating</title><p>The protective coating solution (Solution II) was prepared by gradually adding pre-weighed hydroxypropylmethylcellulose to the purified water with continuous stirring until it was completely dissolved and homogenized. After that, Solution II was sprayed onto the active cores in fluidized bed coaters using the same parameters as used in step I, active coating.</p></sec><sec id="sec2dot2dot3-medicina-60-00427"><title>2.2.3. Enteric Coating</title><p>First, a titanium dioxide suspension was prepared by adding a weighed amount of titanium dioxide to the purified water and mixing it until it was homogeneous. In order to obtain the dispersion for enteric coating III, Eudragit L30-D55, PlasAcryl, and the prepared titanium dioxide suspension were added to weighed purified water with continuous stirring using an overhead stirrer for at least 120 min. </p><p>In all three stages of the coating process, 1.2 mm diameter nozzles were used, with a spray air pressure of 1–3 bar. After the coated pellets were dried at the end of all three steps, the prepared product was unloaded using the Frewitt ConiWitt-150 vacuum system and calibrator without the installation of a sieve or a knife. The coated pellets were sieved through 1.5 mm sieves to separate the undesired agglomerates. The prepared pellets were mixed with talc and then filled into hard gelatin capsules in the Zanasi 40E capsule-filling machine (IMA S.p.A., Bologna, Italy). The capsule sizes were No. 2 for the strength of 20 mg and No. 0 for the strength of 40 mg.</p><p>The omeprazole content of one capsule was determined using high-performance liquid chromatography (HPLC) with an ultraviolet (UV) detector. </p></sec></sec><sec id="sec2dot3-medicina-60-00427"><title>2.3. Dissolution Study</title><p>Dissolution tests were performed according to the USP monograph by using the “Distek 2500” dissolution tester (USP type II apparatus with a paddle) at a stirrer rotation speed of 100 rpm and the dissolution medium temperature of 37.0 ± 0.5 °C. An acid resistance test was performed in a dissolution medium of 500 ml of 0.1 M hydrochloric acid (HCl) pH 1.2 for 2 h. After two hours, for the dissolution buffer stage, 400 mL of 0.235 M dibasic sodium phosphate was added to the 500 mL of 0.1 M hydrochloric acid medium in the vessel and adjusted, if necessary, with 2 M hydrochloric acid or 2 M sodium hydroxide to the pH of 6.8 ± 0.05. Samples were taken at 10, 15, 20, 30, and 45 min. The amount of omeprazole released was determined by HPLC. The original drug Losec and the prepared samples were compared using similarity factors f<sub>2</sub>. The dissolution kinetics of drugs are considered similar when the similarity factor f<sub>2</sub> is equal to or greater than 50 [<xref rid="B13-medicina-60-00427" ref-type="bibr">13</xref>]. </p></sec><sec id="sec2dot4-medicina-60-00427"><title>2.4. Stability Study</title><p>Stability studies were conducted under conditions appropriate for climate zone II according to the ICH guidelines for stability testing and local regulations of Kazakhstan [<xref rid="B14-medicina-60-00427" ref-type="bibr">14</xref>,<xref rid="B15-medicina-60-00427" ref-type="bibr">15</xref>]. Qualified climate chambers were used for long-term studies at the temperature of 25 °C ± 2 °C and the relative humidity (RH) of 60% RH ± 5% RH and for accelerated studies with the regime of 40 °C ± 2 °C/75% and RH ± 5% RH.</p></sec><sec id="sec2dot5-medicina-60-00427"><title>2.5. Bioequivalence Study</title><p>The objective was to compare the rate and extent of absorption followed by a bioequivalence assessment of the generic and reference (originator) drugs after a single dose of each drug at a dose of 40 mg.</p><sec id="sec2dot5dot1-medicina-60-00427"><title>2.5.1. Study Products</title><p>Two finished drugs of omeprazole were compared:</p><p>Reference formulation (R): Losec<sup>®</sup>, enteric capsules, 20 mg (2 capsules), No. 14, AstraZeneca AB, Södertälje, Sweden (batch number 3070122, expiration date May 2024).</p><p>Test formulation (T): omeprazole Viva Pharm, enteric capsules, 40 mg, No. 30, Viva Pharm LLP, Almaty, Kazakhstan (batch number 00122, expiration date November 2024).</p></sec><sec id="sec2dot5dot2-medicina-60-00427"><title>2.5.2. Ethics Compliance and Subjects</title><p>The study was conducted in accordance with the conclusion of the local commission on bioethics issues of the Center for Nuclear Medicine and Oncology of the Health Department of the Abai region (No 1 dated 26 January 2023), and the clinical study protocol (the protocol) was approved by the National Center of Medical Drug Expertise of the Ministry of Health of Kazakhstan (No BE-Omep-2022/02, version 4, dated 6 April 2023) in compliance with the principles of the Declaration of Helsinki (Seoul, 2008), Good Clinical Practice (GCP), and local regulations on bioequivalence study [<xref rid="B16-medicina-60-00427" ref-type="bibr">16</xref>]. The clinical part of the study was conducted in the Center for Nuclear Medicine and Oncology of the Health Department of Abai region, Abay region, Semey City, Kutzhanova 3, Kazakhstan, and the analytical part was conducted in the laboratory of pharmacokinetics and metabolomic analysis of the Institute of Translation Medicine and Biotechnology of Sechenov University, 117418, Moscow, Nakhimovsky prospect 45.</p><p>Thirty male and female volunteers aged 18–45 participated in the screening. The screening procedure followed the study protocol before the first study period. After obtaining written informed consent from the volunteer, the screening included registration of demographic data, physical examination, medical history, measurement of vital signs (blood pressure, heart rate, respiratory rate, body temperature), assessment of well-being, electrocardiogram, clinical laboratory tests (complete blood count, urinalysis, biochemical parameters, hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus antibodies, microreaction, alcohol test, pregnancy test, and urine drug test), and the assessment of applicable inclusion and exclusion criteria. Detailed descriptions of the inclusion and exclusion criteria used in this study and the criteria for subject withdrawal from participating are presented in the supporting material. Six volunteers were excluded after the screening based on the clinical laboratory test results. As a result, 24 healthy volunteers, 16 males and 8 females aged 18–45 years (mean age 29.5 years), were included in the study. All volunteers in the study were continuously monitored and participated until the completion of the study.</p></sec><sec id="sec2dot5dot3-medicina-60-00427"><title>2.5.3. Study Design and Safety</title><p>The study consisted of screening, two study periods, and a washout period (crossover study design). The duration of the screening period was up to 10 days. Each study period lasted for 13 h, and the washout period was seven days. The total time of the study for one volunteer was no more than 20 days.</p><p>At each period of the study, in the morning, after overnight fasting (minimum of eight hours), the volunteers were administered a single dose of 1 capsule with a dosage of 40 mg of the test drug or two capsules containing 20 mg of the reference drug; they swallowed the whole capsule without chewing and drank 250 mL of water. Water consumption was limited to 1 hour before taking the drug and 1 hour after taking the medicine. The first meal was 5 min after taking the medications, and lunch was taken 6 h after the drug administration. A standard diet, including food and beverages, was established for all volunteers during all study periods.</p><p>A total of 576 blood samples were collected from 24 volunteers in two phases of the study. Sampling time was at 0.00 (zero sample, blank point, 15 min before drug administration), 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 8.00, and 12.00 h after the drug administration. After 12 h, the volunteer’s venous catheter was removed. Blood in an amount of 5 mL was collected into heparinized tubes and processed within 20 min. Plasma was separated by centrifugation for 15 min at a speed of at least 3000 rpm/min and then stored at a temperature of −20 °C until it was sent to the pharmacokinetic laboratory.</p><p>During the study, according to the schedule (<xref rid="medicina-60-00427-t001" ref-type="table">Table 1</xref>), appropriate procedures were performed to ensure the safety and well-being of the volunteers, to identify adverse events, and to assess the possibility of further participation of volunteers in the study.</p></sec><sec id="sec2dot5dot4-medicina-60-00427"><title>2.5.4. Analytical Method</title><p>Omeprazole concentrations were determined by a validated method of HPLC with tandem mass spectrometry on a Waters Acquity UPLC device with a Xevo TQS micro tandem quadrupole mass spectrometric detector, Waters Corporation, Milford, MA, USA (HPLC-MS/MS), and an Acquity UPLC BEH C18 analytical and pre-analytical column (2.1 × 50 μm; 1.7 μm), Waters Corporation, USA, using mobile phase A (0.1% solution of formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile) [<xref rid="B17-medicina-60-00427" ref-type="bibr">17</xref>,<xref rid="B18-medicina-60-00427" ref-type="bibr">18</xref>,<xref rid="B19-medicina-60-00427" ref-type="bibr">19</xref>]. A gradient elution program was applied with a 99:1 ratio of mobile phase A to B, which reversed during the analysis. The following software was used for validation: results processing software package Target Lynx Application Manager from Waters Corporation, USA; for statistical processing of the analysis results, the Jamovi 2.01 program (R 4.0 package), Microsoft Excel, or Minitab 16 from Minitab Inc., State College, PA, USA, was used. </p><p>The external standard method, linear regression, least square regression, and a 25.0–2000 ng/mL calibration range for omeprazole were used to detect omeprazole concentration. Calibration standards and quality control (QC) samples were prepared independently using individually prepared solutions. All samples (calibration standards, QC samples, and test samples) were processed as a single batch of samples.</p><p>One series consisted of samples that were prepared simultaneously, i.e., processed sequentially without interruption by the same laboratory operator using the same reagents and under the same conditions. The study attempted to ensure that all samples from a single study subject were analyzed in a single analytical run. In this case, QC samples were distributed throughout the analytical cycle to ensure control of the accuracy and precision of the entire process [<xref rid="B17-medicina-60-00427" ref-type="bibr">17</xref>,<xref rid="B18-medicina-60-00427" ref-type="bibr">18</xref>].</p></sec><sec id="sec2dot5dot5-medicina-60-00427"><title>2.5.5. Pharmacokinetic and Statistical Analysis</title><p>Descriptive statistics were calculated and presented for the main and additional pharmacokinetic (PK) parameters of omeprazole (N, median, arithmetic mean, geometric mean, minimum and maximum values, standard deviation, coefficient of variation). For logarithmically transformed PK parameters and omeprazole Cmax and AUC<sub>0-t</sub>, a bioequivalence assessment was carried out by the analysis of variance (ANOVA) in a mixed-effects model and the analysis of LSM (T/R) ratios of in-transformed PK parameters. Drugs were considered bioequivalent if the 90% confidence interval for the ratio of the geometric mean values of Cmax and AUC<sub>0-t</sub> of omeprazole was 80–125%. The analysis of variance was used to test the hypothesis of the statistical significance of the contribution of each of these factors to the observed variability. The estimate of residual variation obtained using variance analysis was used to calculate the 90% confidence interval for log-transformed values of the corresponding pharmacokinetic parameter. When selecting samples, the volunteers were not divided into subgroups; therefore, a modified statistical model was not required. The main parameters considered were the logarithmically transformed parameters AUC<sub>0→t</sub> (area under the curve from 0 to 12 h), C<sub>max</sub> (maximum value of the drug concentration in the blood), and the C<sub>max</sub>/AUC<sub>0-t ratio</sub>. The statistical analysis included the following procedures: calculation of basic and ordinal statistics, analysis of variance, graphical methods, computation of confidence intervals, calculation and analysis of bioavailability ratios, and testing of interval tests. The differences between the mean values of pharmacokinetic parameters ln(C<sub>max</sub>), ln(AUC<sub>0-t</sub>), and ln(C<sub>max</sub>/AUC<sub>0-t</sub>) were assessed at a 5% significance level, by analyzing the sum-of-squares (SS), degrees of freedom (DFs), mean squares (MSs), F ratio, and P-value using parametric analysis of ANOVA. The contributions of the factors “drug” (differences between drugs), “subject sequence” (differences between volunteers, interindividual differences), “sequence” (variability due to the sequence of drug administration), and “period” (variability due to the study design) were examined as sources of variation [<xref rid="B19-medicina-60-00427" ref-type="bibr">19</xref>].</p></sec></sec></sec><sec sec-type="results" id="sec3-medicina-60-00427"><title>3. Results</title><sec id="sec3dot1-medicina-60-00427"><title>3.1. Development of the Composition and the Production Technology of the Drug</title><p>The quantitative content of the active substance and the dissolution profile test results defined necessary corrections in the formulation and technology to achieve a finished product meeting the quality specification requirements. The omeprazole content in one capsule had to be from 18.0 to 22.0 mg/cap (for the dosage of 20 mg) and from 36.0 to 44.0 mg/cap (for the dosage of 40 mg) and was detected by the HPLC assay method. Another critical test, the dissolution study, determined an amount of omeprazole released at different pH conditions, showing how the formulation was protected in the acid-resistance stage (1.2 pH) and was sufficient at the buffer stage (6.8 pH). Thereby, the qualitative and quantitative composition of the pellets, in particular, the concentration of the coating solutions/dispersions and the technological parameters, was slightly adjusted to the characteristics of the equipment and based on the results of the tests for the quantitative content of the active ingredient and the dissolution profile tests. This was carried out in the course of multiple experiments in the production of laboratory and pilot sizes of batches. The technological parameters of the production processes were also amended according to the type and technical features of the equipment at the Viva Pharm site.</p><p>The formulation adjustments included an increase in the quantity of MCC pellets per capsule from 60.45% to 62.44% and a change in the size from 500 to 700 µm in order to obtain a thinner API layer. Furthermore, polyethylene glycol was replaced with PlasAcryl<sup>®</sup> HTP20 to improve product efficiency and reduce the complexity of technological operations. The content of hydroxypropyl cellulose was reduced from 2.1% to 0.44% until a sufficient result of API release was reached. Hydroxypropylmethylcellulose (from 7.97% to 8.67%), Eudragit L30-D55 (from 5.76% to 8.75%), and PlasAcryl (from 1.07% to 1.49%) were added due to the increase in the core area and to achieve better protective and enteric layers. Titanium dioxide (0.44%) was added to the composition for whitening, and talc (0.18%) for better lubrication. Finally, Composition 4 was prepared and used to manufacture the production batches for stability and bioequivalence studies (<xref rid="medicina-60-00427-t002" ref-type="table">Table 2</xref>).</p><p>It was found that the quality of the product was very sensitive and also dependent on the technical parameters of the coating process. The intermediate product reacted differently to temperature fluctuation, air pressure, inlet volume, and other conditions.</p><p>The following process parameters were found to be the most appropriate: The cores were preheated to 42 °C in the active coating process and kept at 34–37 °C. After the layering was complete, the active beads were dried at the product temperature of 40 °C for 30 min. The inlet air temperature was kept within the range of 62–70 °C. For the protective coating process, the cores were preheated at the product temperature of 42 °C, coated at 38–42 °C, and dried at 40 °C for 30 min. For both coating processes, the inlet air temperature range of 62–70 °C was used.</p><p>In the enteric coating step, the fluidized bed coater container was preheated at 40–42 °C. The layering process was started at a stable incoming air temperature of 40 °C for 30 min and a container temperature of 30 °C. During the coating of the cores, the temperature of the product was kept at 25–28 °C, and for drying, at 32 °C. The inlet air temperature was maintained at 40–47 °C.</p></sec><sec id="sec3dot2-medicina-60-00427"><title>3.2. Dissolution Study</title><p>As for the dissolution of omeprazole, 20 and 40 mg enteric capsules were compared with the reference drug Losec<sup>®</sup>, 20 mg enteric capsules (<xref rid="medicina-60-00427-f001" ref-type="fig">Figure 1</xref>, <xref rid="app1-medicina-60-00427" ref-type="app">Tables S1 and S2</xref>).</p><p>The dissolution was performed at pH 1.2 for 2 h, followed by 45 min at pH 6.8. The amount of omeprazole released at pH 1.2 was evaluated at a single point in 120 min. Both the test and reference drugs met this requirement. The test and reference drugs released from 3.0% to 10.6% and 1.3% to 5.7% of the omeprazole, respectively (<xref rid="app1-medicina-60-00427" ref-type="app">Tables S1 and S2</xref>). At pH 6.8, 90.8 to 92.3% of omeprazole and 85.9 to 93.8% of the reference and test drugs were released (<xref rid="medicina-60-00427-f001" ref-type="fig">Figure 1</xref>, <xref rid="app1-medicina-60-00427" ref-type="app">Tables S1 and S2</xref>).</p><p>Since both drugs containing 20 mg of omeprazole had a release level of the active substance of more than 85% at 15 min, the similarity coefficient calculation was not carried out. The dissolution profiles of the drugs were considered similar (<xref rid="medicina-60-00427-t003" ref-type="table">Table 3</xref>, <xref rid="medicina-60-00427-f001" ref-type="fig">Figure 1</xref>). In the case of 40 mg dosage, the similarity coefficient f<sub>2</sub> was greater than 50, and the dissolution profiles of the drugs were also considered similar (<xref rid="app1-medicina-60-00427" ref-type="app">Table S2</xref>).</p></sec><sec id="sec3dot3-medicina-60-00427"><title>3.3. Stability Study</title><p>Since the formulation is sensitive to the environment, the following two types of packaging were selected to protect the drug from moisture, air oxygen, gas vapor, and microbiological contamination: 1. a bottle made of high-density polyethylene, tightly sealed with an aluminum membrane, with a child-resistant polypropylene screw cap; 2. aluminum foil blisters (Alu/Alu): cold-forming aluminum foil with oriented polyamide, aluminum, polyvinylchloride (OPA/ALU/PVC), and aluminum foil coated with polyvinyl chloride film.</p><p>A series of stability studies were conducted on laboratory-scale experimental batches and approximately ten pilot-scale sets, including the batch intended for the bioequivalence study for each strength and container closure system mentioned above. For both conditions, the study specification included the following tests: average weight and mass uniformity test, dissolution test, acid-resistance stage test, buffer stage test, impurity assay, and microbiological purity test. The evaluated batches passed the accelerated six-month and long-term twelve-month studies, further continuing the assessment (<xref rid="app1-medicina-60-00427" ref-type="app">Tables S3 and S4</xref>).</p></sec><sec id="sec3dot4-medicina-60-00427"><title>3.4. Bioequivalence Study</title><sec id="sec3dot4dot1-medicina-60-00427"><title>3.4.1. Subjects</title><p>An open, randomized, crossover, two-period bioequivalence study (BES) of the generic omeprazole formulation, enteric capsules, 40 mg, was conducted in comparison with the original product Losec<sup>®</sup>, enteric capsules, 20 mg (two capsules), to evaluate the pharmacokinetic parameters and relative bioavailability of the drugs on 24 healthy volunteers.</p><p>No adverse events were identified during the BES study, and the volunteers tolerated both drugs well. At the end of the clinical part of the study, biological material in the amount of 576 biosamples in the form of blood plasma was collected and sent for bioanalytical research.</p></sec><sec id="sec3dot4dot2-medicina-60-00427"><title>3.4.2. Assessment of PK parameters</title><p>Data from 24 volunteers who completed the study according to the protocol were included for the calculation of the pharmacokinetic parameters and statistical analysis (<xref rid="app1-medicina-60-00427" ref-type="app">Tables S5–S8</xref>). The analysis was carried out based on the assumption of a non-normal distribution of parameters. To calculate 90% confidence intervals, the values of the analyzed indicators were logarithmized, and then an ANOVA was performed using the Certara Phoenix WinNonlin program and EquivTest.</p><p><xref rid="medicina-60-00427-f002" ref-type="fig">Figure 2</xref> shows the average pharmacokinetic profiles of omeprazole after the administration of the test and reference drugs in linear coordinates and semi-logarithmic ones. Standard deviations in the pharmacokinetic profiles are placed in the supporting material (<xref rid="app1-medicina-60-00427" ref-type="app">Tables S7 and S8</xref>) for better clarity. Most average values of the test and reference drugs are very similar, and it might not be clear which standard deviation belongs to the test and which to the reference drug.</p><p>The comparative analysis of the main pharmacokinetic parameters for the test and reference drugs showed that the studied drugs entered the systemic circulation from the gastrointestinal tract at an equal rate (<xref rid="medicina-60-00427-t003" ref-type="table">Table 3</xref>).</p><p>The time to reach the maximum omeprazole concentration (T<sub>max</sub>) averaged 2.54 ± 0.44 h for the test and 2.44 ± 0.43 h for the reference drug. The difference between T<sub>max</sub> values for the test and the reference averaged 0.1 h. The presented data indicated no statistically significant differences between the studied medicines before the maximum concentration (T<sub>max</sub>) was reached. At the same time, the average maximum concentrations of omeprazole determined in the blood plasma of volunteers (C<sub>max</sub>) were 1321 ± 249.0 ng/mL and 1274 ± 233 ng/mL for the test and the reference product.</p><p>The analysis of the primary parameter characterizing the degree and rate of bioavailability of the active substance from the dosage form, and the area under the pharmacokinetic curve (AUC<sub>0-t</sub>), indicated insignificant variability in this parameter. The average AUC<sub>0-t</sub> values for the test and reference drug were 4521 ± 841 ng/mL·h and 4371 ± 695 ng/mL·h, respectively. The average value for the AUC<sub>0-∞</sub> parameter was 4636 ± 814 ng/mL·h for the test drug and 4502 ± 640 ng/mL·h for the reference. At the same time, no statistically significant differences were revealed for the compared values. The data in <xref rid="medicina-60-00427-t004" ref-type="table">Table 4</xref> show the assessment of the criteria for the sufficiency of the observation period for the study drugs. The values of the ratio AUC<sub>0-t</sub>/AUC<sub>0-∞</sub> were more than 80%, which indicated that the specified criteria were met.</p><p>The analysis of variance of pharmacokinetic parameters did not reveal any significant sources of variation. Testing was also performed to identify outlier individual differences in log-transformed AUC, C<sub>max</sub>, and C<sub>max</sub>/AUC<sub>0-t</sub> values by plotting standardized differences (mean-centered and standard-deviation-normalized). No outliers were identified when assessing the location of the value indicators for the logarithmically transformed values of AUC, C<sub>max,</sub> and C<sub>max</sub>/AUC<sub>0-t</sub>. The obtained data do not exceed the permissible limits [−3σ;3σ], are symmetrical relative to the x-axis, and indicate a normal distribution of individual differences.</p><p>By assessing the parameters F and p-value of the analysis of variance (ANOVA) for the pharmacokinetic parameters ln(C<sub>max</sub>), ln(AUC<sub>0-t</sub>), and ln(C<sub>max</sub>/AUC<sub>0-t</sub>), it was concluded that the factors “drug”, “period”, “sequence”, and “subject sequence” did not cause any significant differences between the test and reference drugs. The power of the statistical tests for calculations of intra-subject variation was 99.9% for the ln(C<sub>max</sub>) pharmacokinetic parameter, 100.0% for ln(AUC<sub>0→t</sub>), and 100.0% for ln(C<sub>max</sub>/AUC<sub>0→t</sub>). This shows that the power of statistical tests was sufficient (<xref rid="medicina-60-00427-t005" ref-type="table">Table 5</xref>).</p><p>The 90% confidence intervals (CIs) for the μT/μR geometric mean ratios for logarithmically transformed omeprazole pharmacokinetic parameters were as follows:<list list-type="order"><list-item><p>lnC<sub>max</sub>: 95.02–113.15%; μT/μR = 103.69;</p></list-item><list-item><p>lnAUC<sub>0-t</sub>: 96.03–110.74%; μT/μR = 103.13;</p></list-item><list-item><p>lnC<sub>max</sub>/AUC<sub>0-t</sub>: 96.58–104.67%; μT/μR = 100.54.</p></list-item></list></p><p>The CIs were entirely within the range of values for bioequivalence: 80–125% for lnC<sub>max</sub> and lnAUC<sub>0-t</sub> and 75–133% for lnC<sub>max</sub>/AUC<sub>0-t</sub>.</p></sec></sec></sec><sec sec-type="discussion" id="sec4-medicina-60-00427"><title>4. Discussion</title><p>Since omeprazole is unstable in acidic pH conditions, the main challenge was to obtain adequate protective enteric layers on the pellets with the required release profiles. A hydroxypropyl methylcellulose sub-coat was applied to prevent the migration of omeprazole layered on the beads into the enteric coating during its application [<xref rid="B20-medicina-60-00427" ref-type="bibr">20</xref>,<xref rid="B21-medicina-60-00427" ref-type="bibr">21</xref>]. The experimental part of the laboratory-scale batches solved the most problematic issues related to the size of the cores, the quantity and ratio of excipients, and the preparation methods of the coating solutions. However, during the technology transfer to the production scale, unsatisfactory dissolution test results led to adjusting the quantitative and qualitative composition. Furthermore, it was discovered that the technological parameters of all three coating processes, due to their complexity, directly impact the product’s quality characteristics and can cause even more straightforward consequences, such as sticking of the pellets. On a production scale, reducing the inlet air temperature and consequently the product temperature led to effective results in product quality, process optimization, and loss reduction.</p><p>One important quality parameter was the acid resistance of the developed dosage form. According to the USP monograph, no more than 15% of a drug can be released from the dosage form within 120 min at pH 1.2 [<xref rid="B13-medicina-60-00427" ref-type="bibr">13</xref>]. Both the test and reference drugs have fulfilled this requirement in the performed dissolution study. At elevated pH, 6.8, at least 75% of the drug should be released after 2.5 h for a dosage of 20 mg or 70% for 40 mg. Again, both drugs met the specification criteria.</p><p>HDPE bottles and aluminum foil blisters were used for the packaging closure system to evaluate the protective effect of the packaging materials on the developed product quality characteristics. According to the ICH guidance on stability testing, the studied batches had the same formulation and were packaged in the same container closure system proposed for the market [<xref rid="B14-medicina-60-00427" ref-type="bibr">14</xref>]. The original drug Losec<sup>®</sup> had a shelf life of 24 months. The aim was to reach the same term or longer for the developed generic formulation. For long-term studies, testing frequency was established every three months over the first year, every six months over the second year, and annually until the end of the specification. At the accelerated storage condition, more frequent time points (0, 1, 2, 3, and 6 months from a 6-month study) were determined to analyze the trend of the change in quality characteristics [<xref rid="B14-medicina-60-00427" ref-type="bibr">14</xref>,<xref rid="B15-medicina-60-00427" ref-type="bibr">15</xref>]. During the accelerated six-month and long-term twelve-month studies, the developed formulation in both packaging materials at each control point passed the average weight and mass uniformity test, dissolution test, acid-resistance stage test, buffer stage test, impurity assay, and microbiological purity test and met all the specification criteria. The results of the stability studies were considered sufficient at the time of the marketing authorization submission. They had been aimed to be continued for a time, covering the proposed shelf life of 24 months.</p><p>Achieving compliance with the criteria of the dissolution test in the acid resistance stage and the buffer stage and confirmation of product stability allowed the evaluation of the generic formulation in the BES. Based on the results of validation, it was established that the developed method of HPLC with tandem mass spectrometry can be used in pharmacokinetic and toxicokinetic studies in all phases of clinical trials, including studies of comparative pharmacokinetics and bioequivalence of drugs containing omeprazole. Similar analytical systems have been used successfully in other bioequivalence studies with omeprazole [<xref rid="B22-medicina-60-00427" ref-type="bibr">22</xref>,<xref rid="B23-medicina-60-00427" ref-type="bibr">23</xref>]. The clinical part of the study included the preparation of the BES, selection of volunteers, control of the intake of study drugs, blood sampling, and preparation of plasma for further bioanalytical study. A bioequivalence assessment focuses on a comparison of the drug absorption rates and extents of two formulations, not the therapeutic effectiveness of a formulation [<xref rid="B24-medicina-60-00427" ref-type="bibr">24</xref>]. For this reason, a control or placebo group was not included in the study. According to the EMEA Guideline on the investigation of bioequivalence, the subject population for bioequivalence studies should be selected with the aim of permitting the detection of differences between pharmaceutical products [<xref rid="B24-medicina-60-00427" ref-type="bibr">24</xref>]. Reducing subject variability is recommended; thus, a bioequivalence study does not monitor pharmacokinetic differences among different subject groups. Subjects should be, for example, healthy volunteers, 18 years of age or older, and preferably have a Body Mass Index between 18.5 and 30 kg/m<sup>2</sup>. These recommendations regarding subject selection were followed in the study, similar to another bioequivalence study with omeprazole [<xref rid="B22-medicina-60-00427" ref-type="bibr">22</xref>]. During the BES, no adverse events were observed. Drug–drug and drug–disease interactions were not evaluated. The values of pharmacokinetic parameters AUC<sub>0-t</sub> and C<sub>max</sub> found in this study were approximately twice as large as those in a bioequivalence study with half-dose omeprazole [<xref rid="B22-medicina-60-00427" ref-type="bibr">22</xref>]. Based on the data obtained as part of the analysis of variance, 90% confidence intervals were constructed [<xref rid="B25-medicina-60-00427" ref-type="bibr">25</xref>,<xref rid="B26-medicina-60-00427" ref-type="bibr">26</xref>,<xref rid="B27-medicina-60-00427" ref-type="bibr">27</xref>]. The conclusion about the bioequivalence of the compared drugs was made using an approach based on the assessment of 90% confidence intervals for the ratios of the mean values of the logarithmically transformed pharmacokinetic parameters AUC<sub>0-t</sub>, C<sub>max</sub>, and C<sub>max</sub>/AUC<sub>0-t</sub>. The limits for AUC and C<sub>max</sub> are in the range of 80–125%. For C<sub>max</sub>/AUC values, which were characterized by more significant variability, these limits are 75.00–133.00% [<xref rid="B16-medicina-60-00427" ref-type="bibr">16</xref>]. A comparative analysis of the pharmacokinetic parameters of omeprazole, which was a part of the study drug, showed that the test drug omeprazole Viva Pharm, enteric capsules, 40 mg, is bioequivalent to the reference drug Losec<sup>®</sup>, enteric capsules, 20 mg (two capsules).</p></sec><sec sec-type="conclusions" id="sec5-medicina-60-00427"><title>5. Conclusions</title><p>The quantitative and qualitative composition and technology for producing a new generic enteric form of omeprazole in capsules were developed and implemented at the solid-dosage-form production facility of the company Viva Pharm LLP, located in Kazakhstan. The technological parameters of the production process were established and specified in production protocols for commercialized product batches. The developed drug in two types of packaging has passed the stability test. An analytical normative document consisting of full quality control test methods was created for the experimental part and the registration dossier. The equivalence of the generic formulation omeprazole Viva Pharm, enteric capsules, to the innovative drug Losec<sup>®</sup>, enteric capsules, was proved by the dissolution profile test and BES. The new generic drug is aimed to be commercialized in the pharmaceutical market of the Republic of Kazakhstan after obtaining marketing authorization. Similarly to Europe, Kazakhstan relies on the localization of pharmaceutical drug production as one of its primary strategies to ensure that its population has access to affordable and high-quality medicines.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-medicina-60-00427"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/medicina60030427/s1">https://www.mdpi.com/article/10.3390/medicina60030427/s1</uri>: Subject inclusion criteria; Criteria for non-inclusion of subjects; Criteria for stopping subjects from participating in the study; Table S1: Comparative assessment of the release kinetics of omeprazole, dosage 20 mg; Table S2: Comparative assessment of the release kinetics of omeprazole, dosage 40 m; Table S3: Long-term stability study results of Omeprazole Viva Pharm, enteric capsules, 20 mg and 40 mg (batch size: 45.68 kg size/200,000 caps. (20 mg)/100,000 caps. (40 mg). Conditions: Temperature: 25 °C ± 2 °C, and the relative humidity (RH) 60% ± 5%; Table S4: Accelerated stability study results of Omeprazole Viva Pharm, enteric capsules, 20 mg and 40 mg (batch size: 45.68 kg size/200,000 caps. (20 mg)/100,000 caps. (40 mg). Conditions: Temperature: 40 °C ± 2 °C, and the relative humidity (RH) 75% ± 5%; Table S5: Concentrations of omeprazole in the blood plasma of volunteers (ng/mL) after a single dose of the drug Omeprazole (test drug “T”); Table S6: Concentrations of omeprazole in the blood plasma of volunteers (ng/mL) after a single dose of Losec<sup>®</sup> (reference drug “R”); Table S7: Pharmacokinetic parameters of omeprazole in the blood plasma of volunteers after a single dose of the drug Omeprazole (test drug “T”); Table S8: Pharmacokinetic parameters of omeprazole in the blood plasma of volunteers after a single dose of Losec<sup>®</sup> (reference drug “R”).</p><supplementary-material id="medicina-60-00427-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medicina-60-00427-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, G.K. and D.V.; methodology, G.K. and D.V.; software, A.K.; validation, G.K., and A.K.; formal analysis, G.K.; investigation, G.K.; resources, G.K.; data curation, A.K.; writing—original draft preparation, G.K. and D.V.; writing—review and editing, G.K. and D.V.; visualization, G.K. and D.V.; supervision, D.V.; project administration, G.K.; funding acquisition, G.K. and A.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the conclusions of the Local Commission on Bioethical Issues of the Center for Nuclear Medicine and Oncology of the Health Department of Abai region (No.1 dated 26 January 2023), and the clinical study protocol (the protocol) was approved by the National Center of Medical Drug Expertise of the Ministry of Health of Kazakhstan (No. BE-Omep-2022/02, version 4, dated 6 April 2023) in compliance with the principles of the Declaration of Helsinki (Seoul, 2008), Good Clinical Practice (GCP), and local regulations on bioequivalence study.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available in the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-medicina-60-00427"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dekhnich</surname><given-names>N.N.</given-names></name>
</person-group><article-title>Proton pump inhibitors in the treatment of acid-dependent diseases</article-title><source>Bull. Smolensk. State Med. Acad.</source><year>2011</year><volume>1</volume><fpage>21</fpage><lpage>24</lpage></element-citation></ref><ref id="B2-medicina-60-00427"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lazebnik</surname><given-names>L.B.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>E.D.</given-names></name>
<name name-style="western"><surname>Mikheeva</surname><given-names>O.M.</given-names></name>
</person-group><article-title>The use of proton pump inhibitors for the treatment of acid-related diseases</article-title><source>Arch. Intern. Med.</source><year>2013</year><volume>3</volume><fpage>56</fpage></element-citation></ref><ref id="B3-medicina-60-00427"><label>3.</label><element-citation publication-type="book"><source>Product Monograph Losec<sup>®</sup> (Omeprazole Delayed Release Capsules) 20 mg Omeprazole H<sup>+</sup>, K<sup>+</sup>-ATPase Inhibitor</source><publisher-name>AstraZeneca Canada Inc.</publisher-name><publisher-loc>Mississauga, ON, Canada</publisher-loc><year>2017</year></element-citation></ref><ref id="B4-medicina-60-00427"><label>4.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name name-style="western"><surname>Junggren</surname><given-names>U.K.</given-names></name>
<name name-style="western"><surname>Sjöstrand</surname><given-names>S.E.</given-names></name>
</person-group><article-title>Substituted Pyridylsulfinylbenzimidazoles Having Gastric Acid Secretion Properties, Pharmaceutical Preparations Containing Same, and Intermediates for Their Preparation</article-title><patent>Patent No. EP0005129A1</patent><day>31</day><month>October</month><year>1979</year></element-citation></ref><ref id="B5-medicina-60-00427"><label>5.</label><element-citation publication-type="webpage"><article-title>Trends in Drug Patenting—Case Studies: The Cases: 5. Omeprazole. apps.who.int</article-title><day>2</day><month>October</month><year>2010</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://apps.who.int/medicinedocs/en/d/Js4915e/2.5.html" ext-link-type="uri">http://apps.who.int/medicinedocs/en/d/Js4915e/2.5.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-08-22">(accessed on 22 August 2019)</date-in-citation></element-citation></ref><ref id="B6-medicina-60-00427"><label>6.</label><element-citation publication-type="webpage"><article-title>Leading chemical substances dispensed in England in 2022, by number of items</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.statista.com/statistics/378445/prescription-cost-analysis-top-twenty-chemicals-by-items-in-england//" ext-link-type="uri">https://www.statista.com/statistics/378445/prescription-cost-analysis-top-twenty-chemicals-by-items-in-england//</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-25">(accessed on 25 February 2024)</date-in-citation></element-citation></ref><ref id="B7-medicina-60-00427"><label>7.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Omeprazole</collab>
</person-group><article-title>Drug Usage Statistics, United States, 2013–2021</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clincalc.com/DrugStats/Drugs/Omeprazole//" ext-link-type="uri">https://clincalc.com/DrugStats/Drugs/Omeprazole//</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-25">(accessed on 25 February 2024)</date-in-citation></element-citation></ref><ref id="B8-medicina-60-00427"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Kumisbek</surname><given-names>G.K.</given-names></name>
<name name-style="western"><surname>David</surname><given-names>V.</given-names></name>
</person-group><source>Relevance of Application and Market Review of Proton Pump Inhibitors and Omeprazole//Natural Sciences and Medicine: Theory and Practice: Collection. Art. by Mother XL-XLI International Scientific-Practical Conf. 11–12</source><publisher-name>SibAK</publisher-name><publisher-loc>Novosibirsk, Russia</publisher-loc><year>2021</year><fpage>42</fpage><lpage>48</lpage></element-citation></ref><ref id="B9-medicina-60-00427"><label>9.</label><element-citation publication-type="webpage"><article-title>RSE on REM “National Center for Expertise of Medicines and Medical Devices” of the Committee for Medical and Pharmaceutical Control of the Ministry of Health of the Republic of Kazakhstan Home Page</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://register.ndda.kz/category/search_prep" ext-link-type="uri">http://register.ndda.kz/category/search_prep</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-12-07">(accessed on 7 December 2021)</date-in-citation></element-citation></ref><ref id="B10-medicina-60-00427"><label>10.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name name-style="western"><surname>Bai</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Xin</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name>
</person-group><source>Enteric-Coated Pellet Preparation of Proton Pump Inhibitor and Preparation Method Thereof</source><patent>Patent No. CN102119927B</patent><day>26</day><month>December</month><year>2012</year><comment>CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.: Shijiazhuang, China</comment></element-citation></ref><ref id="B11-medicina-60-00427"><label>11.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>J.-R.</given-names></name>
</person-group><article-title>Preparation of Enteric Pharmaceutical Dosage Forms for Omerprazole and Lansoprazole</article-title><patent>Patent No. US 6,726,927 B2</patent><day>27</day><month>April</month><year>2004</year><comment>Sage Pharmaceuticals, Inc.: Shreveport, LA, USA, 2012</comment></element-citation></ref><ref id="B12-medicina-60-00427"><label>12.</label><element-citation publication-type="patent"><person-group person-group-type="author">
<name name-style="western"><surname>Bengtsson</surname><given-names>I.S.</given-names></name>
<name name-style="western"><surname>Lovgren</surname><given-names>K.I.</given-names></name>
</person-group><article-title>Pharmaceutical Formulation of Omeprazole</article-title><source>US Patent</source><patent>Patent No5,690,960</patent><day>25</day><month>November</month><year>1997</year><comment>Astra Aktiebolag: Sodertalje, Sweden</comment></element-citation></ref><ref id="B13-medicina-60-00427"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>United States Pharmacopeia</collab>
</person-group><source>USP Monographs, Omeprazole Delayed-Release Capsules</source><comment>Doc ID: GUID-71E87DD7-0164-42C0-8027-A9211B069968_1_en-US</comment><publisher-name>USP-NF (United States Pharmacopeia)</publisher-name><publisher-loc>Rockville, MD, USA</publisher-loc><year>2023</year><pub-id pub-id-type="doi">10.31003/USPNF_M58645_01_01</pub-id></element-citation></ref><ref id="B14-medicina-60-00427"><label>14.</label><element-citation publication-type="webpage"><article-title>ICH Topic Q 1 A (R2) Stability Testing of New Drug Substances and Products. Note for Guidance on Stability Testing: Stability Testing of New Drug Substances and Products (CPMP/ICH/2736/99)</article-title><source>The ICH Official Website.</source><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ich.org/page/quality-guidelines" ext-link-type="uri">https://www.ich.org/page/quality-guidelines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-23">(accessed on 23 November 2023)</date-in-citation></element-citation></ref><ref id="B15-medicina-60-00427"><label>15.</label><element-citation publication-type="webpage"><article-title>On Approval of the Rules for Conducting Stability Studies by the Manufacturer of a Medicinal Product, Establishing a Shelf Life and Re-Monitoring of Medicinal Products Order of the Minister of Health of the Republic of Kazakhstan. Dated 28 October 2020. No. KR DSM-165/2020. Registered with the Ministry of Justice of the Republic of Kazakhstan on 30 October 2020. No. 21545</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adilet.zan.kz/rus/index/docs" ext-link-type="uri">https://adilet.zan.kz/rus/index/docs</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-23">(accessed on 23 November 2023)</date-in-citation></element-citation></ref><ref id="B16-medicina-60-00427"><label>16.</label><element-citation publication-type="book"><source>Rules for Conducting Bioequivalence Studies of Medicinal Products within the Framework of the Eurasian Economic Union</source><comment>No. 85</comment><publisher-name>Council of the Eurasian Economic Commission</publisher-name><publisher-loc>Moscow, Russia</publisher-loc><year>2016</year></element-citation></ref><ref id="B17-medicina-60-00427"><label>17.</label><element-citation publication-type="book"><source>Guidance for Industry: Bioanalytical Method Validation</source><publisher-name>US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evolution and Research (CDER), US Government Printing Office</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2018</year></element-citation></ref><ref id="B18-medicina-60-00427"><label>18.</label><element-citation publication-type="book"><source>Guideline on Bioanalytical Method Validation</source><comment>EMEA/CHMP/EWP/192217/2009</comment><publisher-name>European Medicines Agency, Committee for Medicinal Products for Human Use (EMEA)</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2011</year></element-citation></ref><ref id="B19-medicina-60-00427"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Mironov</surname><given-names>N.</given-names></name>
</person-group><source>Guidelines for Examination of Medicinal Products</source><publisher-name>Federal State Budgetary Institution “NTsESMP”</publisher-name><publisher-loc>Moscow, Russia</publisher-loc><year>2014</year><volume>Volume 1</volume></element-citation></ref><ref id="B20-medicina-60-00427"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Šalandová</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Franc</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Hofmann</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Dumicic</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kukačková</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Červená</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Beránek</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Srbek</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Repický</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Vladovičová</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>The effect of the composition of a fixed dose combination on bioequivalence results</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>546</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.05.030</pub-id><pub-id pub-id-type="pmid">29758343</pub-id></element-citation></ref><ref id="B21-medicina-60-00427"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>He</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Fan</surname><given-names>L.-F.</given-names></name>
<name name-style="western"><surname>Du</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Xiang</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>C.-L.</given-names></name>
<name name-style="western"><surname>Bai</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Chang</surname><given-names>Y.-Z.</given-names></name>
<name name-style="western"><surname>Cao</surname><given-names>D.-Y.</given-names></name>
</person-group><article-title>Design and in Vitro/in Vivo Evaluation of Multi-layer Film Coated Pellets for Omeprazole</article-title><source>Chem. Pharm. Bull.</source><year>2009</year><volume>57</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1248/cpb.57.122</pub-id><pub-id pub-id-type="pmid">19182399</pub-id></element-citation></ref><ref id="B22-medicina-60-00427"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Joti</surname><given-names>J.J.</given-names></name>
<name name-style="western"><surname>Nahar</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Hasan</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Azad</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Ullah</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Islam</surname><given-names>S.M.</given-names></name>
<name name-style="western"><surname>Hasnat</surname><given-names>A.</given-names></name>
</person-group><article-title>Bioequivalence and Pharmacokinetic Study of Two Different Omeprazole Capsule Formulations in Healthy Bangladeshi Volunteers</article-title><source>Arzneimittelforschung</source><year>2009</year><volume>59</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1296382</pub-id><pub-id pub-id-type="pmid">19517893</pub-id></element-citation></ref><ref id="B23-medicina-60-00427"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mansouri</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Ghozal</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Behloul</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Adda Abbou</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Makhlouf</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Nekhoul</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Hadjaz</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Mansouri</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Bioequivalence of Two Brands of Omeprazole 20 mg Gastro-Resistant Capsules in 18 Healthy Algerian Volunteers: A Pilot Study</article-title><source>J. Pharm. Pharmacol.</source><year>2017</year><volume>5</volume><fpage>877</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.17265/2328-2150/2017.12.005</pub-id></element-citation></ref><ref id="B24-medicina-60-00427"><label>24.</label><element-citation publication-type="book"><source>Guideline on the Investigation of Bioequivalence</source><comment>EMEA/CPMP/EWP/QWP/1401/98</comment><publisher-name>European Medicines Agency, Committee for Medicinal Products for Human Use (EMEA)</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2011</year></element-citation></ref><ref id="B25-medicina-60-00427"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Chow</surname><given-names>S.C.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>J.P.</given-names></name>
</person-group><source>Design and Analysis of Bioavailability and Bioequivalence Studies</source><publisher-name>Marcel Dekker Inc.</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>1992</year></element-citation></ref><ref id="B26-medicina-60-00427"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hauschke</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Kieser</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Diletti</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Burke</surname><given-names>M.</given-names></name>
</person-group><article-title>Sample size determination for proving equivalence based on the ratio of two means for normally distributed data</article-title><source>Stat. Med.</source><year>1999</year><volume>18</volume><fpage>93</fpage><lpage>105</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0258(19990115)18:1&amp;#x0003c;93::AID-SIM992&amp;#x0003e;3.0.CO;2-8</pub-id><pub-id pub-id-type="pmid">9990695</pub-id></element-citation></ref><ref id="B27-medicina-60-00427"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Berger</surname><given-names>R.L.</given-names></name>
<name name-style="western"><surname>Hsu</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Bioequivalence Trials, Intersection-Union Tests and Confidence Sets</article-title><source>Stat. Sci.</source><year>1996</year><volume>11</volume><fpage>283</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1214/ss/1032280304</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="medicina-60-00427-f001" orientation="portrait"><label>Figure 1</label><caption><p>Comparison of dissolution profiles of the test drug and the reference drug Losec<sup>®</sup> at pH 6.8: (<bold>A</bold>)—20 mg dose; (<bold>B</bold>)—40 mg dose.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00427-g001.jpg"/></fig><fig position="float" id="medicina-60-00427-f002" orientation="portrait"><label>Figure 2</label><caption><p>Averaged pharmacokinetic profiles of the test drug and the reference drug Losec<sup>®</sup>: (<bold>A</bold>)—in linear coordinates; (<bold>B</bold>)—in semi-logarithmic coordinates.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medicina-60-00427-g002.jpg"/></fig><table-wrap position="float" id="medicina-60-00427-t001" orientation="portrait"><object-id pub-id-type="pii">medicina-60-00427-t001_Table 1</object-id><label>Table 1</label><caption><p>Schedule of the bioequivalence study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Period of Study/Procedure</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Screening</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Study Periods</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Final Examination</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Washout Period</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thermometry (temperature should be between 36.0° and 36.6°)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before screening</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before period I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Seven days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Before <break/>period II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duration of period </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">up to 10 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Informed consent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inclusion criteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-inclusion criteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demographic and <break/>anthropometric data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medical history</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Physical examination, assessment of vital signs (blood pressure, heart rate, body temperature)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laboratory examination (clinical blood test, biochemical blood test, general urine test)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laboratory examination (clinical blood test, biochemical blood test, general urine test)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urine pregnancy test</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urine analysis for psychotropic and narcotic substances, <break/>psychoactive drugs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcohol test <break/>(breathalyzer/test strips)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electrocardiogram</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Randomization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of T or R drug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood sampling for PC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assessment of A.E.s/SAEs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr></tbody></table></table-wrap><table-wrap position="float" id="medicina-60-00427-t002" orientation="portrait"><object-id pub-id-type="pii">medicina-60-00427-t002_Table 2</object-id><label>Table 2</label><caption><p>Chronology of composition changes (per capsule).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Component</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition 1 (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition 2 (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition 3 (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Composition 4 (%)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microcrystalline cellulose (MCC) pellets</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutral cores</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.44</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">API</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.76</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lactose monohydrate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Filler</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.44</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium lauryl sulfate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solubilizer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sodium pyrophosphate <break/>dodecahydrate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Buffer agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.14</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydrohypropylmethyl-<break/>cellulose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Film-former/<break/>Binder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.67</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydrohypropylcellulose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Film-former/<break/>Binder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eudragit L30-D55 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enteric <break/>coating agent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PlasAcryl </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-tacking<break/>/Plasticizer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.49</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyethylene glycol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Titanium dioxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Talc</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lubricant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0,12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0,18</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purified water <sup>1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solvent</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Total capsule content weight, %</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>100</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>100</bold>
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Weight of capsule content: 20 mg</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>218.0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>220.0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>227.27</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>228.4</bold>
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Weight of capsule content: 40 mg</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>436.0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>440.0</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>454.54</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>456.8</bold>
</td></tr><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Capsule shell—body and cap composition, %:</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Titanium dioxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorant</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gelatin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Base</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">up to 100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">up to 100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">up to 100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">up to 100</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Not contained in the finished product.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="medicina-60-00427-t003" orientation="portrait"><object-id pub-id-type="pii">medicina-60-00427-t003_Table 3</object-id><label>Table 3</label><caption><p>The average pharmacokinetic parameters and relative bioavailability of omeprazole for the test and reference products.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T1/2, h</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">tmax, h</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cmax, ng/mL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0-t</sub>, ng/mL·h</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0-∞</sub> ng/mL·h</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">(AUC0-t/<sub>AUC0-∞</sub>), %</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cmax/AUC<sub>0-t</sub>, h<sup>−1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cmax/AUC<sub>0-∞</sub>, h<sup>−1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">kel</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Test</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arithmetic mean</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1320.578</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4520.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4635.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.347</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2936</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2856</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3819</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geometric mean</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1299.250</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4448.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4571.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.320</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2921</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2842</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3799</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1304.045</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4416.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4496.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.164</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2878</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2803</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3776</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">945.489</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2880.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3044.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.859</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2415</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2390</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3341</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1984.091</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6454.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6571.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.969</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3503</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3374</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4897</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard <break/>deviation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">249.011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">840.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">814.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.295</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0311</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0292</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0415</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV, %</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.9</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Reference</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arithmetic mean</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1273.837</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4370.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4502.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.841</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2914</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2821</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3844</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geometric mean</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1253.036</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4313.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4456.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.803</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2905</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2812</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3824</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1284.560</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4491.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4568.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.192</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2932</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2878</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3751</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">782.761</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2773.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2988.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.755</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2546</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2509</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3145</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1789.898</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5566.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5650.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.532</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3403</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3244</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4810</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard <break/>deviation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">233.311</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">695.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">640.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.742</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0233</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0226</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0418</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CV, %</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.9</td></tr></tbody></table></table-wrap><table-wrap position="float" id="medicina-60-00427-t004" orientation="portrait"><object-id pub-id-type="pii">medicina-60-00427-t004_Table 4</object-id><label>Table 4</label><caption><p>The criteria for the observation period sufficiency.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Drug</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Geometric Mean Values of Pharmacokinetic Parameters</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">AUC<sub>0-t</sub>/ AUC<sub>0-∞</sub>, %</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Criteria for the Observation Period Sufficiency:<break/>AUC<sub>0-t</sub> &gt; 80% × AUC<sub>0-∞</sub></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0-t</sub>,<break/>ng/mL·h</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0-∞</sub>,<break/>ng/mL·h</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Test</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4448.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4571.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reference</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4313.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4456.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td></tr></tbody></table></table-wrap><table-wrap position="float" id="medicina-60-00427-t005" orientation="portrait"><object-id pub-id-type="pii">medicina-60-00427-t005_Table 5</object-id><label>Table 5</label><caption><p>Assessment of BES statistical test power for test and reference.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PK Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MSE<sub>W</sub> (σ<sup>2</sup>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CV<sub>intra</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CV<sub>intra</sub> (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Significance Level</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group Sizes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Power</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ln(C<sub>max</sub>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03105</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1776</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.76</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">α = 5%</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">(12, 12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ln(AUC<sub>0→t</sub>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02067</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1445</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ln(C<sub>max</sub>/<sub>AUC0→t</sub>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00659</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0813</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100.0</td></tr></tbody></table></table-wrap></floats-group></article><article id="bcpt14095" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Basic Clin Pharmacol Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Basic Clin Pharmacol Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">BCPT</journal-id><journal-title-group><journal-title>Basic &amp; Clinical Pharmacology &amp; Toxicology</journal-title></journal-title-group><issn pub-type="ppub">1742-7835</issn><issn pub-type="epub">1742-7843</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11617642</article-id><article-id pub-id-type="pmcid-ver">PMC11617642.1</article-id><article-id pub-id-type="pmcaid">11617642</article-id><article-id pub-id-type="pmcaiid">11617642</article-id><article-id pub-id-type="pmid">39385496</article-id><article-id pub-id-type="doi">10.1111/bcpt.14095</article-id><article-id pub-id-type="publisher-id">BCPT14095</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="heading"><subject>Clinical Pharmacology</subject></subj-group></subj-group></article-categories><title-group><article-title>Improving CYP2C19 phenotyping using stereoselective omeprazole and 5‐hydroxy‐omeprazole metabolic ratios</article-title><alt-title alt-title-type="left-running-head">Abouir et al.</alt-title></title-group><contrib-group><contrib id="bcpt14095-cr-0001" contrib-type="author"><name name-style="western"><surname>Abouir</surname><given-names initials="K">Kenza</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4401-432X</contrib-id><xref rid="bcpt14095-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bcpt14095-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bcpt14095-cr-0002" contrib-type="author"><name name-style="western"><surname>Varesio</surname><given-names initials="E">Emmanuel</given-names></name><xref rid="bcpt14095-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="bcpt14095-cr-0003" contrib-type="author"><name name-style="western"><surname>Déglon</surname><given-names initials="J">Julien</given-names></name><xref rid="bcpt14095-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bcpt14095-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="bcpt14095-cr-0004" contrib-type="author"><name name-style="western"><surname>Samer</surname><given-names initials="C">Caroline</given-names></name><xref rid="bcpt14095-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bcpt14095-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="bcpt14095-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="bcpt14095-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Daali</surname><given-names initials="Y">Youssef</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8391-9383</contrib-id><xref rid="bcpt14095-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="bcpt14095-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="bcpt14095-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>youssef.daali@hcuge.ch</email></address></contrib></contrib-group><aff id="bcpt14095-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Division of Clinical Pharmacology and Toxicology</named-content>
<institution>Geneva University Hospitals</institution>
<city>Geneva</city>
<country country="CH">Switzerland</country>
</aff><aff id="bcpt14095-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">School of Pharmaceutical Sciences; Institute of Pharmaceutical Sciences of Western Switzerland</named-content>
<institution>University of Geneva</institution>
<city>Geneva</city>
<country country="CH">Switzerland</country>
</aff><aff id="bcpt14095-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Forensic Toxicology and Chemistry Unit, University Center of Legal Medicine Lausanne‐Geneva, Lausanne University Hospital</named-content>
<institution>Geneva University Hospital</institution>
<city>Lausanne</city>
<country country="CH">Switzerland</country>
</aff><aff id="bcpt14095-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>University of Geneva</institution>
<city>Geneva</city>
<country country="CH">Switzerland</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Youssef Daali, Faculty of Medicine, University of Geneva, Geneva, Switzerland.<break/>
Email: <email>youssef.daali@hcuge.ch</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2024</year></pub-date><volume>135</volume><issue seq="80">6</issue><issue-id pub-id-type="pmc-issue-id">476362</issue-id><issue-id pub-id-type="doi">10.1111/bcpt.v135.6</issue-id><fpage>755</fpage><lpage>766</lpage><history><date date-type="rev-recd"><day>12</day><month>8</month><year>2024</year></date><date date-type="received"><day>26</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>06</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-06 00:25:33.900"><day>06</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2024 The Author(s). <italic toggle="yes">Basic &amp; Clinical Pharmacology &amp; Toxicology</italic> published by John Wiley &amp; Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BCPT-135-755.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:BCPT-135-755.pdf"/><abstract><title>Abstract</title><p>Omeprazole (OME) is a CYP2C19 phenotyping probe, marketed as a racemic <italic toggle="yes">(S)</italic>/<italic toggle="yes">(R)</italic> mixture or as an S‐enantiomer. Both CYP2C19 and CYP3A4 enzymes mediate (R)‐OME hydroxylation to (R)‐5‐hydroxyomeprazole, while (S)‐OME is exclusively hydroxylated via CYP2C19. This study investigates OME and its 5‐hydroxymetabolite enantiomers' pharmacokinetics using data from two studies involving healthy volunteers. In Study A, volunteers received OME alone in Session 1, OME combined with voriconazole and fluvoxamine in Session 2 and finally OME with rifampicin in Session 3. In Study B, volunteers received OME alone in Session 1, OME combined with voriconazole in Session 2 and finally OME with fluvoxamine in Session 3. Despite low metabolic ratio values of (S)‐OME, detectable modulation of CYP2C19 activity suggests both (R)‐ and (S)‐OME isomers could effectively assess CYP2C19 activity. Further research is needed for precise cut‐offs in different phenotype groups.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bcpt14095-kwd-0001">5‐hydroxy‐omeprazole</kwd><kwd id="bcpt14095-kwd-0002">CYP2C19</kwd><kwd id="bcpt14095-kwd-0003">enantiomers</kwd><kwd id="bcpt14095-kwd-0004">omeprazole</kwd><kwd id="bcpt14095-kwd-0005">phenotyping</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Swiss National Research Foundation</funding-source><award-id>SNF 320030_18236</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="4"/><page-count count="12"/><word-count count="6100"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:05.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bcpt14095-cit-9001">
<string-name name-style="western">
<surname>Abouir</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>Varesio</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western">
<surname>Déglon</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Samer</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Daali</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Improving CYP2C19 phenotyping using stereoselective omeprazole and 5‐hydroxy‐omeprazole metabolic ratios</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. <year>2024</year>;<volume>135</volume>(<issue>6</issue>):<fpage>755</fpage>‐<lpage>766</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcpt.14095</pub-id>
<pub-id pub-id-type="pmcid">PMC11617642</pub-id><pub-id pub-id-type="pmid">39385496</pub-id></mixed-citation>
</p><fn-group id="bcpt14095-ntgp-0001"><fn id="bcpt14095-note-0001"><p>
<bold>Funding information</bold> This work was supported by a research grant from the Swiss National Research Foundation (SNF 320030_18236).</p></fn></fn-group></notes></front><body id="bcpt14095-body-0001"><boxed-text position="float" content-type="box" id="bcpt14095-blk-0001" orientation="portrait"><caption><title>Plain English Summary</title></caption><p>Omeprazole is widely used for CYP2C19 phenotyping. When administered as a racemic mixture, (R‐S)‐omeprazole undergoes stereoselective metabolism and is primarily metabolized to (R)‐5‐hydroxyomeprazole via CYP2C19/CYP3A and (S)‐5‐hydroxyomeprazole via CYP2C19. The goal of our study was to provide additional data concerning omeprazole stereoselective hydroxylation and evaluate the potential use of omeprazole enantiomeric metabolic ratio (R or S) to improve CYP2C19 phenotyping. We demonstrated that both omeprazole enantiomers could be used for CYP2C19 activity assessment. However, the (S)‐enantiomer metabolic ratio at 2 h after omeprazole administration and the AUC ratio performed better, particularly for induction. We also proposed validated cut‐offs for CYP2C19 phenotyping using (S)‐omeprazole.</p></boxed-text><sec id="bcpt14095-sec-0003"><label>1</label><title>INTRODUCTION</title><p>Cytochrome P450 2C19 (CYP2C19) enzyme is estimated to metabolize approximately 15% of all marketed drugs, among which proton pump inhibitors, antiplatelet agents, antidepressants, beta‐blockers, benzodiazepines and many other compounds.<xref rid="bcpt14095-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="bcpt14095-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>CYP2C19 metabolism is largely affected by genetic polymorphisms, leading to serious therapeutic complications.<xref rid="bcpt14095-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Moreover, drug–drug interactions (DDIs) are recognized as a major cause in CYP2C19 activity variability. The Dutch Pharmacogenetic Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) have established guidelines for several CYP2C19 substrates based on genetic test results.<xref rid="bcpt14095-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="bcpt14095-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> However, while genotyping provides valuable information about genetic predisposition, it does not capture the dynamic aspects of enzyme activity influenced by endogenous and environmental factors. The standard approach for measuring CYP2C19 activity is phenotyping. In addition to the information provided by genotyping, phenotyping provides clinically relevant information about the in vivo activity of enzymes at a given moment and considers the combination of genetic, endogenous and environmental factors. CYP450 phenotyping consists of administering a probe drug metabolized by a specific cytochrome and assessing different pharmacokinetic parameters of the probe drug and the related metabolite, allowing the definition of an individual metabolic profile.<xref rid="bcpt14095-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="bcpt14095-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="bcpt14095-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>One of the first strategies developed to assess CYP2C19 activity was using mephenytoin as a probe drug. However, mephenytoin's narrow therapeutic index and association with a higher risk of adverse effects, mainly severe toxicity in CYP2C19 poor metabolizers (PMs), made it less ideal for routine phenotyping. Over time, there has been a transition from utilizing mephenytoin to omeprazole (OME) as a probe drug for CYP2C19 phenotyping.<xref rid="bcpt14095-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Unlike mephenytoin, OME has a wider therapeutic window and is better tolerated, making it a safer and more practical alternative for CYP2C19 phenotyping.</p><p>OME carries a chiral centre (the sulfinyl group) and was initially marketed as a racemic mixture of <italic toggle="yes">(R)‐(+)‐</italic> and (<italic toggle="yes">S)‐(−)‐</italic>enantiomers before studies revealed stereoselective enzyme‐catalysed metabolism.<xref rid="bcpt14095-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> When administered as a racemic mixture, OME undergoes stereoselective metabolism and is primarily metabolized to 5‐hydroxyomeprazole (referred to in this article as OH‐OME), 3‐hydroxyomeprazole, 5‐O‐Desmethylomeprazole and OME sulfone (OME‐SUL) by CYP2C19 and CYP3A4 (Figure <xref rid="bcpt14095-fig-0001" ref-type="fig">1</xref>). <italic toggle="yes">(R)‐</italic>OME hydroxylation to <italic toggle="yes">(R)‐</italic>5‐hydroxyomeprazole is mediated by both CYP2C19 and CYP3A4, in contrast to <italic toggle="yes">(S)‐</italic>OME, which is exclusively hydroxylated to 5‐hydroxyomeprazole via CYP2C19. This makes the <italic toggle="yes">(S)‐</italic>isomer a promising candidate for CYP2C19 activity assessment. Another rationale for this work is that esomeprazole (=<italic toggle="yes">(S)‐</italic>OME) is one of the most widely prescribed drugs. Using esomeprazole as a means of CYP2C19 phenotyping could prevent treatment interruption for some patients, as is currently the case. Although all these advantages are encouraging, it is important to note that <italic toggle="yes">(S)‐</italic>isomer clearance is described to be significantly lower than that of the <italic toggle="yes">(R)‐</italic>isomer.<xref rid="bcpt14095-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="bcpt14095-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Schematic representation of the metabolic pathways of omeprazole. Blue star: major metabolism pathway.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="BCPT-135-755-g002.jpg"/></fig><p>Our work aimed to provide additional data concerning OME stereoselective hydroxylation to the OH‐OME enzyme‐catalysed metabolism pathway via CYP2C19. The study analysed samples from healthy volunteers receiving oral OME racemate alone, after CYP2C19 enzyme inhibition using either voriconazole and fluvoxamine simultaneously or separately to evaluate the importance of the CYP3A pathway in <italic toggle="yes">(R)‐</italic>OME metabolism, and after CYP2C19 induction using rifampicin. The purpose was to assess inhibition and induction impact on <italic toggle="yes">(R)‐</italic> and <italic toggle="yes">(S)‐</italic>metabolic ratio, hence CYP2C19 activity and OME enantiomers' suitability for CYP2C19 phenotyping.</p></sec><sec sec-type="materials-and-methods" id="bcpt14095-sec-0004"><label>2</label><title>MATERIALS AND METHODS</title><sec id="bcpt14095-sec-0005"><label>2.1</label><title>Study design and population</title><p>The first set of data (Study A) was from a previous study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> Identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01731067">NCT01731067</ext-link>) involving 10 healthy male volunteers who received sequentially 5 mg OME racemate for CYP2C19 phenotyping (Session 1: control session). During the inhibition session, participants received 5 mg of OME after taking fluvoxamine (50 mg) 12 h before OME administration and fluvoxamine (50 mg) and voriconazole (400 mg) 2 h before OME administration (Session 2: inhibition session).</p><p>Volunteers in Study A were genotyped for CYP2C19, and only normal or rapid metabolizers (*1/*1 and *1/*17) were included in the clinical trial.</p><p>Co‐administration of voriconazole and fluvoxamine during the same session was designed to inhibit cytochromes 2C9, 2C19 and 3A4 (by voriconazole) and CYP1A2 (by fluvoxamine). OME 5 mg was also administered after pretreatment with rifampicin (600 mg, one tablet every evening for 7 days until the day before OME administration) (Session 3: induction session). Venous blood samples (3 ml) were taken before (Time 0) and 0.5, 1, 2, 3, 4, 6 and 8 h after OME administration and were used to extract the plasma. Corresponding dried plasma spots (DPS) were analysed in this study. Further details of the study have been described elsewhere.<xref rid="bcpt14095-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>A second data set (Study B) was extracted from a recent phase 1, open‐label, monocentric parallel study in healthy volunteers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05264142">NCT05264142</ext-link>). Included subjects were allocated in three groups according to their genotype. Only the study's normal metabolizer‐genotyped volunteers (<italic toggle="yes">n</italic> = 15) were considered (CYP2C19*1/*1) in this work.</p><p>In the first session, Study B volunteers received 10 mg OME for CYP2C19 phenotyping (control session or Session 1). During the inhibition sessions, participants received 10 mg of OME after taking voriconazole (400 mg 2 h before OME administration) at Session 2 (voriconazole inhibition session) and fluvoxamine (50 mg, 12 and 2 h before OME administration) at Session 3 (fluvoxamine inhibition session). Dried blood spots (DBS) were taken before (Time 0) and 2, 3, 6 and 8 h after probe administration.</p><p>Given that voriconazole acts as both a moderate inhibitor of CYP2C19 and a strong inhibitor of CYP3A4, and given the involvement of CYP3A4 in CYP2C19‐mediated hydroxylation of <italic toggle="yes">(R)‐</italic>OME, a comparison was made with dataset B, where CYP2C19 inhibition was performed in two steps, using voriconazole and fluvoxamine separately. The study was conducted in accordance with the Basic &amp; Clinical Pharmacology &amp; Toxicology policy for experimental and clinical studies.<xref rid="bcpt14095-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p></sec><sec id="bcpt14095-sec-0006"><label>2.2</label><title>Analytical method</title><p>OME and OH‐OME concentrations in plasma and blood were determined using an in‐house validated stereoselective 2D high‐performance liquid chromatography–mass spectrometry analysis.<xref rid="bcpt14095-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p><p>For sample preparation, 10 mm diameter discs covering the entire DPS (Study A) and 8 mm diameter discs covering the entire DBS (Study B) were cut and folded into the bottom of individual LC vials containing a 300 μL inert insert. For extraction, methanol (100 μL) containing the internal standard was added to each vial. The extracted solution was diluted twofold with water (100 μL) before injection.</p><p>DPS and DBS analysis was carried out using an LC–MS/MS system comprising a QTRAP 6500 mass spectrometer from SCIEX (Toronto, Canada) and an Agilent 1290 Infinity II LC system with an additional Agilent 1100 LC pump (Agilent, Palo Alto, USA) for the first and second dimensions, respectively. Non‐stereoselective online extraction and enrichment were performed using a Discovery HS C18 short reversed‐phase column (20 × 2.1 mm ID, 5 μm, 120 Å, Supelco) equipped with an online filter (size 0.004‐in. ID × 2 μm depth × 0.5 μm porosity, Phenomenex). Stereoselective separation was carried out on a chiral column based on chlorinated phenylcarbamate cellulose (150 × 2 mm ID, 3 μm, 1000 Å, Lux Cellulose‐4, Phenomenex). The mobile phases for the first reversed‐phase dimension consisted of (A1) water and (B1) methanol, and (A2) water and (B2) acetonitrile for the second stereoselective dimension. Both columns were operated at a flow rate of 300 μL/min. The method used was fully validated according to international criteria.<xref rid="bcpt14095-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p></sec><sec id="bcpt14095-sec-0007"><label>2.3</label><title>Statistical analysis</title><p>The single‐point metabolic ratios (MRs) were determined as the concentration ratio between the metabolite and the administered substance: 5‐hydroxyomeprazole/omeprazole (OH‐OME/OME) at a given time‐point. The pharmacokinetic parameters were estimated by standard non‐compartmental methods using Pkanalix 2023R1 (Lixoft SAS, a Simulations Plus company). The area under the curve (AUC) ratios were determined as the ratio between the AUC of the metabolite and the AUC of the administered probe.</p><p>The results are presented as a median or mean ratio and a 90% confidence interval (CI). The MR and AUC ratios were compared using a nonparametric Wilcoxon <italic toggle="yes">t</italic>‐test. The correlation between AUC ratios and single‐point MRs of volunteers was compared using the Pearson test. A probability of <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p><p>All statistical analyses were performed using the DATAtab Online Statistics Calculator (DATAtab Team [2023] DATAtab e.U. Graz, Austria).</p></sec></sec><sec sec-type="results" id="bcpt14095-sec-0008"><label>3</label><title>RESULTS</title><sec id="bcpt14095-sec-0009"><label>3.1</label><title>Subjects</title><p>For Study A, 10 healthy male volunteers were enrolled and completed the study. They were of Caucasian ethnicity, aged between 20 and 36 years (median age 23) with a body mass index (BMI) between 19.9 and 24.4 (median BMI of 22.0) (details described in the research article by Bosilkovska et al.<xref rid="bcpt14095-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>).</p><p>For Study B, 15 healthy males and females were enrolled and completed the study. All participants were of Caucasian ethnicity, with eight females and seven males aged between 21 and 47 years (median age 28) with a BMI between 18.7 and 31.8 (median BMI 21.6).</p></sec><sec id="bcpt14095-sec-0010"><label>3.2</label><title>Study A</title><sec id="bcpt14095-sec-0011"><label>3.2.1</label><title>Pharmacokinetic data</title><p>As shown in Figure <xref rid="bcpt14095-fig-0002" ref-type="fig">2A</xref> and Table <xref rid="bcpt14095-tbl-0001" ref-type="table">1</xref>, the pharmacokinetic profiles of <italic toggle="yes">(S)‐</italic>OME and <italic toggle="yes">(R)‐</italic>OME were similar in distribution and elimination. No statistically significant differences were observed between either enantiomer with respect to time to maximum concentration (T<sub>max</sub>: 2 h) at each session. Maximum concentration (C<sub>max</sub>) and AUC were significantly different for OME enantiomers between the control session as well as for the inhibited and induced one (C<sub>max</sub> of 87.11, 415.34 and 8 vs. 126.52, 446.1 and 10.8 nmol·L<sup>−1</sup>, respectively, for the (R) and (S)‐OME at baseline inhibition and induction, and AUC of 178.62, 1582.69 and 16.35 vs. 234.94, 1746.22 and 21.97 h·nmol·L<sup>−1</sup>, respectively, for the (R) and (S)‐OME at baseline inhibition and induction). Moreover, AUC and C<sub>max</sub> were significantly lower (<italic toggle="yes">p</italic> &lt; 0.05) for <italic toggle="yes">(R)‐</italic>OME than for <italic toggle="yes">(S)‐</italic>OME at the three sessions.</p><fig position="float" fig-type="FIGURE" id="bcpt14095-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Study A pharmacokinetics. (A) (R)‐ and (S)‐OME and 5‐hydroxyomeprazole (OH‐OME) median plasma concentration time profiles. Session 1 (control session): 5 mg omeprazole (OME) intake alone; Session 2 (voriconazole inhibition session): 5 mg OME intake after inhibition via voriconazole and fluvoxamine; Session 3 (rifampicin induction session): 5 mg OME intake after induction via rifampicin. (B) Area under the curve (AUC) ratio (OH‐OME/OME) for (S)‐ and (R)‐isomers (** = <italic toggle="no">p</italic> &lt; 0.01). (C) Median metabolic ratio (MR)‐time profile of (S)‐OH‐OME/(S)‐OME and (R)‐OH‐OME/(S)‐OME (* = <italic toggle="no">p</italic> &lt; 0.05, ** = <italic toggle="no">p</italic> &lt; 0.01).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="BCPT-135-755-g001.jpg"/></fig><table-wrap position="float" id="bcpt14095-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Pharmacokinetic parameters of (R) and (S)‐OME alone (baseline) or with cytochrome P450 2C19 (CYP2C19) inhibitors (inh.) and inducer (ind.).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1"/><th colspan="5" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">
<italic toggle="no">(R)</italic>‐</th><th colspan="5" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">
<italic toggle="no">(S)</italic>‐</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Inh.</th><th align="left" valign="bottom" rowspan="1" colspan="1">Inh. ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">Baseline</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ind.</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ind. ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">Inh.</th><th align="left" valign="bottom" rowspan="1" colspan="1">Inh. ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">Baseline</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ind.</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ind. ratio</th></tr></thead><tbody valign="top"><tr><td colspan="11" align="left" valign="top" rowspan="1">OME</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–8</sub> (h·nmol·L<sup>−1</sup>)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1582.69</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.86</td><td align="char" char="." valign="top" rowspan="1" colspan="1">178.62</td><td align="char" char="." valign="top" rowspan="1" colspan="1">16.35</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1746.22</td><td align="char" char="." valign="top" rowspan="1" colspan="1">7.43</td><td align="char" char="." valign="top" rowspan="1" colspan="1">234.94</td><td align="char" char="." valign="top" rowspan="1" colspan="1">21.97</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub> (nmol·L<sup>−1</sup>)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">415.34</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.77</td><td align="char" char="." valign="top" rowspan="1" colspan="1">87.113</td><td align="char" char="." valign="top" rowspan="1" colspan="1">7.99</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td><td align="char" char="." valign="top" rowspan="1" colspan="1">446.1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.53</td><td align="char" char="." valign="top" rowspan="1" colspan="1">126.52</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10.8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CL (nmol·L<sup>−1</sup>)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">20.35</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.07</td><td align="char" char="." valign="top" rowspan="1" colspan="1">278.6</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1571.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5.64</td><td align="char" char="." valign="top" rowspan="1" colspan="1">16.428</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">215.15</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1404.4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6.53</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">R/S ratio at 2 h</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.03</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.47</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.70</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.76</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.09</td><td rowspan="2" colspan="5" align="left" valign="top"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">R/S ratio at 4 h</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.65</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.67</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.76</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.14</td></tr><tr><td colspan="11" align="left" valign="top" rowspan="1">OH‐OME</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">AUC <sub>0–8</sub> (h·nmol·L<sup>−1</sup>)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">153.24</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.81</td><td align="char" char="." valign="top" rowspan="1" colspan="1">190.17</td><td align="char" char="." valign="top" rowspan="1" colspan="1">43.68</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.23</td><td align="char" char="." valign="top" rowspan="1" colspan="1">43.6</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.51</td><td align="char" char="." valign="top" rowspan="1" colspan="1">17.39</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6.66</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">C<sub>max</sub> (nmol·L<sup>−1</sup>)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">38.79</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.48</td><td align="char" char="." valign="top" rowspan="1" colspan="1">80.934</td><td align="char" char="." valign="top" rowspan="1" colspan="1">22.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.27</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11.48</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.38</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.3</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.7</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.33</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CL (nmol·L<sup>−1</sup>)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">115.05</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.69</td><td align="char" char="." valign="top" rowspan="1" colspan="1">166.48</td><td align="char" char="." valign="top" rowspan="1" colspan="1">541.39</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.25</td><td align="char" char="." valign="top" rowspan="1" colspan="1">712.19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.44</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1619.78</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3842.63</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2.37</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">R/S ratio at 2 h</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.37</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.34</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.89</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td><td rowspan="2" colspan="5" align="left" valign="top"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">R/S ratio at 4 h</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.38</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.34</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9.93</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.14</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hydroxylation index</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.12</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">1.12</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4.16</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">0.03</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">0.08</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.44</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="bcpt14095-ntgp-0002"><fn id="bcpt14095-note-0002"><p>
<italic toggle="yes">Note</italic>: Hydroxylation index corresponds to the median ratio of the AUC<sub>0–8</sub> of OH‐OME and AUC<sub>0–8</sub> of OME for each enantiomer and at different sessions.</p></fn><fn id="bcpt14095-note-0003"><p>Abbreviations: AUC, area under the curve; Inh., inhibited; Ind., induced; OH‐OME, 5‐hydroxyomeprazole; OME, omeprazole.</p></fn></table-wrap-foot></table-wrap><p>
<italic toggle="yes">(S)‐</italic>OH‐OME and <italic toggle="yes">(R)‐</italic>OH‐OME pharmacokinetic profiles exhibited notable differences in terms of distribution and elimination characteristics. As for the parent compound, no statistically significant differences in terms of T<sub>max</sub> were observed between <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OH‐OME.</p><p>Regardless of the session considered, the average C<sub>max</sub> of <italic toggle="yes">(S)‐</italic>OH‐OME was 7.1‐fold lower than that of <italic toggle="yes">(R)‐</italic>OH‐OME enantiomer (9.8, 3.4 and 8.2‐fold, respectively, for control, inhibition and induction sessions). Similarly, <italic toggle="yes">(S)‐</italic>OH‐OME's AUC was, on average, 7.0‐fold lower than <italic toggle="yes">(R)‐</italic>OH‐OME's AUC (11.0, 3.5 and 8.2‐fold, respectively, for control inhibition and induction sessions).</p></sec><sec id="bcpt14095-sec-0012"><label>3.2.2</label><title>Effect of the CYP2C19 inhibition and induction</title><p>The distribution of the AUC ratios (OH‐OME/OME) after OME alone and after its administration with fluvoxamine and voriconazole or rifampicin is presented in Figure <xref rid="bcpt14095-fig-0002" ref-type="fig">2B</xref>.</p><p>As expected, at inhibition session, (<italic toggle="yes">S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME AUC significantly increased (8.1‐folds on average), hence decreasing both <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic> AUC ratios and reflecting the inhibition effect.</p><p>When considering the parent compound enantiomers separately, we note that <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic> AUC are, on average, 7.4 and 8.9‐fold higher after inhibition (Table <xref rid="bcpt14095-tbl-0001" ref-type="table">1</xref>). Comparatively, we observe a 2.51 and 0.81‐fold increase in <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OH‐OME AUC after inhibition.</p><p>Statistically significant differences regarding the AUC ratio were observed among the three sessions (<italic toggle="yes">p</italic> &lt; 0.01). Median AUC ratios (CI) for <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic> at the control session were 0.11 (0.08; 0.12) and 1.76 (0.93; 2.47), respectively, in contrast to 0.02 (0.01; 0.04) and 0.17 (0.09; 0.27) at the inhibited session.</p><p>Pretreatment with rifampicin significantly decreased <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME AUC (10.7‐fold on average compared to the control session), increasing the AUC ratio. The average induction impact on <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME enantiomers was of a 10.7 and 10.9‐fold decrease for (<italic toggle="yes">S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME, respectively. When considering the metabolite enantiomers, we note a 2.6‐ and 4.4‐fold decrease for <italic toggle="yes">(S)</italic> and <italic toggle="yes">(R)‐</italic>OH‐OME AUC, respectively. Median AUC ratios (CI) for <italic toggle="yes">(S)‐ and (R)</italic>‐isomers at the induction session were 0.28 (0.23; 0.4) and 3.26 (2.24; 4.36), respectively.</p></sec><sec id="bcpt14095-sec-0013"><label>3.2.3</label><title>MR ratios</title><p>The first set (Study A) distributions of the MR OH‐OME/OME at times 2, 3, 4 and 6 h for each enantiomer after OME alone and after coadministration with voriconazole and fluvoxamine or rifampicin are presented in Figure <xref rid="bcpt14095-fig-0002" ref-type="fig">2C</xref>.</p><p>Statistically significant differences were observed for <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>enantiomers between the control session and the inhibited one, with <italic toggle="yes">p</italic> &lt; 0.05 at times 2, 4 and 6 h for <italic toggle="yes">(S)</italic>‐isomer and <italic toggle="yes">p</italic> &lt; 0.01 at times 3 h for <italic toggle="yes">(S)‐</italic> and 2, 3, 4 and 6 h for <italic toggle="yes">(R)‐</italic>enantiomer.</p><p>Comparatively, statistically significant differences were observed between the control session and the induced one at time points 4 and 6 h (<italic toggle="yes">p</italic> &lt; 0.05) and 2 and 3 h (<italic toggle="yes">p</italic> &lt; 0.01) for the <italic toggle="yes">(S)‐</italic>enantiomer. No statistical differences were observed for the <italic toggle="yes">(R)‐</italic>enantiomer when considering the induction session. Median (CI) <italic toggle="yes">(R)‐</italic> and <italic toggle="yes">(S)‐</italic>(OH‐OME/OME) MRs over time are presented in Table <xref rid="bcpt14095-tbl-0002" ref-type="table">2</xref>.</p><table-wrap position="float" id="bcpt14095-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>OME (R) and (S) median area under the curve (AUC) ratios at the control (ctrl.), inhibited (inh.) and induced session (ind.)—Study A.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Time</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Sesssion 1 (ctrl.)</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Sesssion 2 (inh.)</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Sesssion 3 (ind.)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Median (R)‐OH‐OME/(R)‐OME (CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median (S)‐OH‐OME/(S)‐OME (CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median (R)‐OH‐OME/(R)‐OME (CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median (S)‐OH‐OME/(S)‐OME (CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median (R)‐OH‐OME/(R)‐OME (CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Median (S)‐OH‐OME/(S)‐OME (CI)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.17 (0.74; 2.19)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.09 (0.0; 0.36)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.08 (0.05; 0.13)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.02 (0; 0.07)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.48 (1.65; 3.78)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.28 (0.22; 0.69)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.44 (1.04; 4.59)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.13 (0.07; 0.23)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.12 (0.09; 0.19)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.02 (−0.01; 0.08)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.71 (2.55; 5.34)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.4 (0.3; 0.78)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.4 (1.13; 5.67)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.12 (0.08; 0.19)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.17 (0.11; 0.28)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.03 (−0.01; 0.1)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.6 (3.02; 5.66)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.41 (0.33; 0.79)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.07 (2.51; 4.22)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.14 (0.04; 0.41)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.24 (0.08; 0.68)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0.03 (0.02; 0.05)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.01 (2.37; 4.36)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1 (0.54; 1.01)</td></tr></tbody></table><table-wrap-foot id="bcpt14095-ntgp-0003"><fn id="bcpt14095-note-0004"><p>Abbreviations: CI, confidence interval; OH‐OME, 5‐hydroxyomeprazole; OME, omeprazole.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="bcpt14095-sec-0014"><label>3.3</label><title>Study B</title><sec id="bcpt14095-sec-0015"><label>3.3.1</label><title>Pharmacokinetic data</title><p>Figure <xref rid="bcpt14095-fig-0003" ref-type="fig">3A</xref> shows the pharmacokinetic profiles of <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME and OH‐OME when the OME racemic mixture is given alone and when administered with voriconazole and fluvoxamine, respectively (distinctly at Session 2: voriconazole and Session 3: fluvoxamine).</p><fig position="float" fig-type="FIGURE" id="bcpt14095-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Study B pharmacokinetics. (A) (R)‐ and (S)‐OME and 5‐hydroxyomeprazole (OH‐OME) median plasma concentration time profiles. Session 1 (control session): 10 mg omeprazole (OME) intake alone; Session 2 (voriconazole inhibition session): 10 mg OME intake after inhibition via voriconazole; Session 3 (fluvoxamine inhibition session): 5 mg OME intake after inhibition via fluvoxamine. (B) Area under the curve (AUC) ratio (OH‐OME/OME) for (S)‐ and (R)‐isomers (** = <italic toggle="no">p</italic> &lt; 0.01, ns = not significant). (C) Median metabolic ratio (MR)‐time profile (OH‐OME/OME) for (S)‐ and (R)‐isomers (* = <italic toggle="no">p</italic> &lt; 0.05, ** = <italic toggle="no">p</italic> &lt; 0.01).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="BCPT-135-755-g003.jpg"/></fig><p>Pharmacokinetic profiles of (S)‐OME and (R)‐OME were similar in terms of distribution and elimination. No statistically significant differences were observed in the time to maximum concentration (T<sub>max</sub>: 2 h) between the enantiomers across the study arms. In the control arm, AUC and C<sub>max</sub> were significantly lower for (R)‐OME compared to (S)‐OME (AUC: 167 vs. 228 h·ng·ml<sup>−1</sup>; C<sub>max</sub>: 80 vs. 108 ng·ml<sup>−1</sup>; <italic toggle="yes">p</italic> &lt; 0.01). When co‐administered with voriconazole, the differences were not significant (AUC: 593 vs. 715 h·ng·ml<sup>−1</sup>; C<sub>max</sub>: 161 vs. 193 ng·ml<sup>−1</sup>; <italic toggle="yes">p</italic> = 0.73). Similarly, with fluvoxamine, no significant differences were observed (AUC: 585 vs. 605 h·ng·ml<sup>−1</sup>; C<sub>max</sub>: 197 vs. 208 ng·ml<sup>−1</sup>; <italic toggle="yes">p</italic> = 0.93).</p></sec><sec id="bcpt14095-sec-0016"><label>3.3.2</label><title>Effect of the CYP2C19 inhibition</title><p>In comparison to the control session, the median AUC of (R)‐OME was 3.8 times higher under voriconazole and 4.3 times higher under fluvoxamine. The median AUC for <italic toggle="yes">(S)‐</italic>OME was 3.4 times higher when administered with voriconazole and 3.0 times higher with fluvoxamine. Comparatively, for <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OH‐OME AUC, no statistically significant difference was observed between inhibition with voriconazole and with fluvoxamine.</p><p>In Study B, median AUC ratios (CI) for <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME at the control session were 0.09 (0.05; 0.24) and 2.19 (1.60; 5.15), respectively (Figure <xref rid="bcpt14095-fig-0003" ref-type="fig">3B</xref>).</p><p>(S)‐isomer median AUC ratio was 0.05 (0.03; 0.06) when co‐administered with voriconazole <italic toggle="yes">versus</italic> 0.05 (0.04; 0.06) with fluvoxamine. <italic toggle="yes">(R)‐</italic>isomer median AUC ratio was 0.52 (0.33; 1.09) with voriconazole <italic toggle="yes">versus</italic> 0.37 (0.31; 0.59) with fluvoxamine. Both <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>isomers median AUC ratios were statistically different between the control and voriconazole and between the control and fluvoxamine (<italic toggle="yes">p</italic> &lt; 0.01), but not statistically different when comparing inhibition with voriconazole and fluvoxamine (<italic toggle="yes">p</italic> = 0.43 for <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">p</italic> = 0.06 for <italic toggle="yes">(R)‐</italic>enantiomer).</p></sec><sec id="bcpt14095-sec-0017"><label>3.3.3</label><title>MR ratios</title><p>The second data set (Study B) shows similar results to the MR ratios obtained in Study A. Statistically significant differences were observed between the control and fluvoxamine inhibition at times 2 and 3 h (<italic toggle="yes">p</italic> &lt; 0.05) for <italic toggle="yes">(S)‐</italic>enantiomer and at 2, 3 and 6 h (<italic toggle="yes">p</italic> &lt; 0.01) for <italic toggle="yes">(R)</italic>‐enantiomer (Figure <xref rid="bcpt14095-fig-0003" ref-type="fig">3C</xref>).</p></sec><sec id="bcpt14095-sec-0018"><label>3.3.4</label><title>Spearman rank correlation</title><p>The Spearman rank correlation coefficients (Ps) between each enantiomer AUC ratio and MRs in Study A at 2, 3, 4 and 6 h after OME administration alone, with voriconazole and fluvoxamine or with rifampicin are shown in Table <xref rid="bcpt14095-tbl-0003" ref-type="table">3</xref>.</p><table-wrap position="float" id="bcpt14095-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Spearman rank correlations (ρs) between OME (R) and (S) AUClast ratios of metabolite/probe and the metabolic ratios at various time points at different sessions.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="3" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Phenotyping index</th><th rowspan="3" align="left" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Sampling time (h)</th><th colspan="6" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">
<italic toggle="no">(S)</italic>‐</th><th colspan="6" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">
<italic toggle="no">(R)</italic>‐</th></tr><tr style="border-bottom:solid 1px #000000"><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Inhibition</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Baseline</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Induction</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Inhibition</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Baseline</th><th colspan="2" align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Induction</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Ps</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>‐value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ps</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>‐value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ps</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>‐value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ps</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>‐value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ps</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>‐value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Ps</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>‐value</th></tr></thead><tbody valign="top"><tr><td rowspan="5" align="left" valign="top" colspan="1">[OH‐OME]/[OME]</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.97</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.78</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.008</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.84</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.002</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.94</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.17</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.647</td></tr><tr><td align="char" char="." valign="top" rowspan="1" colspan="1">3</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.86</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.95</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.79</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.006</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.78</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.008</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.92</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.52</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.128</td></tr><tr><td align="char" char="." valign="top" rowspan="1" colspan="1">4</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.92</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.74</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.014</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.73</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.016</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.89</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.79</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.006</td></tr><tr><td align="char" char="." valign="top" rowspan="1" colspan="1">6</td><td align="char" char="." valign="top" rowspan="1" colspan="1">−0.15</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.689</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.86</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">−0.29</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.415</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.58</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.077</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.88</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">−0.04</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.907</td></tr><tr><td align="char" char="." valign="top" rowspan="1" colspan="1">8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">−0.34</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.331</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.005</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.11</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.772</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.88</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.001</td><td align="char" char="." valign="top" rowspan="1" colspan="1">−0.13</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.727</td></tr></tbody></table><table-wrap-foot id="bcpt14095-ntgp-0004"><fn id="bcpt14095-note-0005"><p>Abbreviations: OH‐OME, 5‐hydroxyomeprazole; OME, omeprazole.</p></fn></table-wrap-foot></table-wrap><p>These results go together with the MR results observed, except for the <italic toggle="yes">(R)‐</italic>enantiomer‐induced session where, even though a good correlation between the AUC ratio and the MR is kept, it is difficult to measure CYP2C19 activity as no significant difference was observed.</p></sec><sec id="bcpt14095-sec-0019"><label>3.3.5</label><title>Cut‐off determination</title><p>In this study, we developed specific threshold values using the results from Study A based on the 2‐h MR to distinguish individuals with normal CYP2C19 activity from those with decreased (Session 2—Study A) or increased (Session 3—Study A) activity for each enantiomer. These threshold values were established as a preliminary criterion for CYP2C19 phenotyping using <italic toggle="yes">(S)</italic>‐enantiomer, thus providing a practical and clinically relevant approach.</p><p>Established thresholds for <italic toggle="yes">(S)</italic>‐ and <italic toggle="yes">(R)</italic>‐enantiomers are presented in Table <xref rid="bcpt14095-tbl-0004" ref-type="table">4</xref> and Figure <xref rid="bcpt14095-fig-0004" ref-type="fig">4</xref>.</p><table-wrap position="float" id="bcpt14095-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Proposed thresholds for cytochrome P450 2C19 (CYP2C19) phenotyping using <italic toggle="no">(R)</italic>‐ and <italic toggle="no">(S)‐</italic>omeprazole (OME) isomers.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">(S)</italic>‐enantiomer</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">(R)</italic>‐enantiomer</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Rapid metabolizer (RM)</td><td align="char" char="±" valign="top" rowspan="1" colspan="1">0.46 ± 0.38</td><td align="char" char="±" valign="top" rowspan="1" colspan="1">2.71 ± 1.72</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Normal metabolizer (NM)</td><td align="char" char="±" valign="top" rowspan="1" colspan="1">0.18 ± 0.29</td><td align="char" char="±" valign="top" rowspan="1" colspan="1">1.47 ± 1.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Poor metabolizer (PM)</td><td align="char" char="±" valign="top" rowspan="1" colspan="1">0.04 ± 0.06</td><td align="char" char="±" valign="top" rowspan="1" colspan="1">0.09 ± 0.06</td></tr></tbody></table></table-wrap><fig position="float" fig-type="FIGURE" id="bcpt14095-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>(A) (S)‐(5‐hydroxyomeprazole [OH‐OME]/omeprazole [OME]) cut‐off determination with Study A and verification with Study B. (B) (R)‐(OH‐OME/OME) cut‐off determination with Study A and verification with Study B.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="BCPT-135-755-g004.jpg"/></fig><p>When we applied proposed thresholds from Study A to the participants with the NM genotype in Study B, the results fell in line with our expectations. In the control session, where participants received OME alone to simulate individuals with normal activity, the median MR value for the <italic toggle="yes">(S)‐</italic>enantiomer closely matched the cut‐offs established in Study A, while the median MR value for the <italic toggle="yes">(R)‐</italic>enantiomer suggested an RM phenotype.</p></sec></sec></sec><sec id="bcpt14095-sec-0020"><label>4</label><title>DISCUSSION AND CONCLUSION</title><p>The primary focus of this investigation was to assess how <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME enantiomers pharmacokinetic properties, in addition to their corresponding hydroxylated metabolites, are affected by the presence of inhibitors (fluvoxamine and voriconazole, both independently and in combination) and an inducer (rifampicin).</p><p>The study aimed to evaluate CYP2C19 phenotyping accuracy using a specific metabolic pathway not affected by CYP3A and to evaluate the possibility of phenotyping patients taking esomeprazole as antacid therapy. We utilized pharmacokinetic data from two different sets of experiments, referred to as Study A and Study B.</p><p>In Study A, <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME enantiomers pharmacokinetic profiles demonstrated similarities in terms of distribution and elimination characteristics. The same order of concentration magnitude of the parent molecule was measured for the two enantiomers, underlining the administered OME racemic character. Statistically significant differences were observed for <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>MR between control and modulated sessions (inhibited and induced).</p><p>
<italic toggle="yes">(S)‐</italic>isomer did show significant differences for both inhibited and induced sessions, contrary to <italic toggle="yes">(R)‐</italic>isomer, which did not show any significant difference at the induction session. <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>OH‐OME enantiomers C<sub>max</sub> and AUC values were significantly different between Sessions 1, 2 and 3. Notably, <italic toggle="yes">(R)‐</italic>OH‐OME consistently displayed higher AUC values in comparison to <italic toggle="yes">(S)‐</italic>OH‐OME.</p><p>As described previously, upon its rapid absorption, OME undergoes a stereoselective first‐pass metabolism mediated by CYP2C19 in favour of <italic toggle="yes">(R)‐</italic>enantiomer, explaining the lower OME AUC and the difference in AUC between both enantiomers once they have been metabolized.<xref rid="bcpt14095-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Moreover, it is of utmost significance to emphasize that the metabolic conversion of the <italic toggle="yes">(R)‐</italic>enantiomer occurs via CYP2C19 and CYP3A4, giving rise to the creation of <italic toggle="yes">(R)‐</italic>5‐OH‐OME. Conversely, the primary metabolic process for the <italic toggle="yes">(S)‐</italic>enantiomer revolves around CYP2C19, resulting in the formation of 5‐O desmethylomeprazole and a minor pathway resulting in the production of <italic toggle="yes">(S)‐</italic>5‐OH‐OME.<xref rid="bcpt14095-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>Within the framework of this study, our central objective was primarily oriented towards elucidating the hydroxylation pathway for both the <italic toggle="yes">(R)‐</italic> and <italic toggle="yes">(S)‐</italic>enantiomers. This signifies that we extensively explored the principal route for the <italic toggle="yes">(R)</italic>‐isomer while also considering a minor route for the <italic toggle="yes">(S)‐</italic>enantiomer.</p><p>OME coadministration with CYP2C19 inhibitors, voriconazole and fluvoxamine, led to a significant decrease in OH‐OME/OME AUC ratios, reflecting the inhibitory effect on (<italic toggle="yes">S)‐</italic> and <italic toggle="yes">(R)‐</italic>OME metabolism. It should be noted that, although our study did not specifically focus on the combination of fluvoxamine and voriconazole, this combination resulted in a significant increase in AUC due to the dual inhibition of CYP2C19 by both drugs. This highlights the importance of considering complex interactions when co‐administering multiple inhibitors. OME enzyme‐catalysed stereoselective metabolism led to slower metabolic clearance of <italic toggle="yes">(S)‐</italic>OME compared to the <italic toggle="yes">(R)‐</italic>isomer as described by Abelo et al., and inhibition index was 1.9‐fold higher on <italic toggle="yes">(R)‐</italic>OME when compared to <italic toggle="yes">(S)‐</italic>OME.</p><p>A great deal of variability in the measured concentrations is observable when the <italic toggle="yes">(R)‐</italic>enantiomer is compared with the <italic toggle="yes">(S)</italic> one. However, concomitant use of fluvoxamine (strong CYP2C19 inhibitor) and voriconazole (moderate CY2C19 and strong CY3A4 inhibitor) during the inhibition session (Study A) involves that both CYP2C19 and CYP3A4 pathways were inhibited and could explain this stronger inhibition at the level of the <italic toggle="yes">(R)‐</italic>enantiomer.<xref rid="bcpt14095-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>To evaluate the role of CYP3A4 in the enantiomer metabolism pathway and assess whether it can impact CYP2C19 phenotyping results when <italic toggle="yes">(R)</italic>‐enantiomer is considered, we analysed samples from Study B (voriconazole and fluvoxamine administered distinctly at Sessions 2 and 3, respectively).</p><p>This second set of data corroborated the trends observed in Study A, with statistically significant differences in AUC values for both enantiomers when CYP2C19 was inhibited moderately (voriconazole) or strongly (fluvoxamine). Median AUC ratios for <italic toggle="yes">(S)‐</italic> and <italic toggle="yes">(R)‐</italic>isomers were not statistically different between Sessions 2 and 3 (<italic toggle="yes">p</italic> = 0.43 for <italic toggle="yes">(S)</italic> and <italic toggle="yes">p</italic> = 0.06 for <italic toggle="yes">(R)</italic>), indicating that the involvement of CYP3A4 in the metabolism of the <italic toggle="yes">(R)‐</italic>enantiomer may have little effect on this pathway. As discussed by Abelo et al., CYP3A4 mainly supports the sulfone metabolite formation from <italic toggle="yes">(R)‐</italic>OME, whereas hydroxylation and 5‐O‐desmethylation are minor pathways via this enzyme.<xref rid="bcpt14095-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>Pretreatment with rifampicin led to a significant increase in the OH‐OME/OME AUC ratios. The induction index was 1.8 for the <italic toggle="yes">(R)‐</italic>enantiomer <italic toggle="yes">versus</italic> 2.5‐fold for the <italic toggle="yes">(S)‐</italic>enantiomer, making it a better candidate for measuring CYP2C19 induction.</p><p>At the induction session, rifampicin, as a moderate inducer of CYP2C19 and a strong inducer of CYP3A4, may have had an effect on the CYP2C19 and CYP3A4 pathways in addition to minor ones, introducing variability and impacting statistical significance in our study. Previous studies have reported a similar extent of CYP2C19 induction by rifampicin (4.2‐ and 2.6‐fold).<xref rid="bcpt14095-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p><p>Spearman correlation results showed that an important correlation existed between AUC<sub>last</sub> ratio and MRs in plasma even when the CYP activity was modulated. The best correlation was observed at 4 h and was just as significant for <italic toggle="yes">(S)‐</italic> as for <italic toggle="yes">(R)‐</italic>enantiomer. Previous studies have used a single‐point MR at 3 or 4 h as a phenotyping index, which corroborates with our results.<xref rid="bcpt14095-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="bcpt14095-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>In this study, we established specific threshold values using the 2‐h MR data from Study A to distinguish individuals with normal, decreased, or increased CYP2C19 activity for both <italic toggle="yes">(R)</italic> and <italic toggle="yes">(S)‐</italic>OME enantiomers, providing a practical approach for CYP2C19 phenotyping. These thresholds were confirmed as robust and clinically relevant, particularly for the <italic toggle="yes">(S)</italic>‐enantiomer that consistently revealed phenotypic variations when inhibitors were present. The median MR value for the <italic toggle="yes">(R)‐</italic>enantiomer suggested an RM phenotype, which was unexpected for NM individuals. This indicates that (<italic toggle="yes">R)‐</italic>enantiomer may not be as reliable for phenotyping under these conditions. However, Study B volunteer genotyping was performed investigating only the three most common CYP2C19 variants (CYP2C19*2, *3 and *17), and the wild‐type *1 allele was assigned by default when none of the other mutations screened (*2, *3 and *17) were detected. We cannot therefore rule out the possibility that our volunteers have much rarer variants (other than *2, *3 and *17) and that this may have introduced a bias into our study.</p><p>An ideal phenotyping probe is a substrate for a transporter or an enzyme that is completely specific. Because currently for CYP2C19 we do not dispose of completely specific probes, it is essential to choose probes with a sufficient degree of selectivity to reflect enzyme activity in various settings. The presented results in this study indicate that we can measure CYP2C19 modulation, hence CYP2C19 phenotype, in a reasonably comparable way between both OME isomers. Because of its lower metabolic clearance, the <italic toggle="yes">(S)</italic>‐OME isomer seemed at first sight to be a better candidate for CYP2C19 phenotyping. A slightly more detailed analysis of the pharmacokinetic parameters and the effect of inhibition and induction on each of the enantiomers enabled us to show that CYP3A4 was only minimally involved in the <italic toggle="yes">(R)‐</italic>OME isomer metabolism pathway and that inhibition and induction were as measurable for the <italic toggle="yes">(R)‐</italic> as for the <italic toggle="yes">(S)‐</italic>enantiomer. The difference between both isomers lay in that the measured AUC ratios of the <italic toggle="yes">(R)‐</italic>OH‐OME were, on average, 10 times higher than those of the <italic toggle="yes">(S)‐</italic>OH‐OME, which may constitute a limitation from the point of view of the available analytical method limit of quantification. Moreover, the use of metabolic or AUC ratios is advantageous for probes having more than one metabolizing path because they give information on the activity of a single CYP implicated in a specific pathway.<xref rid="bcpt14095-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In the present investigation, a notable limitation stems from the omission of an exploration into alternative metabolic pathways. Subsequently, conducting additional research on the primary metabolic route for each enantiomer, which involves 5‐hydroxylation for the <italic toggle="yes">(R)</italic>‐enantiomer and 5‐O‐desmethylation for the <italic toggle="yes">(S)</italic>‐enantiomer, alongside concurrent analysis of the minor pathway, may offer valuable insights. Larger population studies should be conducted to evaluate the distribution of CYP2C19 activity regarding each OME isomer, allowing precise cut‐off determination and validation between the different phenotype groups.</p><p>In conclusion, this study showed that both <italic toggle="yes">(R)‐</italic> and <italic toggle="yes">(S)‐</italic>OME enantiomers can be used for CYP2C19 activity assessment. <italic toggle="yes">(R)</italic>‐OME enantiomer, induction of CYP2C19 was not as reliable as for (S)‐enantiomer. We demonstrated that the <italic toggle="yes">(S)</italic>‐enantiomer MR at 2 h and AUC ratio can be used as phenotyping metrics for the CYP2C19 phenotyping. We proposed validated cut‐offs for CYP2C19 phenotyping using <italic toggle="yes">(S)‐</italic>OME enantiomer, which could facilitate certain clinical situations. The currently available method for CYP2C19 phenotyping requires the administration of OME necessitating, in some cases, the discontinuation of treatment that has already been in place for some time, the most frequent of them being esomeprazole. The cut‐offs determined from our study will allow to determine CYP2C19 phenotype in such patients using their own treatment by sampling blood or DBS 2 or 3 h after esomeprazole intake.</p><p>Future studies with both single and multiple doses of esomeprazole are necessary to confirm the feasibility and accuracy of this approach. Between January 2013 and April 2014, 56.2% of patients under clopidogrel had a co‐prescription of esomeprazole (<italic toggle="yes">(S)‐</italic>OME) at Geneva University Hospitals.<sup>21</sup> Once validated in a larger setting, CYP2C19 phenotyping with (<italic toggle="yes">S)‐</italic>OME isomers (esomeprazole) could be applied as a tool in clinical practice or specific scenarios.</p></sec><sec sec-type="COI-statement" id="bcpt14095-sec-0021"><title>CONFLICT OF INTEREST STATEMENT</title><p>The other authors have no conflict of interest to declare regarding this manuscript.</p></sec></body><back><ack id="bcpt14095-sec-0129"><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank Fabienne Doffey Lazeyras for the technical help and Mylène Docquier and her team (iGE3 Genomic Platform) of the University of Geneva for their help and availability during the conduct of the genotyping experiment. Open access funding provided by Universite de Geneve.</p></ack><sec sec-type="data-availability" id="bcpt14095-sec-0023"><title>DATA AVAILABILITY STATEMENT</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list id="bcpt14095-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="bcpt14095-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0002">
<string-name name-style="western">
<surname>Guengerich</surname>
<given-names>FP</given-names>
</string-name>. <article-title>Cytochrome P450s and other enzymes in drug metabolism and toxicity</article-title>. <source>AAPS j</source>. <year>2006</year>;<volume>8</volume>(<issue>1</issue>):<fpage>E101</fpage>‐<lpage>E111</lpage>. doi:<pub-id pub-id-type="doi">10.1208/aapsj080112</pub-id>
<pub-id pub-id-type="pmid">16584116</pub-id>
<pub-id pub-id-type="pmcid">PMC2751428</pub-id></mixed-citation></ref><ref id="bcpt14095-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0003">
<string-name name-style="western">
<surname>Li‐Wan‐Po</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Girard</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Farndon</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western">
<surname>Cooley</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Lithgow</surname>
<given-names>J</given-names>
</string-name>. <article-title>Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17</article-title>. <source>Br J Clin Pharmacol</source>. <year>2010</year>;<volume>69</volume>(<issue>3</issue>):<fpage>222</fpage>‐<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2125.2009.03578.x</pub-id>
<pub-id pub-id-type="pmid">20233192</pub-id>
<pub-id pub-id-type="pmcid">PMC2829691</pub-id></mixed-citation></ref><ref id="bcpt14095-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0004">
<string-name name-style="western">
<surname>Hirota</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Eguchi</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Ieiri</surname>
<given-names>I</given-names>
</string-name>. <article-title>Impact of genetic polymorphisms in <italic toggle="yes">CYP2C9</italic> and <italic toggle="yes">CYP2C19</italic> on the pharmacokinetics of clinically used drugs</article-title>. <source>Drug Metab Pharmacokinet</source>. <year>2013</year>;<volume>28</volume>(<issue>1</issue>):<fpage>28</fpage>‐<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.2133/dmpk.DMPK-12-RV-085</pub-id>
<pub-id pub-id-type="pmid">23165865</pub-id>
</mixed-citation></ref><ref id="bcpt14095-bib-0004"><label>4</label><mixed-citation publication-type="book" id="bcpt14095-cit-0005">
<collab collab-type="authors">(DPWG), T.D.P.W.G</collab>
. <source>Annotation of DPWG Guideline for clopidogrel and CYP2C19</source>. [12.10.2023]. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pharmgkb.org/guidelineAnnotation/PA166104956" ext-link-type="uri">https://www.pharmgkb.org/guidelineAnnotation/PA166104956</ext-link>
</mixed-citation></ref><ref id="bcpt14095-bib-0005"><label>5</label><mixed-citation publication-type="book" id="bcpt14095-cit-0006">
<collab collab-type="authors">(CPIC), T.C.P.I.C</collab>
. <source>CPIC® Guideline for Clopidogrel and CYP2C19</source>. [12.10.2023]; Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/" ext-link-type="uri">https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/</ext-link>
</mixed-citation></ref><ref id="bcpt14095-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0007">
<string-name name-style="western">
<surname>Bosilkovska</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Samer</surname>
<given-names>CF</given-names>
</string-name>, <string-name name-style="western">
<surname>Déglon</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Geneva cocktail for cytochrome p450 and P‐glycoprotein activity assessment using dried blood spots</article-title>. <source>Clin Pharmacol Ther</source>. <year>2014</year>;<volume>96</volume>(<issue>3</issue>):<fpage>349</fpage>‐<lpage>359</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.2014.83</pub-id>
<pub-id pub-id-type="pmid">24722393</pub-id>
<pub-id pub-id-type="pmcid">PMC4151019</pub-id></mixed-citation></ref><ref id="bcpt14095-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0008">
<string-name name-style="western">
<surname>Derungs</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Donzelli</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Berger</surname>
<given-names>B</given-names>
</string-name>, <string-name name-style="western">
<surname>Noppen</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Krähenbühl</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Haschke</surname>
<given-names>M</given-names>
</string-name>. <article-title>Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the Basel cocktail: a randomized crossover study</article-title>. <source>Clin Pharmacokinet</source>. <year>2016</year>;<volume>55</volume>(<issue>1</issue>):<fpage>79</fpage>‐<lpage>91</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40262-015-0294-y</pub-id>
<pub-id pub-id-type="pmid">26123704</pub-id>
<pub-id pub-id-type="pmcid">PMC4712254</pub-id></mixed-citation></ref><ref id="bcpt14095-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0009">
<string-name name-style="western">
<surname>Frye</surname>
<given-names>RF</given-names>
</string-name>, <string-name name-style="western">
<surname>Matzke</surname>
<given-names>GR</given-names>
</string-name>, <string-name name-style="western">
<surname>Adedoyin</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Porter</surname>
<given-names>JA</given-names>
</string-name>, <string-name name-style="western">
<surname>Branch</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Validation of the five‐drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug‐metabolizing enzymes</article-title>. <source>Clin Pharmacol Ther</source>. <year>1997</year>;<volume>62</volume>(<issue>4</issue>):<fpage>365</fpage>‐<lpage>376</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0009-9236(97)90114-4</pub-id>
<pub-id pub-id-type="pmid">9357387</pub-id>
</mixed-citation></ref><ref id="bcpt14095-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0010">
<string-name name-style="western">
<surname>Desta</surname>
<given-names>Z</given-names>
</string-name>, <string-name name-style="western">
<surname>Zhao</surname>
<given-names>X</given-names>
</string-name>, <string-name name-style="western">
<surname>Shin</surname>
<given-names>JG</given-names>
</string-name>, <string-name name-style="western">
<surname>Flockhart</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Clinical significance of the cytochrome P450 2C19 genetic polymorphism</article-title>. <source>Clin Pharmacokinet</source>. <year>2002</year>;<volume>41</volume>(<issue>12</issue>):<fpage>913</fpage>‐<lpage>958</lpage>. doi:<pub-id pub-id-type="doi">10.2165/00003088-200241120-00002</pub-id>
<pub-id pub-id-type="pmid">12222994</pub-id>
</mixed-citation></ref><ref id="bcpt14095-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0011">
<string-name name-style="western">
<surname>Li</surname>
<given-names>XQ</given-names>
</string-name>, <string-name name-style="western">
<surname>Weidolf</surname>
<given-names>L</given-names>
</string-name>, <string-name name-style="western">
<surname>Simonsson</surname>
<given-names>R</given-names>
</string-name>, <string-name name-style="western">
<surname>Andersson</surname>
<given-names>TB</given-names>
</string-name>. <article-title>Enantiomer/enantiomer interactions between the S‐ and R‐ isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2005</year>;<volume>315</volume>(<issue>2</issue>):<fpage>777</fpage>‐<lpage>787</lpage>. doi:<pub-id pub-id-type="doi">10.1124/jpet.105.090928</pub-id>
<pub-id pub-id-type="pmid">16093273</pub-id>
</mixed-citation></ref><ref id="bcpt14095-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0012">
<string-name name-style="western">
<surname>Abelö</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Andersson</surname>
<given-names>TB</given-names>
</string-name>, <string-name name-style="western">
<surname>Antonsson</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Naudot</surname>
<given-names>AK</given-names>
</string-name>, <string-name name-style="western">
<surname>Skånberg</surname>
<given-names>I</given-names>
</string-name>, <string-name name-style="western">
<surname>Weidolf</surname>
<given-names>L</given-names>
</string-name>. <article-title>Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes</article-title>. <source>Drug Metab Dispos</source>. <year>2000</year>;<volume>28</volume>(<issue>8</issue>):<fpage>966</fpage>‐<lpage>972</lpage>.<pub-id pub-id-type="pmid">10901708</pub-id>
</mixed-citation></ref><ref id="bcpt14095-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0013">
<string-name name-style="western">
<surname>Tveden‐Nyborg</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western">
<surname>Bergmann</surname>
<given-names>TK</given-names>
</string-name>, <string-name name-style="western">
<surname>Jessen</surname>
<given-names>N</given-names>
</string-name>, <string-name name-style="western">
<surname>Simonsen</surname>
<given-names>U</given-names>
</string-name>, <string-name name-style="western">
<surname>Lykkesfeldt</surname>
<given-names>J</given-names>
</string-name>. <article-title>BCPT 2023 policy for experimental and clinical studies</article-title>. <source>Basic Clin Pharmacol Toxicol</source>. <year>2023</year>;<volume>133</volume>(<issue>4</issue>):<fpage>391</fpage>‐<lpage>396</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcpt.13944</pub-id>
<pub-id pub-id-type="pmid">37732406</pub-id>
</mixed-citation></ref><ref id="bcpt14095-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0014">
<string-name name-style="western">
<surname>Abouir</surname>
<given-names>K</given-names>
</string-name> et al. <article-title>Stereoselective separation of omeprazole and 5‐hydroxy‐omeprazole using dried plasma spots and a heart‐cutting 2D‐LC approach for accurate CYP2C19 phenotyping</article-title>. <source>J Chromatogr B</source>. <year>2023</year>;<elocation-id>123962</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jchromb.2023.123962</pub-id><pub-id pub-id-type="pmid">38096743</pub-id></mixed-citation></ref><ref id="bcpt14095-bib-0014"><label>14</label><mixed-citation publication-type="book" id="bcpt14095-cit-0016">
<collab collab-type="authors">EMA</collab>
. <source>Guideline on bioanalytical method validation</source>. <year>2009</year>. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf</ext-link>.</mixed-citation></ref><ref id="bcpt14095-bib-0015"><label>15</label><mixed-citation publication-type="book" id="bcpt14095-cit-0017">
<string-name name-style="western">
<given-names>David A.</given-names>
<surname>Flockhart</surname>
</string-name>, <source>Drug Interactions Flockhart Table</source> [12.10.2023]; Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://drug-interactions.medicine.iu.edu/MainTable.aspx" ext-link-type="uri">https://drug-interactions.medicine.iu.edu/MainTable.aspx</ext-link>
</mixed-citation></ref><ref id="bcpt14095-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0018">
<string-name name-style="western">
<surname>Kanebratt</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>Diczfalusy</surname>
<given-names>U</given-names>
</string-name>, <string-name name-style="western">
<surname>Bäckström</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4β‐hydroxycholesterol</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>84</volume>(<issue>5</issue>):<fpage>589</fpage>‐<lpage>594</lpage>. doi:<pub-id pub-id-type="doi">10.1038/clpt.2008.132</pub-id>
<pub-id pub-id-type="pmid">18650803</pub-id>
</mixed-citation></ref><ref id="bcpt14095-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0019">
<string-name name-style="western">
<surname>Sim</surname>
<given-names>SC</given-names>
</string-name>, <string-name name-style="western">
<surname>Risinger</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Dahl</surname>
<given-names>M‐L</given-names>
</string-name>, et al. <article-title>A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants</article-title>. <source>Clin Pharmacol Ther</source>. <year>2006</year>;<volume>79</volume>(<issue>1</issue>):<fpage>103</fpage>‐<lpage>113</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clpt.2005.10.002</pub-id>
<pub-id pub-id-type="pmid">16413245</pub-id>
</mixed-citation></ref><ref id="bcpt14095-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0020">
<string-name name-style="western">
<surname>Chang</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Dahl</surname>
<given-names>ML</given-names>
</string-name>, <string-name name-style="western">
<surname>Tybring</surname>
<given-names>G</given-names>
</string-name>, <string-name name-style="western">
<surname>Gotharson</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western">
<surname>Bertilsson</surname>
<given-names>L</given-names>
</string-name>. <article-title>Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S‐mephenytoin hydroxylation phenotype and CYP2C19 genotype</article-title>. <source>Pharmacogenet Genomics</source>. <year>1995</year>;<volume>5</volume>(<issue>6</issue>):<fpage>358</fpage>‐<lpage>363</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00008571-199512000-00004</pub-id>
<pub-id pub-id-type="pmid">8747407</pub-id></mixed-citation></ref><ref id="bcpt14095-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0021">
<string-name name-style="western">
<surname>Fernando de Andrés</surname>
<given-names>ST</given-names>
</string-name>, <string-name name-style="western">
<surname>Bovera</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Fariñas</surname>
<given-names>H</given-names>
</string-name>, <string-name name-style="western">
<surname>Terán</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western">
<surname>Llerena</surname>
<given-names>A</given-names>
</string-name>. <article-title>Multiplex phenotyping for systems medicine: a one‐point optimized practical sampling strategy for simultaneous estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 activities using a cocktail approach</article-title>. <source>OMICS: J Integr Biol</source>. <year>2016</year>;<volume>20</volume>(<issue>2</issue>):<fpage>88</fpage>‐<lpage>96</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/omi.2015.0131</pub-id><pub-id pub-id-type="pmid">26600202</pub-id></mixed-citation></ref><ref id="bcpt14095-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="bcpt14095-cit-0022">
<string-name name-style="western">
<surname>Vernaz</surname>
<given-names>N</given-names>
</string-name>, <string-name name-style="western">
<surname>Rollason</surname>
<given-names>V</given-names>
</string-name>, <string-name name-style="western">
<surname>Adlere</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines</article-title>. <source>Pharmacol Res Perspect</source>. <year>2016</year>;<volume>4</volume>(<issue>3</issue>):<elocation-id>e00234</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/prp2.234</pub-id>
<pub-id pub-id-type="pmid">27433344</pub-id>
<pub-id pub-id-type="pmcid">PMC4876144</pub-id></mixed-citation></ref></ref-list></back></article><article id="jvim17198" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">J Vet Intern Med</journal-id><journal-id journal-id-type="pmc-domain-id">2684</journal-id><journal-id journal-id-type="pmc-domain">jvim</journal-id><journal-id journal-id-type="publisher-id">JVIM</journal-id><journal-title-group><journal-title>Journal of Veterinary Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">0891-6640</issn><issn pub-type="epub">1939-1676</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11586560</article-id><article-id pub-id-type="pmcid-ver">PMC11586560.1</article-id><article-id pub-id-type="pmcaid">11586560</article-id><article-id pub-id-type="pmcaiid">11586560</article-id><article-id pub-id-type="pmid">39439219</article-id><article-id pub-id-type="doi">10.1111/jvim.17198</article-id><article-id pub-id-type="publisher-id">JVIM17198</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Standard Article</subject></subj-group><subj-group subj-group-type="heading"><subject>SMALL ANIMAL</subject><subj-group subj-group-type="heading"><subject>Standard Article</subject><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The effect of concurrent clopidogrel and omeprazole administration on clopidogrel metabolism and platelet function in healthy cats</article-title><alt-title alt-title-type="left-running-head">Plante et al.</alt-title></title-group><contrib-group><contrib id="jvim17198-cr-0001" contrib-type="author"><name name-style="western"><surname>Plante</surname><given-names initials="C">Christina</given-names></name><xref rid="jvim17198-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jvim17198-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Lee</surname><given-names initials="PM">Pamela M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6003-0496</contrib-id><xref rid="jvim17198-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>plee@vrcc.com</email></address></contrib><contrib id="jvim17198-cr-0003" contrib-type="author"><name name-style="western"><surname>Haines</surname><given-names initials="JM">Jillian M.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8066-838X</contrib-id><xref rid="jvim17198-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jvim17198-cr-0004" contrib-type="author"><name name-style="western"><surname>Nelson</surname><given-names initials="OL">O. Lynne</given-names></name><xref rid="jvim17198-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jvim17198-cr-0005" contrib-type="author"><name name-style="western"><surname>Martinez</surname><given-names initials="SE">Stephanie E.</given-names></name><xref rid="jvim17198-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jvim17198-cr-0006" contrib-type="author"><name name-style="western"><surname>Court</surname><given-names initials="MH">Michael H.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2122-9977</contrib-id><xref rid="jvim17198-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="jvim17198-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>University of Montreal</institution>
<city>Saint‐Hyacinthe</city>
<named-content content-type="country-part">Quebec</named-content>
<country country="CA">Canada</country>
</aff><aff id="jvim17198-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>VRCC Veterinary Specialty and Emergency Hospital</institution>
<city>Englewood</city>
<named-content content-type="country-part">Colorado</named-content>
<country country="US">USA</country>
</aff><aff id="jvim17198-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Washington State University</institution>
<city>Pullman</city>
<named-content content-type="country-part">Washington</named-content>
<country country="US">USA</country>
</aff><aff id="jvim17198-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Kansas State University</institution>
<city>Manhattan</city>
<named-content content-type="country-part">Kansas</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Pamela M. Lee, VRCC Veterinary Specialty and Emergency Hospital, 3550 S Jason St, Englewood, CO 80110, USA.<break/>
Email: <email>plee@vrcc.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><season>Nov-Dec</season><year>2024</year></pub-date><volume>38</volume><issue seq="270">6</issue><issue-id pub-id-type="pmc-issue-id">475687</issue-id><issue-id pub-id-type="doi">10.1111/jvim.v38.6</issue-id><fpage>3206</fpage><lpage>3214</lpage><history><date date-type="received"><day>20</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>05</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>26</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-26 00:25:44.637"><day>26</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2024 The Author(s). <italic toggle="yes">Journal of Veterinary Internal Medicine</italic> published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JVIM-38-3206.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JVIM-38-3206.pdf"/><abstract><title>Abstract</title><sec id="jvim17198-sec-0001"><title>Background</title><p>Some studies in humans show that the concurrent use of clopidogrel and omeprazole decreases plasma clopidogrel active metabolite (CAM) concentrations and clopidogrel antiplatelet effects. Whether this drug interaction occurs in cats is unknown.</p></sec><sec id="jvim17198-sec-0002"><title>Hypothesis</title><p>We hypothesized that administration of clopidogrel with omeprazole would decrease plasma CAM concentrations and decrease clopidogrel antiplatelet effects in healthy cats.</p></sec><sec id="jvim17198-sec-0003"><title>Animals</title><p>Ten domestic cats.</p></sec><sec id="jvim17198-sec-0004"><title>Methods</title><p>In this 2‐sequence, 2‐period, 2‐treatment randomized crossover study, healthy cats were randomly assigned to receive clopidogrel only (18.75 mg PO q24h) or clopidogrel with omeprazole (1 mg/kg PO q12h) for 10 days, followed by a 2‐week washout period, and then the opposite treatment for another 10 days. Blood was collected by jugular venipuncture on days 0, 5, and 10. Plasma CAM concentrations were measured using high‐performance liquid chromatography‐tandem mass spectrometry. Platelet function was evaluated using Plateletworks, Multiplate Analyzer, and Platelet Function Analyzer‐100 (PFA‐100).</p></sec><sec id="jvim17198-sec-0005"><title>Results</title><p>Multiplate Analyzer and PFA‐100 detected no difference in platelet function between days or treatment groups. Plateletworks detected a significant difference (<italic toggle="no">P</italic> &lt; .001) in platelet function from day 0 to 5 and day 0 to 10 in both treatment groups but no difference between treatment groups. Plasma CAM concentrations were significantly lower on day 10 (<italic toggle="no">P</italic> &lt; .02) in cats receiving both medications versus clopidogrel only.</p></sec><sec id="jvim17198-sec-0006"><title>Conclusions and Clinical Importance</title><p>Concurrent omeprazole and clopidogrel administration was associated with altered pharmacokinetics on day 10, but no difference in pharmacodynamics between the 2 treatment groups. The short‐term use of clopidogrel and omeprazole does not seem to alter platelet function significantly.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jvim17198-kwd-0001">clopidogrel active metabolite</kwd><kwd id="jvim17198-kwd-0002">Multiplate Analyzer</kwd><kwd id="jvim17198-kwd-0003">Platelet Function Analyzer‐100</kwd><kwd id="jvim17198-kwd-0004">Plateletworks</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>William R. Jones Endowment to Washington State University</funding-source></award-group><award-group id="funding-0002"><funding-source>Washington State University College of Veterinary Medicine Intramural Grant</funding-source><award-id>17A‐2530‐9847</award-id></award-group><award-group id="funding-0003"><funding-source>Washington State University Veterinary Clinical Sciences Resident Grant</funding-source><award-id>17A‐2530‐0177</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="9"/><word-count count="6700"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November/December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:25.11.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jvim17198-cit-9001">
<string-name name-style="western">
<surname>Plante</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Lee</surname>
<given-names>PM</given-names>
</string-name>, <string-name name-style="western">
<surname>Haines</surname>
<given-names>JM</given-names>
</string-name>, <string-name name-style="western">
<surname>Nelson</surname>
<given-names>OL</given-names>
</string-name>, <string-name name-style="western">
<surname>Martinez</surname>
<given-names>SE</given-names>
</string-name>, <string-name name-style="western">
<surname>Court</surname>
<given-names>MH</given-names>
</string-name>. <article-title>The effect of concurrent clopidogrel and omeprazole administration on clopidogrel metabolism and platelet function in healthy cats</article-title>. <source>J Vet Intern Med</source>. <year>2024</year>;<volume>38</volume>(<issue>6</issue>):<fpage>3206</fpage>‐<lpage>3214</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jvim.17198</pub-id>
<pub-id pub-id-type="pmcid">PMC11586560</pub-id><pub-id pub-id-type="pmid">39439219</pub-id></mixed-citation>
</p></notes></front><body id="jvim17198-body-0001"><def-list list-content="abbreviations" id="jvim17198-dl-0001"><title>Abbreviations</title><def-item><term id="jvim17198-li-0001">ADP</term><def id="jvim17198-li-0002"><p>adenosine diphosphate</p></def></def-item><def-item><term id="jvim17198-li-0003">ATE</term><def id="jvim17198-li-0004"><p>aortic thromboembolism</p></def></def-item><def-item><term id="jvim17198-li-0005">AUC</term><def id="jvim17198-li-0006"><p>area under the curve</p></def></def-item><def-item><term id="jvim17198-li-0007">BMAP</term><def id="jvim17198-li-0008"><p>2‐bromo‐3′ methoxyacetophenone</p></def></def-item><def-item><term id="jvim17198-li-0009">CAM</term><def id="jvim17198-li-0010"><p>clopidogrel active metabolite</p></def></def-item><def-item><term id="jvim17198-li-0011">CAM‐D</term><def id="jvim17198-li-0012"><p>derivatized clopidogrel active metabolite</p></def></def-item><def-item><term id="jvim17198-li-0013">CT</term><def id="jvim17198-li-0014"><p>closure time</p></def></def-item><def-item><term id="jvim17198-li-0015">CYP</term><def id="jvim17198-li-0016"><p>cytochrome P450</p></def></def-item><def-item><term id="jvim17198-li-0017">EDTA</term><def id="jvim17198-li-0018"><p>ethylenediaminetetraacetic acid</p></def></def-item><def-item><term id="jvim17198-li-0019">FeLV</term><def id="jvim17198-li-0020"><p>feline leukemia virus</p></def></def-item><def-item><term id="jvim17198-li-0021">FIV</term><def id="jvim17198-li-0022"><p>feline immunodeficiency virus</p></def></def-item><def-item><term id="jvim17198-li-0023">HPLC‐MS/MS</term><def id="jvim17198-li-0024"><p>high‐performance liquid chromatography with tandem mass spectrometry</p></def></def-item><def-item><term id="jvim17198-li-0025">LC‐MS/MS</term><def id="jvim17198-li-0026"><p>liquid chromatography with tandem mass spectrometry</p></def></def-item><def-item><term id="jvim17198-li-0027">PFA‐100</term><def id="jvim17198-li-0028"><p>Platelet Function Analyzer‐100</p></def></def-item></def-list><sec id="jvim17198-sec-0007"><label>1</label><title>INTRODUCTION</title><p>Aortic thromboembolism (ATE) is a well‐recognized complication of heart disease in cats. The REVEAL study showed that over one‐third of cats with hypertrophic cardiomyopathy will develop congestive heart failure, ATE, or both.<xref rid="jvim17198-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Mortality rates of cats with ATE are high, ranging from 61% to 67% depending on the study even with thrombolytic or thromboprophylaxis treatment.<xref rid="jvim17198-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jvim17198-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jvim17198-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="jvim17198-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jvim17198-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jvim17198-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jvim17198-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> As such, prevention of cardiogenic ATE in cats is crucial. Clopidogrel decreases the reoccurrence of ATE in cats with heart disease in comparison with aspirin.<xref rid="jvim17198-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Therefore, clopidogrel is the antiplatelet medication of choice in cats with cardiomyopathies.</p><p>Clopidogrel is a prodrug that is converted by hepatic esterases to an inactive clopidogrel carboxylic acid or by the hepatic cytochrome P450 (CYP) system to the clopidogrel active metabolite (CAM), which then irreversibly binds platelet P2Y<sub>12</sub> receptors to inhibit adenosine diphosphate (ADP)‐induced platelet aggregation.<xref rid="jvim17198-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Alterations in CYP enzymes may alter clopidogrel metabolism thereby resulting in changes in clopidogrel efficacy. In humans, polymorphisms of the gene encoding CYP 2C19 subfamily play a major role in determining clopidogrel efficacy resulting in low or high responders to clopidogrel.<xref rid="jvim17198-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jvim17198-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> A previous study identified single nucleotide polymorphisms in the feline CYP2C gene that partly explained individual differences in plasma CAM concentrations.<xref rid="jvim17198-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>In 1 study, approximately 47% of cats with hypertrophic cardiomyopathy had concurrent diseases.<xref rid="jvim17198-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> As such, many cats with heart disease will require additional medications. One such drug is omeprazole, a proton pump inhibitor used to treat gastric ulceration secondary to diseases such as neoplasia, inflammatory bowel disease, or hypereosinophilic syndrome.<xref rid="jvim17198-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jvim17198-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="jvim17198-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jvim17198-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> In humans, concern exists for the coadministration of clopidogrel with proton pump inhibitors<xref rid="jvim17198-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jvim17198-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> because omeprazole is an inhibitor of CYP2C19.<xref rid="jvim17198-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jvim17198-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Some studies in humans demonstrate that concurrent clopidogrel and omeprazole administration decreases plasma CAM concentrations, decreases clopidogrel antiplatelet effects, and increases the risk of major adverse cardiac events.<xref rid="jvim17198-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="jvim17198-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> However, some studies do not show an increase in adverse events with the concurrent use of omeprazole with clopidogrel.<xref rid="jvim17198-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jvim17198-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Despite this ongoing debate, the Food and Drug Administration warns against concomitant use of these 2 drugs.<xref rid="jvim17198-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</p><p>Whether this drug interaction occurs in cats is unknown. A study performed in healthy dogs demonstrated that clopidogrel plus omeprazole was associated with increased plasma clopidogrel carboxylic acid concentrations and no significant alteration in antiplatelet effects.<xref rid="jvim17198-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> No published validated assay to measure CAM was available in small animals at the time of the study. Since then, an assay to quantify CAM in feline plasma has been validated.<xref rid="jvim17198-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Our objective was to determine whether concurrent clopidogrel and omeprazole administration interferes with the metabolism and antiplatelet effects of clopidogrel in healthy cats. We hypothesized that concurrent clopidogrel and omeprazole use would alter clopidogrel metabolism, decrease plasma CAM concentrations, and decrease clopidogrel antiplatelet effects. Our specific aims were to evaluate the effects on clopidogrel metabolism by measuring clopidogrel parent, CAM, and clopidogrel carboxylic acid and to analyze antiplatelet effects.</p></sec><sec sec-type="materials-and-methods" id="jvim17198-sec-0008"><label>2</label><title>MATERIALS AND METHODS</title><sec id="jvim17198-sec-0009"><label>2.1</label><title>Study design</title><p>Our study was designed as a 2‐sequence, 2‐period, 2‐treatment randomized crossover study. Cats were randomized to receive either clopidogrel (Plavix, Bristol‐Myers Squibb/Sanofi Pharmaceuticals Partnership, Bridgewater, New Jersey, USA) or clopidogrel with omeprazole (omeprazole delayed release capsules; Lannett Company Inc., Philadelphia, Pennsylvania, USA) for 10 days followed by a minimum washout period of 14 days. After the washout period, the cats received the opposite treatment for 10 days. All cats were given clopidogrel at a dosage of 18.75 mg PO q24h.<xref rid="jvim17198-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jvim17198-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> To obtain 18.75 mg of active drug in each dose, the 75 mg clopidogrel tablets were weighed, crushed, divided by weight, and loaded into empty gelatin capsules. For omeprazole, all cats were given enteric‐coated omeprazole granules (1.1 mg omeprazole per granule) placed in gelatin capsules to achieve a dosage of 1 mg/kg PO q12h.<xref rid="jvim17198-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="jvim17198-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</p></sec><sec id="jvim17198-sec-0010"><label>2.2</label><title>Animals</title><p>The study protocol was approved by the Washington State University Institutional Animal Care and Use Committee. Healthy client‐owned cats were recruited through a volunteer, informed consent basis with a goal of enrolling 10 cats. Assuming a significance level of .05, a power of .90 to detect a baseline‐adjusted mean difference of 19.2 between treatment groups for percent aggregation measured by Plateletworks or for seconds measured by the Platelet Function Analyzer‐100 (PFA‐100) was calculated with a sample size of 8 cats per group. By obtaining 10 cats, a dropout or noncompliance of 1 cat per sequence would still allow adequate power. A baseline‐adjusted mean difference of 19.2 was selected based on the SD for Plateletworks and PFA‐100 calculated in a previous study utilizing these platelet function tests in cats receiving clopidogrel.<xref rid="jvim17198-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>Health status was determined by medical history, physical examination, CBC, biochemistry panel, urinalysis, feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) testing, and echocardiography. Total T4 concentration also was evaluated for cats &gt;8 years of age. All blood tests and urinalysis were performed by the Washington State University Clinical Pathology Laboratory. Echocardiograms were performed by 3 investigators (PML, OLN, and CP). Conventional 2D, M‐mode, and Doppler examinations were performed using an echocardiographic system and transducers ranging from 4 to 10 MHz. Cats were judged unhealthy and excluded from the study if they had a history of gastrointestinal signs, abnormal blood test results, abnormal echocardiogram, or if they were FIV or FeLV positive or both. Cats also were excluded if they were receiving medications other than flea, tick, and parasite preventatives or if their temperaments were not amendable to multiple blood collections.</p><p>To ensure safety from multiple blood collections, only cats weighing &gt;4.0 kg lean body weight were recruited. All cats were weighed at the beginning and end of the study to allow for weight normalization of pharmacokinetic data.</p></sec><sec id="jvim17198-sec-0011"><label>2.3</label><title>Blood sample collection</title><p>Blood was collected by jugular venipuncture before treatment (day 0) and 2 hours post medication administration on days 5 and 10 of treatment for packed cell volume, total protein concentration, platelet function analysis as well as plasma clopidogrel, CAM, clopidogrel carboxylic acid, and omeprazole concentrations.</p><p>To confirm medication administration at home, medication diaries were completed by owners and pill counts were performed before each blood collection. On sample collection days, cats were fasted for at least 8 hours to minimize possible effects of food on drug absorption. Treatments were given in hospital to ensure administration and to coordinate the 2 hours post‐treatment blood collection.</p><p>Jugular venipuncture was performed using a 21‐gauge × ¾ inch butterfly needle connected to a 12 mL syringe. The blood was aliquoted into different tubes in the following order: 1 mL in 2‐bromo‐3′ methoxyacetophenone (BMAP) with ethylenediaminetetraacetic acid (EDTA) tube, 1 mL in Plateletworks ADP agonist tube, 1 mL in Plateletworks EDTA tube, 2 mL in citrate tube, and 1.6 mL in hirudin tube. Blood was added to the BMAP EDTA tubes first because CAM is unstable. The addition of BMAP allows formation of a derivatized CAM (CAM‐D) that is then stable for later quantification.<xref rid="jvim17198-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> All blood samples for clopidogrel and omeprazole drug and metabolite quantification were centrifuged, and the plasma was stored at −80°C until assay. After jugular venipuncture, a neck wrap was placed and monitored for at least 20 minutes to minimize the risk of bleeding. A maximum of 7 mL of blood was collected from each cat at each visit.</p></sec><sec id="jvim17198-sec-0012"><label>2.4</label><title>Platelet function testing</title><sec id="jvim17198-sec-0013"><label>2.4.1</label><title>Platelet Function Analyzer‐100</title><p>The 2 mL samples of blood collected into the citrate tube were analyzed using the PFA‐100 (Dade Behring Inc., Newark, New Jersey, USA). Pending sample analysis, the citrated tubes were gently rocked continuously. Samples were processed as previously described.<xref rid="jvim17198-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="jvim17198-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Collagen‐ADP cartridges were used. For each cat at each time point, 2 analyses were performed sequentially, and closure times (CTs) were averaged. Because the PFA‐100 has an upper limit of 300 seconds, any samples that were measured as &gt;300 seconds were assigned a value of 300 seconds for analysis. All samples were analyzed within 1 hour of blood collection.</p></sec><sec id="jvim17198-sec-0014"><label>2.4.2</label><title>Multiplate Analyzer</title><p>The 1.6 mL samples of blood collected into hirudin blood tubes were analyzed using the Multiplate Analyzer (Diapharma Group Inc., West Chester, Ohio, USA). Samples were processed as previously described.<xref rid="jvim17198-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> A volume of 20 μL of ADPtest reagent (Diapharma Group Inc.) was added to 300 μL of whole blood to create a working concentration of 6.5 μM ADP. One test cell per time point with ADP agonist was used because each test cell performs assays in duplicate. Samples were analyzed within 2 hours of blood sample collection.</p></sec><sec id="jvim17198-sec-0015"><label>2.4.3</label><title>Plateletworks</title><p>The 1 mL samples of blood collected into EDTA blood tubes and the 1 mL samples of blood collected into ADP agonist blood tubes were used for Plateletworks (Helena Laboratories, Beaumont, Texas, USA). Platelet counts were obtained from each blood tube using flow cytometry by the Washington State University Clinical Pathology Advia machine (Advia 120 Hematology System, Siemens Healthinners, Erlangen, Germany) within 10 minutes of blood collection. Samples were processed as previously prescribed.<xref rid="jvim17198-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="jvim17198-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="jvim17198-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="jvim17198-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Platelet aggregation was assessed using the following formula:<disp-formula id="jvim17198-disp-0001">
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="jats-math-1" display="block" overflow="scroll"><mml:mrow><mml:mfenced open="(" close=")"><mml:mfrac><mml:mrow><mml:mtext>EDTA platelet count</mml:mtext><mml:mo>−</mml:mo><mml:mi>ADP</mml:mi><mml:mspace width="0.25em"/><mml:mtext>platelet count</mml:mtext></mml:mrow><mml:mtext>EDTA platelet count</mml:mtext></mml:mfrac></mml:mfenced><mml:mo linebreak="goodbreak">×</mml:mo><mml:mn>100</mml:mn><mml:mo linebreak="goodbreak">=</mml:mo><mml:mo>%</mml:mo><mml:mspace width="0.5em"/><mml:mtext>aggregation</mml:mtext></mml:mrow></mml:math>
</disp-formula>
</p></sec></sec><sec id="jvim17198-sec-0016"><label>2.5</label><title>Drug and metabolite concentrations</title><p>The 1‐mL samples of blood collected into tubes with BMAP with EDTA were utilized for measurement of plasma clopidogrel, CAM‐D, clopidogrel carboxylic acid, omeprazole, and omeprazole metabolite concentrations. Clopidogrel, CAM‐D, and clopidogrel carboxylic acid were quantified using high‐performance liquid chromatography with tandem mass spectrometry as previously described.<xref rid="jvim17198-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jvim17198-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>For confirmation of owner compliance, plasma omeprazole and omeprazole metabolite concentrations also were determined by liquid chromatography with tandem mass spectrometry (LC‐MS/MS) as previously described with modifications.<xref rid="jvim17198-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Twenty‐five microliter aliquots of plasma were mixed with 75 μL of −20°C internal standard solution (100 ng/mL pantoprazole in methanol), vortex mixed for approximately 10 seconds and allowed to stand for 10 minutes at 4°C, then centrifuged at 150 000 g for 10 minutes at 4°C. Supernatants were transferred into clean microcentrifuge tubes and centrifuged again at 15 000 g for 10 minutes at 4°C. Supernatants were added to a 96‐well polypropylene plate containing 100 μL of water per well and injected into the LC‐MS/MS system. Data were acquired using multiple reaction monitoring of mass transition pairs at <italic toggle="yes">m/</italic>z 346.2/198.2 for omeprazole, <italic toggle="yes">m/</italic>z 362.0/214.0 for 5‐hydroxy omeprazole, <italic toggle="yes">m/</italic>z 362.0/150.1 for omeprazole sulfone, and <italic toggle="yes">m/z</italic> 384.2/200.1 for the internal standard (pantoprazole). Quantification of omeprazole and metabolites was based on calibration curves (1‐1000 ng/mL for omeprazole and 5‐hydroxy omeprazole and 1‐500 ng/mL for omeprazole sulfone) constructed using the peak area ratios of the analyte of interest to the internal standard against the analyte concentrations using 1/x weighted least squares linear regression.</p></sec><sec id="jvim17198-sec-0017"><label>2.6</label><title>Statistical analysis</title><p>All data analyses were performed using SigmaPlot 13 software (Systat Software Inc., San Jose, California, USA). For between‐day comparisons within a treatment group, Kruskal‐Wallis 1‐way analysis of variance (ANOVA) on ranks was used. If the ANOVA was significant (<italic toggle="yes">P</italic> &lt; .05) then a multiple comparisons test (Tukey test) was performed. For comparisons between treatment groups within the same day, normality of data distribution was tested using the Shapiro‐Wilk test. Normally distributed data were analyzed using paired <italic toggle="yes">t</italic> test and nonnormally distributed data were analyzed using Wilcoxon signed‐rank test. A <italic toggle="yes">P</italic>‐value of &lt; .05 was deemed statistically significant.</p></sec></sec><sec sec-type="results" id="jvim17198-sec-0018"><label>3</label><title>RESULTS</title><sec id="jvim17198-sec-0019"><label>3.1</label><title>Animals</title><p>Twenty‐five cats were screened to enroll 10 cats that met the inclusion criteria of apparently healthy based on history, physical examination, normal laboratory test results, normal echocardiogram, appropriate temperament, and adequate body weight. The 10 cats consisted of 9 domestic mixed breed cats and 1 Siamese mixed breed cat. Eight cats were castrated males and 2 cats were spayed females. Median age was 4 years (range, 2‐9 years) with a median weight of 5.1 kg (range 4.0‐7.0 kg). Only 1 cat had to be sedated because of mildly aggressive temperament. Gabapentin (Method Pharmaceuticals, LLC, Arlington, Texas, USA) 150 mg PO 2 hours before blood collection was used before each blood collection for cat #16.</p></sec><sec id="jvim17198-sec-0020"><label>3.2</label><title>Platelet function testing</title><sec id="jvim17198-sec-0021"><label>3.2.1</label><title>Platelet Function Analyzer‐100</title><p>For the clopidogrel‐only group, median CTs for days 0, 5, and 10 were 74.5 seconds (range, 52‐179 seconds), 107 seconds (range, 63‐205 seconds), and 125 seconds (range, 66‐300 seconds), respectively. For the clopidogrel with omeprazole group, median CT on days 0, 5, and 10 were 95.5 seconds (range, 62‐159 seconds), 109 seconds (range, 67‐300 seconds), and 85 seconds (range, 76‐208 seconds), respectively. No significant difference in platelet function was identified between days within each treatment group (<italic toggle="yes">P</italic> &gt; .05; ANOVA on ranks), or between treatment groups on each day (<italic toggle="yes">P</italic> &gt; .05; Wilcoxon signed‐rank test; Figure <xref rid="jvim17198-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="jvim17198-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Platelet Function Analyzer‐100 (PFA‐100) closure times in seconds in cats treated with clopidogrel only (C only) or concurrent clopidogrel with omeprazole (C + O). The box and whisker plots demonstrate the median (line), interquartile range (box), and total range (whiskers). Outliers are represented by points outside of the whiskers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JVIM-38-3206-g002.jpg"/></fig></sec><sec id="jvim17198-sec-0022"><label>3.2.2</label><title>Multiplate Analyzer</title><p>For the clopidogrel‐only group, the median areas under the curve (AUC) on days 0, 5, and 10 were 311 U (range, 55‐426 U), 286 U (range, 144‐603 U), and 240 U (range, 155‐380 U), respectively. For the clopidogrel with omeprazole group, the median AUC on days 0, 5, and 10 were 190 U (range, 7‐522 U), 318 U (range, 117‐394 U), and 295 U (range, 92‐493 U), respectively. No significant difference in platelet function was identified between days within each treatment group (<italic toggle="yes">P</italic> &gt; .05; ANOVA on ranks), or between treatment groups on each treatment day (<italic toggle="yes">P</italic> &gt; .05; Wilcoxon signed‐rank test; Figure <xref rid="jvim17198-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="FIGURE" id="jvim17198-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Multiplate analyzer using adenosine diphosphate agonist results showing area under the curve in cats treated with clopidogrel only (C only) or concurrent clopidogrel with omeprazole (C + O). The box and whisker plots demonstrate the median (line), interquartile range (box), and total range (whiskers). Outliers are represented by points outside of the whiskers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="JVIM-38-3206-g004.jpg"/></fig></sec><sec id="jvim17198-sec-0023"><label>3.2.3</label><title>Plateletworks</title><p>For the clopidogrel‐only group, median percent aggregations on days 0, 5, and 10 were 95.5% (range, 57%‐98%), −17% (range, −29% to 2%), and −9% (range, −45% to 3%), respectively. For the clopidogrel with omeprazole group, median percent aggregations on days 0, 5, and 10 were 97% (range, 88%‐99%), −12.5% (range, −26% to −2%), and −14% (range, −26% to 1%), respectively. When comparing between treatment days, a significant decrease (<italic toggle="yes">P</italic> &lt; .001; ANOVA on ranks) in platelet aggregation was identified when comparing day 0 to day 5 (<italic toggle="yes">P</italic> &lt; .001; Tukey test) and day 0 to day 10 (<italic toggle="yes">P</italic> &lt; .001; Tukey test) in both treatment groups. However, no significant difference (<italic toggle="yes">P</italic> &gt; .05; Wilcoxon signed‐rank test) was identified in platelet function between the 2 treatment groups on any treatment day (Figure <xref rid="jvim17198-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="jvim17198-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Percent aggregation determined by Plateletworks in cats treated with clopidogrel only (C only) or concurrent clopidogrel and omeprazole (C + O). The box and whiskers plot demonstrate the median (line), interquartile range (box), and total range (whiskers). Outliers are represented by points outside the whiskers. * and ** are statistically different from concentrations on day 0 for C and C + O, respectively (<italic toggle="yes">P</italic> &lt; 0.05).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="JVIM-38-3206-g003.jpg"/></fig></sec></sec><sec id="jvim17198-sec-0024"><label>3.3</label><title>Drug and metabolite concentrations</title><p>Omeprazole and omeprazole metabolite concentrations were 0 ng/mL for all time points in cats receiving clopidogrel only and for day 0 in all cats receiving clopidogrel and omeprazole. The days 5 and 10 plasma concentrations for omeprazole, omeprazole sulfone, and 5‐hydroxomeprazole for cats receiving both clopidogrel and omeprazole are shown in Table <xref rid="jvim17198-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="jvim17198-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Plasma concentrations of omeprazole, omeprazole sulfone, and 5‐hydroxomeprzole in cats receiving clopidogrel and omeprazole on day 5 and day 10 of treatment. Values are expressed as median and range.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Day</th><th align="left" valign="bottom" rowspan="1" colspan="1">Omeprazole (ng/mL)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Omeprazole sulfone (ng/mL)</th><th align="left" valign="bottom" rowspan="1" colspan="1">5‐hydroxomeprazole (ng/mL)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">84 (0‐362)</td><td align="left" valign="top" rowspan="1" colspan="1">176 (7‐387)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (0‐74)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">22 (0‐777)</td><td align="left" valign="top" rowspan="1" colspan="1">46 (15‐506)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (0‐122)</td></tr></tbody></table></table-wrap><p>The day 0 CAM‐D, clopidogrel parent, and clopidogrel carboxylic acid plasma concentrations were 0 ng/mL for all cats in both treatment groups. The plasma concentrations of CAM‐D, clopidogrel parent, and clopidogrel carboxylic acid on days 5 and 10 for both treatment groups are presented in Table <xref rid="jvim17198-tbl-0002" ref-type="table">2</xref>. No significant difference was identified in plasma CAM‐D concentrations between days 5 and 10 within each treatment group (<italic toggle="yes">P</italic> &gt; .05; paired <italic toggle="yes">t</italic> test). The CAM‐D concentrations also were not significantly different (<italic toggle="yes">P</italic> &gt; .05; paired <italic toggle="yes">t</italic> test) between treatment groups on day 5 (Figure <xref rid="jvim17198-fig-0004" ref-type="fig">4</xref>). However, as shown in Figure <xref rid="jvim17198-fig-0004" ref-type="fig">4</xref>, significantly lower CAM‐D concentrations were found on day 10 for the clopidogrel with omeprazole group in comparison with the clopidogrel‐only group (<italic toggle="yes">P</italic> = .02; paired <italic toggle="yes">t</italic> test). No significant differences were identified in plasma clopidogrel concentrations between days 5 and 10 for each treatment group or between treatment groups on each treatment day (<italic toggle="yes">P</italic> &gt; .05; paired <italic toggle="yes">t</italic> test). Furthermore, no significant difference was found in plasma clopidogrel carboxylic acid concentrations between days 5 and 10 within each treatment group (<italic toggle="yes">P</italic> &gt; .05; paired <italic toggle="yes">t</italic> test). Clopidogrel carboxylic acid concentrations also were not significantly different between treatment groups on day 5 (<italic toggle="yes">P</italic> &gt; .05; paired <italic toggle="yes">t</italic> test). However, a significantly lower clopidogrel carboxylic acid concentration was found on day 10 in the clopidogrel with the omeprazole group when compared with the clopidogrel‐only group (<italic toggle="yes">P</italic> &lt; .001).</p><table-wrap position="float" id="jvim17198-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Plasma concentrations of the derivatized clopidogrel active metabolite (CAM‐D), clopidogrel parent, and clopidogrel carboxylic acid on days 5 and 10 in cats receiving either clopidogrel alone (C only) or concurrent clopidogrel and omeprazole (C + O).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" align="left" valign="bottom" colspan="1">Day</th><th colspan="2" align="left" valign="bottom" rowspan="1">CAM‐D (ng/mL)</th><th colspan="2" align="left" valign="bottom" rowspan="1">Clopidogrel parent (ng/mL)</th><th colspan="2" align="left" valign="bottom" rowspan="1">Clopidogrel carboxylic acid (ng/mL)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">C only</th><th align="left" valign="bottom" rowspan="1" colspan="1">C + O</th><th align="left" valign="bottom" rowspan="1" colspan="1">C only</th><th align="left" valign="bottom" rowspan="1" colspan="1">C + O</th><th align="left" valign="bottom" rowspan="1" colspan="1">C only</th><th align="left" valign="bottom" rowspan="1" colspan="1">C + O</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">29.7 (6‐117)</td><td align="left" valign="top" rowspan="1" colspan="1">8.8 (0‐82)</td><td align="left" valign="top" rowspan="1" colspan="1">82 (8‐251)</td><td align="left" valign="top" rowspan="1" colspan="1">40 (0‐266)</td><td align="left" valign="top" rowspan="1" colspan="1">3343 (1195‐8615)</td><td align="left" valign="top" rowspan="1" colspan="1">2230 (557‐9735)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">29.8 (5‐119)</td><td align="left" valign="top" rowspan="1" colspan="1">9.3<xref rid="jvim17198-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref> (3–37)</td><td align="left" valign="top" rowspan="1" colspan="1">88 (4‐271)</td><td align="left" valign="top" rowspan="1" colspan="1">43 (9‐213)</td><td align="left" valign="top" rowspan="1" colspan="1">4228 (2240‐6150)</td><td align="left" valign="top" rowspan="1" colspan="1">2148<xref rid="jvim17198-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref> (405‐4360)</td></tr></tbody></table><table-wrap-foot id="jvim17198-ntgp-0001"><fn id="jvim17198-note-0001"><p>
<italic toggle="yes">Note</italic>: Values are expressed as median and range.</p></fn><fn id="jvim17198-note-0002"><label>
<sup>a</sup>
</label><p>Significantly lower plasma CAM‐D concentrations in comparison to plasma CAM‐D concentrations on day 10 in cats receiving clopidogrel only.</p></fn><fn id="jvim17198-note-0003"><label>
<sup>b</sup>
</label><p>Significantly lower plasma clopidogrel carboxylic acid concentrations in comparison to plasma clopidogrel carboxylic acid concentrations on day 10 in cats receiving clopidogrel only.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="jvim17198-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Clopidogrel active metabolite derivatized (CAM‐D) plasma concentrations measured in 10 cats on day 5 and day 10 after starting daily treatment with clopidogrel only (C only) or with concurrent clopidogrel with omeprazole (C + O). Each cat received both treatments in a randomized cross‐over design with at least 2 weeks of washout between treatments. Filled circles represent CAM‐D concentrations for individual cats with connecting lines indicating the differences between treatments. Significantly lower CAM‐D concentrations were observed with C + O treatment compared with C‐only treatment on day 10 (<italic toggle="yes">P</italic> = 0.02; paired <italic toggle="yes">t</italic> test) but not on day 5 (<italic toggle="yes">P</italic> &gt; 0.05).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="JVIM-38-3206-g001.jpg"/></fig></sec></sec><sec sec-type="discussion" id="jvim17198-sec-0025"><label>4</label><title>DISCUSSION</title><p>All cats completed both periods of the study and the washout period was appropriate based on finding no detectable plasma drug concentrations at blood sampling before treatment (day 0). Our results show that the concurrent use of clopidogrel and omeprazole led to decreased plasma CAM‐D concentrations at day 10. However, a decrease in platelet function as measured by PFA‐100, Multiplate Analyzer, and Plateletworks was not identified.</p><p>In cats, a gold standard test for evaluating platelet function does not exist. As such, 3 different platelet function tests were used in our study. Another study in cats used the same 3 platelet function tests and found a difference in platelet function in cats receiving clopidogrel with both PFA‐100 and Plateletworks, but not with the Multiplate.<xref rid="jvim17198-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> In our study, of the 3 platelet function tests, only Plateletworks identified a difference in platelet function between treatment days. Another study using the Multiplate to evaluate platelet function in cats with heart disease receiving clopidogrel did identify a difference.<xref rid="jvim17198-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> These differences in results may be a consequence of differences in sample preparation and handling and suggest that the Multiplate may not be the best option for monitoring the effects of clopidogrel in cats until sample handling is further investigated and standardized.</p><p>The PFA‐100 also has been shown to variably detect changes in platelet function in cats receiving clopidogrel.<xref rid="jvim17198-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="jvim17198-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> As a result, the PFA‐100 may not be sensitive enough to consistently evaluate platelet function in cats receiving clopidogrel. The PFA‐200 system (not available in the USA) allows for more sensitive and specific evaluation of P2Y12 receptor blockade caused by clopidogrel.<xref rid="jvim17198-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> The P2Y cartridge for the PFA‐200 could have detected changes in our study that were not seen with the PFA‐100.</p><p>In our study, although Plateletworks detected a decrease in platelet function from day 0 to day 5 and from day 0 to day 10, no difference was identified between treatment groups despite having 66% lower median plasma CAM‐D concentrations on day 10 in the clopidogrel with omeprazole group (median, 9.3 ng/mL; range, 3‐37 ng/mL) compared with the clopidogrel only group (median, 29.8 ng/mL; range, 5‐119 ng/mL). This discrepancy between pharmacodynamic and pharmacokinetic results may be a result of lack of sensitivity of Plateletworks to detect small changes in platelet function. Alternatively, it is possible that the lower plasma CAM‐D concentrations observed in the omeprazole‐treated cats still exceeded concentrations needed to achieve maximal inhibition of platelet function.</p><p>Other potential causes for differences in findings between modalities could relate to the anticoagulant type used for each and the differences in ADP concentration. Given the higher potential for spontaneous aggregation to occur in citrated anticoagulated blood and the improved aggregation responses seen in hirudin anticoagulated blood found in Multiplate optimization studies in dogs, hirudin is considered the most appropriate option when assessing platelet function using the Multiplate.<xref rid="jvim17198-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="jvim17198-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="jvim17198-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Optimization studies assessing anticoagulant choice in cats using the PFA‐100 have not been performed. Previous studies in cats that have utilized the PFA‐100 for determining reference ranges and testing clopidogrel effects have utilized citrated blood.<xref rid="jvim17198-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="jvim17198-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="jvim17198-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> For these reasons, citrate anticoagulated blood also was used for our study. Plateletworks agonist tubes also contain citrate anticoagulant.<xref rid="jvim17198-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="jvim17198-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Additionally, Plateletworks and the PFA‐100 have predetermined ADP concentrations that vary with each other as well as with the concentration used in the Multiplate in our study. These concentration variations also could have contributed to modality differences in our results.</p><p>Our study was performed in healthy cats with no evidence of heart disease. Cats with hypertrophic cardiomyopathy have been shown to have increased platelet activation.<xref rid="jvim17198-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> It is not known if the decrease in plasma CAM‐D concentrations identified in the combined clopidogrel and omeprazole group could have a more clinically relevant effect on platelet function in diseased cats. As such, concurrent clopidogrel and omeprazole should be used with caution in cats with heart disease. Prospective studies are needed to elucidate the degree of risk associated with combined clopidogrel and omeprazole treatment in a diseased population of cats. Genetic polymorphism for P2RY<sub>1</sub> in cats also could alter the risk of ATE in cats with heart disease. A recent study found that cats with genetic polymorphism in the P2RY<sub>1</sub> gene had an altered response to clopidogrel treatment resulting in decreased platelet inhibition. The use of combined clopidogrel and omeprazole in cats with P2RY<sub>1</sub> polymorphisms could cause further decreased efficacy of clopidogrel. As mentioned, studies in the human medical literature are contradictory regarding how omeprazole influences clopidogrel treatment. Even in very recent studies, authors mention that this topic warrants better randomized trials.<xref rid="jvim17198-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> These drug interactions are complex and are likely the combination of many different interactions. By having more information on these interactions in cats, we may be able to eventually target which cats are more at risk of having this drug interaction, making way for better individualized medicine.</p><p>Lower CAM‐D concentrations on day 10 in the clopidogrel with omeprazole group suggest that omeprazole alters the metabolism of clopidogrel. Only 1 other veterinary study has evaluated the effect of concurrent omeprazole with clopidogrel on platelet function.<xref rid="jvim17198-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> This study was performed in healthy dogs and also showed no difference in platelet function between treatment groups. The CAM concentrations were not evaluated, but an increase in the inactive clopidogrel carboxylic acid concentration was detected in dogs receiving clopidogrel with omeprazole. Our study showed the opposite in cats. On day 10, our cats had significantly lower concentrations of clopidogrel carboxylic acid in the clopidogrel with omeprazole group. The reasons for this effect of omeprazole and the difference in effect between species is unclear but may involve changes in clopidogrel carboxylic acid formation or clearance. Clopidogrel carboxylic acid is further metabolized by glucuronidation to clopidogrel acyl‐β‐D‐glucuronide, which is found in human plasma at concentrations approximating 10% that of the parent metabolite (PMID: 21656175). Consequently, measurement of clopidogrel acyl‐β‐D‐glucuronide concentrations in dog and cat plasma might help elucidate the mechanism underlying the effect of omeprazole on clopidogrel carboxylic acid concentrations.</p><p>In some humans at high risk of reinfarction where the combination of using clopidogrel and omeprazole with the potential decrease in antiplatelet effect cannot be risked, other proton‐pump inhibitors can be used. Indeed, not all proton‐pump inhibitors have been shown to alter clopidogrel metabolism. Drugs such as pantoprazole and lansoprazole do not seem to affect platelet function in humans treated with clopidogrel.<xref rid="jvim17198-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="jvim17198-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> In cats, not many studies have been done to evaluate the efficacy of other proton‐pump inhibitors. Pantoprazole could be an alternative to omeprazole in cats judged to be at higher risk of ATE in cats already receiving clopidogrel. However, currently, no studies have evaluated the pharmacodynamics or pharmacokinetics of PO pantoprazole.</p><p>In humans, many other drugs have been shown to interact with clopidogrel metabolism.<xref rid="jvim17198-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Amlodipine and diltiazem are among those drugs that could potentially decrease antiplatelet function in humans receiving clopidogrel. These medications are used for treating, respectively, systemic hypertension and some supraventricular arrhythmias in cats, which could be comorbidities in cats with hypertrophic cardiomyopathy. Whether these drug interaction occurs in cats is not known and additional studies would be helpful to determine if a risk is present in cats receiving those medications and clopidogrel.</p><p>Our study had several limitations. It was performed in healthy cats. Whether these results can be extended to cats with disorders of thrombosis is unclear. Our sample size was small with a total of 10 cats enrolled. Although a significant difference was observed between the CAM‐D and clopidogrel carboxylic acid concentrations in the different treatment groups on day 10, a larger sample size may show a statistical difference for CAM‐D and clopidogrel carboxylic acid concentrations at day 5. However, it is also possible that a larger sample size may not identify a difference between groups at day 5. Our study period for each treatment group was only 10 days. This data may not reflect more chronic concurrent administration of clopidogrel and omeprazole. One of the cats in our study received gabapentin before each blood collection. Some studies in humans have shown that gabapentin can affect platelet function.<xref rid="jvim17198-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="jvim17198-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> However, several studies in cats have not identified this interaction.<xref rid="jvim17198-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="jvim17198-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="jvim17198-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Although no studies have been published that evaluate the effects of platelet function with the combination of gabapentin, omeprazole, and clopidogrel, the use of gabapentin is unlikely to have affected our results, especially because only 1 cat received this combination of medications. Given the baseline aggregation variability seen with the Multiplate Analyzer in cats in our study as well as others, the Multiplate may not be the best instrument to evaluate platelet function in cats.<xref rid="jvim17198-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> The variability of the Multiplate also may have affected the statistical result of our study.</p><p>In summary, short‐term administration of clopidogrel with omeprazole in healthy cats resulted in a pharmacokinetic interaction by altering clopidogrel metabolism. However, a corresponding pharmacodynamic interaction in platelet function as measured by PFA‐100, Multiplate Analyzer, and Plateletworks was not appreciated. Importantly, whether this drug interaction is present in a diseased population of cats is unclear. Additional prospective studies are needed to help establish guidelines for the concurrent use of clopidogrel and omeprazole in cats with cardiomyopathies and other comorbidities.</p></sec><sec sec-type="COI-statement" id="jvim17198-sec-0027"><title>CONFLICT OF INTEREST DECLARATION</title><p>Authors declare no conflict of interest.</p></sec><sec id="jvim17198-sec-0028"><title>OFF‐LABEL ANTIMICROBIAL DECLARATION</title><p>Authors declare no off‐label use of antimicrobials.</p></sec><sec id="jvim17198-sec-0029"><title>INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION</title><p>Approved by the Washington State University IACUC.</p></sec><sec id="jvim17198-sec-0030"><title>HUMAN ETHICS APPROVAL DECLARATION</title><p>Authors declare human ethics approval was not needed for this study.</p></sec></body><back><ack id="jvim17198-sec-0026"><title>ACKNOWLEDGMENTS</title><p>This study was funded in part by the Washington State University Veterinary Clinical Sciences Resident Grant, ID# 17A‐2530‐0177, the Washington State University College of Veterinary Medicine Intramural Grant ID# 17A‐2530‐9847, and the William R. Jones Endowment to Washington State University. The authors thank veterinary technician Raychel Fairchild for her assistance with animal handling, veterinary technician Rebecca Connors for her assistance with genotyping, and laboratory technician Zhaohui Zhu with sample processing.</p></ack><ref-list id="jvim17198-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="jvim17198-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jvim17198-cit-0001">
<string-name name-style="western">
<surname>Fox</surname>
<given-names>PR</given-names>
</string-name>, <string-name name-style="western">
<surname>Keene</surname>
<given-names>BW</given-names>
</string-name>, <string-name name-style="western">
<surname>Lamb</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>International collaborative study to assess cardiovascular risk and evaluate long‐term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: the REVEAL study</article-title>. <source>J Vet Intern Med</source>. <year>2018</year>;<volume>32</volume>:<fpage>930</fpage>‐<lpage>943</lpage>.<pub-id pub-id-type="pmid">29660848</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvim.15122</pub-id><pub-id pub-id-type="pmcid">PMC5980443</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jvim17198-cit-0002">
<string-name name-style="western">
<surname>Laste</surname>
<given-names>NJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Harpster</surname>
<given-names>NK</given-names>
</string-name>. <article-title>A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977‐1993</article-title>. <source>J Am Anim Hosp Assoc</source>. <year>1995</year>;<volume>31</volume>:<fpage>492</fpage>‐<lpage>500</lpage>.<pub-id pub-id-type="pmid">8581544</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.5326/15473317-31-6-492</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jvim17198-cit-0003">
<string-name name-style="western">
<surname>E. Moore</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>Morris</surname>
<given-names>N</given-names>
</string-name>, <string-name name-style="western">
<surname>Dhupa</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Retrospective study of streptokinase administration in 46 cats with arterial thromboembolism</article-title>. <source>J Vet Emerg Crit Care</source>. <year>2000</year>;<volume>10</volume>:<fpage>245</fpage>‐<lpage>257</lpage>.</mixed-citation></ref><ref id="jvim17198-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jvim17198-cit-0004">
<string-name name-style="western">
<surname>Schoeman</surname>
<given-names>JP</given-names>
</string-name>. <article-title>Feline distal aortic thromboembolism: a review of 44 cases (1990‐1998)</article-title>. <source>J Feline Med Surg</source>. <year>1999</year>;<volume>1</volume>:<fpage>221</fpage>‐<lpage>231</lpage>.<pub-id pub-id-type="pmid">11714239</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/jfms.1999.0049</pub-id><pub-id pub-id-type="pmcid">PMC10822380</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jvim17198-cit-0005">
<string-name name-style="western">
<surname>Smith</surname>
<given-names>SA</given-names>
</string-name>, <string-name name-style="western">
<surname>Tobias</surname>
<given-names>AH</given-names>
</string-name>, <string-name name-style="western">
<surname>Jacob</surname>
<given-names>KA</given-names>
</string-name>, <string-name name-style="western">
<surname>Fine</surname>
<given-names>DM</given-names>
</string-name>, <string-name name-style="western">
<surname>Grumbles</surname>
<given-names>PL</given-names>
</string-name>. <article-title>Arterial thromboembolism in cats: acute crisis in 127 cases (1992‐2001) and long‐term management with low‐dose aspirin in 24 cases</article-title>. <source>J Vet Intern Med</source>. <year>2003</year>;<volume>17</volume>:<fpage>73</fpage>‐<lpage>83</lpage>.<pub-id pub-id-type="pmid">12564730</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1892/0891-6640(2003)017&lt;0073:aticac&gt;2.3.co;2</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jvim17198-cit-0006">
<string-name name-style="western">
<surname>Rush</surname>
<given-names>JE</given-names>
</string-name>, <string-name name-style="western">
<surname>Freeman</surname>
<given-names>LM</given-names>
</string-name>, <string-name name-style="western">
<surname>Fenollosa</surname>
<given-names>NK</given-names>
</string-name>, <string-name name-style="western">
<surname>Brown</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990‐1999)</article-title>. <source>J Am Vet Med Assoc</source>. <year>2002</year>;<volume>220</volume>:<fpage>202</fpage>‐<lpage>207</lpage>.<pub-id pub-id-type="pmid">12126131</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2460/javma.2002.220.202</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jvim17198-cit-0007">
<string-name name-style="western">
<surname>Guillaumin</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>DeFrancesco</surname>
<given-names>TC</given-names>
</string-name>, <string-name name-style="western">
<surname>Scansen</surname>
<given-names>BA</given-names>
</string-name>, et al. <article-title>Bilateral lysis of aortic saddle thrombus with early tissue plasminogen activator (BLASTT): a prospective, randomized, placebo‐controlled study in feline acute aortic thromboembolism</article-title>. <source>J Feline Med Surg</source>. <year>2022</year>;<volume>24</volume>:<fpage>e535</fpage>‐<lpage>e545</lpage>.<pub-id pub-id-type="pmid">36350753</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1098612X221135105</pub-id><pub-id pub-id-type="pmcid">PMC10812363</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jvim17198-cit-0008">
<string-name name-style="western">
<surname>Hogan</surname>
<given-names>DF</given-names>
</string-name>, <string-name name-style="western">
<surname>Fox</surname>
<given-names>PR</given-names>
</string-name>, <string-name name-style="western">
<surname>Jacob</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double‐blind, randomized, positive‐controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT)</article-title>. <source>J Vet Cardiol</source>. <year>2015</year>;<volume>17</volume>(<issue>Suppl 1</issue>):<fpage>S306</fpage>‐<lpage>S317</lpage>.<pub-id pub-id-type="pmid">26776588</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvc.2015.10.004</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jvim17198-cit-0009">
<string-name name-style="western">
<surname>Zhang</surname>
<given-names>YJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Li</surname>
<given-names>MP</given-names>
</string-name>, <string-name name-style="western">
<surname>Tang</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Chen</surname>
<given-names>XP</given-names>
</string-name>. <article-title>Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives</article-title>. <source>Int J Environ Res Public Health</source>. <year>2017</year>;<volume>14</volume>:301.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph14030301</pub-id><pub-id pub-id-type="pmcid">PMC5369137</pub-id><pub-id pub-id-type="pmid">28335443</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jvim17198-cit-0010">
<string-name name-style="western">
<surname>Kim</surname>
<given-names>KA</given-names>
</string-name>, <string-name name-style="western">
<surname>Park</surname>
<given-names>PW</given-names>
</string-name>, <string-name name-style="western">
<surname>Hong</surname>
<given-names>SJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Park</surname>
<given-names>JY</given-names>
</string-name>. <article-title>The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>84</volume>:<fpage>236</fpage>‐<lpage>242</lpage>.<pub-id pub-id-type="pmid">18323861</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.20</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jvim17198-cit-0011">
<string-name name-style="western">
<surname>Brandt</surname>
<given-names>JT</given-names>
</string-name>, <string-name name-style="western">
<surname>Close</surname>
<given-names>SL</given-names>
</string-name>, <string-name name-style="western">
<surname>Iturria</surname>
<given-names>SJ</given-names>
</string-name>, et al. <article-title>Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel</article-title>. <source>J Thromb Haemost</source>. <year>2007</year>;<volume>5</volume>:<fpage>2429</fpage>‐<lpage>2436</lpage>.<pub-id pub-id-type="pmid">17900275</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1538-7836.2007.02775.x</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jvim17198-cit-0012">
<string-name name-style="western">
<surname>Lee</surname>
<given-names>PM</given-names>
</string-name>, <string-name name-style="western">
<surname>Faus</surname>
<given-names>MCL</given-names>
</string-name>, <string-name name-style="western">
<surname>Court</surname>
<given-names>MH</given-names>
</string-name>. <article-title>High interindividual variability in plasma clopidogrel active metabolite concentrations in healthy cats is associated with sex and cytochrome P450 2C genetic polymorphism</article-title>. <source>J Vet Pharmacol Ther</source>. <year>2019</year>;<volume>42</volume>:<fpage>16</fpage>‐<lpage>25</lpage>.<pub-id pub-id-type="pmid">30251376</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvp.12717</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jvim17198-cit-0013">
<string-name name-style="western">
<surname>Liptak</surname>
<given-names>JM</given-names>
</string-name>, <string-name name-style="western">
<surname>Hunt</surname>
<given-names>GB</given-names>
</string-name>, <string-name name-style="western">
<surname>Barrs</surname>
<given-names>VR</given-names>
</string-name>, et al. <article-title>Gastroduodenal ulceration in cats: eight cases and a review of the literature</article-title>. <source>J Feline Med Surg</source>. <year>2002</year>;<volume>4</volume>:<fpage>27</fpage>‐<lpage>42</lpage>.<pub-id pub-id-type="pmid">11869053</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/jfms.2001.0148</pub-id><pub-id pub-id-type="pmcid">PMC10829154</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jvim17198-cit-0014">
<string-name name-style="western">
<surname>Jergens</surname>
<given-names>AE</given-names>
</string-name>, <string-name name-style="western">
<surname>Moore</surname>
<given-names>FM</given-names>
</string-name>, <string-name name-style="western">
<surname>Haynes</surname>
<given-names>JS</given-names>
</string-name>, <string-name name-style="western">
<surname>Miles</surname>
<given-names>KG</given-names>
</string-name>. <article-title>Idiopathic inflammatory bowel disease in dogs and cats: 84 cases (1987‐1990)</article-title>. <source>J Am Vet Med Assoc</source>. <year>1992</year>;<volume>201</volume>:<fpage>1603</fpage>‐<lpage>1608</lpage>.<pub-id pub-id-type="pmid">1289345</pub-id>
</mixed-citation></ref><ref id="jvim17198-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jvim17198-cit-0015">
<string-name name-style="western">
<surname>Takeuchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name name-style="western">
<surname>Matsuura</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Fujino</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Hypereosinophilic syndrome in two cats</article-title>. <source>J Vet Med Sci</source>. <year>2008</year>;<volume>70</volume>:<fpage>1085</fpage>‐<lpage>1089</lpage>.<pub-id pub-id-type="pmid">18981665</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1292/jvms.70.1085</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jvim17198-cit-0016">
<string-name name-style="western">
<surname>Bottero</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western">
<surname>Pierini</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Ruggiero</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western">
<surname>Cattaneo</surname>
<given-names>D</given-names>
</string-name>, <string-name name-style="western">
<surname>Campanile</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Benvenuti</surname>
<given-names>E</given-names>
</string-name>. <article-title>Gastroduodenal ulceration detected endoscopically in cats: retrospective study of 61 patients</article-title>. <source>J Feline Med Surg</source>. <year>2022</year>;<volume>24</volume>:<fpage>e347</fpage>‐<lpage>e352</lpage>.<pub-id pub-id-type="pmid">35848606</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1098612X221109802</pub-id><pub-id pub-id-type="pmcid">PMC10812314</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jvim17198-cit-0017">
<string-name name-style="western">
<surname>Abraham</surname>
<given-names>NS</given-names>
</string-name>, <string-name name-style="western">
<surname>Hlatky</surname>
<given-names>MA</given-names>
</string-name>, <string-name name-style="western">
<surname>Antman</surname>
<given-names>EM</given-names>
</string-name>, et al. <article-title>ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use</article-title>. <source>Am J Gastroenterol</source>. <year>2010</year>;<volume>105</volume>:<fpage>2533</fpage>‐<lpage>2549</lpage>.<pub-id pub-id-type="pmid">21131924</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2010.445</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jvim17198-cit-0018">
<string-name name-style="western">
<surname>Wang</surname>
<given-names>ZY</given-names>
</string-name>, <string-name name-style="western">
<surname>Chen</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Zhu</surname>
<given-names>LL</given-names>
</string-name>, et al. <article-title>Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy</article-title>. <source>Ther Clin Risk Manag</source>. <year>2015</year>;<volume>11</volume>:<fpage>449</fpage>‐<lpage>467</lpage>.<pub-id pub-id-type="pmid">25848291</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/TCRM.S80437</pub-id><pub-id pub-id-type="pmcid">PMC4373598</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jvim17198-cit-0019">
<string-name name-style="western">
<surname>Agewall</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Cattaneo</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Collet</surname>
<given-names>JP</given-names>
</string-name>, et al. <article-title>Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy</article-title>. <source>Eur Heart J</source>. <year>2013</year>;<volume>34</volume>(<issue>1708–1713</issue>):<fpage>1713a</fpage>‐<lpage>1713b</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/eht042</pub-id><pub-id pub-id-type="pmid">23425521</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jvim17198-cit-0020">
<string-name name-style="western">
<surname>Zvyaga</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Chang</surname>
<given-names>SY</given-names>
</string-name>, <string-name name-style="western">
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19</article-title>. <source>Drug Metab Dispos</source>. <year>2012</year>;<volume>40</volume>:<fpage>1698</fpage>‐<lpage>1711</lpage>.<pub-id pub-id-type="pmid">22648560</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.112.045575</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jvim17198-cit-0021">
<string-name name-style="western">
<surname>Ferreiro</surname>
<given-names>JL</given-names>
</string-name>, <string-name name-style="western">
<surname>Ueno</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Capodanno</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2010</year>;<volume>3</volume>:<fpage>436</fpage>‐<lpage>441</lpage>.<pub-id pub-id-type="pmid">20858862</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.110.957829</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jvim17198-cit-0022">
<string-name name-style="western">
<surname>Frelinger</surname>
<given-names>AL</given-names>
<suffix>3rd</suffix>
</string-name>, <string-name name-style="western">
<surname>Lee</surname>
<given-names>RD</given-names>
</string-name>, <string-name name-style="western">
<surname>Mulford</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>A randomized, 2‐period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady‐state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>59</volume>:<fpage>1304</fpage>‐<lpage>1311</lpage>.<pub-id pub-id-type="pmid">22464259</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2011.12.024</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jvim17198-cit-0023">
<string-name name-style="western">
<surname>Vaduganathan</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Cannon</surname>
<given-names>CP</given-names>
</string-name>, <string-name name-style="western">
<surname>Cryer</surname>
<given-names>BL</given-names>
</string-name>, et al. <article-title>Efficacy and safety of proton‐pump inhibitors in high‐risk cardiovascular subsets of the COGENT trial</article-title>. <source>Am J Med</source>. <year>2016</year>;<volume>129</volume>:<fpage>1002</fpage>‐<lpage>1005</lpage>.<pub-id pub-id-type="pmid">27143321</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2016.03.042</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jvim17198-cit-0024">
<string-name name-style="western">
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name name-style="western">
<surname>Cryer</surname>
<given-names>BL</given-names>
</string-name>, <string-name name-style="western">
<surname>Contant</surname>
<given-names>CF</given-names>
</string-name>, et al. <article-title>Clopidogrel with or without omeprazole in coronary artery disease</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>1909</fpage>‐<lpage>1917</lpage>.<pub-id pub-id-type="pmid">20925534</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1007964</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0025"><label>25</label><mixed-citation publication-type="miscellaneous" id="jvim17198-cit-0025">
<collab collab-type="authors">Plavix [package insert]</collab>
. <article-title>Bridgewater, NJ: Bristol‐Myers Squibb/Sanofi Pharmaceuticals Partnership</article-title>. <year>1997</year>.</mixed-citation></ref><ref id="jvim17198-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jvim17198-cit-0026">
<string-name name-style="western">
<surname>Thames</surname>
<given-names>BE</given-names>
</string-name>, <string-name name-style="western">
<surname>Lovvorn</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Papich</surname>
<given-names>MG</given-names>
</string-name>, et al. <article-title>The effects of clopidogrel and omeprazole on platelet function in normal dogs</article-title>. <source>J Vet Pharmacol Ther</source>. <year>2017</year>;<volume>40</volume>:<fpage>130</fpage>‐<lpage>139</lpage>.<pub-id pub-id-type="pmid">27452307</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvp.12340</pub-id><pub-id pub-id-type="pmcid">PMC6513019</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jvim17198-cit-0027">
<string-name name-style="western">
<surname>Lyngby</surname>
<given-names>JG</given-names>
</string-name>, <string-name name-style="western">
<surname>Court</surname>
<given-names>MH</given-names>
</string-name>, <string-name name-style="western">
<surname>Lee</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Validation of a method for quantitation of the clopidogrel active metabolite, clopidogrel, clopidogrel carboxylic acid, and 2‐oxo‐clopidogrel in feline plasma</article-title>. <source>J Vet Cardiol</source>. <year>2017</year>;<volume>19</volume>:<fpage>384</fpage>‐<lpage>395</lpage>.<pub-id pub-id-type="pmid">28602635</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvc.2017.03.004</pub-id><pub-id pub-id-type="pmcid">PMC5557681</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jvim17198-cit-0028">
<string-name name-style="western">
<surname>Hogan</surname>
<given-names>DF</given-names>
</string-name>, <string-name name-style="western">
<surname>Ward</surname>
<given-names>MP</given-names>
</string-name>. <article-title>Effect of clopidogrel on tissue‐plasminogen activator‐induced in vitro thrombolysis of feline whole blood thrombi</article-title>. <source>Am J Vet Res</source>. <year>2004</year>;<volume>65</volume>:<fpage>715</fpage>‐<lpage>719</lpage>.<pub-id pub-id-type="pmid">15198208</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2460/ajvr.2004.65.715</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jvim17198-cit-0029">
<string-name name-style="western">
<surname>Parkinson</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Tolbert</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>Messenger</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Evaluation of the effect of orally administered acid suppressants on intragastric pH in cats</article-title>. <source>J Vet Intern Med</source>. <year>2015</year>;<volume>29</volume>:<fpage>104</fpage>‐<lpage>112</lpage>.<pub-id pub-id-type="pmid">25537303</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvim.12493</pub-id><pub-id pub-id-type="pmcid">PMC4858072</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jvim17198-cit-0030">
<string-name name-style="western">
<surname>Sutalo</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Ruetten</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Hartnack</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>The effect of orally administered ranitidine and once‐daily or twice‐daily orally administered omeprazole on intragastric pH in cats</article-title>. <source>J Vet Intern Med</source>. <year>2015</year>;<volume>29</volume>:<fpage>840</fpage>‐<lpage>846</lpage>.<pub-id pub-id-type="pmid">25966746</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvim.12580</pub-id><pub-id pub-id-type="pmcid">PMC4895399</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jvim17198-cit-0031">
<string-name name-style="western">
<surname>Ho</surname>
<given-names>KK</given-names>
</string-name>, <string-name name-style="western">
<surname>Abrams‐Ogg</surname>
<given-names>AC</given-names>
</string-name>, <string-name name-style="western">
<surname>Wood</surname>
<given-names>RD</given-names>
</string-name>, et al. <article-title>Assessment of platelet function in healthy cats in response to commonly prescribed antiplatelet drugs using three point‐of‐care platelet function tests</article-title>. <source>J Feline Med Surg</source>. <year>2017</year>;<volume>19</volume>:<fpage>638</fpage>‐<lpage>647</lpage>.<pub-id pub-id-type="pmid">27170631</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1098612X16648182</pub-id><pub-id pub-id-type="pmcid">PMC11128806</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jvim17198-cit-0032">
<string-name name-style="western">
<surname>Ho</surname>
<given-names>KK</given-names>
</string-name>, <string-name name-style="western">
<surname>Abrams‐Ogg</surname>
<given-names>AC</given-names>
</string-name>, <string-name name-style="western">
<surname>Wood</surname>
<given-names>RD</given-names>
</string-name>, et al. <article-title>Assessment of platelet function in healthy sedated cats using three whole blood platelet function tests</article-title>. <source>J Vet Diagn Invest</source>. <year>2015</year>;<volume>27</volume>:<fpage>352</fpage>‐<lpage>360</lpage>.<pub-id pub-id-type="pmid">25943127</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1040638715584994</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jvim17198-cit-0033">
<string-name name-style="western">
<surname>Teuber</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Mischke</surname>
<given-names>R</given-names>
</string-name>. <article-title>Influence of a low dosage of clopidogrel on platelet function in cats as measured by the platelet function analyser PFA‐100 and the multiplate analyser</article-title>. <source>Res Vet Sci</source>. <year>2016</year>;<volume>109</volume>:<fpage>149</fpage>‐<lpage>156</lpage>.<pub-id pub-id-type="pmid">27892864</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rvsc.2016.09.011</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jvim17198-cit-0034">
<string-name name-style="western">
<surname>Hamel‐Jolette</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Dunn</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Bédard</surname>
<given-names>C</given-names>
</string-name>. <article-title>Plateletworks: a screening assay for clopidogrel therapy monitoring in healthy cats</article-title>. <source>Can J Vet Res</source>. <year>2009</year>;<volume>73</volume>(<issue>1</issue>):<fpage>73</fpage>‐<lpage>76</lpage>.<pub-id pub-id-type="pmid">19337399</pub-id>
<pub-id pub-id-type="pmcid">PMC2613601</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jvim17198-cit-0035">
<string-name name-style="western">
<surname>Martinez</surname>
<given-names>SE</given-names>
</string-name>, <string-name name-style="western">
<surname>Shi</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Zhu</surname>
<given-names>HJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Perez Jimenez</surname>
<given-names>TE</given-names>
</string-name>, <string-name name-style="western">
<surname>Zhu</surname>
<given-names>Z</given-names>
</string-name>, <string-name name-style="western">
<surname>Court</surname>
<given-names>MH</given-names>
</string-name>. <article-title>Absolute quantitation of drug‐metabolizing cytochrome P450 enzymes and accessory proteins in dog liver microsomes using label‐free standard‐free analysis reveals interbreed variability</article-title>. <source>Drug Metab Dispos</source>. <year>2019</year>;<volume>47</volume>:<fpage>1314</fpage>‐<lpage>1324</lpage>.<pub-id pub-id-type="pmid">31427433</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.119.088070</pub-id><pub-id pub-id-type="pmcid">PMC6800445</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jvim17198-cit-0036">
<string-name name-style="western">
<surname>Ueda</surname>
<given-names>Y</given-names>
</string-name>, <string-name name-style="western">
<surname>Li</surname>
<given-names>RHL</given-names>
</string-name>, <string-name name-style="western">
<surname>Nguyen</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>A genetic polymorphism in P2RY(1) impacts response to clopidogrel in cats with hypertrophic cardiomyopathy</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>:<fpage>12522</fpage>.<pub-id pub-id-type="pmid">34131167</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-91372-3</pub-id><pub-id pub-id-type="pmcid">PMC8206363</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jvim17198-cit-0037">
<string-name name-style="western">
<surname>Kornya</surname>
<given-names>MR</given-names>
</string-name>, <string-name name-style="western">
<surname>Abrams‐Ogg</surname>
<given-names>ACG</given-names>
</string-name>, <string-name name-style="western">
<surname>Blois</surname>
<given-names>SL</given-names>
</string-name>, <string-name name-style="western">
<surname>Wood</surname>
<given-names>RD</given-names>
</string-name>. <article-title>Investigation of platelet function analyzer 200 platelet function measurements in healthy cats and cats receiving clopidogrel</article-title>. <source>J Vet Diagn Invest</source>. <year>2023</year>;<volume>35</volume>:<fpage>664</fpage>‐<lpage>670</lpage>.<pub-id pub-id-type="pmid">37646490</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/10406387231197440</pub-id><pub-id pub-id-type="pmcid">PMC10621536</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jvim17198-cit-0038">
<string-name name-style="western">
<surname>Kalbantner</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>Baumgarten</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Mischke</surname>
<given-names>R</given-names>
</string-name>. <article-title>Measurement of platelet function in dogs using a novel impedance aggregometer</article-title>. <source>Vet J</source>. <year>2010</year>;<volume>185</volume>:<fpage>144</fpage>‐<lpage>151</lpage>.<pub-id pub-id-type="pmid">19879171</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tvjl.2009.05.028</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jvim17198-cit-0039">
<string-name name-style="western">
<surname>Defontis</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Côté</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Stirn</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Ledieu</surname>
<given-names>D</given-names>
</string-name>. <article-title>Optimization of Multiplate(®) whole blood platelet aggregometry in the Beagle dog and Wistar rat for ex vivo drug toxicity testing</article-title>. <source>Exp Toxicol Pathol</source>. <year>2013</year>;<volume>65</volume>:<fpage>637</fpage>‐<lpage>644</lpage>.<pub-id pub-id-type="pmid">22884258</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.etp.2012.07.003</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jvim17198-cit-0040">
<string-name name-style="western">
<surname>Jandrey</surname>
<given-names>KE</given-names>
</string-name>, <string-name name-style="western">
<surname>Norris</surname>
<given-names>JW</given-names>
</string-name>, <string-name name-style="western">
<surname>MacDonald</surname>
<given-names>KA</given-names>
</string-name>, et al. <article-title>Platelet function in clinically healthy cats and cats with hypertrophic cardiomyopathy: analysis using the Platelet Function Analyzer‐100</article-title>. <source>Vet Clin Pathol</source>. <year>2008</year>;<volume>37</volume>:<fpage>385</fpage>‐<lpage>388</lpage>.<pub-id pub-id-type="pmid">19055572</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1939-165X.2008.00062.x</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jvim17198-cit-0041">
<string-name name-style="western">
<surname>Kornya</surname>
<given-names>MR</given-names>
</string-name>, <string-name name-style="western">
<surname>Abrams‐Ogg</surname>
<given-names>ACG</given-names>
</string-name>, <string-name name-style="western">
<surname>Blois</surname>
<given-names>SL</given-names>
</string-name>, <string-name name-style="western">
<surname>Wood</surname>
<given-names>RD</given-names>
</string-name>. <article-title>Validation of Plateletworks ADP for the ProCyte Dx analyzer</article-title>. <source>J Vet Intern Med</source>. <year>2023</year>;<volume>37</volume>:<fpage>518</fpage>‐<lpage>527</lpage>.<pub-id pub-id-type="pmid">36856192</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvim.16670</pub-id><pub-id pub-id-type="pmcid">PMC10061176</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jvim17198-cit-0042">
<string-name name-style="western">
<surname>Tablin</surname>
<given-names>F</given-names>
</string-name>, <string-name name-style="western">
<surname>Schumacher</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Pombo</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Platelet activation in cats with hypertrophic cardiomyopathy</article-title>. <source>J Vet Intern Med</source>. <year>2014</year>;<volume>28</volume>:<fpage>411</fpage>‐<lpage>418</lpage>.<pub-id pub-id-type="pmid">24612013</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvim.12325</pub-id><pub-id pub-id-type="pmcid">PMC4857988</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jvim17198-cit-0043">
<string-name name-style="western">
<surname>Chetty</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Ravenstijn</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western">
<surname>Manchandani</surname>
<given-names>P</given-names>
</string-name>. <article-title>Clopidogrel dosing: current successes and emerging factors for further consideration</article-title>. <source>Clin Pharmacol Ther</source>. <year>2021</year>;<volume>109</volume>:<fpage>1203</fpage>‐<lpage>1211</lpage>.<pub-id pub-id-type="pmid">32970826</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2055</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jvim17198-cit-0044">
<string-name name-style="western">
<surname>Bouziana</surname>
<given-names>SD</given-names>
</string-name>, <string-name name-style="western">
<surname>Tziomalos</surname>
<given-names>K</given-names>
</string-name>. <article-title>Clinical relevance of clopidogrel‐proton pump inhibitors interaction</article-title>. <source>World J Gastrointest Pharmacol Ther</source>. <year>2015</year>;<volume>6</volume>:<fpage>17</fpage>‐<lpage>21</lpage>.<pub-id pub-id-type="pmid">25949846</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.4292/wjgpt.v6.i2.17</pub-id><pub-id pub-id-type="pmcid">PMC4419089</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jvim17198-cit-0045">
<string-name name-style="western">
<surname>Cuisset</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Frere</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Quilici</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Comparison of omeprazole and pantoprazole influence on a high 150‐mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>:<fpage>1149</fpage>‐<lpage>1153</lpage>.<pub-id pub-id-type="pmid">19761935</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2009.05.050</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jvim17198-cit-0046">
<string-name name-style="western">
<surname>Bates</surname>
<given-names>ER</given-names>
</string-name>, <string-name name-style="western">
<surname>Lau</surname>
<given-names>WC</given-names>
</string-name>, <string-name name-style="western">
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Clopidogrel‐drug interactions</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>:<fpage>1251</fpage>‐<lpage>1263</lpage>.<pub-id pub-id-type="pmid">21392639</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2010.11.024</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jvim17198-cit-0047">
<string-name name-style="western">
<surname>Pan</surname>
<given-names>CF</given-names>
</string-name>, <string-name name-style="western">
<surname>Shen</surname>
<given-names>MY</given-names>
</string-name>, <string-name name-style="western">
<surname>Wu</surname>
<given-names>CJ</given-names>
</string-name>, et al. <article-title>Inhibitory mechanisms of gabapentin, an antiseizure drug, on platelet aggregation</article-title>. <source>J Pharm Pharmacol</source>. <year>2007</year>;<volume>59</volume>:<fpage>1255</fpage>‐<lpage>1261</lpage>.<pub-id pub-id-type="pmid">17883897</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1211/jpp.59.9.0010</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jvim17198-cit-0048">
<string-name name-style="western">
<surname>Baglo</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Pouplard</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Valentin</surname>
<given-names>JB</given-names>
</string-name>, <string-name name-style="western">
<surname>Guéry</surname>
<given-names>EA</given-names>
</string-name>, <string-name name-style="western">
<surname>Gruel</surname>
<given-names>Y</given-names>
</string-name>, <string-name name-style="western">
<surname>Vayne</surname>
<given-names>C</given-names>
</string-name>. <article-title>Acquired platelet defect associated with gabapentin treatment: a case‐report</article-title>. <source>Platelets</source>. <year>2021</year>;<volume>32</volume>:<fpage>846</fpage>‐<lpage>849</lpage>.<pub-id pub-id-type="pmid">32835556</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09537104.2020.1809645</pub-id></mixed-citation></ref><ref id="jvim17198-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jvim17198-cit-0049">
<string-name name-style="western">
<surname>Kornya</surname>
<given-names>MR</given-names>
</string-name>, <string-name name-style="western">
<surname>Abrams‐Ogg</surname>
<given-names>ACG</given-names>
</string-name>, <string-name name-style="western">
<surname>Blois</surname>
<given-names>SL</given-names>
</string-name>, <string-name name-style="western">
<surname>Wood</surname>
<given-names>RD</given-names>
</string-name>. <article-title>Validation of storage and shipping of feline blood samples for analysis on the Platelet Function Analyzer‐200 for determining the effect of clopidogrel</article-title>. <source>Vet Clin Pathol</source>. <year>2023</year>;<volume>52</volume>:<fpage>588</fpage>‐<lpage>595</lpage>.<pub-id pub-id-type="pmid">37488077</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/vcp.13265</pub-id></mixed-citation></ref></ref-list></back></article><article id="psp413075" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">2038</journal-id><journal-id journal-id-type="pmc-domain">cptpsp</journal-id><journal-id journal-id-type="publisher-id">PSP4</journal-id><journal-title-group><journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title></journal-title-group><issn pub-type="epub">2163-8306</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10864925</article-id><article-id pub-id-type="pmcid-ver">PMC10864925.1</article-id><article-id pub-id-type="pmcaid">10864925</article-id><article-id pub-id-type="pmcaiid">10864925</article-id><article-id pub-id-type="pmid">38130031</article-id><article-id pub-id-type="doi">10.1002/psp4.13075</article-id><article-id pub-id-type="publisher-id">PSP413075</article-id><article-id pub-id-type="other">PSP-2023-0171</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></subj-group></article-categories><title-group><article-title>Use of physiologically‐based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended‐release nifedipine</article-title><alt-title alt-title-type="right-running-head">Modeling of omeprazole and oral ER nifedipine DDI</alt-title><alt-title alt-title-type="left-running-head">Tan et al.</alt-title></title-group><contrib-group><contrib id="psp413075-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Tan</surname><given-names initials="ML">Ming‐Liang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1457-2168</contrib-id><xref rid="psp413075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>mingliang.tan@fda.hhs.gov</email></address></contrib><contrib id="psp413075-cr-0002" contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="Z">Zongming</given-names></name><xref rid="psp413075-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413075-cr-0003" contrib-type="author"><name name-style="western"><surname>Babiskin</surname><given-names initials="A">Andrew</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9968-0197</contrib-id><xref rid="psp413075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413075-cr-0004" contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="MJ">Myong‐Jin</given-names></name><xref rid="psp413075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413075-cr-0005" contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="L">Lanyan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5378-2948</contrib-id><xref rid="psp413075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413075-cr-0006" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="L">Lei</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0639-3162</contrib-id><xref rid="psp413075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413075-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhao</surname><given-names initials="L">Liang</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0257-9082</contrib-id><xref rid="psp413075-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>liang.zhao@fda.hhs.gov</email><email>mingliang.tan@fda.hhs.gov</email></address></contrib></contrib-group><aff id="psp413075-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Office of Research and Standards, Office of Generic Drugs</named-content>
<institution>Center for Drug Evaluation and Research, U.S. Food and Drug Administration</institution>
<city>Silver Spring</city>
<named-content content-type="country-part">Maryland</named-content>
<country country="US">USA</country>
</aff><aff id="psp413075-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Office of Testing and Research, Office of Pharmaceutical Quality</named-content>
<institution>Center for Drug Evaluation and Research, U.S. Food and Drug Administration</institution>
<city>St. Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
Liang Zhao and Ming‐Liang Tan, Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring MD, 20993, USA.<break/>
Email: <email>liang.zhao@fda.hhs.gov</email> and <email>mingliang.tan@fda.hhs.gov</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2024</year></pub-date><volume>13</volume><issue seq="70">2</issue><issue-id pub-id-type="pmc-issue-id">455826</issue-id><issue-id pub-id-type="doi">10.1002/psp4.v13.2</issue-id><fpage>247</fpage><lpage>256</lpage><history><date date-type="rev-recd"><day>20</day><month>10</month><year>2023</year></date><date date-type="received"><day>21</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>15</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-15 00:25:12.480"><day>15</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">Published 2023. This article is a U.S. Government work and is in the public domain in the USA. <italic toggle="yes">CPT: Pharmacometrics &amp; Systems Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PSP4-13-247.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PSP4-13-247.pdf"/><abstract><title>Abstract</title><p>Proton pump inhibitors (PPIs) can affect the release of drugs from their dosage forms in vivo by elevating the gastric pH. Our recent clinical study has demonstrated that drug–drug interactions (DDIs) exist between a PPI, omeprazole, and nifedipine extended‐release formulations, where systemic exposure of nifedipine was increased in subjects after multiple‐dose pretreatment of omeprazole. However, the mechanism of the observed DDIs between omeprazole and nifedipine has not been well‐understood, as the DDI may also be mediated through CYP3A4 enzyme inhibition in addition to the elevated gastric pH caused by omeprazole. This study used physiologically‐based pharmacokinetic (PBPK) modeling and simulations to investigate the underlying mechanism of these complex DDIs. A formulation exhibiting differences in in vitro dissolution across physiological pH range and another formulation where pH does not impact dissolution appreciably (e.g., an osmotic pump) were chosen to characterize the potential impact of pH. The PBPK models incorporated two‐stage in vitro release profiles via US Pharmacopeia 2 apparatus. PBPK simulations suggest that the elevated gastric pH following multiple‐dose administration of omeprazole has a minimal effect on nifedipine pharmacokinetics (PKs), whereas CYP3A4‐mediated DDI is likely the main driver to the observed change of nifedipine PKs in the presence of omeprazole. Compared to the osmotic formulation, the slightly increased exposure of nifedipine can be accounted for by the enhanced drug release in the pH‐dependent formulation. The reported model‐based approach may be useful in DDI risk assessments, product formulation designs, and bioequivalence evaluations.</p></abstract><counts><fig-count count="5"/><table-count count="1"/><page-count count="10"/><word-count count="5961"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.6 mode:remove_FC converted:14.02.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="PSP413075-cit-2001">
<string-name name-style="western">
<surname>Tan</surname>
<given-names>M‐L</given-names>
</string-name>, <string-name name-style="western">
<surname>Gao</surname>
<given-names>Z</given-names>
</string-name>, <string-name name-style="western">
<surname>Babiskin</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Use of physiologically‐based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended‐release nifedipine</article-title>. <source>CPT Pharmacometrics Syst Pharmacol</source>. <year>2024</year>;<volume>13</volume>:<fpage>247</fpage>‐<lpage>256</lpage>. doi:<pub-id pub-id-type="doi">10.1002/psp4.13075</pub-id>
<pub-id pub-id-type="pmcid">PMC10864925</pub-id><pub-id pub-id-type="pmid">38130031</pub-id></mixed-citation>
</p></notes></front><body id="psp413075-body-0001"><p>
<boxed-text position="anchor" content-type="box" orientation="portrait"><caption><title>Study Highlights</title></caption><p>
<list list-type="simple" id="psp413075-list-0001"><list-item id="psp413075-li-0001"><p>
<bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
</p></list-item></list>
</p><p>Our recent clinical study indicates that drug–drug interactions (DDIs) exist among a proton pump inhibitor, omeprazole, and nifedipine extended‐release formulations. However, the mechanism of the observed DDIs has not been well‐understood as the DDIs may also be mediated through CYP3A4 enzyme inhibition in addition to the elevated gastric pH caused by omeprazole.
<list list-type="simple" id="psp413075-list-0002"><list-item id="psp413075-li-0002"><p>
<bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold>
</p></list-item></list>
</p><p>Can the DDIs caused by the elevated gastric pH and mediated through CYP3A4 enzyme be quantified using physiologically‐based pharmacokinetic (PBPK) modeling of drug products with different formulation designs?
<list list-type="simple" id="psp413075-list-0003"><list-item id="psp413075-li-0003"><p>
<bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold>
</p></list-item></list>
</p><p>Our PBPK modeling study suggests that the elevated gastric pH has a minimal effect on nifedipine pharmacokinetics (PKs), whereas CYP3A4‐mediated DDI is likely the main driver to the observed change of nifedipine PKs in the presence of omeprazole.
<list list-type="simple" id="psp413075-list-0004"><list-item id="psp413075-li-0004"><p>
<bold>HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?</bold>
</p></list-item></list>
</p><p>Quantitative understanding of the different DDI mechanisms is important in drug DDI risk assessments, product formulation designs, and bioequivalence evaluations.</p></boxed-text>
</p><sec id="psp413075-sec-0003"><title>INTRODUCTION</title><p>Bioequivalence (BE) has been defined as “the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study”.<xref rid="psp413075-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> In vivo pharmacokinetic (PK) BE studies for oral products are often not conducted in subjects with disease conditions (unless safety concerns necessitate the use of that population) nor in populations who take concomitant drugs. Rather, these studies are often conducted in healthy subjects without taking concomitant medications. However, in clinical settings, a drug product may be administered to patients such as those who have an elevated gastric pH due to achlorhydria or taking concomitantly a gastric acid reducing agent, for example, a proton pump inhibitor (PPI). Whether or not the two products that have been demonstrated to be BE in healthy populations are still BE in these circumstances would warrant additional assessment and evaluation considering possible impact of gastric pH on the product performance. Therefore, product performance under altered gastric pH environment is of importance especially for BE products with different drug release mechanisms (in relation to pH).</p><p>PPIs are widely used to treat gastric acid‐related disorders, such as peptic ulcer disease, nonsteroidal anti‐inflammatory drug‐associated ulcer disease, gastroesophageal reflux diseases, and Zollinger‐Ellison syndrome. PPIs block the gastric H<sup>+</sup>/K<sup>+</sup>‐ATPase to inhibit gastric acid secretion in the final step of acid secretion.<xref rid="psp413075-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="psp413075-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> The elevated gastric pH caused by the treatment of PPIs may alter in vivo drug release for co‐administered drug products that have pH‐dependent solubilities and release profiles. This pH‐modulated drug–drug interaction (DDI) may be further complicated if the PPIs and co‐administered drugs have additional DDI mechanisms such as DDIs mediated by enzymes and/or transporters. The complex issues in PPI‐related DDIs have recently prompted the US Food and Drug Administration (FDA) to issue a federal registry request to collect public comments and input<xref rid="psp413075-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> and subsequently published a draft guidance for industry.<xref rid="psp413075-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>Omeprazole is a PPI used to treat gastric acid‐related disorders, such as gastric ulcers and heartburn. Omeprazole products contain a racemic mixture of R‐omeprazole and S‐omeprazole (esomeprazole). Both enantiomers exhibited nonlinear PK characteristics.<xref rid="psp413075-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> R‐omeprazole and S‐omeprazole are both metabolized by CYP2C19 and CYP3A4 enzymes and in vitro study indicated that CY2C19 contributed 98% and 73%, whereas CYP3A4 contributed 2% and 27% to the metabolism of R‐omeprazole and S‐omeprazole, respectively.<xref rid="psp413075-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> In a cocktail study, some omeprazole metabolites, such as 5‐hydroxyomeprazole and 5′‐O‐desmethylomeprazole, were identified in vivo.<xref rid="psp413075-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> These metabolites inhibit CYP2C19 and CYP3A4 reversibly. In addition, omeprazole and 5′‐O‐desmethylomeprazole were found to be time‐dependent inhibitors (TDIs) of CYP2C19 enzyme, whereas omeprazole and 5‐hydroxyomeprazole to be TDIs of CYP3A4 enzyme.<xref rid="psp413075-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>As a calcium ion influx inhibitor, nifedipine inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle and is indicated for the treatment of angina and hypertension. It is completely absorbed after oral administration, and extensively metabolized by CYP3A4 and 3A5 to highly water‐soluble, inactive metabolites, which accounts for 60% to 80% of the dose excreted in the urine.<xref rid="psp413075-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="psp413075-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Nifedipine is practically water‐insoluble with an enhanced solubility as the pH increases across physiological pHs in the gastrointestinal (GI) tract.<xref rid="psp413075-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> It is available on the market as oral capsules (immediate release [IR]) and extended‐release (ER) tablets. For the ER tablets, there are both osmotic pump and matrix‐based release formulation designs for the products on the market. The osmotic pump formulation is designed to release drugs at a constant release which is pH‐independent, whereas the drug release may be pH‐dependent with matrix designs.</p><p>When nifedipine is co‐administered with PPIs, there is a potential that the increases in gastric pH values associated with PPIs might alter drug release and drug bioavailability (BA) for products with pH‐dependent release characteristics. For example, generic oral ER drug products may use a different controlled release design from that of brand name or reference listed drug (RLD) products, such as osmotic pump versus matrix design, considering that the formulation designs or manufacturing processes of the generic products may not always be the same as that of the RLD due to patent protection, or, in some circumstances, different release mechanisms can be chosen in the ER tablet formulation designs to allow achieving the desired PK profiles and clinical performance. The challenges, however, may occur as these different release mechanisms may cause differences in BA when these products are applied to patients with an elevated gastric pH or population taking concomitant PPIs that alters gastric pH, as these conditions may not have been assessed. Therefore, it is critical to have a mechanistic understanding of the potential impact caused by the formulation differences to ensure the BE, especially for the generic products which use different controlled‐release designs from RLDs.</p><p>To better understand the effect of elevated gastric pH on drug release and the related DDIs for different formulation designs, the Office of Generic Drugs at the FDA funded a clinical study to determine the PK of nifedipine in ER formulations exhibiting either pH‐dependent or pH‐independent drug release with and without pretreatments of omeprazole.<xref rid="psp413075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The push‐pull osmotic pump system has the ability to maintain a constant (i.e., zero‐order) drug release rate, which is independent of drug physical properties and some external parameters, such as dissolution medium pH.<xref rid="psp413075-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> On the other hand, the release of matrix‐based ER tablets is controlled by diffusion driven by a concentration gradient between drug surface concentration and its solubility. The release profile of matrix‐based ER formulations is dependent on drug properties and external parameters, such as drug solubility and dissolution medium pH. The clinical study indicated that the maximum plasma concentration (<italic toggle="yes">C</italic>
<sub>max</sub>) and the area under the curve (AUC) of nifedipine increased after the 7‐day pretreatments of omeprazole (details may be found in a companion paper with this study).<xref rid="psp413075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> However, the underlying questions regarding the mechanism still remain as the DDIs are complicated due to the fact that both pH‐modulated DDI and CYP3A4 enzyme‐mediated DDI may exist in this case.</p><p>Physiologically‐based pharmacokinetic (PBPK) modeling and simulations are useful for predicting drug concentration‐time profiles and DDI.<xref rid="psp413075-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="psp413075-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="psp413075-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="psp413075-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="psp413075-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> The drug parameters, system (i.e., physiological) parameters, and trials design may be handled separately in the PBPK modeling. The effect of drug formulations on the drug release can be accounted for by incorporating in vitro dissolution profiles into the models. Thus, PBPK modeling and simulations provide a practical tool to mechanistically understand the underlying drug absorption, distribution, metabolism, and excretion (ADME) mechanism, and complex DDI.</p><p>In this study, a PBPK modeling approach was used to understand the PPI‐related DDI mechanism and the formulation effect on drug PKs and DDIs. Victim drug nifedipine in both pH‐dependent and pH‐independent release formulations and a PPI, omeprazole, were selected for the analysis. The base models for nifedipine and omeprazole were adapted from our recent PBPK modeling study for omeprazole and nifedipine DDIs in IR formulations.<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> In vitro two‐stage dissolution release profiles of nifedipine were measured and subsequently incorporated into PBPK models to mimic the drug releases in the ER formulations.</p></sec><sec sec-type="methods" id="psp413075-sec-0004"><title>METHODS</title><sec id="psp413075-sec-0005"><title>In vitro dissolution measurement</title><p>To evaluate the effects of different pH dissolution media (i.e., pH 1.2, pH 4.5, and pH 6.8) on drug release, a two‐stage dissolution study was performed on two nifedipine ER 60 mg tablets, PROCARDIA XL from Pfizer (osmotic pump design) and a generic product from Valeant Pharmaceuticals (referencing ADALAT CC). Dissolution media of pH 1.2 HCL, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer solution (all with 1% sodium lauryl sulfate [SLS]) were prepared following US Pharmacopeia (USP) methods. One tablet was placed in each of six dissolution vessels containing stage 1 dissolution media (either pH 1.2 HCL or pH 4.5 acetate buffer with 1% SLS) for 2‐h dissolution testing. After the 2‐h stage 1 dissolution testing, the vessel medium was replaced with the dissolution medium (pH 6.8 phosphate buffer solution) for the 22‐h stage 2 dissolution testing. Dissolution testing using USP Apparatus 2 was performed for each formulation at 37°C with a paddle speed at 50 rpm in 900 mL dissolution medium under each of the above pH conditions for 24 h.</p></sec><sec id="psp413075-sec-0006"><title>Clinical study</title><p>A randomized, single‐dose, four treatment, four‐period crossover study was conducted in healthy adult subjects (male and non‐gravid female subjects) by BioPharma Services. All subjects received 60 mg single dose of nifedipine ER tablets (osmatic pump formulation PROCARDIA XL and Valeant generic product [referencing ADALAT CC]), with or without pretreatment of omeprazole/sodium bicarbonate capsule (40 mg/1100 mg) once daily for 7 days. Sixty‐four subjects were enrolled, and 52 subjects completed the study. Detailed information regarding the study design and PK measurement can be found elsewhere.<xref rid="psp413075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p></sec><sec id="psp413075-sec-0007"><title>PBPK modeling and simulations</title><p>PBPK modeling and simulations were performed using a population‐based ADME PBPK platform, the Simcyp Simulator (V17R1; Certara UK). Each simulation was conducted in 520 subjects (10 trials with 52 subjects for each trial) using the simulator's default virtual healthy volunteer population libraries. The average age, sex, and dosing regimen were matched to our recent clinical trial study design.<xref rid="psp413075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The adapted and verified PBPK base models were first applied to simulator's default virtual populations to simulate the plasma concentration profiles for both pH‐independent and pH‐dependent ER formulations. The gastric pH increase caused by the omeprazole pretreatment was then accounted for by increasing its value to pH = 4.5 from simulator's default value of pH = 1.5 as used in the base model simulations. Finally, CYP3A4‐mediated DDIs were simulated by reducing the maximum rate of metabolite formation by CYP3A4 enzyme, maximum value (<italic toggle="yes">V</italic>
<sub>max</sub>), due to the co‐administration of omeprazole. The workflow chart of PBPK modeling and simulations is depicted in Figure <xref rid="psp413075-fig-0001" ref-type="fig">1</xref>.</p><fig position="float" fig-type="FIGURE" id="psp413075-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Workflow of PBPK modeling and simulations. The bottom‐up PBPK base models were used to predict the pharmacokinetic profiles of nifedipine pH‐dependent and pH‐independent ER tablets in healthy populations. The DDIs mediated by elevated gastric pH and CYP3A4 enzyme due to coadministration of multiple doses of omeprazole were subsequently simulated. DDI, drug‐drug interaction; ER, extended‐release; PBPK, physiologically‐based pharmacokinetic; pH, gastric values used in simulations. <italic toggle="yes">V</italic>
<sub>max</sub>, maximum rate of metabolite formation by CY3A4 enzyme.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PSP4-13-247-g005.jpg"/></fig></sec><sec id="psp413075-sec-0008"><title>Nifedipine model</title><p>A full PBPK distribution model was built by Patel et al.<xref rid="psp413075-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> to describe nifedipine ADME processes after oral administration to humans, using literature and their in‐house data. This model successfully predicted food effect on nifedipine PKs. This published nifedipine PBPK model has been adapted and further verified in our recent PBPK modeling and simulation studies for nifedipine immediate release formulation.<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> In this study, the verified base model was further adapted to model nifedipine ADME in ER formulations by incorporating the measured in vitro dissolution profiles, as mentioned above.</p><p>Nifedipine base model parameters used in this study are summarized in Table <xref rid="psp413075-supitem-0001" ref-type="supplementary-material">S1</xref>. Briefly, the absorption of nifedipine is complete and rapid after oral administration, with its low solubility and high permeability (Biopharmaceutics Classification System class II drug).<xref rid="psp413075-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="psp413075-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="psp413075-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The biorelevant solubilities at different GI segments were predicted based on its aqueous intrinsic solubility (Table <xref rid="psp413075-supitem-0001" ref-type="supplementary-material">S1</xref>) and physiology, such as pH.<xref rid="psp413075-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Nifedipine is strongly bound to plasma proteins and distributed significantly in human tissues.<xref rid="psp413075-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="psp413075-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="psp413075-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> It is extensively metabolized to highly water‐soluble inactive metabolites, primarily by cytochromes P450 CYP3A4 and CYP3A5 enzymes.<xref rid="psp413075-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Between 70% and 80% of the administered dose is excreted as metabolites in the urine, and the detected parent drug in the urine is negligible.<xref rid="psp413075-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="psp413075-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p></sec><sec id="psp413075-sec-0009"><title>Omeprazole model</title><p>The base PBPK models for omeprazole were adapted from our recent study.<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Briefly, PBPK models were built to describe drug ADME characteristics for both R‐ and S‐omeprazole enantiomers. Both R‐omeprazole and S‐omeprazole models were constructed using the in vitro CYP2C19 and CYP3A4 metabolism data.<xref rid="psp413075-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Subsequently, PBPK models for two main active metabolites, 5′‐hydroxyomeprazole (OH OMP) and 5′‐O‐desmethylomeprazole (DM OMP) produced by the CYP enzyme‐mediated metabolism, were constructed.<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Specifically, one enantiomer, R‐ or S‐omeprazole, can be treated as a substrate with its metabolites (OH OMP and DH OMP), whereas the other enantiomer, S‐ or R‐omeprazole, along with its metabolites (OH OMP and DH OMP) can be treated as inhibitors, with each enantiomer representing half of the administered dose in the Simcyp platform. This model setting allows us to simulate complex time‐dependent auto‐inhibition and mutual inhibition. The detailed model parameters and omeprazole model verification can be found in details elsewhere.<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p></sec></sec><sec sec-type="results" id="psp413075-sec-0010"><title>RESULTS</title><sec id="psp413075-sec-0011"><title>In vitro dissolution profiles</title><p>The measured dissolution profiles are plotted in Figure <xref rid="psp413075-fig-0002" ref-type="fig">2</xref> for the PROCARDIA XL and Valeant tablets. The results indicated that almost no nifedipine was released in the first 2 h at two different pH values of 1.2 and 4.5 for PROCARDIA XL tablets. In contrast, the Valeant ER tablets released more than 10% after the first 2 h at both pH conditions. In addition, for PROCARDIA XL, both profiles with different medium pHs exhibit similar linear‐like behaviors at a zero‐order release rate which is independent of medium pH, whereas for the Valeant formulation faster drug release was observed in the higher pH medium than the lower pH. The measured dissolution profiles were incorporated into the nifedipine PBPK models to simulate the nifedipine release in humans.</p><fig position="float" fig-type="FIGURE" id="psp413075-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Two‐stage in vitro dissolution profiles of PROCARDIA XL (red) and Valeant (blue) formulations. The symbols represent averages of six samples for each point: <bold>▲</bold> represents 2 h in pH 1.2 then 22 h in pH 6.8 (both with 1% SLS), while x represent 2 h in pH 4.5 then 22 h in pH 6.8 (1% SLS). Dissolution testing was done using USP apparatus 2 at 50 rpm in 900 mL dissolution media. Insert: first 2 h of in vitro dissolution profiles. SLS, sodium laurel sulfate; USP, US Pharmacopeia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PSP4-13-247-g002.jpg"/></fig></sec><sec id="psp413075-sec-0012"><title>Nifedipine <styled-content style="fixed-case" toggle="no">PBPK</styled-content> models</title><p>The nifedipine PBPK models were used to simulate the plasma concentration‐time profiles of nifedipine following administration of a single dose 60 mg ER tablets. The simulated nifedipine profiles were compared with the corresponding clinically observed data in healthy populations for both pH‐independent release formulation (Figure <xref rid="psp413075-fig-0003" ref-type="fig">3</xref>, left) and pH‐dependent release formulation (Figure <xref rid="psp413075-fig-0003" ref-type="fig">3</xref>, right). The PBPK models captured well the different in vivo concentration‐time profiles for both nifedipine formulations. It is worth mentioning that the different concentration‐time profiles in the simulated results are due to the different in vitro drug release profiles used, depicted in Figure <xref rid="psp413075-fig-0002" ref-type="fig">2</xref> (both in medium of first 2 h in pH 1.2, then 22 h in pH 6.8), as all other model parameters were identical (Table <xref rid="psp413075-supitem-0001" ref-type="supplementary-material">S1</xref>) for the simulations of two formulations. The simulated AUC and <italic toggle="yes">C</italic>
<sub>max</sub> were compared with the clinically observed values and the increase of systemic exposure in pH‐dependent release formulation was captured well when compared to the osmotic formulation in the simulations (Table <xref rid="psp413075-tbl-0001" ref-type="table">1</xref>).</p><fig position="float" fig-type="FIGURE" id="psp413075-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>The simulated drug plasma concentration‐time profiles in healthy populations of single dose 60 mg nifedipine ER tablet with pH‐independent (left) and pH‐dependent (right) formulations. The solid lines are the simulated means values, dotted lines are the 5th and 95th percentiles, and gray lines are for different trials. Data points are clinically observed values.<xref rid="psp413075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> ER, extended‐release.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PSP4-13-247-g001.jpg"/></fig><table-wrap position="float" id="psp413075-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Simulated PK parameters of single dose 60 mg nifedipine pH‐independent and pH‐dependent ER tablets following placebo and multiple dose treatment of omeprazole in healthy subjects, compared with the observed values.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Observed<xref rid="psp413075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Simulated</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (ng/mL)</th><th align="left" valign="bottom" rowspan="1" colspan="1">AUC (ng h/mL)</th><th align="left" valign="bottom" rowspan="1" colspan="1">AUCR</th><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (ng/mL)</th><th align="left" valign="bottom" rowspan="1" colspan="1">AUC (ng h/mL)</th><th align="left" valign="bottom" rowspan="1" colspan="1">AUCR</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="4" valign="top" colspan="1">
<p>pH‐independent</p>
<p>ER tablet</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">NIF</td><td align="char" char="." valign="top" rowspan="1" colspan="1">40.5</td><td align="char" char="." valign="top" rowspan="1" colspan="1">958.6</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NIF pH = 1.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 100%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">38.59</td><td align="char" char="." valign="top" rowspan="1" colspan="1">900.3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">NIF + OMP</td><td align="char" char="." rowspan="3" valign="top" colspan="1">49.6</td><td align="char" char="." rowspan="3" valign="top" colspan="1">1155.9</td><td align="left" rowspan="3" valign="top" colspan="1">1.21</td><td align="left" valign="top" rowspan="1" colspan="1">NIF pH = 4.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 100%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">38.59</td><td align="char" char="." valign="top" rowspan="1" colspan="1">901.4</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NIF pH = 4.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 78%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">48.24</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1163.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NIF pH = 4.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 60%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">59.90</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1512.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.68</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">
<p>pH‐dependent</p>
<p>ER tablet</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">NIF</td><td align="char" char="." valign="top" rowspan="1" colspan="1">86.2</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1059.0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">NIF pH = 1.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 100%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">61.97</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1025.9</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">NIF + OMP</td><td align="char" char="." rowspan="3" valign="top" colspan="1">97.2</td><td align="char" char="." rowspan="3" valign="top" colspan="1">1403.8</td><td align="left" rowspan="3" valign="top" colspan="1">1.33</td><td align="left" valign="top" rowspan="1" colspan="1">NIF pH = 4.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 100%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">71.84</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1050.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NIF pH = 4.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 78%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">90.70</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1377.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NIF pH = 4.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 60%</td><td align="char" char="." valign="top" rowspan="1" colspan="1">113.42</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1821.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.78</td></tr></tbody></table><table-wrap-foot id="psp413075-ntgp-0001"><fn id="psp413075-note-0001"><p>
<italic toggle="yes">Note</italic>: AUCRs between NIF with OMP treatment and NIF only (Observed) or between NIF with pH/<italic toggle="yes">V</italic>
<sub>max</sub> changes and NIF with pH = 1.5/<italic toggle="yes">V</italic>
<sub>max</sub> = 100% (Simulated).</p><p>Abbreviations: AUCR, area under the curve ratios; <italic toggle="yes">C</italic>
<sub>max</sub>, maximum plasma concentration; ER, extended‐release; NIF, nifedipine; OMP, omeprazole; pH, gastric pH values used in simulations; PK, pharmacokinetic; <italic toggle="yes">V</italic>
<sub>max</sub>, maximum rate of metabolite formation by CY3A4 enzyme.</p><p>
<italic toggle="yes">V</italic>
<sub>max</sub> = 60%, the activity of CYP3A4 enzyme was reduced to 60% after 7 days of 40 mg OMP treatment, as simulated from this study; <italic toggle="yes">V</italic>
<sub>max</sub> = 78%, the activity CYP3A4 enzyme was reduced to 78% after 20 mg OMP treatment.<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p></fn></table-wrap-foot></table-wrap></sec><sec id="psp413075-sec-0013"><title>Omeprazole PBPK models</title><p>To study the impact of omeprazole administration on the CYP3A4 enzyme activity, omeprazole PBPK modeling was performed after a daily administration of 40 mg omeprazole enteric‐coated capsule in healthy subjects for 7 days. The simulated time course of the TDI effect of omeprazole on the percentage of active CYP3A4 enzymes both in the gut and liver is shown in Figure <xref rid="psp413075-fig-0004" ref-type="fig">4</xref>. After 7 days of a daily single 40 mg dose treatment, the active CYP3A4 enzymes in the gut and liver were reduced to 84% and 60%, respectively.</p><fig position="float" fig-type="FIGURE" id="psp413075-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Simulated time‐dependent inhibition for gut (dashed line) and liver (solid line) CYP3A4 following the daily administration of omeprazole enteric coated tablet (40 mg).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="PSP4-13-247-g004.jpg"/></fig><p>In order to further validate the omeprazole model, additional PBPK modeling was performed to understand the weak DDI of omeprazole and midazolam, a sensitive CYP3A substrate, observed in a cocktail study where a single dose of 20 mg omeprazole and 0.03 mg/kg midazolam were concurrently administered in combination (cocktail).<xref rid="psp413075-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Overall, the simulated results well‐captured the midazolam PK time‐profiles (Figure <xref rid="psp413075-supitem-0001" ref-type="supplementary-material">S1</xref>) and the simulated midazolam AUC ratios of 1.13 between midazolam in cocktail and midazolam alone is close to the observed value of 1.10 (Table <xref rid="psp413075-supitem-0001" ref-type="supplementary-material">S2</xref>), as reported in the cocktail study.<xref rid="psp413075-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> See details in Supplementary Reading List 2 in Appendix <xref rid="psp413075-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="psp413075-sec-0014"><title>
<styled-content style="fixed-case" toggle="no">PBPK</styled-content> modeling of nifedipine and omeprazole <styled-content style="fixed-case" toggle="no">DDI</styled-content>
</title><p>PPIs are used to increase gastric pH in patients with ulcers or gastroesophageal disease. To study the effect of this increased gastric pH on the drug release and drug exposure, simulations were performed with elevated gastric pH = 4.5 from the Simcyp default value of pH = 1.5 as used in the base model simulations mentioned above. The simulated nifedipine <italic toggle="yes">C</italic>
<sub>max</sub> and AUC values are listed in Table <xref rid="psp413075-tbl-0001" ref-type="table">1</xref>. The simulation results indicated that the increased gastric pH had minimal impact on <italic toggle="yes">C</italic>
<sub>max</sub> and AUC for the pH‐independent release formulation, whereas <italic toggle="yes">C</italic>
<sub>max</sub> and AUC were increased by 16% and 2%, respectively, for the pH‐dependent release formulation (Table <xref rid="psp413075-tbl-0001" ref-type="table">1</xref>).</p><p>In addition to the increased gastric pH values, PPI omeprazole may also affect nifedipine drug exposure through DDI mediated by CYP3A4 enzyme. To simulate the CYP3A4‐mediated DDIs, the <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:msub><mml:mi>max</mml:mi><mml:mrow><mml:mi>CYP</mml:mi><mml:mn>3</mml:mn><mml:mi mathvariant="normal">A</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:mrow></mml:math> was set to 60% of the initial published value in the base PBPK model to account for the reduced metabolism based on the simulated TDI for liver CYP3A4 following the daily administration of 40 mg omeprazole enteric coated tablet for 7 days. Simulations with <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="jats-math-2" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:msub><mml:mi>max</mml:mi><mml:mrow><mml:mi>CYP</mml:mi><mml:mn>3</mml:mn><mml:mi mathvariant="normal">A</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:mrow></mml:math> set to 78% of its initial value, the percentage of the enzyme activity in the liver was reduced to after the daily administration of 20 mg omeprazole enteric coated tablets,<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> were also performed for comparison. The simulated nifedipine <italic toggle="yes">C</italic>
<sub>max</sub> and AUC were increased by 55% and 68% for pH‐independent release formulation, whereas <italic toggle="yes">C</italic>
<sub>max</sub> and AUC were increased by 83% and 78% for pH‐dependent release formulation, respectively, when CYP3A4 enzyme activity was reduced by 60% due to the omeprazole inhibition (Table <xref rid="psp413075-tbl-0001" ref-type="table">1</xref> and Figure <xref rid="psp413075-fig-0005" ref-type="fig">5</xref>).</p><fig position="float" fig-type="FIGURE" id="psp413075-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>The simulated drug plasma concentration‐time profiles in healthy populations of single dose 60 mg nifedipine ER tablet with pH‐independent (left) and pH‐dependent (right) formulations, with daily omeprazole treatment for 7 days prior to the nifedipine administration inducing a change in CYP3A4 <italic toggle="yes">V</italic>
<sub>max</sub> = 60%: the solid black line is the simulated mean value, dotted lines are the 5th and 95th percentiles, and gray lines are for different trials. The blue line is the simulated mean value assuming a change in CYP3A4 <italic toggle="yes">V</italic>
<sub>max</sub> = 78%. Data points are clinically observed values.<xref rid="psp413075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> ER, extended‐release; <italic toggle="yes">V</italic>
<sub>max</sub>, maximum rate of metabolite formation by CY3A4 enzyme.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="PSP4-13-247-g003.jpg"/></fig></sec></sec><sec sec-type="discussion" id="psp413075-sec-0015"><title>DISCUSSION</title><p>Our recent clinical study has shown that DDIs exist among omeprazole, a PPI, and nifedipine where systemic exposure of nifedipine was increased in subjects after multiple dose pretreatment of omeprazole.<xref rid="psp413075-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> However, the mechanism of the observed DDIs between omeprazole and nifedipine has not been well‐understood, as the DDI may be due to pH‐dependent absorption in the presence of an elevated gastric pH caused by omeprazole and/or mediated through CYP3A4 enzyme inhibition. To this end, PBPK modeling and simulations were used to quantitatively investigate the effect of omeprazole on the PKs of nifedipine. Two nifedipine ER formulations, a pH‐independent osmotic pump and a pH‐dependent release design, were examined to mechanistically understand the underlying mechanism of DDIs between omeprazole and nifedipine.</p><p>The nifedipine PBPK base models well captured the PK profiles and total exposures for healthy subjects with normal gastric pH after a single dose of administration without pretreatment of omeprazole. The model was originally developed to study food effect on nifedipine using a bottom‐up approach based on some in vitro data,<xref rid="psp413075-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> which we have successfully applied to predict the DDIs between omeprazole and nifedipine in an IR formulation recently.<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> The incorporation of in vitro release profiles allows us to predict different PK profiles of nifedipine in pH‐independent and pH‐dependent ER formulations, based on their different in vitro release profiles measured in this study. This is one of the examples of utilizing PBPK modeling and simulations to understand the drug in vivo ADME mechanistically, using an in vitro‐in vivo extrapolation approach.</p><p>Pretreatment of omeprazole may increase the gastric pH and subsequently affect the drug releases especially for co‐administered drugs with pH‐dependent formulations. This increased pH can be simulated in the PBPK models by changing gastric pH values of the healthy subjects, as one of the physiological parameters in PBPK models, to an elevated value. The enhanced solubility may be captured in the model based on the elevated pH for the absorption of solubility‐limited drugs, such as nifedipine. The PBPK simulations indicated that the pH effect on the PK of nifedipine osmotic pump formulation was minimal as expected due to its zero‐order or constant release characteristics, whereas the impact of gastric pH on pH‐dependent release formulation of nifedipine is also very limited. This was consistent with the fact that there was almost minimal change in the in vitro two‐stage release profiles at different pH dissolution media before the first 2 h.</p><p>On the other hand, however, the clinically observed exposure changes can be explained for both pH‐independent and pH‐dependent release formulations of nifedipine through PBPK modeling by incorporating the CYP3A4‐mediated DDI mechanism. It is worth noting that the simulated increased drug exposure was slightly larger for the pH‐dependent release formulation compared to that of the osmotic pump formulation when the pH values were kept the same, consistent with what was observed in the clinical study (Table <xref rid="psp413075-tbl-0001" ref-type="table">1</xref>). This characteristic was captured in the simulations because there exists a distribution of CYP3A4 enzyme abundance in GI tract segments (as a system parameter in the PBPK models) and the different drug release time profiles of two formulations (as a drug‐related parameter in the PBPK models) were explicitly incorporated into the PBPK models.</p><p>Overall, PBPK modeling and simulations suggested a minimal impact of elevated gastric pH, caused by omeprazole pretreatment, whereas CYP3A4‐mediated DDI plays a major role in the clinically observed exposure changes. The observed slightly different exposure changes in different formulations can also be modeled through PBPK simulations. This PBPK modeling approach is a very useful tool to understand the complex DDIs and formulation effect on PKs and DDIs mechanistically.</p><p>It is worth mentioning that the mechanistic understanding of drug ADME provides a practical approach in assessing BE during the generic drug development and regulatory evaluation. The FDA usually recommends BE studies with PK end points in healthy subjects, which is generally sufficient to ensure BE in all populations. However, for products having different formulation designs which exhibit differential pH‐dependent drug release profiles, it may warrant additional evaluation to determine if BE in healthy subjects would be sufficient to ensure BE in subjects with an elevated gastric pH for these products. Combining in vitro formulation measurement strategies with PBPK modeling and simulation can play an important role in BE assessment and mitigate the potential non‐BE risk due to pH‐dependent drug release.</p><p>It is also of note that the adapted nifedipine base model was based on its physiochemical properties and in vitro data using a bottom‐up approach without any type of fittings.<xref rid="psp413075-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="psp413075-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Although we could improve the model goodness of fit against the observed PK profiles (e.g., to improve the prediction of <italic toggle="yes">C</italic>
<sub>max</sub> by parameter optimization), we did not carry out this step because the focus of this study was to understand the mechanism of DDIs between omeprazole and nifedipine in ER formulations using a PBPK approach. In addition, the measured in vitro two‐stage release profiles were incorporated into the models to simulate the drug release, mimicking the dissolution media with two different pHs in gastric and GI tracts. A better understanding of in vitro dissolution among different GI tract segments with slightly different pH distribution will further improve the quantitative PBPK predictions, especially for oral ER formulations with pH‐dependent release characteristics. Last, it was not possible to dynamically simulate the complex DDIs mediated by CYP3A4 enzyme between victim and perpetrator drugs investigated in this study due to the complexity required using the current simulator. Instead, a static percentage of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="jats-math-3" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:msub><mml:mi>max</mml:mi><mml:mrow><mml:mi>CYP</mml:mi><mml:mn>3</mml:mn><mml:mi mathvariant="normal">A</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:msub></mml:mrow></mml:mrow></mml:math>, a simulated value of CYP3A4 enzyme activity after pretreatment of omeprazole, was used to simulate CYP3A4‐mediated DDIs. Regardless, it remains a case that an implementation of the measured in vitro release profiles into bottom‐up PBPK models can be used to simulate the in vivo PK profiles for ER formulations.</p><p>In summary, PBPK modeling and simulations provide a practical and useful approach to understand the mechanism of complex DDIs among drug products with different formulations. The impact of elevated gastric pH on nifedipine PKs was minimal after multidose of omeprazole pretreatment. In contrast, the observed exposure increases may be accounted for by CYP3A4‐mediated DDIs between omeprazole and nifedipine. The pH‐dependent release characteristics in the pH‐dependent formulation contributed to the slightly increased exposure changes when compared to the osmotic pump design with pH‐independent release. This mechanistic understanding may provide useful information for drug product formulation designs and regulatory evaluations for BE assessments in the presence of PPI.</p></sec><sec id="psp413075-sec-0016"><title>AUTHOR CONTRIBUTIONS</title><p>M.‐L.T., Z.G., A.B., M.‐J.K., L.F., L.Z., and L.Z. wrote the manuscript. M.‐L.T. designed the research; M.‐L.T. and Z.G. performed the research. M.‐L.T. analyzed the data.</p></sec><sec id="psp413075-sec-0022"><title>FUNDING INFORMATION</title><p>The research was done internally, not suppoted by any specific fund.</p></sec><sec sec-type="COI-statement" id="psp413075-sec-0017"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declared no conflicts of interest.</p></sec><sec id="psp413075-sec-0018"><title>DISCLAIMER</title><p>Views expressed in this article do not necessarily reflect the official policies of the Department of Health and Human Services, nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="psp413075-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Appendix S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-13-247-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="psp413075-bibl-0001"><title>REFERENCES</title><ref id="psp413075-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="psp413075-cit-0001">
<collab collab-type="authors">Electronic Code of Federal Regulations (eCFR)</collab>
. <article-title>e‐CFR Title 21, §314.3(b)</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ecfr.gov/cgi-bin/text-idx?SID=3f1b1dff28036cb6f2b63f7a793e505a%26mc=true%26node=se21.5.314_13%26rgn=div8" ext-link-type="uri">https://www.ecfr.gov/cgi‐bin/text‐idx?SID=3f1b1dff28036cb6f2b63f7a793e505a&amp;mc=true&amp;node=se21.5.314_13&amp;rgn=div8</ext-link>. Accessed May 28, 2021.</mixed-citation></ref><ref id="psp413075-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="psp413075-cit-0002">
<string-name name-style="western">
<surname>Shin</surname>
<given-names>JM</given-names>
</string-name>, <string-name name-style="western">
<surname>Sachs</surname>
<given-names>G</given-names>
</string-name>. <article-title>Pharmacology of proton pump inhibitors</article-title>. <source>Curr Gastroenterol Rep</source>. <year>2008</year>;<volume>10</volume>:<fpage>528</fpage>‐<lpage>534</lpage>.<pub-id pub-id-type="pmid">19006606</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11894-008-0098-4</pub-id><pub-id pub-id-type="pmcid">PMC2855237</pub-id></mixed-citation></ref><ref id="psp413075-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="psp413075-cit-0003">
<string-name name-style="western">
<surname>Wedemeyer</surname>
<given-names>R‐S</given-names>
</string-name>, <string-name name-style="western">
<surname>Blume</surname>
<given-names>H</given-names>
</string-name>. <article-title>Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update</article-title>. <source>Drug Saf</source>. <year>2014</year>;<volume>37</volume>:<fpage>201</fpage>‐<lpage>211</lpage>.<pub-id pub-id-type="pmid">24550106</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-014-0144-0</pub-id><pub-id pub-id-type="pmcid">PMC3975086</pub-id></mixed-citation></ref><ref id="psp413075-bib-0004"><label>4</label><mixed-citation publication-type="miscellaneous" id="psp413075-cit-0004">
<collab collab-type="authors">U.S. Food and Drug Administration</collab>
. <article-title>Framework for assessing pH dependent drug‐drug interactions; establishment of a public docket; request for comments. [Docket No. FDA‐ 2018‐ N‐ 1820]</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.govinfo.gov/content/pkg/FR-2018-05-22/pdf/2018-10927.pdf" ext-link-type="uri">https://www.govinfo.gov/content/pkg/FR‐2018‐05‐22/pdf/2018‐10927.pdf</ext-link>. Accessed May 16, 2020.</mixed-citation></ref><ref id="psp413075-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="psp413075-cit-0005">
<collab collab-type="authors">U.S. Food and Drug Administration. Draft Guidance/Guidance for Industry</collab>
. <article-title>Evaluation of gastric pH‐dependent drug interactions with acid‐reducing agents: study design, data analysis, and clinical implications guidance for industry</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-gastric-ph-dependent-drug-interactions-acid-reducing-agents-study-design-data-analysis" ext-link-type="uri">https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/evaluation‐gastric‐ph‐dependent‐drug‐interactions‐acid‐reducing‐agents‐study‐design‐data‐analysis</ext-link>. Accessed March 30, 2021.</mixed-citation></ref><ref id="psp413075-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="psp413075-cit-0006">
<string-name name-style="western">
<surname>Hassan‐Alin</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Andersson</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Niazi</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Röhss</surname>
<given-names>K</given-names>
</string-name>. <article-title>A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S‐omeprazole (esomeprazole) and R‐omeprazole, in healthy subjects</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2005</year>;<volume>60</volume>:<fpage>779</fpage>‐<lpage>784</lpage>.<pub-id pub-id-type="pmid">15578172</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-004-0841-1</pub-id></mixed-citation></ref><ref id="psp413075-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="psp413075-cit-0007">
<string-name name-style="western">
<surname>Andersson</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Weidolf</surname>
<given-names>L</given-names>
</string-name>. <article-title>Stereoselective disposition of proton pump inhibitors</article-title>. <source>Clin Drug Investig</source>. <year>2008</year>;<volume>28</volume>:<fpage>263</fpage>‐<lpage>279</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00044011-200828050-00001</pub-id><pub-id pub-id-type="pmid">18407713</pub-id></mixed-citation></ref><ref id="psp413075-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="psp413075-cit-0008">
<string-name name-style="western">
<surname>Shirasaka</surname>
<given-names>Y</given-names>
</string-name>, <string-name name-style="western">
<surname>Sager</surname>
<given-names>JE</given-names>
</string-name>, <string-name name-style="western">
<surname>Lutz</surname>
<given-names>JD</given-names>
</string-name>, <string-name name-style="western">
<surname>Davis</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Isoherranen</surname>
<given-names>N</given-names>
</string-name>. <article-title>Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug‐drug interactions</article-title>. <source>Drug Metab Dispos</source>. <year>2013</year>;<volume>41</volume>:<fpage>1414</fpage>‐<lpage>1424</lpage>.<pub-id pub-id-type="pmid">23620487</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.113.051722</pub-id><pub-id pub-id-type="pmcid">PMC3684819</pub-id></mixed-citation></ref><ref id="psp413075-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="psp413075-cit-0009">
<string-name name-style="western">
<surname>Guengerich</surname>
<given-names>FP</given-names>
</string-name>, <string-name name-style="western">
<surname>Martin</surname>
<given-names>MV</given-names>
</string-name>, <string-name name-style="western">
<surname>Beaune</surname>
<given-names>PH</given-names>
</string-name>, <string-name name-style="western">
<surname>Kremers</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western">
<surname>Wolff</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Waxman</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Characterization of rat and human liver microsomal cytochrome P‐450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism</article-title>. <source>J Biol Chem</source>. <year>1986</year>;<volume>261</volume>:<fpage>5051</fpage>‐<lpage>5060</lpage>.<pub-id pub-id-type="pmid">3514607</pub-id>
</mixed-citation></ref><ref id="psp413075-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="psp413075-cit-0010">
<collab collab-type="authors">U.S. Food and Drug Administration</collab>
. <article-title>Drug label: PROCARDIA XL® (nifedipine) extended release tablets for oral use</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019684s023lbl.pdf%3e" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019684s023lbl.pdf</ext-link>. Accessed May 16 2020.</mixed-citation></ref><ref id="psp413075-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="psp413075-cit-0011">
<string-name name-style="western">
<surname>Garbacz</surname>
<given-names>G</given-names>
</string-name>, <string-name name-style="western">
<surname>Golke</surname>
<given-names>B</given-names>
</string-name>, <string-name name-style="western">
<surname>Wedemeyer</surname>
<given-names>RS</given-names>
</string-name>, et al. <article-title>Comparison of dissolution profiles obtained from nifedipine extended release once a day product using different dissolution test apparatuses</article-title>. <source>Eur J Pharm Sci</source>. <year>2009</year>;<volume>38</volume>:<fpage>147</fpage>‐<lpage>155</lpage>.<pub-id pub-id-type="pmid">19591927</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2009.06.010</pub-id></mixed-citation></ref><ref id="psp413075-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="psp413075-cit-0012">
<string-name name-style="western">
<surname>Zhao</surname>
<given-names>L</given-names>
</string-name>, <string-name name-style="western">
<surname>Sun</surname>
<given-names>D</given-names>
</string-name>, <string-name name-style="western">
<surname>Tan</surname>
<given-names>M‐L</given-names>
</string-name>, et al. <article-title>Effect of omeprazole administration on the pharmacokinetics of oral extended‐release nifedipine in healthy subjects</article-title>. <source>Clin Pharm Ther</source>. <year>2023</year>;<volume>114</volume>:<fpage>1134</fpage>‐<lpage>1141</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.3043</pub-id><pub-id pub-id-type="pmid">37669218</pub-id></mixed-citation></ref><ref id="psp413075-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="psp413075-cit-0013">
<string-name name-style="western">
<surname>Verma</surname>
<given-names>RK</given-names>
</string-name>, <string-name name-style="western">
<surname>Krishna</surname>
<given-names>DM</given-names>
</string-name>, <string-name name-style="western">
<surname>Garg</surname>
<given-names>S</given-names>
</string-name>. <article-title>Formulation aspects in the development of osmotically controlled oral drug delivery systems</article-title>. <source>J Control Release</source>. <year>2002</year>;<volume>79</volume>:<fpage>7</fpage>‐<lpage>27</lpage>.<pub-id pub-id-type="pmid">11853915</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-3659(01)00550-8</pub-id></mixed-citation></ref><ref id="psp413075-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="psp413075-cit-0014">
<string-name name-style="western">
<surname>Rostami‐Hodjegan</surname>
<given-names>A</given-names>
</string-name>. <article-title>Physiologically based pharmacokinetics joined with in vitro‐in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology</article-title>. <source>Clin Pharmacol Ther</source>. <year>2012</year>;<volume>92</volume>:<fpage>50</fpage>‐<lpage>61</lpage>.<pub-id pub-id-type="pmid">22644330</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2012.65</pub-id></mixed-citation></ref><ref id="psp413075-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="psp413075-cit-0015">
<string-name name-style="western">
<surname>Zhao</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western">
<surname>Rowland</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Huang</surname>
<given-names>SM</given-names>
</string-name>. <article-title>Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions</article-title>. <source>Clin Pharmacol Ther</source>. <year>2012</year>;<volume>92</volume>:<fpage>17</fpage>‐<lpage>20</lpage>.<pub-id pub-id-type="pmid">22713733</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2012.68</pub-id></mixed-citation></ref><ref id="psp413075-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="psp413075-cit-0016">
<string-name name-style="western">
<surname>Varma</surname>
<given-names>MVS</given-names>
</string-name>, <string-name name-style="western">
<surname>Lin</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Bi</surname>
<given-names>Y‐a</given-names>
</string-name>, <string-name name-style="western">
<surname>Kimoto</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western">
<surname>Rodrigues</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Quantitative rationalization of gemfibrozil drug interactions: consideration of transporters‐enzyme interplay and the role of circulating metabolite gemfibrozil 1‐O‐b‐glucuronide</article-title>. <source>Drug Metab Dispos</source>. <year>2015</year>;<volume>43</volume>:<fpage>1108</fpage>‐<lpage>1118</lpage>.<pub-id pub-id-type="pmid">25941268</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.064303</pub-id></mixed-citation></ref><ref id="psp413075-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="psp413075-cit-0017">
<string-name name-style="western">
<surname>Wu</surname>
<given-names>F</given-names>
</string-name>, <string-name name-style="western">
<surname>Gaohua</surname>
<given-names>L</given-names>
</string-name>, <string-name name-style="western">
<surname>Zhao</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions</article-title>. <source>Pharm Res</source>. <year>2014</year>;<volume>31</volume>:<fpage>1919</fpage>‐<lpage>1929</lpage>.<pub-id pub-id-type="pmid">24590877</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-013-1293-z</pub-id></mixed-citation></ref><ref id="psp413075-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="psp413075-cit-0018">
<string-name name-style="western">
<surname>Tan</surname>
<given-names>ML</given-names>
</string-name>, <string-name name-style="western">
<surname>Zhao</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western">
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Use of physiologically‐based pharmacokinetic (PBPK) modeling to evaluate the effect of chronic kidney disease on the disposition of hepatic CYP2C8 and OATP1B drug substrates</article-title>. <source>Clin Pharmacol Ther</source>. <year>2019</year>;<volume>105</volume>:<fpage>719</fpage>‐<lpage>729</lpage>.<pub-id pub-id-type="pmid">30074626</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1205</pub-id><pub-id pub-id-type="pmcid">PMC8246729</pub-id></mixed-citation></ref><ref id="psp413075-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="psp413075-cit-0019">
<string-name name-style="western">
<surname>Le Merdy</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Tan</surname>
<given-names>M‐L</given-names>
</string-name>, <string-name name-style="western">
<surname>Sun</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Physiologically based pharmacokinetic modeling approach to identify the drug‐drug interaction mechanism of nifedipine and a proton pump inhibitor, omeprazole</article-title>. <source>Eur J Drug Metab Pharmacokinet</source>. <year>2021</year>;<volume>46</volume>:<fpage>41</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">33064292</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13318-020-00649-x</pub-id></mixed-citation></ref><ref id="psp413075-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="psp413075-cit-0020">
<string-name name-style="western">
<surname>Patel</surname>
<given-names>N</given-names>
</string-name>, <string-name name-style="western">
<surname>Polak</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Jamei</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Rostami‐Hodjegan</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Turner</surname>
<given-names>DB</given-names>
</string-name>. <article-title>Quantitative prediction of formulation‐specific food effects and their population variability from in vitro data with the physiologically‐based ADAM model: a case study using the BCS/BDDCS class II drug nifedipine</article-title>. <source>Eur J Pharm Sci</source>. <year>2014</year>;<volume>57</volume>:<fpage>240</fpage>‐<lpage>249</lpage>.<pub-id pub-id-type="pmid">24060671</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2013.09.006</pub-id></mixed-citation></ref><ref id="psp413075-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="psp413075-cit-0021">
<string-name name-style="western">
<surname>Gajendran</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Krämer</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Shah</surname>
<given-names>VP</given-names>
</string-name>, et al. <article-title>Biowaiver monographs for immediate‐release solid oral dosage forms: nifedipine</article-title>. <source>J Pharm Sci</source>. <year>2015</year>;<volume>104</volume>:<fpage>3289</fpage>‐<lpage>3298</lpage>.<pub-id pub-id-type="pmid">26149619</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.24560</pub-id></mixed-citation></ref><ref id="psp413075-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="psp413075-cit-0022">
<string-name name-style="western">
<surname>Chung</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Reitberg</surname>
<given-names>PD</given-names>
</string-name>, <string-name name-style="western">
<surname>Gaffney</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Singleton</surname>
<given-names>W</given-names>
</string-name>. <article-title>Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled‐release formulation of nifedipine</article-title>. <source>Am J Med</source>. <year>1987</year>;<volume>83</volume>:<fpage>10</fpage>‐<lpage>14</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9343(87)90630-9</pub-id><pub-id pub-id-type="pmid">3503594</pub-id></mixed-citation></ref><ref id="psp413075-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="psp413075-cit-0023">
<string-name name-style="western">
<surname>Foster</surname>
<given-names>TS</given-names>
</string-name>, <string-name name-style="western">
<surname>Hamann</surname>
<given-names>SR</given-names>
</string-name>, <string-name name-style="western">
<surname>Richards</surname>
<given-names>VR</given-names>
</string-name>, <string-name name-style="western">
<surname>Bryant</surname>
<given-names>PJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Graves</surname>
<given-names>DA</given-names>
</string-name>, <string-name name-style="western">
<surname>McAllister</surname>
<given-names>RG</given-names>
</string-name>. <article-title>Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects</article-title>. <source>J Clin Pharmacol</source>. <year>1983</year>;<volume>23</volume>:<fpage>161</fpage>‐<lpage>170</lpage>.<pub-id pub-id-type="pmid">6863580</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1983.tb02720.x</pub-id></mixed-citation></ref><ref id="psp413075-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="psp413075-cit-0024">
<string-name name-style="western">
<surname>Ahsan</surname>
<given-names>CH</given-names>
</string-name>, <string-name name-style="western">
<surname>Renwick</surname>
<given-names>AG</given-names>
</string-name>, <string-name name-style="western">
<surname>Waller</surname>
<given-names>DG</given-names>
</string-name>, <string-name name-style="western">
<surname>Challenor</surname>
<given-names>VF</given-names>
</string-name>, <string-name name-style="western">
<surname>George</surname>
<given-names>CF</given-names>
</string-name>, <string-name name-style="western">
<surname>Amanullah</surname>
<given-names>M</given-names>
</string-name>. <article-title>The influence of dose and ethnic origins on the pharmacokinetics of nifedipine</article-title>. <source>Clin Pharmacol Ther</source>. <year>1993</year>;<volume>54</volume>:<fpage>329</fpage>‐<lpage>338</lpage>.<pub-id pub-id-type="pmid">8375129</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.1993.155</pub-id></mixed-citation></ref><ref id="psp413075-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="psp413075-cit-0025">
<string-name name-style="western">
<surname>Krecic‐Shepard</surname>
<given-names>ME</given-names>
</string-name>, <string-name name-style="western">
<surname>Park</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>Barnas</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Slimko</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Kerwin</surname>
<given-names>DR</given-names>
</string-name>, <string-name name-style="western">
<surname>Schwartz</surname>
<given-names>JB</given-names>
</string-name>. <article-title>Race and sex influence clearance of nifedipine: results of a population study</article-title>. <source>Clin Pharmacol Ther</source>. <year>2000</year>;<volume>68</volume>:<fpage>130</fpage>‐<lpage>142</lpage>.<pub-id pub-id-type="pmid">10976544</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.108678</pub-id></mixed-citation></ref><ref id="psp413075-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="psp413075-cit-0026">
<string-name name-style="western">
<surname>Horster</surname>
<given-names>FA</given-names>
</string-name>, <string-name name-style="western">
<surname>Duhm</surname>
<given-names>B</given-names>
</string-name>, <string-name name-style="western">
<surname>Maul</surname>
<given-names>W</given-names>
</string-name>, <string-name name-style="western">
<surname>Mendenwald</surname>
<given-names>H</given-names>
</string-name>, <string-name name-style="western">
<surname>Patzschke</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>Wegner</surname>
<given-names>LA</given-names>
</string-name>. <article-title>Klinische Untersuchungen zur pharmakokinetik von radioaktiv markiertem 4‐(2′‐nitrophenyl)‐2,6‐dimethyl‐1,4‐dihydropyridin‐3,5‐dicarbons¨auredimethylester</article-title>. <source>Arzneimittelforschung</source>. <year>1972</year>;<volume>22</volume>:<fpage>330</fpage>‐<lpage>334</lpage>.<pub-id pub-id-type="pmid">5067485</pub-id>
</mixed-citation></ref><ref id="psp413075-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="psp413075-cit-0027">
<string-name name-style="western">
<surname>Waller</surname>
<given-names>DG</given-names>
</string-name>, <string-name name-style="western">
<surname>Renwick</surname>
<given-names>AG</given-names>
</string-name>, <string-name name-style="western">
<surname>Gruchy</surname>
<given-names>BS</given-names>
</string-name>, <string-name name-style="western">
<surname>George</surname>
<given-names>CF</given-names>
</string-name>. <article-title>The first pass metabolism of nifedipine in man</article-title>. <source>Br J Clin Pharmacol</source>. <year>1984</year>;<volume>18</volume>:<fpage>951</fpage>‐<lpage>954</lpage>.<pub-id pub-id-type="pmid">6529535</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.1984.tb02569.x</pub-id><pub-id pub-id-type="pmcid">PMC1463677</pub-id></mixed-citation></ref><ref id="psp413075-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="psp413075-cit-0028">
<string-name name-style="western">
<surname>Turpault</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Brian</surname>
<given-names>W</given-names>
</string-name>, <string-name name-style="western">
<surname>van Horn</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Pharmacokinetic assessment of a five‐probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A</article-title>. <source>Br J Clin Pharmacol</source>. <year>2009</year>;<volume>68</volume>:<fpage>928</fpage>‐<lpage>935</lpage>.<pub-id pub-id-type="pmid">20002088</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2009.03548.x</pub-id><pub-id pub-id-type="pmcid">PMC2810805</pub-id></mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12737180</article-id><article-id pub-id-type="pmcid-ver">PMC12737180.1</article-id><article-id pub-id-type="pmcaid">12737180</article-id><article-id pub-id-type="pmcaiid">12737180</article-id><article-id pub-id-type="pmid">41471097</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17121582</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-01582</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics of CYP2C19- and CYP3A4-Metabolized Drugs in Cirrhosis Using a Whole-Body PBPK Approach</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Mu</surname><given-names initials="R">Ruijing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-pharmaceutics-17-01582" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="J">Jingjing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><xref rid="af1-pharmaceutics-17-01582" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xiaoli</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af2-pharmaceutics-17-01582" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ling</surname><given-names initials="J">Jing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><xref rid="af3-pharmaceutics-17-01582" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7505-5001</contrib-id><name name-style="western"><surname>Hu</surname><given-names initials="N">Nan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af3-pharmaceutics-17-01582" ref-type="aff">3</xref><xref rid="c1-pharmaceutics-17-01582" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="H">Hanyu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-pharmaceutics-17-01582" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-01582" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Vale</surname><given-names initials="N">Nuno</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Hempel</surname><given-names initials="G">Georg</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-01582"><label>1</label>Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; <email>juiching@stu.cpu.edu.cn</email> (R.M.); <email>jingjing199809@163.com</email> (J.G.)</aff><aff id="af2-pharmaceutics-17-01582"><label>2</label>Mianzhu Municipal Health Bureau, Deyang 618200, China; <email>wshelly001@163.com</email></aff><aff id="af3-pharmaceutics-17-01582"><label>3</label>Department of Pharmacy, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China; <email>lingjing198888@126.com</email></aff><author-notes><corresp id="c1-pharmaceutics-17-01582"><label>*</label>Correspondence: <email>hn_324@163.com</email> (N.H.); <email>shenyhy@cpu.edu.cn</email> (H.Y.)</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>17</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">503138</issue-id><elocation-id>1582</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2025</year></date><date date-type="rev-recd"><day>02</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>25</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-01 07:25:12.810"><day>01</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-17-01582.pdf"/><abstract><p><bold>Background/Objectives</bold>: Cirrhosis significantly alters physiological function and drug metabolism, particularly for medications primarily metabolized by CYP2C19 and CYP3A4. This study aims to establish a physiologically based pharmacokinetic (PBPK) modelling framework capable of predicting pharmacokinetic changes across different stages of cirrhosis, and to determine optimal dosing regimens that achieve drug exposure levels comparable to those in healthy individuals. <bold>Methods</bold>: We constructed a physiologically based pharmacokinetic (PBPK) model that incorporates six drugs, including omeprazole, lansoprazole, midazolam, ondansetron, verapamil, and alfentanil, which are metabolized primarily by CYP2C19 or CYP3A4. The pharmacokinetics of these drugs following oral or injectable administration were simulated in 1000 virtual healthy subjects, and the PBPK model was validated using clinical data. The model was further adapted to account for physiological changes in cirrhotic patients, extending its application to a population of 1000 virtual patients with liver cirrhosis. <bold>Results</bold>: Most observed data fell within the 5th and 95th percentiles of the virtual patient simulation results. Additionally, for most simulations, the area under the concentration-time curve (AUC) and peak concentration (C<sub>max</sub>) were within 0.5- to 2-fold of the observed values. Sensitivity analysis indicated that the reduced expression of metabolizing enzymes increased plasma concentrations of drugs, which was a major factor contributing to the elevated drug exposure in patients with cirrhosis. The clinical dosing regimens of the CYP2C19 substrate omeprazole and the CYP3A4 substrate ondansetron were optimized for use in cirrhotic patients. <bold>Conclusions</bold>: The developed PBPK model successfully predicted the pharmacokinetics of CYP2C19 and CYP3A4 substrates in both healthy individuals and cirrhotic patients and can be effectively used for dose optimization in cirrhotic populations.</p></abstract><kwd-group><kwd>CYP2C19</kwd><kwd>CYP3A4</kwd><kwd>liver cirrhosis</kwd><kwd>physiologically based pharmacokinetic model</kwd><kwd>pharmacokinetics</kwd><kwd>dose optimization</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>82204511</award-id></award-group><award-group><funding-source>China pharmaceutical university “Double First-Class” university project</funding-source><award-id>CPU2022QZ21</award-id></award-group><award-group><funding-source>Top Talent of Changzhou “The 14th Five-Year Plan” High-Level Health Talents Training Project</funding-source><award-id>2022CZBJ042</award-id></award-group><award-group><funding-source>Jiangsu Pharmaceutical Association “Pharmaceutical Research New Voice” Pharmaceutical Scientific Research Project</funding-source><award-id>202564038</award-id></award-group><funding-statement>This work was supported by the National Natural Science Foundation of China (No. 82204511), and the China pharmaceutical university “Double First-Class” university project (No. CPU2022QZ21), and Top Talent of Changzhou “The 14th Five-Year Plan” High-Level Health Talents Training Project (2022CZBJ042) and Jiangsu Pharmaceutical Association “Pharmaceutical Research New Voice” Pharmaceutical Scientific Research Project (202564038).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-01582"><title>1. Introduction</title><p>Globally, approximately 2 million people die each year from liver diseases, with half of these deaths attributed to cirrhosis and the remainder primarily resulting from viral hepatitis and liver cancer [<xref rid="B1-pharmaceutics-17-01582" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-01582" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-01582" ref-type="bibr">3</xref>]. The World Health Organization (WHO) highlights cirrhosis as a major global health burden, responsible for over 1.4 million deaths annually, primarily driven by viral hepatitis, alcohol use, and nonalcoholic fatty liver disease [<xref rid="B4-pharmaceutics-17-01582" ref-type="bibr">4</xref>]. As a progressive liver disease marked by architectural distortion and fibrosis, cirrhosis induces extensive physiological alterations that significantly influence the pharmacokinetics (PK) and pharmacodynamics (PD) of numerous drugs, thereby complicating clinical management [<xref rid="B5-pharmaceutics-17-01582" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-01582" ref-type="bibr">6</xref>].</p><p>The severity of cirrhosis is commonly assessed using the Child-Pugh (CP) classification system (grades A to C) [<xref rid="B7-pharmaceutics-17-01582" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-01582" ref-type="bibr">8</xref>], which provides insights into disease progression, evaluates surgical or medication risks, and informs treatment strategies. Cirrhosis induces a spectrum of physiological changes that collectively influence drug disposition. These changes include reduced hepatic blood flow, decreased hepatocellular enzyme activity, altered plasma protein levels, and impaired biliary excretion. Portal hypertension, a hallmark of cirrhosis, redirects blood flow away from the liver through portosystemic shunting, reducing the effective hepatic extraction of drugs. Additionally, the reduced functional hepatocyte mass diminishes the enzymatic capacity, particularly affecting phase I metabolism mediated by CYP enzymes [<xref rid="B9-pharmaceutics-17-01582" ref-type="bibr">9</xref>]. Cirrhosis also leads to systemic physiological changes, including altered gastrointestinal absorption, renal function, and distribution volume of drugs [<xref rid="B10-pharmaceutics-17-01582" ref-type="bibr">10</xref>]. Hypoalbuminemia, a common feature of cirrhosis, affects the protein binding of highly bound drugs, increasing their unbound concentrations.</p><p>Proton pump inhibitors (PPIs), such as omeprazole and lansoprazole, are extensively metabolized by CYP2C19, with a minor contribution from CYP3A4. Given their widespread use and narrow therapeutic window in certain populations, dose individualization is essential in patients with hepatic impairment. The 2020 guidelines issued by the National Health Commission of the People’s Republic of China recommend limiting omeprazole to ≤20 mg/day in patients with severe liver injury [<xref rid="B11-pharmaceutics-17-01582" ref-type="bibr">11</xref>]. However, as this dose represents the standard therapeutic amount, such a generalized recommendation may be insufficient for managing interindividual differences among cirrhotic patients.</p><p>The cytochrome P450 enzyme system is highly sensitive to liver function impairment. CYP2C19, responsible for the metabolism of drugs such as PPIs and certain antiepileptics exhibits significant interindividual variability in cirrhotic patients [<xref rid="B12-pharmaceutics-17-01582" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-17-01582" ref-type="bibr">13</xref>] and plays a key role in converting clopidogrel into its active thiol metabolite; reduced CYP2C19 activity is strongly associated with clopidogrel resistance and an increased risk of stent thrombosis and other cardiovascular events [<xref rid="B14-pharmaceutics-17-01582" ref-type="bibr">14</xref>]. CYP3A4, the most abundant hepatic CYP enzyme, metabolizes a wide range of drugs, including midazolam, cyclosporine, and statins, and its activity is regulated by both hepatic and extrahepatic factors such as intestinal metabolism. Consequently, CYP3A4 substrate drugs demonstrate significantly altered pharmacokinetics in cirrhotic patients, with midazolam showing markedly increased systemic exposure and prolonged sedation [<xref rid="B15-pharmaceutics-17-01582" ref-type="bibr">15</xref>]. These pharmacokinetic alterations highlight the need for individualized dose adjustment and therapeutic drug monitoring for drugs metabolized by CYP2C19 and CYP3A4 [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-17-01582" ref-type="bibr">17</xref>]. Consistent with these observations, progressive liver injury has been shown to markedly downregulate hepatic metabolic enzyme expression [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]. In CP-C patients, hepatic CYP2C19 and CYP3A4 protein levels are reduced to 12% and 25%, respectively, of those in healthy individuals. Additionally, intestinal CYP3A4 expression is decreased approximately 3-fold. Such reductions in metabolic capacity substantially affect the in vivo disposition of affected drugs.</p><p>Physiologically based pharmacokinetic (PBPK) modeling has emerged as a powerful tool to predict the impact of cirrhosis on drug metabolism. By integrating physiological and biochemical data, PBPK models can simulate the altered pharmacokinetics of CYP2C19 and CYP3A4 substrates in cirrhotic patients. These models incorporate key parameters such as reduced hepatic enzyme activity, altered plasma protein binding, and changes in hepatic blood flow. Cirrhosis-induced physiological changes profoundly affect the pharmacokinetics of CYP2C19 and CYP3A4 substrate drugs, posing challenges to their clinical use. Understanding the pharmacokinetic alterations of these drugs is critical for optimizing therapeutic outcomes and minimizing adverse effects. PBPK modeling hold promise for improving the prediction of drug behavior in this population. Among published PBPK models [<xref rid="B19-pharmaceutics-17-01582" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-01582" ref-type="bibr">20</xref>] for liver injury, many include parameters that have been optimized based on clinical data, rather than being directly measured. Therefore, we attempted to adopt a bottom-up approach to develop the model using parameters from in vitro, and to incorporate as many relevant influencing parameters as possible in the modeling process to make it a highly predictive model.</p><p>In this study, we developed a PBPK model for PPIs, specifically omeprazole and lansoprazole, which are primarily metabolized by CYP2C19. The model was extended to simulate the pharmacokinetics of drugs metabolized by CYP3A4 in cirrhotic patients and to optimize drug dosing in this population.</p></sec><sec id="sec2-pharmaceutics-17-01582"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-01582"><title>2.1. General Workflow</title><p>The workflow for developing the PBPK model applicable to healthy subjects and patients with different grades of cirrhosis is shown in <xref rid="pharmaceutics-17-01582-f001" ref-type="fig">Figure 1</xref>. A virtual population–based PBPK model was established to characterize pharmacokinetic variability across individuals with different physiological states. A total of 1000 virtual individuals were generated. Clinically reported mean physiological parameters (<xref rid="pharmaceutics-17-01582-t001" ref-type="table">Table 1</xref>) were used as the typical values. Inter-individual variability was introduced by assigning random effects to key pharmacokinetic determinants, including the effective intestinal permeability coefficient (P<sub>eff</sub>), the blood unbound fraction (f<sub>u</sub>), hepatic metabolic capacity (V<sub>max</sub> or CL<sub>int</sub>), the blood-to-plasma concentration ratio (R<sub>b</sub>), and the hepatic microsomal protein content (PBSF). These parameters were modeled assuming approximately ±20% variation around their typical values based on clinical and preclinical observations.</p><p>To simulate inter-individual and intra-individual variability, an exponential model and an additive residual error model were applied. The first-order conditional estimation with the Lindstrom–Bates method (FOCE L-B) was used during population model fitting. Pharmacokinetic simulations were performed for each virtual individual and repeated 10 times to incorporate stochastic uncertainty associated with random sampling, resulting in a total of 10,000 PK profiles. The simulation results were processed in descriptive statistics in Phoenix (Version 8.4, Certara, Princeton, NJ, USA), and the 5th, 50th, and 95th percentiles were derived to describe the population distribution of PK profiles.</p><p>The PBPK model was first developed to simulate the pharmacokinetics of omeprazole and lansoprazole in healthy subjects and validated against clinical pharmacokinetic data. After confirmation of adequate predictive performance in a virtual population of 1000 healthy individuals, the model was adapted to liver cirrhosis by updating system specific physiological and biochemical parameters according to disease severity. Subsequently, pharmacokinetics of omeprazole and lansoprazole were predicted in 1000 virtual individuals representing different cirrhosis grades and compared with published clinical observations. Following successful validation in cirrhotic populations, the established PBPK framework was extended to other drugs primarily metabolized by CYP3A4 and CYP2C19, and dosage optimization for cirrhotic patients was performed using plasma exposure in healthy subjects as the reference for therapeutic equivalence.</p></sec><sec id="sec2dot2-pharmaceutics-17-01582"><title>2.2. Model Development</title><p>We developed a whole-body PBPK model consisting of intestinal, gut wall, lung, heart, spleen, liver, kidney, brain, adipose, muscle, skin, stomach, arterial blood, venous blood, and the rest of the body (ROB), which are connected by the blood circulatory system (<xref rid="pharmaceutics-17-01582-f002" ref-type="fig">Figure 2</xref>).</p><p>Drugs are administered either by the intravenous route or the oral route. It is generally accepted that most oral drugs are absorbed in the small intestine (duodenum, jejunum, and ileum) and that the liver is the major metabolizing organ for drugs. In the simulation, it was assumed that the subject drug is eliminated only in the liver and intestine, whereas the absorption of the drug occurs only in the stomach. Drug absorption occurred only in the small intestine. The effective permeability coefficient (P<sub>eff</sub>) was used to indicate the absorption capability of the drug. The essential structure of the whole-body PBPK model and corresponding mass equations were illustrated in <xref rid="app1-pharmaceutics-17-01582" ref-type="app">Supplementary Information</xref>.</p></sec><sec sec-type="subjects" id="sec2dot3-pharmaceutics-17-01582"><title>2.3. PBPK Model Development for LC Patients</title><p>Alterations to pharmacokinetics in the liver cirrhosis state are mainly caused by changes in hepatic blood flow, liver volume, enzymes and drug unbound fraction.</p><p>The drug unbound fraction for patients with liver cirrhosis (<italic toggle="yes">f<sub>u,cirrhosis</sub></italic>) are estimated based on a previously published approach [<xref rid="B21-pharmaceutics-17-01582" ref-type="bibr">21</xref>]. Among these six drugs, except for verapamil and alfentanil, which primarily binds to α1-acid glycoprotein [<xref rid="B22-pharmaceutics-17-01582" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-17-01582" ref-type="bibr">23</xref>], the other drugs primarily bind to albumin [<xref rid="B24-pharmaceutics-17-01582" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-01582" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-01582" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-17-01582" ref-type="bibr">27</xref>]. According to the pKa values of the drug it was assumed that it binds to either α1-acid glycoprotein or albumin, and the calculation was carried out via Equation (1).<disp-formula id="FD1-pharmaceutics-17-01582"><label>(1)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The blood to plasma ratio (<italic toggle="yes">R<sub>B:P</sub></italic>) was calculated as described before [<xref rid="B28-pharmaceutics-17-01582" ref-type="bibr">28</xref>]:<disp-formula id="FD2-pharmaceutics-17-01582"><label>(2)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mo>:</mml:mo><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mi>r</mml:mi><mml:mi>y</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>×</mml:mo><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mi>T</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p><p><italic toggle="yes">HCT</italic> represents hematocrit (<xref rid="pharmaceutics-17-01582-t002" ref-type="table">Table 2</xref>). The <italic toggle="yes">C<sub>Erythrocyte</sub></italic>/<italic toggle="yes">C<sub>Plasma</sub></italic> was calculated from the <italic toggle="yes">R<sub>b</sub></italic> values reported in healthy individuals and was fixed to zero if the calculated ratio was less than zero.</p><p>For the liver volume and blood flow:<disp-formula id="FD3-pharmaceutics-17-01582"><label>(3)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo> </mml:mo><mml:mi>v</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mo> </mml:mo><mml:mi>f</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>In the liver, drug metabolism is usually described by the following processes:<disp-formula id="FD4-pharmaceutics-17-01582"><label>(4)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>n</mml:mi><mml:mi>z</mml:mi><mml:mi>y</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>n</mml:mi><mml:mi>z</mml:mi><mml:mi>y</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo> </mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD5-pharmaceutics-17-01582"><label>(5)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>n</mml:mi><mml:mi>z</mml:mi><mml:mi>y</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>n</mml:mi><mml:mi>z</mml:mi><mml:mi>y</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo> </mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The changes in gastric emptying and intestinal peristalsis rate constants were calculated as follows:<disp-formula id="FD6-pharmaceutics-17-01582"><label>(6)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>h</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
where K<sub>i,cirrhosis</sub> denotes the gastrointestinal transit rate constant in the cirrhotic state, K<sub>i</sub> is the gastrointestinal transit rate constant in the normal state, T<sub>gastric,cirrhosis</sub> denotes the gastrointestinal emptying time in the cirrhotic state, and T<sub>gastric</sub> denotes the gastrointestinal emptying time in the normal state. The gastric emptying time in liver cirrhosis patients was shortened by 1.26 times, thus K<sub>0</sub> increased from 0.08 min<sup>−1</sup> to 0.1 min<sup>−1</sup>. The total gastrointestinal emptying time was shortened from 2 days to 1.6 days. After subtracting the gastric emptying time, the intestinal motility rate increased by approximately 1.25 times, with the values listed in <xref rid="pharmaceutics-17-01582-t002" ref-type="table">Table 2</xref> [<xref rid="B29-pharmaceutics-17-01582" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot4-pharmaceutics-17-01582"><title>2.4. Model Validation</title><p>Using the parameters listed in <xref rid="pharmaceutics-17-01582-t001" ref-type="table">Table 1</xref> and <xref rid="pharmaceutics-17-01582-t002" ref-type="table">Table 2</xref>, plasma concentrations of omeprazole and lansoprazole were predicted in four virtual populations (including normal population, CP-A, CP-B and CP-C patients) following intravenous or oral administration. The drug-specific parameters are listed in <xref rid="app1-pharmaceutics-17-01582" ref-type="app">Supplementary Tables S1 and S2</xref>. The predictions were performed using Phoenix software (Version 8.3.5, Certara, USA, Inc., Princeton, NJ, USA) and were according to the clinical protocol in literatures. The predictions were further compared with clinical observations. To account for inter-individual variability, we used clinically reported mean physiological parameters as a reference and defined variation ranges (e.g., 80–120% of the mean) to represent subject-to-subject differences. By sampling within these ranges, we generated a virtual population of 1000 individuals, each with a unique set of physiological parameters. For each individual, a pharmacokinetic (PK) profile was simulated and replicated 10 times, resulting in a total of 10,000 virtual PK curves. The simulated data were analyzed using the descriptive statistical module in Phoenix, from which the 5th, 50th, and 95th percentile curves were derived to characterize the distribution of PK profiles across the virtual population.</p><p>The model was also applied to other drugs with CYP3A4-mediated metabolism (midazolam, ondansetron, verapamil, alfentanil) to simulate the pharmacokinetic process of the drugs in cirrhosis patients and to optimize the dosage of the drugs in the cirrhosis patients.</p><p>The PBPK model was deemed successful if the simulated AUC or C<sub>max</sub> values fell within 0.5- to 2-fold of the observed data or if the observed data lay within the 5th and 95th percentiles of simulations derived from 1000 virtual subjects. At the same time, it also assessed the average fold error (AFE), the average absolute prediction error (PE%) and the geometric mean-fold error (GMFE) of the predictions.<disp-formula id="FD7-pharmaceutics-17-01582"><label>(7)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm7" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>A</mml:mi><mml:mi>F</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mrow><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>O</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD8-pharmaceutics-17-01582"><label>(8)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm8" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>P</mml:mi><mml:mi>E</mml:mi><mml:mo> </mml:mo><mml:mo>%</mml:mo><mml:mo>=</mml:mo><mml:mi>G</mml:mi><mml:mi>e</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mfenced separators="|"><mml:mrow><mml:mfenced open="|" close="|" separators="|"><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mi>O</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>O</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD9-pharmaceutics-17-01582"><label>(9)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm9" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>G</mml:mi><mml:mi>M</mml:mi><mml:mi>F</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mfenced open="|" close="|" separators="|"><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>O</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Prediction results are deemed satisfactory for AFE values between 0.8 and 1.25, acceptable for values between 0.5–0.8 or 1.25–2, and poor for values below 0.5 or above 2. In addition, PE% values within 25% are considered satisfactory, values within 25–50% are acceptable, and values beyond 50% indicate poor prediction performance. GMFE values ≤ 1.25 are regarded as satisfactory, 1.25–2 as acceptable, and &gt;2 as poor [<xref rid="B30-pharmaceutics-17-01582" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-17-01582" ref-type="bibr">31</xref>].</p><table-wrap position="anchor" id="pharmaceutics-17-01582-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t001_Table 1</object-id><label>Table 1</label><caption><p>Physiological parameters of healthy individuals used in the PBPK model [<xref rid="B32-pharmaceutics-17-01582" ref-type="bibr">32</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Volume (mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Blood Flow (mL/min)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Stomach</td><td align="center" valign="middle" rowspan="1" colspan="1">160</td><td align="center" valign="middle" rowspan="1" colspan="1">38</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lungs</td><td align="center" valign="middle" rowspan="1" colspan="1">1170</td><td align="center" valign="middle" rowspan="1" colspan="1">5600</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Muscle</td><td align="center" valign="middle" rowspan="1" colspan="1">35,000</td><td align="center" valign="middle" rowspan="1" colspan="1">750</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Heart</td><td align="center" valign="middle" rowspan="1" colspan="1">310</td><td align="center" valign="middle" rowspan="1" colspan="1">240</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Brain</td><td align="center" valign="middle" rowspan="1" colspan="1">1450</td><td align="center" valign="middle" rowspan="1" colspan="1">700</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adipose</td><td align="center" valign="middle" rowspan="1" colspan="1">10,000</td><td align="center" valign="middle" rowspan="1" colspan="1">260</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Skin</td><td align="center" valign="middle" rowspan="1" colspan="1">7800</td><td align="center" valign="middle" rowspan="1" colspan="1">300</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Liver</td><td align="center" valign="middle" rowspan="1" colspan="1">1690</td><td align="center" valign="middle" rowspan="1" colspan="1">300</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kidneys</td><td align="center" valign="middle" rowspan="1" colspan="1">280</td><td align="center" valign="middle" rowspan="1" colspan="1">1240</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spleen</td><td align="center" valign="middle" rowspan="1" colspan="1">190</td><td align="center" valign="middle" rowspan="1" colspan="1">80</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rest of body</td><td align="center" valign="middle" rowspan="1" colspan="1">5100</td><td align="center" valign="middle" rowspan="1" colspan="1">592</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Artery blood</td><td align="center" valign="middle" rowspan="1" colspan="1">1730</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Venous blood</td><td align="center" valign="middle" rowspan="1" colspan="1">3470</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duodenum</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">118</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Jejunum</td><td align="center" valign="middle" rowspan="1" colspan="1">209</td><td align="center" valign="middle" rowspan="1" colspan="1">413</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ileum</td><td align="center" valign="middle" rowspan="1" colspan="1">139</td><td align="center" valign="middle" rowspan="1" colspan="1">244</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cecum</td><td align="center" valign="middle" rowspan="1" colspan="1">116</td><td align="center" valign="middle" rowspan="1" colspan="1">44</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Colon</td><td align="center" valign="middle" rowspan="1" colspan="1">1116</td><td align="center" valign="middle" rowspan="1" colspan="1">281</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">r<sub>1</sub>(cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.00</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">r<sub>2</sub>(cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.63</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">r<sub>3</sub>(cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.45</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>0</sub> (min<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>1</sub> (min<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>2</sub> (min<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>3</sub> (min<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>4</sub> (min<sup>−1</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K<sub>5</sub> (min<sup>−1</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="pharmaceutics-17-01582-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t002_Table 2</object-id><label>Table 2</label><caption><p>Physiological parameters of patients with cirrhosis used in the PBPK model.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Parameters</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Units</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Child–Pugh Class</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-A</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-B</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-C</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Q<sub>total</sub> [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">mL/min</td><td align="center" valign="middle" rowspan="1" colspan="1">5600</td><td align="center" valign="middle" rowspan="1" colspan="1">6496</td><td align="center" valign="middle" rowspan="1" colspan="1">7392</td><td align="center" valign="middle" rowspan="1" colspan="1">7896</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hepatic arterial blood flow [<xref rid="B33-pharmaceutics-17-01582" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">mL/min</td><td align="center" valign="middle" rowspan="1" colspan="1">300</td><td align="center" valign="middle" rowspan="1" colspan="1">376</td><td align="center" valign="middle" rowspan="1" colspan="1">416</td><td align="center" valign="middle" rowspan="1" colspan="1">509</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Liver volume fraction [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Functional liver size [<xref rid="B28-pharmaceutics-17-01582" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Albumin [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">g/L</td><td align="center" valign="middle" rowspan="1" colspan="1">44.7</td><td align="center" valign="middle" rowspan="1" colspan="1">41.1</td><td align="center" valign="middle" rowspan="1" colspan="1">33.9</td><td align="center" valign="middle" rowspan="1" colspan="1">26.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">α1-acid glycoprotein [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">g/L</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hematocrit [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">%</td><td align="center" valign="middle" rowspan="1" colspan="1">40.9</td><td align="center" valign="middle" rowspan="1" colspan="1">36.6</td><td align="center" valign="middle" rowspan="1" colspan="1">32.9</td><td align="center" valign="middle" rowspan="1" colspan="1">31.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CYP3A4<sub>liver</sub> content [<xref rid="B34-pharmaceutics-17-01582" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">pmol/mg protein</td><td align="center" valign="middle" rowspan="1" colspan="1">137</td><td align="center" valign="middle" rowspan="1" colspan="1">107</td><td align="center" valign="middle" rowspan="1" colspan="1">70.2</td><td align="center" valign="middle" rowspan="1" colspan="1">42.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CYP3A4<sub>gut</sub> content [<xref rid="B34-pharmaceutics-17-01582" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">pmol/mg protein</td><td align="center" valign="middle" rowspan="1" colspan="1">65.4</td><td align="center" valign="middle" rowspan="1" colspan="1">65.4</td><td align="center" valign="middle" rowspan="1" colspan="1">39.9</td><td align="center" valign="middle" rowspan="1" colspan="1">31.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duodenal CYP3A4 abundance</td><td align="center" valign="middle" rowspan="1" colspan="1">nmol</td><td align="center" valign="middle" rowspan="1" colspan="1">9.7</td><td align="center" valign="middle" rowspan="1" colspan="1">9.7</td><td align="center" valign="middle" rowspan="1" colspan="1">5.92</td><td align="center" valign="middle" rowspan="1" colspan="1">4.70</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Jejunal CYP3A4 abundance</td><td align="center" valign="middle" rowspan="1" colspan="1">nmol</td><td align="center" valign="middle" rowspan="1" colspan="1">38.4</td><td align="center" valign="middle" rowspan="1" colspan="1">38.4</td><td align="center" valign="middle" rowspan="1" colspan="1">23.42</td><td align="center" valign="middle" rowspan="1" colspan="1">18.62</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ileal CYP3A4 abundance</td><td align="center" valign="middle" rowspan="1" colspan="1">nmol</td><td align="center" valign="middle" rowspan="1" colspan="1">22.4</td><td align="center" valign="middle" rowspan="1" colspan="1">22.4</td><td align="center" valign="middle" rowspan="1" colspan="1">13.67</td><td align="center" valign="middle" rowspan="1" colspan="1">10.86</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CYP2C19<sub>liver</sub> content [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">pmol/mg protein</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">4.50</td><td align="center" valign="middle" rowspan="1" colspan="1">3.60</td><td align="center" valign="middle" rowspan="1" colspan="1">1.70</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CYP1A2<sub>liver</sub> content [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">pmol/mg protein</td><td align="center" valign="middle" rowspan="1" colspan="1">52</td><td align="center" valign="middle" rowspan="1" colspan="1">32.9</td><td align="center" valign="middle" rowspan="1" colspan="1">13.6</td><td align="center" valign="middle" rowspan="1" colspan="1">6.10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CYP2D6<sub>liver</sub> content [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">pmol/mg protein</td><td align="center" valign="middle" rowspan="1" colspan="1">8.0</td><td align="center" valign="middle" rowspan="1" colspan="1">6.10</td><td align="center" valign="middle" rowspan="1" colspan="1">2.60</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PBSF</td><td align="center" valign="middle" rowspan="1" colspan="1">mg protein</td><td align="center" valign="middle" rowspan="1" colspan="1">82,472</td><td align="center" valign="middle" rowspan="1" colspan="1">66,802.32</td><td align="center" valign="middle" rowspan="1" colspan="1">53,606.8</td><td align="center" valign="middle" rowspan="1" colspan="1">43,710.16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>0</sub>
</td><td align="center" valign="middle" rowspan="1" colspan="1">min<sup>−1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>1</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">min<sup>−1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.088 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.088 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">min<sup>−1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.038 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.038 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.038 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>3</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">min<sup>−1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.050 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.050 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.050 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">K<sub>4</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">min<sup>−1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.003</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.004 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.004 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K<sub>5</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">min<sup>−1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001 </td></tr></tbody></table><table-wrap-foot><fn><p>PBSF is the physiological scale factor, which is calculated based on the Functional liver size ratio. The gastric transit rate constant (K<sub>0–5</sub>) is based on the ratio of gastrointestinal empty time. The CP parameter changes are based on the ratios reported in the literatures and the healthy individual parameters in <xref rid="pharmaceutics-17-01582-t001" ref-type="table">Table 1</xref>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2dot5-pharmaceutics-17-01582"><title>2.5. Sensitivity Analysis</title><p>Sensitivity analysis was conducted on key parameters, including gastric emptying rate (K<sub>t</sub>), plasma unbound fraction of the drug (f<sub>u</sub>), and metabolic enzyme activities (characterized by V<sub>max</sub> or CL<sub>int</sub> of CYP2C19 and CYP3A4), based on their actual variation ranges.</p></sec><sec id="sec2dot6-pharmaceutics-17-01582"><title>2.6. Dose Optimization</title><p>Three virtual patient groups were categorized based on different degrees of cirrhosis, with 1000 individuals in each group. Healthy individuals (70 kg) were used as a reference population. The clinical doses for patients were optimized to ensure that their AUC values were comparable to those of healthy individuals receiving the prescribed dose, with deviations within 15%.</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-01582"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-01582"><title>3.1. Drug Data Set</title><p>Two drugs primarily metabolized by CYP2C19 and four drugs primarily metabolized by CYP3A4 were selected from data published in PubMed based on the following criteria:<list list-type="simple"><list-item><label>(1)</label><p>Pharmacokinetic parameters (e.g., AUC or plasma drug concentration) following intravenous and/or oral administration in patients with cirrhosis were available.</p></list-item><list-item><label>(2)</label><p>Clinical pharmacokinetic data could be obtained from different reports. The collected clinical reports are summarized in <xref rid="pharmaceutics-17-01582-t003" ref-type="table">Table 3</xref>.</p></list-item><list-item><label>(3)</label><p>The pharmacokinetic data were collected from multiple published studies using different analytical methods, which may introduce variability in the validation dataset and influence the comparison between model predictions and observed values.</p></list-item></list></p></sec><sec id="sec3dot2-pharmaceutics-17-01582"><title>3.2. CYP2C19 Substrate Drugs</title><sec><title>Omeprazole and Lansoprazole</title><p>After gastric emptying, enteric formulations should dissolve rapidly in the duodenum. Therefore, the administration time from the stomach to the duodenum is defined as the lag time. We assumed that the drug dissolves rapidly when 90% of the drug reaches the duodenum after gastric emptying [<xref rid="B70-pharmaceutics-17-01582" ref-type="bibr">70</xref>]. These two drugs are metabolized primarily by CYP2C19 to hydroxylated metabolites, and the rest are metabolized by CYP3A4 to sulphonated metabolites in humans. The pharmacokinetic profile of single-dose oral administration of 20 mg and 40 mg omeprazole in healthy individuals, and single-dose oral administration of 10 mg omeprazole in the three cirrhotic states was predicted using the developed PBPK model. Also, the pharmacokinetics of single dose oral administration of 15 mg, 30 mg, 60 mg lansoprazole in healthy individuals and single dose oral administration of 30 mg lansoprazole in cirrhotic states of three grades were predicted. The predictions were then validated with observations from the clinical research literature, respectively, and the predictions are shown in <xref rid="pharmaceutics-17-01582-f003" ref-type="fig">Figure 3</xref>.</p></sec></sec><sec id="sec3dot3-pharmaceutics-17-01582"><title>3.3. CYP3A4 Substrate Drugs</title><sec id="sec3dot3dot1-pharmaceutics-17-01582"><title>3.3.1. Midazolam and Ondansetron</title><p>Midazolam is a typical benzodiazepine anaesthetic with anti-anxiety, sedative and hypnotic properties. Midazolam is predominantly metabolized by hepatic CYP3A4, producing approximately 70% 1-hydroxymidazolam and less than 5% 4-hydroxymidazolam. Ondansetron is primarily metabolized to hydroxylated ondansetron by CYP3A4, with additional contributions from CYP2D6 and CYP1A2. The PBPK model was employed to predict the pharmacokinetic profiles of ondansetron administered as a single 8 mg oral dose, single 8 mg intravenous dose, and single 24 mg intravenous dose in a healthy population, as well as a single 8 mg intravenous dose in individuals with three grades of cirrhosis.</p></sec><sec id="sec3dot3dot2-pharmaceutics-17-01582"><title>3.3.2. Verapamil and Alfentanil</title><p>Verapamil is primarily metabolized in the liver, predominantly by CYP3A4 through N-demethylation to form norverapamil, with additional contributions from CYP3A5 and CYP2C8. Alfentanil is a short-acting opioid analgesic primarily metabolized by the hepatic CYP3A4 enzyme. It also serves as an in vivo probe for assessing hepatic CYP3A4 activity and drug-drug interactions. The developed PBPK model was employed to predict the pharmacokinetics of alfentanil in a healthy population following a single oral dose across four groups, intravenous infusion across three groups, and a single intravenous dose in individuals with cirrhosis under one dosing regimen. The predictions were then validated with observations from the clinical research literature, respectively, and the predictions are shown in <xref rid="pharmaceutics-17-01582-f004" ref-type="fig">Figure 4</xref>.</p></sec></sec><sec id="sec3dot4-pharmaceutics-17-01582"><title>3.4. Development of PBPK Model and Validation Using Pharmacokinetic Parameters from Healthy Subjects Following i.v. or Oral Administrations</title><p>Plasma concentration-time profiles after intravenous or oral administration of these six drugs in healthy subjects were simulated using the established PBPK model and compared with clinical observations. The AUC or C<sub>max</sub> values were predicted using 50th percentile profiles and compared with the clinical observations (<xref rid="pharmaceutics-17-01582-t004" ref-type="table">Table 4</xref>, <xref rid="pharmaceutics-17-01582-t005" ref-type="table">Table 5</xref>, <xref rid="pharmaceutics-17-01582-t006" ref-type="table">Table 6</xref>, <xref rid="pharmaceutics-17-01582-t007" ref-type="table">Table 7</xref>, <xref rid="pharmaceutics-17-01582-t008" ref-type="table">Table 8</xref> and <xref rid="pharmaceutics-17-01582-t009" ref-type="table">Table 9</xref>). 95% (143/150) of the predicted pharmacokinetic parameters were within 0.5–2-fold of the observed values. A few outliers were mainly observed for AUC values. These discrepancies may stem from differences in analytical methods used across studies (such as RIA, HPLC-UV, or LC–MS/MS), which can lead to variability in reported concentrations. In addition, population differences or unmodeled physiological variability might also contribute to these deviations.</p></sec><sec id="sec3dot5-pharmaceutics-17-01582"><title>3.5. Prediction of Pharmacokinetic Profiles of Intravenous or Oral CYP3A4 and CYP2C19 Substrates in Cirrhosis Patients Using the Developed PBPK Model</title><p>Following validation of the developed PBPK model in healthy subjects, the model was applied to predict the pharmacokinetic profiles of CYP3A4 and CYP2C19 substrate drugs after intravenous or oral administration in 1000 virtual patients with cirrhosis (<xref rid="pharmaceutics-17-01582-f005" ref-type="fig">Figure 5</xref>). Pharmacokinetic parameters were estimated using the mean profiles derived from 1000 simulations. The results indicated that the concentrations of most drugs in cirrhosis patients fell within the 5th and 95th percentiles of the pharmacokinetic profiles of the 1000 virtual cirrhotic patients.</p><p>The AFE, PE and GMFE values of six drugs were calculated using parameters of C<sub>max</sub>, T<sub>max</sub>, and AUC<sub>0–t</sub>. The results (<xref rid="pharmaceutics-17-01582-t010" ref-type="table">Table 10</xref>) showed that the predictions for all six drugs were within acceptable ranges.</p></sec><sec id="sec3dot6-pharmaceutics-17-01582"><title>3.6. Sensitivity Analysis of Model Parameters</title><p>Plasma concentration-time curves following single-dose oral administration of 20 mg omeprazole, 30 mg lansoprazole, 5 mg midazolam, 80 mg verapamil, and 3 mg alfentanil, as well as intravenous administration of 10 mg verapamil and 8 mg ondansetron, illustrate the sensitivity of pharmacokinetics. Parameters such as gastrointestinal emptying rate, hepatic metabolizing enzyme activity, and plasma unbound drug fraction may influence drug pharmacokinetics. Sensitivity analysis was performed based on the variation ranges of the parameters listed in <xref rid="pharmaceutics-17-01582-t001" ref-type="table">Table 1</xref> and <xref rid="pharmaceutics-17-01582-t002" ref-type="table">Table 2</xref>. For omeprazole and lansoprazole, sensitivity analyses for CYP2C19 activity were conducted at 1/3-, 1-, and 3-fold to account for the variability in metabolic parameters associated with genetic polymorphisms [<xref rid="B70-pharmaceutics-17-01582" ref-type="bibr">70</xref>].</p><p>The results indicated that the tested parameters affected the pharmacokinetic profiles of the drugs to varying extents (<xref rid="pharmaceutics-17-01582-f006" ref-type="fig">Figure 6</xref>). For omeprazole oral, CYP2C19 &gt; f<sub>u</sub> &gt; K<sub>t</sub> &gt; CYP3A4; for lansoprazole oral, f<sub>u</sub> &gt; CYP2C19 &gt; K<sub>t</sub> &gt;&gt; CYP3A4; for midazolam, verapamil and alfentanil oral, f<sub>u</sub> ≈ CYP3A4 &gt; K<sub>t</sub>. For ondansetron, f<sub>u</sub> &gt; CYP3A4 &gt; CYP1A2 &gt; CYP2D6; for verapamil, CYP3A4 &gt; f<sub>u</sub> &gt; K<sub>t</sub>. For orally administered drugs, the gastric emptying rate (K<sub>t</sub>) primarily influenced the time to peak concentration. CYP2C19 played a more significant role than CYP3A4 in the metabolism of omeprazole and lansoprazole, a 66% reduction in CYP2C19 activity has an effect on AUC that is almost equivalent to a 50% reduction in unbound fraction. Whereas CYP3A4 was the primary contributor for the other four drugs, a 50% reduction in CYP3A4 activity has an effect on AUC that is almost equivalent to a 50% reduction in unbound fraction. Additionally, the plasma unbound drug fraction predominantly affected drug distribution to tissues, making it a key parameter for both intravenous and oral administration routes. The contribution of f<sub>u</sub>, K<sub>t</sub> and changes in different metabolic enzymes to the plasma concentrations of CYP2C19 and CYP3A4 substrates and their combined effects were also simulated. The results showed that any decrease in metabolizing enzyme activity resulted in an increase in the plasma concentration; whereas a decrease in f<sub>u</sub> values resulted in a decrease in the plasma concentration. The net effect was an increase in the plasma concentration. For oral drugs (Omeprazole for example), the decrease in the value of K<sub>t</sub> resulted in delayed absorption of the drug and slowed down the rate of absorption in the intestines, with a significant backward shift of Tmax and an increasing trend in the plasma concentration of the drug.</p></sec><sec id="sec3dot7-pharmaceutics-17-01582"><title>3.7. Dosage Optimization Results</title><p>To illustrate the variability in pharmacokinetics within the cirrhosis patient population, we conducted direct comparisons using box-whisker analysis. As shown in <xref rid="pharmaceutics-17-01582-f007" ref-type="fig">Figure 7</xref>, at the clinically prescribed dose administered, the AUC ratio of omeprazole (20 mg orally) in patients with CP-A, CP-B, and CP-C versus healthy subjects was 1:2.5:3.1:3.6; and the AUC ratio of ondansetron (8 mg i.v.) was 1:1.4:1.5:1.8. In addition, for the antiemetic ondansetron, the C<sub>max</sub> was strongly correlated with the effect; therefore, a C<sub>max</sub> ratio of 1:1.4:1.6:1.6 was calculated for an oral dose of 8 mg ondansetron.</p><p>For plasma exposures to be equivalent, the oral dose of omeprazole should be adjusted to 8 mg (CP-A), 6.5 mg (CP-B), and 5.5 mg (CP-C), while the intravenous dose of ondansetron should be adjusted to 6 mg (CP-A), 5 mg (CP-B), and 4.5 mg (CP-C). When 8 mg ondansetron orally, the dosage should be adjusted to 6 mg (CP-A), 5 mg (CP-B), and 4.5 mg (CP-C). This would suggest that for ondansetron, the dose optimized with AUC and C<sub>max</sub> as indicators is consistent.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-17-01582"><title>4. Discussion</title><p>Hepatic drug clearance primarily depends on hepatic blood flow, the activity of drug-metabolizing enzymes, and the concentration of unbound drug in plasma [<xref rid="B71-pharmaceutics-17-01582" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-17-01582" ref-type="bibr">72</xref>]. In cirrhosis, histological structural abnormalities lead to changes in hepatic blood flow. As the disease progresses, increased vasodilation contributes to the development of hepatorenal syndrome [<xref rid="B73-pharmaceutics-17-01582" ref-type="bibr">73</xref>], which subsequently elevates cardiac output [<xref rid="B74-pharmaceutics-17-01582" ref-type="bibr">74</xref>]. Additionally, altered levels of cholecystokinin in cirrhotic patients impair gallbladder contraction, resulting in prolonged gastric emptying time [<xref rid="B75-pharmaceutics-17-01582" ref-type="bibr">75</xref>]. In patients with cirrhosis, the overall activity of the CYP450 enzyme system is significantly impaired due to a reduction in hepatocyte number, decreased hepatic blood flow, and the loss of functional liver size. Compared with healthy individuals, CYP2C19 expression is reduced by 32%, 26%, and 12% in CP-A, CP-B, and CP-C patients, respectively, while CYP3A4 expression is reduced by 59%, 39%, and 25% [<xref rid="B18-pharmaceutics-17-01582" ref-type="bibr">18</xref>]. However, changes in drug exposure cannot be solely determined based on cirrhosis grades, as liver extraction ratio of drugs varies, and the activity of different CYP isoforms is affected to varying degrees by the physiological alterations associated with cirrhosis.</p><p>The whole-body PBPK model systematically simulates drug pharmacokinetics in healthy individuals by integrating changes in physiological parameters and extending these simulations to patients with varying degrees of cirrhosis. Compared to empirical PK-PD models or semi-PBPK models, whole-body PBPK models provide more detailed information on physiological parameters and drug metabolism mechanisms, leading to enhanced predictive capability [<xref rid="B76-pharmaceutics-17-01582" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceutics-17-01582" ref-type="bibr">77</xref>]. These models facilitate in vivo exposure predictions in the early stages of drug clinical trials, without the need for extensive clinical data [<xref rid="B78-pharmaceutics-17-01582" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-17-01582" ref-type="bibr">79</xref>,<xref rid="B80-pharmaceutics-17-01582" ref-type="bibr">80</xref>]. These predictions offer valuable references for clinical trial dose setting in patients with liver dysfunction. Meanwhile, the construction of a whole-body PBPK model can provide valuable insights into the impact of physiological changes on pharmacokinetics under disease conditions and can be used to optimize drug dosing for patient groups in response to disease progression.</p><p>Our simulation results demonstrated that nearly all observed plasma concentrations of the drugs fell within the 5th and 95th percentiles of the virtual population simulations generated by the developed PBPK model. Additionally, the predicted-to-observed ratios for most pharmacokinetic parameters, including AUC and C<sub>max</sub>, were within the range of 0.5 to 2.0, indicating that the whole-body PBPK model accurately predicted the pharmacokinetics of midazolam, omeprazole, lansoprazole, ondansetron, verapamil, and alfentanil in both healthy and cirrhotic populations. Sensitivity analysis was conducted using parameter values reported in the literature and the extent of variation in these parameters in healthy and cirrhotic populations. The results revealed that decreased expression of CYP2C19 or CYP3A4 was the primary contributor to the increased in vivo exposure of their substrate drugs, while changes in gastrointestinal transit rates delayed the time to peak concentration. Moreover, elevated plasma unbound drug fractions led to greater drug distribution into tissues, reducing plasma concentrations transiently; however, the net effect was an increase in plasma drug exposure [<xref rid="B81-pharmaceutics-17-01582" ref-type="bibr">81</xref>].</p><p>It is widely acknowledged that dose adjustments are necessary for cirrhotic patients when drug exposure levels exceed twice that of the healthy population. According to our model predictions, the AUC ratios of omeprazole (20 mg orally) in patients with CP-A, CP-B, and CP-C compared to healthy subjects were 1:2.5:3.1:3.6, respectively. In contrast, the AUC ratios of ondansetron (8 mg intravenously) were 1:1.4:1.5:1.8. These findings highlight that, even within the same cirrhosis grade, some drugs may not require additional dose adjustments, whereas others could lead to significant drug accumulation. Although it is reasonable to use AUC and C<sub>max</sub> as indicators for dose optimization, for more extensive situations, it may be necessary to consider indicators such as drug exposure in specific organs or the duration of exposure above threshold concentrations to ensure drug safety. This underscores the potential utility of the PBPK model for optimizing clinical dosing in cirrhotic patients.</p><p>However, this study has certain limitations. Due to the limited availability of human physiological data and corresponding clinical studies in cirrhotic patients, the PBPK model primarily accounted for changes in parameters such as hepatic blood flow, CYP450 enzyme activity, cardiac output, and plasma unbound drug fraction. Other potential influencing factors, such as the impact of cirrhosis on metabolizing enzyme activity across different ages or genotypes, were not included [<xref rid="B82-pharmaceutics-17-01582" ref-type="bibr">82</xref>]. It was demonstrated that for the CYP2C9 substrate drug, lornoxicam, the effect of cirrhosis grade on pharmacokinetics was greater than the effect of genotypic differences [<xref rid="B83-pharmaceutics-17-01582" ref-type="bibr">83</xref>]. And this study focused on the effect of CYP2C19 and CYP3A4 impairment on drug exposure, the model structure already includes dynamic enzyme activity and substrate-competition terms, indicating its potential for drug–drug interaction assessment when reliable inhibition/induction parameters are available. Future extensions of the model may therefore support optimisation of combination therapy in cirrhotic patients. Although the complexity of the discussion limits genotypic depth, our model provided a basis for accurate assessment of genotypes for CYP2C19 and CYP3A4 substrate drugs subsequent studies. Additionally, although the Child-Pugh class was used as a category in our study to simulate pharmacokinetic changes in different hepatic function states, it is important to note that this system of comprehensive categories based on a wide range of clinical physiological parameters does not adequately reflect the variability of physiological parameters of the patients in each class. The PBPK model was developed using typical parameter values and an assumed 20% variation, which may underestimate the inter-individual pharmacokinetic variability observed in real populations. Future refinements could incorporate known genetic variability to improve prediction accuracy. In future applications expansion, the individual variability values of real patients could be integrated to improve prediction accuracy and clinical adaptability. In data collection, we included as many relevant publications as possible. However, different detection methods vary in terms of sensitivity, specificity, and interference resistance. For example, RIA methods may have cross-reactivity or poor specificity, which may affect the accuracy of some blood drug concentration data.</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-17-01582"><title>5. Conclusions</title><p>A whole-body PBPK model of CYP2C19 and CYP3A4 substrates containing omeprazole, lansoprazole, midazolam, ondansetron, verapamil, and alfentanil was developed in healthy subjects. After validation with clinical data reported in literatures, the PBPK model was applied to patients with different grades of cirrhosis to predict pharmacokinetic profiles. The developed PBPK model can also be used to guide dose optimization in the liver cirrhosis patient population.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank Nan Hu and Hanyu Yang for their helpful advice in writing the English manuscript.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-01582"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17121582/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17121582/s1</uri>, K<sub>t:p</sub> values were calculated using the method of Rodgers et al [<xref rid="B84-pharmaceutics-17-01582" ref-type="bibr">84</xref>]. Table S1. Drug-specific parameters primarily mediated by CYP2C19 metabolism [<xref rid="B70-pharmaceutics-17-01582" ref-type="bibr">70</xref>,<xref rid="B85-pharmaceutics-17-01582" ref-type="bibr">85</xref>,<xref rid="B86-pharmaceutics-17-01582" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceutics-17-01582" ref-type="bibr">87</xref>,<xref rid="B88-pharmaceutics-17-01582" ref-type="bibr">88</xref>,<xref rid="B89-pharmaceutics-17-01582" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceutics-17-01582" ref-type="bibr">90</xref>,<xref rid="B91-pharmaceutics-17-01582" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceutics-17-01582" ref-type="bibr">92</xref>]; Table S2. Drug-specific parameters primarily mediated by CYP3A4 metabolism [<xref rid="B93-pharmaceutics-17-01582" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceutics-17-01582" ref-type="bibr">94</xref>,<xref rid="B95-pharmaceutics-17-01582" ref-type="bibr">95</xref>,<xref rid="B96-pharmaceutics-17-01582" ref-type="bibr">96</xref>,<xref rid="B97-pharmaceutics-17-01582" ref-type="bibr">97</xref>,<xref rid="B98-pharmaceutics-17-01582" ref-type="bibr">98</xref>,<xref rid="B99-pharmaceutics-17-01582" ref-type="bibr">99</xref>,<xref rid="B100-pharmaceutics-17-01582" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceutics-17-01582" ref-type="bibr">101</xref>].</p><supplementary-material id="pharmaceutics-17-01582-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-17-01582-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, formal analysis, validation, data curation, R.M. and X.W.; Data curation, validation, N.H. and H.Y.; Methodology, investigation, resources, writing—original draft preparation J.G., R.M. and J.L.; Software, visualization, R.M. Visualization, writing—review and editing, supervision, project administration, N.H. and H.Y. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are contained within the article and the <xref rid="app1-pharmaceutics-17-01582" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AUC</td><td align="left" valign="middle" rowspan="1" colspan="1">the area under the curve</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AUC<sub>0–t</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">the area under the curve from 0 to the last measurable concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">C<sub>max</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">the peak concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T<sub>max</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">time to peak drug concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CYP2C19</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytochrome P450 2C19</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CYP3A4</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytochrome P450 3A4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LC</td><td align="left" valign="middle" rowspan="1" colspan="1">liver cirrhosis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">f<sub>u</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">the unbound fraction of drug</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CL</td><td align="left" valign="middle" rowspan="1" colspan="1">clearance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R<sub>b</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">the ratio of drug concentration in blood to plasma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PBSF</td><td align="left" valign="middle" rowspan="1" colspan="1">the physiologically based scaling factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">K<sub>t</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">the transit rate constant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">K<sub>t:p</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">the ratio of drug concentration in tissue to plasma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PBPK</td><td align="left" valign="middle" rowspan="1" colspan="1">physiologically based pharmacokinetic</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceutics-17-01582"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ginès</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Krag</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Abraldes</surname><given-names>J.G.</given-names></name>
<name name-style="western"><surname>Solà</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Fabrellas</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Kamath</surname><given-names>P.S.</given-names></name>
</person-group><article-title>Liver cirrhosis</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>1359</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)01374-X</pub-id><pub-id pub-id-type="pmid">34543610</pub-id></element-citation></ref><ref id="B2-pharmaceutics-17-01582"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Devarbhavi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Asrani</surname><given-names>S.K.</given-names></name>
<name name-style="western"><surname>Arab</surname><given-names>J.P.</given-names></name>
<name name-style="western"><surname>Nartey</surname><given-names>Y.A.</given-names></name>
<name name-style="western"><surname>Pose</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Kamath</surname><given-names>P.S.</given-names></name>
</person-group><article-title>Global burden of liver disease: 2023 update</article-title><source>J. Hepatol.</source><year>2023</year><volume>79</volume><fpage>516</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.03.017</pub-id><pub-id pub-id-type="pmid">36990226</pub-id></element-citation></ref><ref id="B3-pharmaceutics-17-01582"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Huang</surname><given-names>D.Q.</given-names></name>
<name name-style="western"><surname>Terrault</surname><given-names>N.A.</given-names></name>
<name name-style="western"><surname>Tacke</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Gluud</surname><given-names>L.L.</given-names></name>
<name name-style="western"><surname>Arrese</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Bugianesi</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Loomba</surname><given-names>R.</given-names></name>
</person-group><article-title>Global epidemiology of cirrhosis—Aaetiology, trends and predictions</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2023</year><volume>20</volume><fpage>388</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1038/s41575-023-00759-2</pub-id><pub-id pub-id-type="pmid">36977794</pub-id><pub-id pub-id-type="pmcid">PMC10043867</pub-id></element-citation></ref><ref id="B4-pharmaceutics-17-01582"><label>4.</label><element-citation publication-type="webpage"><article-title>Global Hepatitis Programme</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis" ext-link-type="uri">https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-12-04">(accessed on 4 December 2025)</date-in-citation></element-citation></ref><ref id="B5-pharmaceutics-17-01582"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Roehlen</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Crouchet</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Baumert</surname><given-names>T.F.</given-names></name>
</person-group><article-title>Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>875</elocation-id><pub-id pub-id-type="doi">10.3390/cells9040875</pub-id><pub-id pub-id-type="pmid">32260126</pub-id><pub-id pub-id-type="pmcid">PMC7226751</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-01582"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dhar</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Baglieri</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Kisseleva</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Brenner</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Mechanisms of liver fibrosis and its role in liver cancer</article-title><source>Exp. Biol. Med.</source><year>2020</year><volume>245</volume><fpage>96</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1177/1535370219898141</pub-id><pub-id pub-id-type="pmid">31924111</pub-id><pub-id pub-id-type="pmcid">PMC7016420</pub-id></element-citation></ref><ref id="B7-pharmaceutics-17-01582"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pugh</surname><given-names>R.N.</given-names></name>
<name name-style="western"><surname>Murray-Lyon</surname><given-names>I.M.</given-names></name>
<name name-style="western"><surname>Dawson</surname><given-names>J.L.</given-names></name>
<name name-style="western"><surname>Pietroni</surname><given-names>M.C.</given-names></name>
<name name-style="western"><surname>Williams</surname><given-names>R.</given-names></name>
</person-group><article-title>Transection of the oesophagus for bleeding oesophageal varices</article-title><source>Br. J. Surg.</source><year>1973</year><volume>60</volume><fpage>646</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1002/bjs.1800600817</pub-id><pub-id pub-id-type="pmid">4541913</pub-id></element-citation></ref><ref id="B8-pharmaceutics-17-01582"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nishikawa</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Osaki</surname><given-names>Y.</given-names></name>
</person-group><article-title>Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis</article-title><source>Mediat. Inflamm.</source><year>2015</year><volume>2015</volume><fpage>872152</fpage><pub-id pub-id-type="doi">10.1155/2015/872152</pub-id><pub-id pub-id-type="pmid">26494949</pub-id><pub-id pub-id-type="pmcid">PMC4606163</pub-id></element-citation></ref><ref id="B9-pharmaceutics-17-01582"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Engelmann</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Clària</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Szabo</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Bosch</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Bernardi</surname><given-names>M.</given-names></name>
</person-group><article-title>Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction</article-title><source>J. Hepatol.</source><year>2021</year><volume>75</volume><issue>(Suppl. S1)</issue><fpage>S49</fpage><lpage>S66</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.01.002</pub-id><pub-id pub-id-type="pmid">34039492</pub-id><pub-id pub-id-type="pmcid">PMC9272511</pub-id></element-citation></ref><ref id="B10-pharmaceutics-17-01582"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tsochatzis</surname><given-names>E.A.</given-names></name>
<name name-style="western"><surname>Bosch</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Burroughs</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Liver cirrhosis</article-title><source>Lancet</source><year>2014</year><volume>383</volume><fpage>1749</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)60121-5</pub-id><pub-id pub-id-type="pmid">24480518</pub-id></element-citation></ref><ref id="B11-pharmaceutics-17-01582"><label>11.</label><element-citation publication-type="gov"><article-title>Guidelines for the Clinical Use of Proton Pump Inhibitors</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nhc.gov.cn/yzygj/c100068/202012/b59f1401666645009b64aee17185c87b.shtml" ext-link-type="uri">https://www.nhc.gov.cn/yzygj/c100068/202012/b59f1401666645009b64aee17185c87b.shtml</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-12-04">(accessed on 4 December 2025)</date-in-citation></element-citation></ref><ref id="B12-pharmaceutics-17-01582"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>El Rouby</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Lima</surname><given-names>J.J.</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Proton pump inhibitors: From CYP2C19 pharmacogenetics to precision medicine</article-title><source>Expert. Opin. Drug Metab. Toxicol.</source><year>2018</year><volume>14</volume><fpage>447</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1080/17425255.2018.1461835</pub-id><pub-id pub-id-type="pmid">29620484</pub-id><pub-id pub-id-type="pmcid">PMC5942154</pub-id></element-citation></ref><ref id="B13-pharmaceutics-17-01582"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Desta</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Shin</surname><given-names>J.G.</given-names></name>
<name name-style="western"><surname>Flockhart</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Clinical significance of the cytochrome P450 2C19 genetic polymorphism</article-title><source>Clin. Pharmacokinet.</source><year>2002</year><volume>41</volume><fpage>913</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.2165/00003088-200241120-00002</pub-id><pub-id pub-id-type="pmid">12222994</pub-id></element-citation></ref><ref id="B14-pharmaceutics-17-01582"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Mega</surname><given-names>J.L.</given-names></name>
<name name-style="western"><surname>Close</surname><given-names>S.L.</given-names></name>
<name name-style="western"><surname>Wiviott</surname><given-names>S.D.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Hockett</surname><given-names>R.D.</given-names></name>
<name name-style="western"><surname>Brandt</surname><given-names>J.T.</given-names></name>
<name name-style="western"><surname>Walker</surname><given-names>J.R.</given-names></name>
<name name-style="western"><surname>Antman</surname><given-names>E.M.</given-names></name>
<name name-style="western"><surname>Macias</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Braunwald</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Cytochrome p-450 polymorphisms and response to clopidogrel</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>360</volume><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0809171</pub-id><pub-id pub-id-type="pmid">19106084</pub-id></element-citation></ref><ref id="B15-pharmaceutics-17-01582"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hamdy</surname><given-names>N.A.</given-names></name>
<name name-style="western"><surname>Kennedy</surname><given-names>H.J.</given-names></name>
<name name-style="western"><surname>Nicholl</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Triger</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Sedation for gastroscopy: A comparative study of midazolam and Diazemuls in patients with and without cirrhosis</article-title><source>Br. J. Clin. Pharmacol.</source><year>1986</year><volume>22</volume><fpage>643</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1986.tb02952.x</pub-id><pub-id pub-id-type="pmid">3552010</pub-id><pub-id pub-id-type="pmcid">PMC1401217</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-01582"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Duthaler</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Bachmann</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Suenderhauf</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Grandinetti</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Pfefferkorn</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Haschke</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hruz</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Bouitbir</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Krähenbühl</surname><given-names>S.</given-names></name>
</person-group><article-title>Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently</article-title><source>Clin. Pharmacokinet.</source><year>2022</year><volume>61</volume><fpage>1039</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1007/s40262-022-01119-0</pub-id><pub-id pub-id-type="pmid">35570253</pub-id><pub-id pub-id-type="pmcid">PMC9287224</pub-id></element-citation></ref><ref id="B17-pharmaceutics-17-01582"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Delcò</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Tchambaz</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Schlienger</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Drewe</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Krähenbühl</surname><given-names>S.</given-names></name>
</person-group><article-title>Dose adjustment in patients with liver disease</article-title><source>Drug Saf.</source><year>2005</year><volume>28</volume><fpage>529</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.2165/00002018-200528060-00005</pub-id><pub-id pub-id-type="pmid">15924505</pub-id></element-citation></ref><ref id="B18-pharmaceutics-17-01582"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Johnson</surname><given-names>T.N.</given-names></name>
<name name-style="western"><surname>Boussery</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Rowland-Yeo</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Tucker</surname><given-names>G.T.</given-names></name>
<name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name>
</person-group><article-title>A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance</article-title><source>Clin. Pharmacokinet.</source><year>2010</year><volume>49</volume><fpage>189</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.2165/11318160-000000000-00000</pub-id><pub-id pub-id-type="pmid">20170207</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-01582"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>He</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Mu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Wen</surname><given-names>Q.</given-names></name>
</person-group><article-title>Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model</article-title><source>Eur. J. Pharm. Sci.</source><year>2022</year><volume>179</volume><fpage>106298</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2022.106298</pub-id><pub-id pub-id-type="pmid">36162752</pub-id></element-citation></ref><ref id="B20-pharmaceutics-17-01582"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kalam</surname><given-names>M.N.</given-names></name>
<name name-style="western"><surname>Rasool</surname><given-names>M.F.</given-names></name>
<name name-style="western"><surname>Alqahtani</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Imran</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Rehman</surname><given-names>A.U.</given-names></name>
<name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name>
</person-group><article-title>Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients</article-title><source>Drug Des. Dev. Ther.</source><year>2021</year><volume>15</volume><fpage>1195</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S297981</pub-id><pub-id pub-id-type="pmcid">PMC7982780</pub-id><pub-id pub-id-type="pmid">33762817</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-01582"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Mu</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>234</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16020234</pub-id><pub-id pub-id-type="pmid">38399287</pub-id><pub-id pub-id-type="pmcid">PMC10893190</pub-id></element-citation></ref><ref id="B22-pharmaceutics-17-01582"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>McGowan</surname><given-names>F.X.</given-names></name>
<name name-style="western"><surname>Reiter</surname><given-names>M.J.</given-names></name>
<name name-style="western"><surname>Pritchett</surname><given-names>E.L.</given-names></name>
<name name-style="western"><surname>Shand</surname><given-names>D.G.</given-names></name>
</person-group><article-title>Verapamil plasma binding: Relationship to alpha 1-acid glycoprotein and drug efficacy</article-title><source>Clin. Pharmacol. Ther.</source><year>1983</year><volume>33</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1038/clpt.1983.66</pub-id><pub-id pub-id-type="pmid">6831827</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-01582"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Belpaire</surname><given-names>F.M.</given-names></name>
<name name-style="western"><surname>Bogaert</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum</article-title><source>Int. J. Clin. Pharmacol. Ther. Toxicol.</source><year>1991</year><volume>29</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">2071261</pub-id></element-citation></ref><ref id="B24-pharmaceutics-17-01582"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cartee</surname><given-names>N.M.P.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Binding of omeprazole to protein targets identified by monoclonal antibodies</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0239464</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0239464</pub-id><pub-id pub-id-type="pmid">32946534</pub-id><pub-id pub-id-type="pmcid">PMC7500594</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-01582"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Landes</surname><given-names>B.D.</given-names></name>
<name name-style="western"><surname>Petite</surname><given-names>J.P.</given-names></name>
<name name-style="western"><surname>Flouvat</surname><given-names>B.</given-names></name>
</person-group><article-title>Clinical pharmacokinetics of lansoprazole</article-title><source>Clin. Pharmacokinet.</source><year>1995</year><volume>28</volume><fpage>458</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.2165/00003088-199528060-00004</pub-id><pub-id pub-id-type="pmid">7656504</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-01582"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hamaoka</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Oda</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Hase</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Mizutani</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Nakamoto</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ishizaki</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Asada</surname><given-names>A.</given-names></name>
</person-group><article-title>Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study</article-title><source>Clin. Pharmacol. Ther.</source><year>1999</year><volume>66</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1053/cp.1999.v66.100038001</pub-id><pub-id pub-id-type="pmid">10460064</pub-id></element-citation></ref><ref id="B27-pharmaceutics-17-01582"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Simpson</surname><given-names>K.H.</given-names></name>
<name name-style="western"><surname>Hicks</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Clinical pharmacokinetics of ondansetron. A review</article-title><source>J. Pharm. Pharmacol.</source><year>1996</year><volume>48</volume><fpage>774</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1996.tb03973.x</pub-id><pub-id pub-id-type="pmid">8887724</pub-id></element-citation></ref><ref id="B28-pharmaceutics-17-01582"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Barton</surname><given-names>H.A.</given-names></name>
<name name-style="western"><surname>Maurer</surname><given-names>T.S.</given-names></name>
</person-group><article-title>A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2015</year><volume>4</volume><fpage>338</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1002/psp4.39</pub-id><pub-id pub-id-type="pmid">26225262</pub-id><pub-id pub-id-type="pmcid">PMC4505828</pub-id></element-citation></ref><ref id="B29-pharmaceutics-17-01582"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Karlsen</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Fynne</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Grønbæk</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Krogh</surname><given-names>K.</given-names></name>
</person-group><article-title>Small intestinal transit in patients with liver cirrhosis and portal hypertension: A descriptive study</article-title><source>BMC Gastroenterol.</source><year>2012</year><volume>12</volume><elocation-id>176</elocation-id><pub-id pub-id-type="doi">10.1186/1471-230X-12-176</pub-id><pub-id pub-id-type="pmid">23216853</pub-id><pub-id pub-id-type="pmcid">PMC3520867</pub-id></element-citation></ref><ref id="B30-pharmaceutics-17-01582"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pepin</surname><given-names>X.J.H.</given-names></name>
<name name-style="western"><surname>Johansson Soares Medeiros</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Deris Prado</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Suarez Sharp</surname><given-names>S.</given-names></name>
</person-group><article-title>The Development of an Age-Appropriate Fixed Dose Combination for Tuberculosis Using Physiologically-Based Pharmacokinetic Modeling (PBBM) and Risk Assessment</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>1587</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16121587</pub-id><pub-id pub-id-type="pmid">39771565</pub-id><pub-id pub-id-type="pmcid">PMC11680012</pub-id></element-citation></ref><ref id="B31-pharmaceutics-17-01582"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Han</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name>
</person-group><article-title>Prediction of Pharmacokinetics for CYP3A4-Metabolized Drugs in Pediatrics and Geriatrics Using Dynamic Age-Dependent Physiologically Based Pharmacokinetic Models</article-title><source>Pharmaceutics</source><year>2025</year><volume>17</volume><elocation-id>214</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics17020214</pub-id><pub-id pub-id-type="pmid">40006581</pub-id><pub-id pub-id-type="pmcid">PMC11860008</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-01582"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kong</surname><given-names>W.M.</given-names></name>
<name name-style="western"><surname>Sun</surname><given-names>B.B.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Z.J.</given-names></name>
<name name-style="western"><surname>Zheng</surname><given-names>X.K.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>K.J.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>J.X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>P.H.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>R.J.</given-names></name>
<etal/>
</person-group><article-title>Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans</article-title><source>Acta Pharmacol. Sin.</source><year>2020</year><volume>41</volume><fpage>852</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1038/s41401-019-0353-2</pub-id><pub-id pub-id-type="pmid">31969689</pub-id><pub-id pub-id-type="pmcid">PMC7468366</pub-id></element-citation></ref><ref id="B33-pharmaceutics-17-01582"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Small</surname><given-names>B.G.</given-names></name>
<name name-style="western"><surname>Hatley</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Jamei</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Gardner</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>T.N.</given-names></name>
</person-group><article-title>Incorporation and Performance Verification of Hepatic Portal Blood Flow Shunting in Minimal and Full PBPK Models of Liver Cirrhosis</article-title><source>Clin. Pharmacol. Ther.</source><year>2023</year><volume>114</volume><fpage>1264</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1002/cpt.3032</pub-id><pub-id pub-id-type="pmid">37620290</pub-id></element-citation></ref><ref id="B34-pharmaceutics-17-01582"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ladumor</surname><given-names>M.K.</given-names></name>
<name name-style="western"><surname>Storelli</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Lai</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Enogieru</surname><given-names>O.J.</given-names></name>
<name name-style="western"><surname>Chothe</surname><given-names>P.P.</given-names></name>
<name name-style="western"><surname>Evers</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Unadkat</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Predicting changes in the pharmacokinetics of CYP3A-metabolized drugs in hepatic impairment and insights into factors driving these changes</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2023</year><volume>12</volume><fpage>261</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1002/psp4.12901</pub-id><pub-id pub-id-type="pmcid">PMC9931433</pub-id><pub-id pub-id-type="pmid">36540952</pub-id></element-citation></ref><ref id="B35-pharmaceutics-17-01582"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Andersson</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Regårdh</surname><given-names>C.G.</given-names></name>
<name name-style="western"><surname>Lou</surname><given-names>Y.C.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Dahl</surname><given-names>M.L.</given-names></name>
<name name-style="western"><surname>Bertilsson</surname><given-names>L.</given-names></name>
</person-group><article-title>Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects</article-title><source>Pharmacogenetics</source><year>1992</year><volume>2</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1097/00008571-199202000-00005</pub-id><pub-id pub-id-type="pmid">1302040</pub-id></element-citation></ref><ref id="B36-pharmaceutics-17-01582"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Noubarani</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kobarfard</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Motevalian</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Keyhanfar</surname><given-names>F.</given-names></name>
</person-group><article-title>Variation in omeprazole pharmacokinetics in a random Iranian population: A pilot study</article-title><source>Biopharm. Drug Dispos.</source><year>2012</year><volume>33</volume><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1002/bdd.1805</pub-id><pub-id pub-id-type="pmid">22890488</pub-id></element-citation></ref><ref id="B37-pharmaceutics-17-01582"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hu</surname><given-names>X.P.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>J.M.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>Y.M.</given-names></name>
<name name-style="western"><surname>Mei</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>X.H.</given-names></name>
</person-group><article-title>Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people</article-title><source>J. Clin. Pharm. Ther.</source><year>2007</year><volume>32</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.2007.00851.x</pub-id><pub-id pub-id-type="pmid">17875119</pub-id></element-citation></ref><ref id="B38-pharmaceutics-17-01582"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Sakai</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Aoyama</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Kita</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Sakaeda</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Nishiguchi</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Nishitora</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Hohda</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Sirasaka</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Tamura</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Tanigawara</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects</article-title><source>Pharm. Res.</source><year>2001</year><volume>18</volume><fpage>721</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1023/A:1011035007591</pub-id><pub-id pub-id-type="pmid">11474773</pub-id></element-citation></ref><ref id="B39-pharmaceutics-17-01582"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Furuta</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Ohashi</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Kobayashi</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Iida</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Yoshida</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Shirai</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Takashima</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kosuge</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Hanai</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Chiba</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans</article-title><source>Clin. Pharmacol. Ther.</source><year>1999</year><volume>66</volume><fpage>265</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/S0009-9236(99)70034-2</pub-id><pub-id pub-id-type="pmid">10511062</pub-id></element-citation></ref><ref id="B40-pharmaceutics-17-01582"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Román</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ochoa</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Sánchez-Rojas</surname><given-names>S.D.</given-names></name>
<name name-style="western"><surname>Talegón</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Prieto-Pérez</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Rivas</surname><given-names>Â.</given-names></name>
<name name-style="western"><surname>Abad-Santos</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Cabaleiro</surname><given-names>T.</given-names></name>
</person-group><article-title>Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole</article-title><source>Pharmacogenomics</source><year>2014</year><volume>15</volume><fpage>1893</fpage><lpage>1901</lpage><pub-id pub-id-type="doi">10.2217/pgs.14.141</pub-id><pub-id pub-id-type="pmid">25495411</pub-id></element-citation></ref><ref id="B41-pharmaceutics-17-01582"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cawello</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Mueller-Voessing</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Fichtner</surname><given-names>A.</given-names></name>
</person-group><article-title>Pharmacokinetics of lacosamide and omeprazole coadministration in healthy volunteers: Results from a phase I, randomized, crossover trial</article-title><source>Clin. Drug Investig.</source><year>2014</year><volume>34</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1007/s40261-014-0177-2</pub-id><pub-id pub-id-type="pmid">24567279</pub-id></element-citation></ref><ref id="B42-pharmaceutics-17-01582"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jin</surname><given-names>S.K.</given-names></name>
<name name-style="western"><surname>Kang</surname><given-names>T.S.</given-names></name>
<name name-style="western"><surname>Eom</surname><given-names>S.O.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>J.I.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>H.J.</given-names></name>
<name name-style="western"><surname>Roh</surname><given-names>J.</given-names></name>
</person-group><article-title>CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole</article-title><source>J. Clin. Pharm. Ther.</source><year>2009</year><volume>34</volume><fpage>437</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.2008.01012.x</pub-id><pub-id pub-id-type="pmid">19583677</pub-id></element-citation></ref><ref id="B43-pharmaceutics-17-01582"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Cho</surname><given-names>J.Y.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>K.S.</given-names></name>
<name name-style="western"><surname>Jang</surname><given-names>I.J.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>B.H.</given-names></name>
<name name-style="western"><surname>Shin</surname><given-names>S.G.</given-names></name>
<name name-style="western"><surname>Yim</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19</article-title><source>Br. J. Clin. Pharmacol.</source><year>2002</year><volume>53</volume><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2002.01366.x</pub-id><pub-id pub-id-type="pmid">11966672</pub-id><pub-id pub-id-type="pmcid">PMC1874278</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-01582"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yasui-Furukori</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Takahata</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Nakagami</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Yoshiya</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Inoue</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Kaneko</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Tateishi</surname><given-names>T.</given-names></name>
</person-group><article-title>Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes</article-title><source>Br. J. Clin. Pharmacol.</source><year>2004</year><volume>57</volume><fpage>487</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2003.02047.x</pub-id><pub-id pub-id-type="pmid">15025747</pub-id><pub-id pub-id-type="pmcid">PMC1884483</pub-id></element-citation></ref><ref id="B45-pharmaceutics-17-01582"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hussein</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Granneman</surname><given-names>G.R.</given-names></name>
<name name-style="western"><surname>Mukherjee</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Samara</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Hogan</surname><given-names>D.L.</given-names></name>
<name name-style="western"><surname>Koss</surname><given-names>M.A.</given-names></name>
<name name-style="western"><surname>Isenberg</surname><given-names>J.I.</given-names></name>
</person-group><article-title>Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole</article-title><source>Br. J. Clin. Pharmacol.</source><year>1993</year><volume>36</volume><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1993.tb00386.x</pub-id><pub-id pub-id-type="pmid">12959285</pub-id><pub-id pub-id-type="pmcid">PMC1364610</pub-id></element-citation></ref><ref id="B46-pharmaceutics-17-01582"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Amer</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Karol</surname><given-names>M.D.</given-names></name>
<name name-style="western"><surname>Pan</surname><given-names>W.J.</given-names></name>
<name name-style="western"><surname>Griffin</surname><given-names>J.S.</given-names></name>
<name name-style="western"><surname>Lukasik</surname><given-names>N.L.</given-names></name>
<name name-style="western"><surname>Locke</surname><given-names>C.S.</given-names></name>
<name name-style="western"><surname>Chiu</surname><given-names>Y.L.</given-names></name>
</person-group><article-title>Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules</article-title><source>Clin. Ther.</source><year>2004</year><volume>26</volume><fpage>2076</fpage><lpage>2083</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2004.12.008</pub-id><pub-id pub-id-type="pmid">15823771</pub-id></element-citation></ref><ref id="B47-pharmaceutics-17-01582"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Doan</surname><given-names>T.T.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Griffin</surname><given-names>J.S.</given-names></name>
<name name-style="western"><surname>Lukasik</surname><given-names>N.L.</given-names></name>
<name name-style="western"><surname>O’Dea</surname><given-names>R.F.</given-names></name>
<name name-style="western"><surname>Pan</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects</article-title><source>Am. J. Health Syst. Pharm.</source><year>2001</year><volume>58</volume><fpage>1512</fpage><lpage>1519</lpage><pub-id pub-id-type="doi">10.1093/ajhp/58.16.1512</pub-id><pub-id pub-id-type="pmid">11515348</pub-id></element-citation></ref><ref id="B48-pharmaceutics-17-01582"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Miura</surname><given-names>M.</given-names></name>
</person-group><article-title>Enantioselective disposition of lansoprazole and rabeprazole in human plasma</article-title><source>Yakugaku Zasshi</source><year>2006</year><volume>126</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1248/yakushi.126.395</pub-id><pub-id pub-id-type="pmid">16755125</pub-id></element-citation></ref><ref id="B49-pharmaceutics-17-01582"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Flouvat</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Delhotal-Landes</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Cournot</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Dellatolas</surname><given-names>F.</given-names></name>
</person-group><article-title>Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects</article-title><source>Br. J. Clin. Pharmacol.</source><year>1993</year><volume>36</volume><fpage>467</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1993.tb00398.x</pub-id><pub-id pub-id-type="pmid">12959297</pub-id><pub-id pub-id-type="pmcid">PMC1364622</pub-id></element-citation></ref><ref id="B50-pharmaceutics-17-01582"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Delhotal-Landes</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Flouvat</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Duchier</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Molinie</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Dellatolas</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Lemaire</surname><given-names>M.</given-names></name>
</person-group><article-title>Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity</article-title><source>Eur. J. Clin. Pharmacol.</source><year>1993</year><volume>45</volume><fpage>367</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1007/BF00265957</pub-id><pub-id pub-id-type="pmid">8299672</pub-id></element-citation></ref><ref id="B51-pharmaceutics-17-01582"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tian</surname><given-names>D.D.</given-names></name>
<name name-style="western"><surname>Leonowens</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Cox</surname><given-names>E.J.</given-names></name>
<name name-style="western"><surname>González-Pérez</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Frederick</surname><given-names>K.S.</given-names></name>
<name name-style="western"><surname>Scarlett</surname><given-names>Y.V.</given-names></name>
<name name-style="western"><surname>Fisher</surname><given-names>M.B.</given-names></name>
<name name-style="western"><surname>Paine</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach</article-title><source>Drug Metab. Dispos.</source><year>2019</year><volume>47</volume><fpage>724</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1124/dmd.119.087007</pub-id><pub-id pub-id-type="pmid">31028057</pub-id><pub-id pub-id-type="pmcid">PMC6556520</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-01582"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shih</surname><given-names>P.S.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Pharmacokinetics of midazolam and 1’-hydroxymidazolam in Chinese with different CYP3A5 genotypes</article-title><source>Drug Metab. Dispos.</source><year>2002</year><volume>30</volume><fpage>1491</fpage><lpage>1496</lpage><pub-id pub-id-type="doi">10.1124/dmd.30.12.1491</pub-id><pub-id pub-id-type="pmid">12433824</pub-id></element-citation></ref><ref id="B53-pharmaceutics-17-01582"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kupferschmidt</surname><given-names>H.H.</given-names></name>
<name name-style="western"><surname>Ha</surname><given-names>H.R.</given-names></name>
<name name-style="western"><surname>Ziegler</surname><given-names>W.H.</given-names></name>
<name name-style="western"><surname>Meier</surname><given-names>P.J.</given-names></name>
<name name-style="western"><surname>Krähenbühl</surname><given-names>S.</given-names></name>
</person-group><article-title>Interaction between grapefruit juice and midazolam in humans</article-title><source>Clin. Pharmacol. Ther.</source><year>1995</year><volume>58</volume><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0009-9236(95)90068-3</pub-id><pub-id pub-id-type="pmid">7628179</pub-id></element-citation></ref><ref id="B54-pharmaceutics-17-01582"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Teng</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Butler</surname><given-names>K.</given-names></name>
</person-group><article-title>The effect of ticagrelor on the metabolism of midazolam in healthy volunteers</article-title><source>Clin. Ther.</source><year>2013</year><volume>35</volume><fpage>1025</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2013.06.003</pub-id><pub-id pub-id-type="pmid">23870610</pub-id></element-citation></ref><ref id="B55-pharmaceutics-17-01582"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Guo</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Mao</surname><given-names>G.F.</given-names></name>
<name name-style="western"><surname>Xia</surname><given-names>D.Y.</given-names></name>
<name name-style="western"><surname>Su</surname><given-names>X.Y.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>L.S.</given-names></name>
</person-group><article-title>Pharmacokinetics of midazolam tablet in different Chinese ethnic groups</article-title><source>J. Clin. Pharm. Ther.</source><year>2011</year><volume>36</volume><fpage>406</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.2010.01178.x</pub-id><pub-id pub-id-type="pmid">21545620</pub-id></element-citation></ref><ref id="B56-pharmaceutics-17-01582"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lepper</surname><given-names>E.R.</given-names></name>
<name name-style="western"><surname>Hicks</surname><given-names>J.K.</given-names></name>
<name name-style="western"><surname>Verweij</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhai</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Figg</surname><given-names>W.D.</given-names></name>
<name name-style="western"><surname>Sparreboom</surname><given-names>A.</given-names></name>
</person-group><article-title>Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection</article-title><source>J. Chromatogr. B</source><year>2004</year><volume>806</volume><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2004.04.003</pub-id><pub-id pub-id-type="pmid">15171944</pub-id></element-citation></ref><ref id="B57-pharmaceutics-17-01582"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dale</surname><given-names>O.</given-names></name>
<name name-style="western"><surname>Nilsen</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Loftsson</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Hjorth Tønnesen</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Klepstad</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kaasa</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Holand</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Djupesland</surname><given-names>P.G.</given-names></name>
</person-group><article-title>Intranasal midazolam: A comparison of two delivery devices in human volunteers</article-title><source>J. Pharm. Pharmacol.</source><year>2006</year><volume>58</volume><fpage>1311</fpage><lpage>1318</lpage><pub-id pub-id-type="doi">10.1211/jpp.58.10.0003</pub-id><pub-id pub-id-type="pmid">17034653</pub-id></element-citation></ref><ref id="B58-pharmaceutics-17-01582"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>VanDenBerg</surname><given-names>C.M.</given-names></name>
<name name-style="western"><surname>Kazmi</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Stewart</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Weidler</surname><given-names>D.J.</given-names></name>
<name name-style="western"><surname>Tenjarla</surname><given-names>S.N.</given-names></name>
<name name-style="western"><surname>Ward</surname><given-names>E.S.</given-names></name>
<name name-style="western"><surname>Jann</surname><given-names>M.W.</given-names></name>
</person-group><article-title>Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion</article-title><source>Am. J. Health Syst. Pharm.</source><year>2000</year><volume>57</volume><fpage>1046</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1093/ajhp/57.11.1046</pub-id><pub-id pub-id-type="pmid">10876746</pub-id></element-citation></ref><ref id="B59-pharmaceutics-17-01582"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hsyu</surname><given-names>P.H.</given-names></name>
<name name-style="western"><surname>Pritchard</surname><given-names>J.F.</given-names></name>
<name name-style="western"><surname>Bozigian</surname><given-names>H.P.</given-names></name>
<name name-style="western"><surname>Lloyd</surname><given-names>T.L.</given-names></name>
<name name-style="western"><surname>Griffin</surname><given-names>R.H.</given-names></name>
<name name-style="western"><surname>Shamburek</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Krishna</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Barr</surname><given-names>W.H.</given-names></name>
</person-group><article-title>Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum</article-title><source>Pharm. Res.</source><year>1994</year><volume>11</volume><fpage>156</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1023/A:1018974501232</pub-id><pub-id pub-id-type="pmid">8140047</pub-id></element-citation></ref><ref id="B60-pharmaceutics-17-01582"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Pritchard</surname><given-names>J.F.</given-names></name>
<name name-style="western"><surname>Bryson</surname><given-names>J.C.</given-names></name>
<name name-style="western"><surname>Kernodle</surname><given-names>A.E.</given-names></name>
<name name-style="western"><surname>Benedetti</surname><given-names>T.L.</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers</article-title><source>Clin. Pharmacol. Ther.</source><year>1992</year><volume>51</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/clpt.1992.7</pub-id><pub-id pub-id-type="pmid">1531044</pub-id></element-citation></ref><ref id="B61-pharmaceutics-17-01582"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ashforth</surname><given-names>E.I.</given-names></name>
<name name-style="western"><surname>Palmer</surname><given-names>J.L.</given-names></name>
<name name-style="western"><surname>Bye</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Bedding</surname><given-names>A.</given-names></name>
</person-group><article-title>The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine</article-title><source>Br. J. Clin. Pharmacol.</source><year>1994</year><volume>37</volume><fpage>389</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1994.tb04294.x</pub-id><pub-id pub-id-type="pmid">8018461</pub-id><pub-id pub-id-type="pmcid">PMC1364741</pub-id></element-citation></ref><ref id="B62-pharmaceutics-17-01582"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Blake</surname><given-names>J.C.</given-names></name>
<name name-style="western"><surname>Palmer</surname><given-names>J.L.</given-names></name>
<name name-style="western"><surname>Minton</surname><given-names>N.A.</given-names></name>
<name name-style="western"><surname>Burroughs</surname><given-names>A.K.</given-names></name>
</person-group><article-title>The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment</article-title><source>Br. J. Clin. Pharmacol.</source><year>1993</year><volume>35</volume><fpage>441</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1993.tb04164.x</pub-id><pub-id pub-id-type="pmid">8485026</pub-id><pub-id pub-id-type="pmcid">PMC1381558</pub-id></element-citation></ref><ref id="B63-pharmaceutics-17-01582"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dominic</surname><given-names>J.A.</given-names></name>
<name name-style="western"><surname>Bourne</surname><given-names>D.W.</given-names></name>
<name name-style="western"><surname>Tan</surname><given-names>T.G.</given-names></name>
<name name-style="western"><surname>Kirsten</surname><given-names>E.B.</given-names></name>
<name name-style="western"><surname>McAllister</surname><given-names>R.G.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration</article-title><source>J. Cardiovasc. Pharmacol.</source><year>1981</year><volume>3</volume><fpage>25</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1097/00005344-198101000-00003</pub-id><pub-id pub-id-type="pmid">6160352</pub-id></element-citation></ref><ref id="B64-pharmaceutics-17-01582"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hla</surname><given-names>K.K.</given-names></name>
<name name-style="western"><surname>Henry</surname><given-names>J.A.</given-names></name>
<name name-style="western"><surname>Latham</surname><given-names>A.N.</given-names></name>
</person-group><article-title>Pharmacokinetics and pharmacodynamics of two formulations of verapamil</article-title><source>Br. J. Clin. Pharmacol.</source><year>1987</year><volume>24</volume><fpage>661</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1987.tb03226.x</pub-id><pub-id pub-id-type="pmid">3435694</pub-id><pub-id pub-id-type="pmcid">PMC1386339</pub-id></element-citation></ref><ref id="B65-pharmaceutics-17-01582"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dadashzadeh</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Javadian</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Sadeghian</surname><given-names>S.</given-names></name>
</person-group><article-title>The effect of gender on the pharmacokinetics of verapamil and norverapamil in human</article-title><source>Biopharm. Drug Dispos.</source><year>2006</year><volume>27</volume><fpage>329</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1002/bdd.512</pub-id><pub-id pub-id-type="pmid">16892180</pub-id></element-citation></ref><ref id="B66-pharmaceutics-17-01582"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Somogyi</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Albrecht</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Kliems</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Schäfer</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Eichelbaum</surname><given-names>M.</given-names></name>
</person-group><article-title>Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis</article-title><source>Br. J. Clin. Pharmacol.</source><year>1981</year><volume>12</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1981.tb01854.x</pub-id><pub-id pub-id-type="pmid">7248141</pub-id><pub-id pub-id-type="pmcid">PMC1401748</pub-id></element-citation></ref><ref id="B67-pharmaceutics-17-01582"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kharasch</surname><given-names>E.D.</given-names></name>
<name name-style="western"><surname>Hoffer</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Walker</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Sheffels</surname><given-names>P.</given-names></name>
</person-group><article-title>Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity</article-title><source>Clin. Pharmacol. Ther.</source><year>2003</year><volume>73</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1067/mcp.2003.30</pub-id><pub-id pub-id-type="pmid">12621385</pub-id></element-citation></ref><ref id="B68-pharmaceutics-17-01582"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Schwagmeier</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Boerger</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Meissner</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Striebel</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Pharmacokinetics of intranasal alfentanil</article-title><source>J. Clin. Anesth.</source><year>1995</year><volume>7</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/0952-8180(94)00023-W</pub-id><pub-id pub-id-type="pmid">7598917</pub-id></element-citation></ref><ref id="B69-pharmaceutics-17-01582"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ferrier</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Marty</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Bouffard</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Haberer</surname><given-names>J.P.</given-names></name>
<name name-style="western"><surname>Levron</surname><given-names>J.C.</given-names></name>
<name name-style="western"><surname>Duvaldestin</surname><given-names>P.</given-names></name>
</person-group><article-title>Alfentanil pharmacokinetics in patients with cirrhosis</article-title><source>Anesthesiology</source><year>1985</year><volume>62</volume><fpage>480</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1097/00000542-198504000-00018</pub-id><pub-id pub-id-type="pmid">3920934</pub-id></element-citation></ref><ref id="B70-pharmaceutics-17-01582"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zhi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name>
</person-group><article-title>Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms</article-title><source>Pharm. Res.</source><year>2023</year><volume>40</volume><fpage>1735</fpage><lpage>1750</lpage><pub-id pub-id-type="doi">10.1007/s11095-023-03531-y</pub-id><pub-id pub-id-type="pmid">37226024</pub-id></element-citation></ref><ref id="B71-pharmaceutics-17-01582"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nies</surname><given-names>A.S.</given-names></name>
<name name-style="western"><surname>Shand</surname><given-names>D.G.</given-names></name>
<name name-style="western"><surname>Wilkinson</surname><given-names>G.R.</given-names></name>
</person-group><article-title>Altered hepatic blood flow and drug disposition</article-title><source>Clin. Pharmacokinet.</source><year>1976</year><volume>1</volume><fpage>135</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.2165/00003088-197601020-00005</pub-id><pub-id pub-id-type="pmid">13954</pub-id></element-citation></ref><ref id="B72-pharmaceutics-17-01582"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rowland</surname><given-names>M.</given-names></name>
</person-group><article-title>Protein binding and drug clearance</article-title><source>Clin. Pharmacokinet.</source><year>1984</year><volume>9</volume><issue>(Suppl. S1)</issue><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.2165/00003088-198400091-00002</pub-id><pub-id pub-id-type="pmid">6705422</pub-id></element-citation></ref><ref id="B73-pharmaceutics-17-01582"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Tapper</surname><given-names>E.B.</given-names></name>
<name name-style="western"><surname>Parikh</surname><given-names>N.D.</given-names></name>
</person-group><article-title>Diagnosis and Management of Cirrhosis and Its Complications: A Review</article-title><source>JAMA</source><year>2023</year><volume>329</volume><fpage>1589</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.5997</pub-id><pub-id pub-id-type="pmid">37159031</pub-id><pub-id pub-id-type="pmcid">PMC10843851</pub-id></element-citation></ref><ref id="B74-pharmaceutics-17-01582"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zardi</surname><given-names>E.M.</given-names></name>
<name name-style="western"><surname>Abbate</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Zardi</surname><given-names>D.M.</given-names></name>
<name name-style="western"><surname>Dobrina</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Margiotta</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Van Tassell</surname><given-names>B.W.</given-names></name>
<name name-style="western"><surname>Afeltra</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Sanyal</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Cirrhotic cardiomyopathy</article-title><source>J. Am. Coll. Cardiol.</source><year>2010</year><volume>56</volume><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2009.12.075</pub-id><pub-id pub-id-type="pmid">20688208</pub-id></element-citation></ref><ref id="B75-pharmaceutics-17-01582"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Acalovschi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Dumitraşcu</surname><given-names>D.L.</given-names></name>
<name name-style="western"><surname>Csakany</surname><given-names>I.</given-names></name>
</person-group><article-title>Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis--a simultaneous sonographic study</article-title><source>Gut</source><year>1997</year><volume>40</volume><fpage>412</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1136/gut.40.3.412</pub-id><pub-id pub-id-type="pmid">9135534</pub-id><pub-id pub-id-type="pmcid">PMC1027095</pub-id></element-citation></ref><ref id="B76-pharmaceutics-17-01582"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Unadkat</surname><given-names>J.D.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Heimbach</surname><given-names>T.</given-names></name>
</person-group><article-title>Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective</article-title><source>Pharm. Res.</source><year>2022</year><volume>39</volume><fpage>1701</fpage><lpage>1731</lpage><pub-id pub-id-type="doi">10.1007/s11095-022-03274-2</pub-id><pub-id pub-id-type="pmid">35552967</pub-id></element-citation></ref><ref id="B77-pharmaceutics-17-01582"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Loisios-Konstantinidis</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Dressman</surname><given-names>J.</given-names></name>
</person-group><article-title>Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and Opportunities</article-title><source>Mol. Pharm.</source><year>2021</year><volume>18</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00903</pub-id><pub-id pub-id-type="pmid">33320002</pub-id></element-citation></ref><ref id="B78-pharmaceutics-17-01582"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Upton</surname><given-names>R.N.</given-names></name>
<name name-style="western"><surname>Foster</surname><given-names>D.J.</given-names></name>
<name name-style="western"><surname>Abuhelwa</surname><given-names>A.Y.</given-names></name>
</person-group><article-title>An introduction to physiologically-based pharmacokinetic models</article-title><source>Paediatr. Anaesth.</source><year>2016</year><volume>26</volume><fpage>1036</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1111/pan.12995</pub-id><pub-id pub-id-type="pmid">27550716</pub-id></element-citation></ref><ref id="B79-pharmaceutics-17-01582"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Reddy</surname><given-names>M.B.</given-names></name>
<name name-style="western"><surname>Cabalu</surname><given-names>T.D.</given-names></name>
<name name-style="western"><surname>de Zwart</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Ramsden</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Dowty</surname><given-names>M.E.</given-names></name>
<name name-style="western"><surname>Taskar</surname><given-names>K.S.</given-names></name>
<name name-style="western"><surname>Badée</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Bolleddula</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Boulu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Fu</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective</article-title><source>Clin. Pharmacol. Ther.</source><year>2025</year><volume>117</volume><fpage>403</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1002/cpt.3477</pub-id><pub-id pub-id-type="pmid">39422118</pub-id><pub-id pub-id-type="pmcid">PMC11739743</pub-id></element-citation></ref><ref id="B80-pharmaceutics-17-01582"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Lei</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name>
</person-group><article-title>Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><elocation-id>972411</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.972411</pub-id><pub-id pub-id-type="pmid">36210839</pub-id><pub-id pub-id-type="pmcid">PMC9543720</pub-id></element-citation></ref><ref id="B81-pharmaceutics-17-01582"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rowland Yeo</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Gil Berglund</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
</person-group><article-title>Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future</article-title><source>Clin. Pharmacol. Ther.</source><year>2024</year><volume>116</volume><fpage>563</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1002/cpt.3289</pub-id><pub-id pub-id-type="pmid">38686708</pub-id></element-citation></ref><ref id="B82-pharmaceutics-17-01582"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Georgieva</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Xenodochidis</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Krasteva</surname><given-names>N.</given-names></name>
</person-group><article-title>Old age as a risk factor for liver diseases: Modern therapeutic approaches</article-title><source>Exp. Gerontol.</source><year>2023</year><volume>184</volume><fpage>112334</fpage><pub-id pub-id-type="doi">10.1016/j.exger.2023.112334</pub-id><pub-id pub-id-type="pmid">37977514</pub-id></element-citation></ref><ref id="B83-pharmaceutics-17-01582"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Jeong</surname><given-names>S.H.</given-names></name>
<name name-style="western"><surname>Jang</surname><given-names>J.H.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>Y.B.</given-names></name>
</person-group><article-title>Physiologically Based Pharmacokinetic (PBPK) Modeling of Lornoxicam: Exploration of doses for CYP2C9 Genotypes and Patients with Cirrhosis</article-title><source>J. Pharm. Sci.</source><year>2022</year><volume>111</volume><fpage>3174</fpage><lpage>3184</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2022.08.035</pub-id><pub-id pub-id-type="pmid">36057318</pub-id></element-citation></ref><ref id="B84-pharmaceutics-17-01582"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Rodgers</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Leahy</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Rowland</surname><given-names>M.</given-names></name>
</person-group><article-title>Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases</article-title><source>J. Pharm. Sci.</source><year>2005</year><volume>94</volume><fpage>1259</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1002/jps.20322</pub-id><pub-id pub-id-type="pmid">15858854</pub-id></element-citation></ref><ref id="B85-pharmaceutics-17-01582"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>T.N.</given-names></name>
<name name-style="western"><surname>Bui</surname><given-names>K.H.</given-names></name>
<name name-style="western"><surname>Cheung</surname><given-names>S.Y.A.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Al-Huniti</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name>
</person-group><article-title>Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children</article-title><source>Clin. Pharmacol. Ther.</source><year>2018</year><volume>104</volume><fpage>188</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1002/cpt.905</pub-id><pub-id pub-id-type="pmid">29027194</pub-id></element-citation></ref><ref id="B86-pharmaceutics-17-01582"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Gaohua</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Jamei</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>S.M.</given-names></name>
<name name-style="western"><surname>Bashaw</surname><given-names>E.D.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: Application to predict drug/genetic interactions</article-title><source>Pharm. Res.</source><year>2014</year><volume>31</volume><fpage>1919</fpage><lpage>1929</lpage><pub-id pub-id-type="doi">10.1007/s11095-013-1293-z</pub-id><pub-id pub-id-type="pmid">24590877</pub-id></element-citation></ref><ref id="B87-pharmaceutics-17-01582"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Qi</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Ge</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Liao</surname><given-names>S.</given-names></name>
</person-group><article-title>Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole</article-title><source>Int. J. Antimicrob. Agents</source><year>2017</year><volume>49</volume><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.11.025</pub-id><pub-id pub-id-type="pmid">28159656</pub-id></element-citation></ref><ref id="B88-pharmaceutics-17-01582"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Katashima</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Yamamoto</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Sugiura</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Sawada</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Iga</surname><given-names>T.</given-names></name>
</person-group><article-title>Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats</article-title><source>Drug Metab. Dispos.</source><year>1995</year><volume>23</volume><fpage>718</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/S0090-9556(25)06649-8</pub-id><pub-id pub-id-type="pmid">7587960</pub-id></element-citation></ref><ref id="B89-pharmaceutics-17-01582"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hanioka</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Tsuneto</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Saito</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Maekawa</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Sawada</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Narimatsu</surname><given-names>S.</given-names></name>
</person-group><article-title>Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: In vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae</article-title><source>Basic. Clin. Pharmacol. Toxicol.</source><year>2008</year><volume>102</volume><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2008.00222.x</pub-id><pub-id pub-id-type="pmid">18312490</pub-id></element-citation></ref><ref id="B90-pharmaceutics-17-01582"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Kim</surname><given-names>K.A.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>M.J.</given-names></name>
<name name-style="western"><surname>Park</surname><given-names>J.Y.</given-names></name>
<name name-style="western"><surname>Shon</surname><given-names>J.H.</given-names></name>
<name name-style="western"><surname>Yoon</surname><given-names>Y.R.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>S.S.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>K.H.</given-names></name>
<name name-style="western"><surname>Chun</surname><given-names>J.H.</given-names></name>
<name name-style="western"><surname>Hyun</surname><given-names>M.H.</given-names></name>
<name name-style="western"><surname>Shin</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes</article-title><source>Drug Metab. Dispos.</source><year>2003</year><volume>31</volume><fpage>1227</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1124/dmd.31.10.1227</pub-id><pub-id pub-id-type="pmid">12975331</pub-id></element-citation></ref><ref id="B91-pharmaceutics-17-01582"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Steere</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Baker</surname><given-names>J.A.</given-names></name>
<name name-style="western"><surname>Hall</surname><given-names>S.D.</given-names></name>
<name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>
</person-group><article-title>Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model</article-title><source>Drug Metab. Dispos.</source><year>2015</year><volume>43</volume><fpage>870</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1124/dmd.114.061523</pub-id><pub-id pub-id-type="pmid">25845826</pub-id></element-citation></ref><ref id="B92-pharmaceutics-17-01582"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yamazaki</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Inoue</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Shaw</surname><given-names>P.M.</given-names></name>
<name name-style="western"><surname>Checovich</surname><given-names>W.J.</given-names></name>
<name name-style="western"><surname>Guengerich</surname><given-names>F.P.</given-names></name>
<name name-style="western"><surname>Shimada</surname><given-names>T.</given-names></name>
</person-group><article-title>Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples</article-title><source>J. Pharmacol. Exp. Ther.</source><year>1997</year><volume>283</volume><fpage>434</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/S0022-3565(24)37072-7</pub-id><pub-id pub-id-type="pmid">9353355</pub-id></element-citation></ref><ref id="B93-pharmaceutics-17-01582"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Hanke</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Turk</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Selzer</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Wiebe</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Fernandez</surname><given-names>É.</given-names></name>
<name name-style="western"><surname>Stopfer</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Nock</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Lehr</surname><given-names>T.</given-names></name>
</person-group><article-title>A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>556</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12060556</pub-id><pub-id pub-id-type="pmid">32560124</pub-id><pub-id pub-id-type="pmcid">PMC7355632</pub-id></element-citation></ref><ref id="B94-pharmaceutics-17-01582"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Qian</surname><given-names>C.Q.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>K.J.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.D.</given-names></name>
</person-group><article-title>Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P-glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover</article-title><source>Eur. J. Pharm. Sci.</source><year>2019</year><volume>134</volume><fpage>194</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.04.026</pub-id><pub-id pub-id-type="pmid">31047967</pub-id></element-citation></ref><ref id="B95-pharmaceutics-17-01582"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Ezuruike</surname><given-names>U.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Pansari</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>De Sousa Mendes</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Neuhoff</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Gardner</surname><given-names>I.</given-names></name>
</person-group><article-title>Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2022</year><volume>11</volume><fpage>805</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1002/psp4.12791</pub-id><pub-id pub-id-type="pmcid">PMC9286711</pub-id><pub-id pub-id-type="pmid">35344639</pub-id></element-citation></ref><ref id="B96-pharmaceutics-17-01582"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Shum</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Shen</surname><given-names>D.D.</given-names></name>
<name name-style="western"><surname>Isoherranen</surname><given-names>N.</given-names></name>
</person-group><article-title>Predicting Maternal-Fetal Disposition of Fentanyl Following Intravenous and Epidural Administration Using Physiologically Based Pharmacokinetic Modeling</article-title><source>Drug Metab. Dispos.</source><year>2021</year><volume>49</volume><fpage>1003</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1124/dmd.121.000612</pub-id><pub-id pub-id-type="pmid">34407992</pub-id><pub-id pub-id-type="pmcid">PMC11022861</pub-id></element-citation></ref><ref id="B97-pharmaceutics-17-01582"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions</article-title><source>J. Pharm. Sci.</source><year>2013</year><volume>102</volume><fpage>2819</fpage><lpage>2836</lpage><pub-id pub-id-type="doi">10.1002/jps.23613</pub-id><pub-id pub-id-type="pmid">23760985</pub-id></element-citation></ref><ref id="B98-pharmaceutics-17-01582"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Obach</surname><given-names>R.S.</given-names></name>
<name name-style="western"><surname>Lombardo</surname><given-names>F.</given-names></name>
<name name-style="western"><surname>Waters</surname><given-names>N.J.</given-names></name>
</person-group><article-title>Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds</article-title><source>Drug Metab. Dispos.</source><year>2008</year><volume>36</volume><fpage>1385</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.020479</pub-id><pub-id pub-id-type="pmid">18426954</pub-id></element-citation></ref><ref id="B99-pharmaceutics-17-01582"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Baneyx</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Parrott</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Meille</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Iliadis</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Lave</surname><given-names>T.</given-names></name>
</person-group><article-title>Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration</article-title><source>Eur. J. Pharm. Sci.</source><year>2014</year><volume>56</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2014.02.002</pub-id><pub-id pub-id-type="pmid">24530864</pub-id></element-citation></ref><ref id="B100-pharmaceutics-17-01582"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Yerasi</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Vurimindi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Devarakonda</surname><given-names>K.</given-names></name>
</person-group><article-title>Frog intestinal perfusion to evaluate drug permeability: Application to p-gp and cyp3a4 substrates</article-title><source>Front. Pharmacol.</source><year>2015</year><volume>6</volume><elocation-id>141</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2015.00141</pub-id><pub-id pub-id-type="pmid">26236236</pub-id><pub-id pub-id-type="pmcid">PMC4500896</pub-id></element-citation></ref><ref id="B101-pharmaceutics-17-01582"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>H.Y.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>P.</given-names></name>
</person-group><article-title>Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration</article-title><source>Acta Pharmacol. Sin.</source><year>2016</year><volume>37</volume><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/aps.2015.122</pub-id><pub-id pub-id-type="pmid">26592516</pub-id><pub-id pub-id-type="pmcid">PMC4753367</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-01582-f001" orientation="portrait"><label>Figure 1</label><caption><p>Workflow for developing whole-body PBPK models in healthy individuals and cirrhotic patients and instructing clinical medication.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01582-g001.jpg"/></fig><fig position="float" id="pharmaceutics-17-01582-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic structure of the whole-body PBPK model. K<sub>ti</sub> represents the gastric emptying rate and intestinal transit rate. Gwi represents the gut wall of the duodenum, jejunum and ileum. K<sub>ai</sub> represents the rate of drug absorption into the gut wall. Q represent the blood flow rate. CL represent the clearance. ROB, rest of body (other tissue).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01582-g002.jpg"/></fig><fig position="float" id="pharmaceutics-17-01582-f003" orientation="portrait"><label>Figure 3</label><caption><p>Predicted (line) and observed (dot) plasma concentrations of omeprazole and lansoprazole in healthy subjects. Omeprazole (<bold>A</bold>,<bold>B</bold>) was administered orally at doses of 20 mg [<xref rid="B35-pharmaceutics-17-01582" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-17-01582" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-17-01582" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-01582" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-17-01582" ref-type="bibr">39</xref>] and 40 mg [<xref rid="B40-pharmaceutics-17-01582" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-17-01582" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-17-01582" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-17-01582" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-17-01582" ref-type="bibr">44</xref>] enteric-coated omeprazole capsules; lansoprazole (<bold>C</bold>–<bold>E</bold>) was administered orally at doses of 15 mg [<xref rid="B45-pharmaceutics-17-01582" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-01582" ref-type="bibr">46</xref>], 30 mg [<xref rid="B45-pharmaceutics-17-01582" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-17-01582" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-17-01582" ref-type="bibr">47</xref>,<xref rid="B49-pharmaceutics-17-01582" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-17-01582" ref-type="bibr">50</xref>] and 60 mg [<xref rid="B48-pharmaceutics-17-01582" ref-type="bibr">48</xref>] enteric-coated omeprazole capsules. The solid line represents the 50th percentile and the dashed lines represent the 5th and 95th percentiles.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01582-g003.jpg"/></fig><fig position="float" id="pharmaceutics-17-01582-f004" orientation="portrait"><label>Figure 4</label><caption><p>Predicted (line) and observed (dot) plasma concentrations of midazolam, ondansetron, verapamil and alfentanil in healthy subjects. The solid line represents the 50th percentile and the dashed lines represent the 5th and 95th percentiles. Midazolam (<bold>A</bold>–<bold>H</bold>) was administered orally at doses of 2 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>], 2.5 mg [<xref rid="B51-pharmaceutics-17-01582" ref-type="bibr">51</xref>], 7.5 mg [<xref rid="B52-pharmaceutics-17-01582" ref-type="bibr">52</xref>,<xref rid="B54-pharmaceutics-17-01582" ref-type="bibr">54</xref>], and 15 mg [<xref rid="B53-pharmaceutics-17-01582" ref-type="bibr">53</xref>,<xref rid="B55-pharmaceutics-17-01582" ref-type="bibr">55</xref>], and intravenously at doses of 1.8 mg [<xref rid="B56-pharmaceutics-17-01582" ref-type="bibr">56</xref>], 2.5 mg [<xref rid="B54-pharmaceutics-17-01582" ref-type="bibr">54</xref>], 3.4 mg [<xref rid="B57-pharmaceutics-17-01582" ref-type="bibr">57</xref>], and 5 mg [<xref rid="B53-pharmaceutics-17-01582" ref-type="bibr">53</xref>]. Ondansetron (<bold>I</bold>–<bold>L</bold>) was administered orally at dose of 8 mg [<xref rid="B59-pharmaceutics-17-01582" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceutics-17-01582" ref-type="bibr">60</xref>], infusion at dose of 8 mg over 5 min [<xref rid="B61-pharmaceutics-17-01582" ref-type="bibr">61</xref>], intravenously at doses of 8 mg [<xref rid="B62-pharmaceutics-17-01582" ref-type="bibr">62</xref>], 24 mg [<xref rid="B58-pharmaceutics-17-01582" ref-type="bibr">58</xref>]. Verapamil (<bold>M</bold>–<bold>Q</bold>) was administered orally at doses of 80 mg [<xref rid="B65-pharmaceutics-17-01582" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-17-01582" ref-type="bibr">66</xref>], 120 mg [<xref rid="B64-pharmaceutics-17-01582" ref-type="bibr">64</xref>], intravenously at dose of 10 mg [<xref rid="B66-pharmaceutics-17-01582" ref-type="bibr">66</xref>], and infusion 14 mg over 4 min [<xref rid="B63-pharmaceutics-17-01582" ref-type="bibr">63</xref>]. Alfentanil (<bold>R</bold>–<bold>X</bold>) was administered orally at doses of 23 μg/kg (1.495 mg), 30 μg/kg (1.95 mg), 43 μg/kg (2.795 mg), 75 μg/kg (4.875 mg) [<xref rid="B67-pharmaceutics-17-01582" ref-type="bibr">67</xref>], and intravenously at doses of 15 μg/kg (0.975 mg) [<xref rid="B67-pharmaceutics-17-01582" ref-type="bibr">67</xref>], 0.54 mg [<xref rid="B68-pharmaceutics-17-01582" ref-type="bibr">68</xref>] and 3 mg [<xref rid="B69-pharmaceutics-17-01582" ref-type="bibr">69</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01582-g004.jpg"/></fig><fig position="float" id="pharmaceutics-17-01582-f005" orientation="portrait"><label>Figure 5</label><caption><p>Predicted (line) and observed (dot) plasma concentrations of omeprazole (<bold>A</bold>–<bold>C</bold>), lansoprazole (<bold>D</bold>–<bold>F</bold>), midazolam (<bold>G</bold>–<bold>I</bold>), ondansetron (<bold>J</bold>–<bold>L</bold>), verapamil (<bold>M</bold>,<bold>N</bold>) and alfentanil (<bold>O</bold>) in LC subjects. Omeprazole (<bold>A</bold>−<bold>C</bold>) was administered orally 10 mg enteric-coated omeprazole capsules [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>]. Lansoprazole (<bold>D</bold>–<bold>F</bold>) was administered orally 30 mg enteric-coated lansoprazole capsules [<xref rid="B50-pharmaceutics-17-01582" ref-type="bibr">50</xref>]. Midazolam was administered orally at a dose of 2 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>]. Ondansetron was administered intravenously at 8 mg [<xref rid="B62-pharmaceutics-17-01582" ref-type="bibr">62</xref>]. Verapamil was administered intravenously at 10 mg and orally 80 mg [<xref rid="B66-pharmaceutics-17-01582" ref-type="bibr">66</xref>]. Alfentanil was administered intravenously at a dose of 3 mg [<xref rid="B69-pharmaceutics-17-01582" ref-type="bibr">69</xref>]. The solid line represents the 50th percentile and the dashed lines represent the 5th and 95th percentiles.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01582-g005.jpg"/></fig><fig position="float" id="pharmaceutics-17-01582-f006" orientation="portrait"><label>Figure 6</label><caption><p>Sensitivity analysis (<bold>A</bold>–<bold>Y</bold>) after oral administration of 20 mg omeprazole (<bold>A</bold>–<bold>D</bold>), 30 mg lansoprazole (<bold>E</bold>–<bold>H</bold>), 5 mg midazolam (<bold>I</bold>–<bold>K</bold>), 80 mg verapamil (<bold>P</bold>), 3 mg alfentanil (<bold>U</bold>–<bold>W</bold>), and intravenous of 8 mg ondansetron (<bold>L</bold>–<bold>O</bold>), 10 mg verapamil (<bold>Q</bold>–<bold>T</bold>). Individual contributions of cirrhosis-induced alterations in K<sub>t</sub>, enzyme activity and f<sub>u</sub> to plasma concentrations of omeprazole (<bold>X</bold>) and ondansetron (<bold>Y</bold>) following oral 20 mg omeprazole and intravenous of 8 mg ondansetron to LC patients and their integrated effects. HV: healthy volunteer value, CP-C: model predicted value of CP-C with all physiological changes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01582-g006.jpg"/></fig><fig position="float" id="pharmaceutics-17-01582-f007" orientation="portrait"><label>Figure 7</label><caption><p>Box-Whisker analysis of omeprazole and ondansetron with adjusted dose design. AUC for omeprazole and ondansetron at clinically recommended doses and after dose optimization (<bold>A</bold>–<bold>D</bold>). Box-Whisker analysis of C<sub>max</sub> for ondansetron at clinically recommended doses and after adjusted dose design (<bold>E</bold>,<bold>F</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-17-01582-g007.jpg"/></fig><table-wrap position="float" id="pharmaceutics-17-01582-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t003_Table 3</object-id><label>Table 3</label><caption><p>Clinical information about CYP2C19 and CYP3A4 substrates in the simulations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Research</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Assays</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subjects (n)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Andersson et al., 1992</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 20 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (14)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B35-pharmaceutics-17-01582" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Noubarani et al., 2012</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 20 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (30)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B36-pharmaceutics-17-01582" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Hu et al., 2007</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 20 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (18)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B37-pharmaceutics-17-01582" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Sakai et al., 2001</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 20 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (18)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B38-pharmaceutics-17-01582" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Furuta et al., 1999</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 20 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (6)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B39-pharmaceutics-17-01582" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Román et al., 2014</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 40 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (35)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B40-pharmaceutics-17-01582" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Cawello et al., 2014</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 40 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (36)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B41-pharmaceutics-17-01582" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Jin et al., 2009</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 40 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (9)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B42-pharmaceutics-17-01582" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Cho et al., 2002</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 40 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (8)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B43-pharmaceutics-17-01582" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">Furukori et al., 2004</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 40 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (6)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B44-pharmaceutics-17-01582" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">Duthaler et al., 2022</td><td align="center" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 10 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">CP (A-C) (36)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">Hussein et al., 1993</td><td align="center" valign="middle" rowspan="1" colspan="1">Lansoprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 15; 30 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (24)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B45-pharmaceutics-17-01582" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">Amer et al., 2004</td><td align="center" valign="middle" rowspan="1" colspan="1">Lansoprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 15; 30 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (36)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B46-pharmaceutics-17-01582" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">Doan et al., 2001</td><td align="center" valign="middle" rowspan="1" colspan="1">Lansoprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 30 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (36)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B47-pharmaceutics-17-01582" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">Miura et al., 2006</td><td align="center" valign="middle" rowspan="1" colspan="1">Lansoprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 60 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (18)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B48-pharmaceutics-17-01582" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">Flouvat et al., 1993</td><td align="center" valign="middle" rowspan="1" colspan="1">Lansoprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 30 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (18)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B49-pharmaceutics-17-01582" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">Delhotal-Landes et al., 1993</td><td align="center" valign="middle" rowspan="1" colspan="1">Lansoprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 30 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC</td><td align="center" valign="middle" rowspan="1" colspan="1">CP (A-C) (24)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B50-pharmaceutics-17-01582" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">Tian et al., 2019</td><td align="center" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 2.5 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (8)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B51-pharmaceutics-17-01582" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">Shih et al., 2002</td><td align="center" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 7.5 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B52-pharmaceutics-17-01582" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">Kupferschmidt et al., 1995</td><td align="center" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 15 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (8)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B53-pharmaceutics-17-01582" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">Teng et al., 2013</td><td align="center" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 7.5 mg;<break/>i.v. 2.5 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (28)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B54-pharmaceutics-17-01582" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">Guo et al., 2011</td><td align="center" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 15 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (49)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B55-pharmaceutics-17-01582" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">Lepper et al., 2004</td><td align="center" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 1.8 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (35)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B56-pharmaceutics-17-01582" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">Dale et al., 2006</td><td align="center" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 3.4 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">GC-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (12)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B57-pharmaceutics-17-01582" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">Duthaler et al., 2022</td><td align="center" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 2 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS/MS</td><td align="center" valign="middle" rowspan="1" colspan="1">CP (A-C) (36)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">VanDenBerg et al., 2000</td><td align="center" valign="middle" rowspan="1" colspan="1">Ondansetron</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 24 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (12)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B58-pharmaceutics-17-01582" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">Hsyu et al., 1994</td><td align="center" valign="middle" rowspan="1" colspan="1">Ondansetron</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 8 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (6)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B59-pharmaceutics-17-01582" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">Pritchard et al., 1992</td><td align="center" valign="middle" rowspan="1" colspan="1">Ondansetron</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 8 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (11)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B60-pharmaceutics-17-01582" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">Ashforth et al., 1994</td><td align="center" valign="middle" rowspan="1" colspan="1">Ondansetron</td><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 8 mg over 5 min</td><td align="center" valign="middle" rowspan="1" colspan="1">GC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (12)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B61-pharmaceutics-17-01582" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">Blake et al., 1993</td><td align="center" valign="middle" rowspan="1" colspan="1">Ondansetron</td><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 8 mg over 5 min</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC</td><td align="center" valign="middle" rowspan="1" colspan="1">CP (A-C) (19)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B62-pharmaceutics-17-01582" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">Dominic et al., 1981</td><td align="center" valign="middle" rowspan="1" colspan="1">Verapamil </td><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 14 mg over 4 min</td><td align="center" valign="middle" rowspan="1" colspan="1">GC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (8)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B63-pharmaceutics-17-01582" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">Hla et al., 1987</td><td align="center" valign="middle" rowspan="1" colspan="1">Verapamil</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 120 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (10)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B64-pharmaceutics-17-01582" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">Dadashzadeh et al., 2006</td><td align="center" valign="middle" rowspan="1" colspan="1">Verapamil</td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 80 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">HPLC-FLD</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (12)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B65-pharmaceutics-17-01582" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">Somogyi et al., 1981</td><td align="center" valign="middle" rowspan="1" colspan="1">Verapamil </td><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 80 mg<break/>i.v. 10 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-UV</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (6)<break/>CP (C) (7)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B66-pharmaceutics-17-01582" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">Kharasch et al., 2003</td><td align="center" valign="middle" rowspan="1" colspan="1">Alfentanil </td><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 0.975 mg; <break/>p.o. 1.495 mg; 1.95 mg; <break/>2.795 mg; 4.875 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">LC-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (10)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B67-pharmaceutics-17-01582" ref-type="bibr">67</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">Schwagmeier et al., 1995</td><td align="center" valign="middle" rowspan="1" colspan="1">Alfentanil </td><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 0.54 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">RIA</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy (10)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B68-pharmaceutics-17-01582" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ferrier et al., 1985</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alfentanil </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v. 3 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RIA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy (10)<break/>CP (C) (11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-pharmaceutics-17-01582" ref-type="bibr">69</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-01582-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t004_Table 4</object-id><label>Table 4</label><caption><p>Observed and predicted values of C<sub>max</sub>, T<sub>max</sub> and AUC<sub>0–t</sub> of omeprazole in healthy subjects and liver cirrhotic patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subjects</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">C<sub>max</sub> (ng/mL)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>max</sub> (Hour)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">AUC<sub>0–t</sub> (ng × Hour/mL)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B35-pharmaceutics-17-01582" ref-type="bibr">35</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">258.37 ± 99.48</td><td align="center" valign="middle" rowspan="1" colspan="1">329.75</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">324.69 ± 120.9</td><td align="center" valign="middle" rowspan="1" colspan="1">926.13</td><td align="center" valign="middle" rowspan="1" colspan="1">2.85 * </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B35-pharmaceutics-17-01582" ref-type="bibr">35</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">203.11 ± 81.17</td><td align="center" valign="middle" rowspan="1" colspan="1">329.75</td><td align="center" valign="middle" rowspan="1" colspan="1">1.62 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">905.00 ± 614.85</td><td align="center" valign="middle" rowspan="1" colspan="1">926.13</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B36-pharmaceutics-17-01582" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">397.2</td><td align="center" valign="middle" rowspan="1" colspan="1">329.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.9</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 </td><td align="center" valign="middle" rowspan="1" colspan="1">825.1</td><td align="center" valign="middle" rowspan="1" colspan="1">939.37</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B37-pharmaceutics-17-01582" ref-type="bibr">37</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">513.9 ± 294.8</td><td align="center" valign="middle" rowspan="1" colspan="1">329.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1644.6 ± 745.8</td><td align="center" valign="middle" rowspan="1" colspan="1">920.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B37-pharmaceutics-17-01582" ref-type="bibr">37</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">566.8 ± 294.8</td><td align="center" valign="middle" rowspan="1" colspan="1">329.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1759.4 ± 838.6</td><td align="center" valign="middle" rowspan="1" colspan="1">920.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B38-pharmaceutics-17-01582" ref-type="bibr">38</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">251.2 ± 46.2</td><td align="center" valign="middle" rowspan="1" colspan="1">329.75</td><td align="center" valign="middle" rowspan="1" colspan="1">1.31 </td><td align="center" valign="middle" rowspan="1" colspan="1">2.8 ± 0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82 </td><td align="center" valign="middle" rowspan="1" colspan="1">623.1 ± 149.1</td><td align="center" valign="middle" rowspan="1" colspan="1">936.21</td><td align="center" valign="middle" rowspan="1" colspan="1">1.50 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B38-pharmaceutics-17-01582" ref-type="bibr">38</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">618.3 ± 141.9</td><td align="center" valign="middle" rowspan="1" colspan="1">329.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53 </td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 ± 0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77 </td><td align="center" valign="middle" rowspan="1" colspan="1">1061.8 ± 269.2</td><td align="center" valign="middle" rowspan="1" colspan="1">936.21</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B39-pharmaceutics-17-01582" ref-type="bibr">39</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">383.9 ± 26.3</td><td align="center" valign="middle" rowspan="1" colspan="1">926.13</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41 *</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">20 mg [<xref rid="B39-pharmaceutics-17-01582" ref-type="bibr">39</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1001.9 ± 160.3</td><td align="center" valign="middle" rowspan="1" colspan="1">926.13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40 mg [<xref rid="B40-pharmaceutics-17-01582" ref-type="bibr">40</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">834.37 ± 394.54</td><td align="center" valign="middle" rowspan="1" colspan="1">634.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1658.69 ± 1271.58</td><td align="center" valign="middle" rowspan="1" colspan="1">1749.81</td><td align="center" valign="middle" rowspan="1" colspan="1">1.05 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40 mg [<xref rid="B40-pharmaceutics-17-01582" ref-type="bibr">40</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">1266.48 ± 477.05</td><td align="center" valign="middle" rowspan="1" colspan="1">634.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">3887.72 ± 2087.92</td><td align="center" valign="middle" rowspan="1" colspan="1">1749.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45 * </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40 mg [<xref rid="B40-pharmaceutics-17-01582" ref-type="bibr">40</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">722.76 ± 346.14</td><td align="center" valign="middle" rowspan="1" colspan="1">634.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1096.7 ± 646.53</td><td align="center" valign="middle" rowspan="1" colspan="1">1749.81</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40 mg [<xref rid="B41-pharmaceutics-17-01582" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">586</td><td align="center" valign="middle" rowspan="1" colspan="1">634.89</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08 </td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 </td><td align="center" valign="middle" rowspan="1" colspan="1">1027</td><td align="center" valign="middle" rowspan="1" colspan="1">1478.09</td><td align="center" valign="middle" rowspan="1" colspan="1">1.44 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40 mg [<xref rid="B42-pharmaceutics-17-01582" ref-type="bibr">42</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">723.0 ± 67.3</td><td align="center" valign="middle" rowspan="1" colspan="1">634.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 </td><td align="center" valign="middle" rowspan="1" colspan="1">2.1 ± 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 </td><td align="center" valign="middle" rowspan="1" colspan="1">1385.6 ± 183.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1733.32</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40 mg [<xref rid="B43-pharmaceutics-17-01582" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">986.56</td><td align="center" valign="middle" rowspan="1" colspan="1">634.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.83</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26 </td><td align="center" valign="middle" rowspan="1" colspan="1">1834.34</td><td align="center" valign="middle" rowspan="1" colspan="1">1834.34</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">40 mg [<xref rid="B44-pharmaceutics-17-01582" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">900</td><td align="center" valign="middle" rowspan="1" colspan="1">634.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.75</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">1.31 </td><td align="center" valign="middle" rowspan="1" colspan="1">1481</td><td align="center" valign="middle" rowspan="1" colspan="1">1691.35</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">10 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">CP-A</td><td align="center" valign="middle" rowspan="1" colspan="1">218</td><td align="center" valign="middle" rowspan="1" colspan="1">188.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">986</td><td align="center" valign="middle" rowspan="1" colspan="1">1015.91</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">10 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>] </td><td align="center" valign="middle" rowspan="1" colspan="1">CP-B</td><td align="center" valign="middle" rowspan="1" colspan="1">273</td><td align="center" valign="middle" rowspan="1" colspan="1">198.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1327</td><td align="center" valign="middle" rowspan="1" colspan="1">1123.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85 </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>] </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">343</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">199.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2111</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1676.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.79 </td></tr></tbody></table><table-wrap-foot><fn><p>NR: Not reported. * Indicates more than 0.5–2-fold range.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-01582-t005" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t005_Table 5</object-id><label>Table 5</label><caption><p>Observed and predicted values of C<sub>max</sub>, T<sub>max</sub> and AUC<sub>0–t</sub> of lansoprazole in healthy subjects and liver cirrhotic patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subjects</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">C<sub>max</sub> (ng/mL)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>max</sub> (Hour)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">AUC<sub>0–t</sub> (ng × Hour/mL)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">15 mg [<xref rid="B45-pharmaceutics-17-01582" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">413 ± 199</td><td align="center" valign="middle" rowspan="1" colspan="1">415.06</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 ± 0.39</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.30 </td><td align="center" valign="middle" rowspan="1" colspan="1">950 ± 593</td><td align="center" valign="middle" rowspan="1" colspan="1">1398.42</td><td align="center" valign="middle" rowspan="1" colspan="1">1.47 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">15 mg [<xref rid="B45-pharmaceutics-17-01582" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">449 ± 150</td><td align="center" valign="middle" rowspan="1" colspan="1">415.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.46 ± 0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03 </td><td align="center" valign="middle" rowspan="1" colspan="1">1334 ± 673</td><td align="center" valign="middle" rowspan="1" colspan="1">1398.42</td><td align="center" valign="middle" rowspan="1" colspan="1">1.05 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">15 mg [<xref rid="B46-pharmaceutics-17-01582" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">578.6</td><td align="center" valign="middle" rowspan="1" colspan="1">415.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 </td><td align="center" valign="middle" rowspan="1" colspan="1">1451</td><td align="center" valign="middle" rowspan="1" colspan="1">1421.86</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30 mg [<xref rid="B45-pharmaceutics-17-01582" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">750 ± 331</td><td align="center" valign="middle" rowspan="1" colspan="1">902.90</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.48 ± 0.99</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01 </td><td align="center" valign="middle" rowspan="1" colspan="1">1763 ± 1056</td><td align="center" valign="middle" rowspan="1" colspan="1">3449.40</td><td align="center" valign="middle" rowspan="1" colspan="1">1.96 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30 mg [<xref rid="B45-pharmaceutics-17-01582" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">773 ± 248</td><td align="center" valign="middle" rowspan="1" colspan="1">902.90</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.56 ± 0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 </td><td align="center" valign="middle" rowspan="1" colspan="1">2678 ± 1144</td><td align="center" valign="middle" rowspan="1" colspan="1">3449.40</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30 mg [<xref rid="B46-pharmaceutics-17-01582" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">1077</td><td align="center" valign="middle" rowspan="1" colspan="1">902.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 </td><td align="center" valign="middle" rowspan="1" colspan="1">2641</td><td align="center" valign="middle" rowspan="1" colspan="1">3546.69</td><td align="center" valign="middle" rowspan="1" colspan="1">1.34 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30 mg [<xref rid="B47-pharmaceutics-17-01582" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">810.4 ± 340.5</td><td align="center" valign="middle" rowspan="1" colspan="1">902.90</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.6 ± 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94 </td><td align="center" valign="middle" rowspan="1" colspan="1">2157 ± 1933</td><td align="center" valign="middle" rowspan="1" colspan="1">3709.69</td><td align="center" valign="middle" rowspan="1" colspan="1">1.72 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30 mg [<xref rid="B49-pharmaceutics-17-01582" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">1148 ± 536</td><td align="center" valign="middle" rowspan="1" colspan="1">902.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 </td><td align="center" valign="middle" rowspan="1" colspan="1">5216 ± 3855</td><td align="center" valign="middle" rowspan="1" colspan="1">3709.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30 mg [<xref rid="B50-pharmaceutics-17-01582" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">1033</td><td align="center" valign="middle" rowspan="1" colspan="1">902.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00 </td><td align="center" valign="middle" rowspan="1" colspan="1">2670</td><td align="center" valign="middle" rowspan="1" colspan="1">3546.69</td><td align="center" valign="middle" rowspan="1" colspan="1">1.33 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">60 mg [<xref rid="B48-pharmaceutics-17-01582" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">1957 ± 413</td><td align="center" valign="middle" rowspan="1" colspan="1">1801.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.9 ± 0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79 </td><td align="center" valign="middle" rowspan="1" colspan="1">5009 ± 919</td><td align="center" valign="middle" rowspan="1" colspan="1">6865.35</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">60 mg [<xref rid="B48-pharmaceutics-17-01582" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">2196 ± 405</td><td align="center" valign="middle" rowspan="1" colspan="1">1801.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82 </td><td align="center" valign="middle" rowspan="1" colspan="1">2.3 ± 0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65 </td><td align="center" valign="middle" rowspan="1" colspan="1">7300 ± 1008</td><td align="center" valign="middle" rowspan="1" colspan="1">6865.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">60 mg [<xref rid="B48-pharmaceutics-17-01582" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">2516 ± 357</td><td align="center" valign="middle" rowspan="1" colspan="1">1801.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72 </td><td align="center" valign="middle" rowspan="1" colspan="1">2.4 ± 0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63 </td><td align="center" valign="middle" rowspan="1" colspan="1">20,132 ± 3570</td><td align="center" valign="middle" rowspan="1" colspan="1">6865.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34 *</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30 mg [<xref rid="B50-pharmaceutics-17-01582" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">CP-A</td><td align="center" valign="middle" rowspan="1" colspan="1">1080</td><td align="center" valign="middle" rowspan="1" colspan="1">864.29</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 </td><td align="center" valign="middle" rowspan="1" colspan="1">5200</td><td align="center" valign="middle" rowspan="1" colspan="1">4841.99 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">30 mg [<xref rid="B50-pharmaceutics-17-01582" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">CP-B</td><td align="center" valign="middle" rowspan="1" colspan="1">1440</td><td align="center" valign="middle" rowspan="1" colspan="1">904.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63 </td><td align="center" valign="middle" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71 </td><td align="center" valign="middle" rowspan="1" colspan="1">11,700</td><td align="center" valign="middle" rowspan="1" colspan="1">7453.58 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.64 </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 mg [<xref rid="B50-pharmaceutics-17-01582" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1140</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">951.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,700</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8305.20 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78 </td></tr></tbody></table><table-wrap-foot><fn><p>NR: Not reported. * Indicates more than 0.5–2-fold range.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-01582-t006" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t006_Table 6</object-id><label>Table 6</label><caption><p>Observed and predicted values of C<sub>max</sub>, T<sub>max</sub> and AUC<sub>0–t</sub> of midazolam in healthy subjects and liver cirrhotic patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subjects</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">C<sub>max</sub> (ng/mL)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>max</sub> (Hour)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">AUC<sub>0–t</sub> (ng × Hour/mL)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 2.5 mg [<xref rid="B51-pharmaceutics-17-01582" ref-type="bibr">51</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">7.56</td><td align="center" valign="middle" rowspan="1" colspan="1">10.62</td><td align="center" valign="middle" rowspan="1" colspan="1">1.40 </td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67 </td><td align="center" valign="middle" rowspan="1" colspan="1">20.69</td><td align="center" valign="middle" rowspan="1" colspan="1">26.80</td><td align="center" valign="middle" rowspan="1" colspan="1">1.30 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 2 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">4.44</td><td align="center" valign="middle" rowspan="1" colspan="1">8.33</td><td align="center" valign="middle" rowspan="1" colspan="1">1.88 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">11.9</td><td align="center" valign="middle" rowspan="1" colspan="1">25.06</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11 * </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 7.5 mg [<xref rid="B52-pharmaceutics-17-01582" ref-type="bibr">52</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">153.95 ± 17.5</td><td align="center" valign="middle" rowspan="1" colspan="1">81.87</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 7.5 mg [<xref rid="B54-pharmaceutics-17-01582" ref-type="bibr">54</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">47.3</td><td align="center" valign="middle" rowspan="1" colspan="1">31.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89 </td><td align="center" valign="middle" rowspan="1" colspan="1">115.4</td><td align="center" valign="middle" rowspan="1" colspan="1">81.87</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 15 mg [<xref rid="B53-pharmaceutics-17-01582" ref-type="bibr">53</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">54.3 ± 6.4</td><td align="center" valign="middle" rowspan="1" colspan="1">65.08</td><td align="center" valign="middle" rowspan="1" colspan="1">1.20 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.62 ± 0.20</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08 </td><td align="center" valign="middle" rowspan="1" colspan="1">143 ± 26</td><td align="center" valign="middle" rowspan="1" colspan="1">157.84</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 15 mg [<xref rid="B55-pharmaceutics-17-01582" ref-type="bibr">55</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">116.2 ± 61.0</td><td align="center" valign="middle" rowspan="1" colspan="1">65.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 ± 0.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67 </td><td align="center" valign="middle" rowspan="1" colspan="1">330.7 ± 139.6</td><td align="center" valign="middle" rowspan="1" colspan="1">195.93</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 15 mg [<xref rid="B55-pharmaceutics-17-01582" ref-type="bibr">55</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">130.2 ± 59.4</td><td align="center" valign="middle" rowspan="1" colspan="1">65.08</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 ± 0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67 </td><td align="center" valign="middle" rowspan="1" colspan="1">365.0 ± 103.8</td><td align="center" valign="middle" rowspan="1" colspan="1">195.93</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">i.v. 1.8 mg [<xref rid="B56-pharmaceutics-17-01582" ref-type="bibr">56</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">96.1 ± 42.7</td><td align="center" valign="middle" rowspan="1" colspan="1">109.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.13 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">i.v. 2.5 mg [<xref rid="B54-pharmaceutics-17-01582" ref-type="bibr">54</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">115.7</td><td align="center" valign="middle" rowspan="1" colspan="1">161.33 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.39 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">i.v. 3.4 mg [<xref rid="B57-pharmaceutics-17-01582" ref-type="bibr">57</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">117.03</td><td align="center" valign="middle" rowspan="1" colspan="1">208.16 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.78 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">i.v. 5 mg [<xref rid="B53-pharmaceutics-17-01582" ref-type="bibr">53</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">199</td><td align="center" valign="middle" rowspan="1" colspan="1">351.01 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.76 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 2 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">CP-A</td><td align="center" valign="middle" rowspan="1" colspan="1">6.37</td><td align="center" valign="middle" rowspan="1" colspan="1">10.32</td><td align="center" valign="middle" rowspan="1" colspan="1">1.62 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">28.95 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.45 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 2 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">CP-B</td><td align="center" valign="middle" rowspan="1" colspan="1">5.83</td><td align="center" valign="middle" rowspan="1" colspan="1">10.73</td><td align="center" valign="middle" rowspan="1" colspan="1">1.84 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">29.7</td><td align="center" valign="middle" rowspan="1" colspan="1">38.49 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.30 </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p.o. 2 mg [<xref rid="B16-pharmaceutics-17-01582" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.13 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.42 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.95 </td></tr></tbody></table><table-wrap-foot><fn><p>NR: Not reported. * Indicates more than 0.5–2-fold range.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-01582-t007" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t007_Table 7</object-id><label>Table 7</label><caption><p>Observed and predicted values of C<sub>max</sub>, T<sub>max</sub> and AUC<sub>0–t</sub> of ondansetron in healthy subjects and liver cirrhotic patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subjects</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">C<sub>max</sub> (ng/mL)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>max</sub> (Hour)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">AUC<sub>0–t</sub> (ng × Hour/mL)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 24 mg [<xref rid="B58-pharmaceutics-17-01582" ref-type="bibr">58</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">1276.4 ± 340.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1650.83 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.29 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 8 mg [<xref rid="B59-pharmaceutics-17-01582" ref-type="bibr">59</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">40 ± 22</td><td align="center" valign="middle" rowspan="1" colspan="1">33.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83</td><td align="center" valign="middle" rowspan="1" colspan="1">1.3 ± 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52</td><td align="center" valign="middle" rowspan="1" colspan="1">225 ± 79</td><td align="center" valign="middle" rowspan="1" colspan="1">123.83</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">p.o. 8 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 8 mg<break/>over 5 min [<xref rid="B61-pharmaceutics-17-01582" ref-type="bibr">61</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">257</td><td align="center" valign="middle" rowspan="1" colspan="1">199.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.78 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 8 mg<break/>over 5 min [<xref rid="B61-pharmaceutics-17-01582" ref-type="bibr">61</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">247</td><td align="center" valign="middle" rowspan="1" colspan="1">199.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 8 mg [<xref rid="B62-pharmaceutics-17-01582" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">279</td><td align="center" valign="middle" rowspan="1" colspan="1">536.51</td><td align="center" valign="middle" rowspan="1" colspan="1">1.92 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 8 mg [<xref rid="B62-pharmaceutics-17-01582" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">CP-A</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">633</td><td align="center" valign="middle" rowspan="1" colspan="1">736.64</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">i.v. 8 mg [<xref rid="B62-pharmaceutics-17-01582" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">CP-B</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">446</td><td align="center" valign="middle" rowspan="1" colspan="1">940.72</td><td align="center" valign="middle" rowspan="1" colspan="1">2.11 * </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v. 8 mg [<xref rid="B62-pharmaceutics-17-01582" ref-type="bibr">62</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1383</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1226.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89 </td></tr></tbody></table><table-wrap-foot><fn><p>NR: Not reported. * Indicates more than 0.5–2-fold range.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-01582-t008" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t008_Table 8</object-id><label>Table 8</label><caption><p>Observed and predicted values of C<sub>max</sub>, T<sub>max</sub> and AUC<sub>0–t</sub> of verapamil in healthy subjects and liver cirrhotic patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subjects</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">C<sub>max</sub> (ng/mL)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>max</sub> (Hour)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">AUC<sub>0–t</sub> (ng × Hour/mL)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 120 mg [<xref rid="B64-pharmaceutics-17-01582" ref-type="bibr">64</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">123 ± 43</td><td align="center" valign="middle" rowspan="1" colspan="1">129.83 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.06 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.05 ± 0.28</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95 </td><td align="center" valign="middle" rowspan="1" colspan="1">450 ± 130</td><td align="center" valign="middle" rowspan="1" colspan="1">412.53 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 80 mg [<xref rid="B65-pharmaceutics-17-01582" ref-type="bibr">65</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">130.66 ± 33.58</td><td align="center" valign="middle" rowspan="1" colspan="1">82.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.54 ± 0.18</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.85 </td><td align="center" valign="middle" rowspan="1" colspan="1">383.67 ± 110.54</td><td align="center" valign="middle" rowspan="1" colspan="1">261.50 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.68 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 80 mg [<xref rid="B65-pharmaceutics-17-01582" ref-type="bibr">65</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">139.28 ± 77.88</td><td align="center" valign="middle" rowspan="1" colspan="1">82.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.60 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.69 ± 0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.45 </td><td align="center" valign="middle" rowspan="1" colspan="1">344.22 ± 239.90</td><td align="center" valign="middle" rowspan="1" colspan="1">261.50</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 80 mg [<xref rid="B66-pharmaceutics-17-01582" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">38.6</td><td align="center" valign="middle" rowspan="1" colspan="1">82.89</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">i.v. 14 mg <break/>over 4 min [<xref rid="B63-pharmaceutics-17-01582" ref-type="bibr">63</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 80 mg [<xref rid="B66-pharmaceutics-17-01582" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">CP-C</td><td align="center" valign="middle" rowspan="1" colspan="1">134.5</td><td align="center" valign="middle" rowspan="1" colspan="1">175.14</td><td align="center" valign="middle" rowspan="1" colspan="1">1.30 </td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v. 10 mg [<xref rid="B66-pharmaceutics-17-01582" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td></tr></tbody></table><table-wrap-foot><fn><p>NR: Not reported. </p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-01582-t009" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t009_Table 9</object-id><label>Table 9</label><caption><p>Observed and predicted values of C<sub>max</sub>, T<sub>max</sub> and AUC<sub>0–t</sub> of alfentanil in healthy subjects and liver cirrhotic patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subjects</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">C<sub>max</sub> (ng/mL)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">T<sub>max</sub> (Hour)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">AUC<sub>0–t</sub> (ng × Hour/mL)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td><td align="center" valign="middle" rowspan="1" colspan="1">Obs</td><td align="center" valign="middle" rowspan="1" colspan="1">Pre</td><td align="center" valign="middle" rowspan="1" colspan="1">Ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 1.495 mg [<xref rid="B67-pharmaceutics-17-01582" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">16 ± 8</td><td align="center" valign="middle" rowspan="1" colspan="1">15.29</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 ± 0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 </td><td align="center" valign="middle" rowspan="1" colspan="1">26 ± 14</td><td align="center" valign="middle" rowspan="1" colspan="1">32.31 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.24 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 1.95 mg [<xref rid="B67-pharmaceutics-17-01582" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">23 ± 16</td><td align="center" valign="middle" rowspan="1" colspan="1">19.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 ± 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 </td><td align="center" valign="middle" rowspan="1" colspan="1">38 ± 22</td><td align="center" valign="middle" rowspan="1" colspan="1">41.90 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 2.795 mg [<xref rid="B67-pharmaceutics-17-01582" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">31 ± 18</td><td align="center" valign="middle" rowspan="1" colspan="1">27.83</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 ± 0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74 </td><td align="center" valign="middle" rowspan="1" colspan="1">57 ± 31</td><td align="center" valign="middle" rowspan="1" colspan="1">57.87 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.02 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p.o. 4.895 mg [<xref rid="B67-pharmaceutics-17-01582" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">50 ± 22</td><td align="center" valign="middle" rowspan="1" colspan="1">51.45</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 ± 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96 </td><td align="center" valign="middle" rowspan="1" colspan="1">105 ± 59</td><td align="center" valign="middle" rowspan="1" colspan="1">107.40 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.02 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">i.v. 0.975 mg [<xref rid="B67-pharmaceutics-17-01582" ref-type="bibr">67</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">i.v. 0.54 mg [<xref rid="B68-pharmaceutics-17-01582" ref-type="bibr">68</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">33.10 ± 13.75</td><td align="center" valign="middle" rowspan="1" colspan="1">21.94</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">i.v. 3 mg [<xref rid="B69-pharmaceutics-17-01582" ref-type="bibr">69</xref>]</td><td align="center" valign="middle" rowspan="1" colspan="1">Healthy</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td><td align="center" valign="middle" rowspan="1" colspan="1">/</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v. 3 mg [<xref rid="B69-pharmaceutics-17-01582" ref-type="bibr">69</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP-C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td></tr></tbody></table><table-wrap-foot><fn><p>NR: Not reported. </p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-17-01582-t010" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-17-01582-t010_Table 10</object-id><label>Table 10</label><caption><p>Prediction performance of the six drugs in healthy and cirrhotic subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drugs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Values</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">T<sub>max</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0–t</sub></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Omeprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">AFE</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.06 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">PE</td><td align="center" valign="middle" rowspan="1" colspan="1">26.47%</td><td align="center" valign="middle" rowspan="1" colspan="1">19.34%</td><td align="center" valign="middle" rowspan="1" colspan="1">22.48%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">GMFE</td><td align="center" valign="middle" rowspan="1" colspan="1">1.41 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.22 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.40 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Lansoprazole</td><td align="center" valign="middle" rowspan="1" colspan="1">AFE</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.04 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">PE</td><td align="center" valign="middle" rowspan="1" colspan="1">13.50%</td><td align="center" valign="middle" rowspan="1" colspan="1">11.79%</td><td align="center" valign="middle" rowspan="1" colspan="1">22.84%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">GMFE</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.19 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.40 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Midazolam</td><td align="center" valign="middle" rowspan="1" colspan="1">AFE</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.78 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.09 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">PE</td><td align="center" valign="middle" rowspan="1" colspan="1">41.17%</td><td align="center" valign="middle" rowspan="1" colspan="1">20.63%</td><td align="center" valign="middle" rowspan="1" colspan="1">32.81%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">GMFE</td><td align="center" valign="middle" rowspan="1" colspan="1">1.57 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.32 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.48 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ondansetron</td><td align="center" valign="middle" rowspan="1" colspan="1">AFE</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.52 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.08 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">PE</td><td align="center" valign="middle" rowspan="1" colspan="1">17.38%</td><td align="center" valign="middle" rowspan="1" colspan="1">48.46%</td><td align="center" valign="middle" rowspan="1" colspan="1">31.88%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">GMFE</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.94 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.45 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Verapamil</td><td align="center" valign="middle" rowspan="1" colspan="1">AFE</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.37 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.78 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">PE</td><td align="center" valign="middle" rowspan="1" colspan="1">30.97%</td><td align="center" valign="middle" rowspan="1" colspan="1">26.32%</td><td align="center" valign="middle" rowspan="1" colspan="1">18.54%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">GMFE</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.41 </td><td align="center" valign="middle" rowspan="1" colspan="1">1.28 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Alfentanil</td><td align="center" valign="middle" rowspan="1" colspan="1">AFE</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 </td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">PE</td><td align="center" valign="middle" rowspan="1" colspan="1">6.54%</td><td align="center" valign="middle" rowspan="1" colspan="1">8.60%</td><td align="center" valign="middle" rowspan="1" colspan="1">7.82%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMFE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.13 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.17 </td></tr></tbody></table><table-wrap-foot><fn><p>Absolute Fold Error (AFE), Prediction Error (PE), and Geometric Mean Fold Error (GMFE).</p></fn></table-wrap-foot></table-wrap></floats-group></article><article article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Dig Dis Sci</journal-id><journal-id journal-id-type="iso-abbrev">Dig Dis Sci</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Digestive Diseases and Sciences</journal-title></journal-title-group><issn pub-type="ppub">0163-2116</issn><issn pub-type="epub">1573-2568</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11920344</article-id><article-id pub-id-type="pmcid-ver">PMC11920344.1</article-id><article-id pub-id-type="pmcaid">11920344</article-id><article-id pub-id-type="pmcaiid">11920344</article-id><article-id pub-id-type="pmid">39537890</article-id><article-id pub-id-type="doi">10.1007/s10620-024-08728-8</article-id><article-id pub-id-type="publisher-id">8728</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Proton-Pump Inhibitors and Fat Absorption in Cystic Fibrosis and Pancreatic Insufficiency: A Randomized Crossover Pilot Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Phillips</surname><given-names initials="AE">Anna Evans</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Brownell</surname><given-names initials="JN">Jefferson N.</given-names></name><address><email>brownellj@chop.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tindall</surname><given-names initials="A">Alyssa</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kiernan</surname><given-names initials="BD">Bridget Dowd</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="D">Dhiren</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gelfond</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stallings</surname><given-names initials="VA">Virginia A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01an3r305</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution>Division of Gastroenterology, Hepatology, and Nutrition, </institution><institution>University of Pittsburgh School of Medicine, </institution></institution-wrap>Pittsburgh, PA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01z7r7q48</institution-id><institution-id institution-id-type="GRID">grid.239552.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0680 8770</institution-id><institution>Division of Gastroenterology, Hepatology, and Nutrition, </institution><institution>Children’s Hospital of Philadelphia, </institution></institution-wrap>3500 Civic Center Blvd., Philadelphia, PA 19104 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00b30xv10</institution-id><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>Department of Pediatrics, Perelman School of Medicine, </institution><institution>University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0190ak572</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution>Division of Gastroenterology, Hepatology, and Nutrition, </institution><institution>New York University, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01p7jjy08</institution-id><institution-id institution-id-type="GRID">grid.262962.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9342</institution-id><institution>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Cardinal Glennon Children’s Medical Center, </institution><institution>Saint Louis University School of Medicine, </institution></institution-wrap>St. Louis, MO USA </aff><aff id="Aff6"><label>6</label>WNY Pediatric Gastroenterology and Nutrition, DGRD, Buffalo, NY USA </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>70</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">484698</issue-id><fpage>968</fpage><lpage>977</lpage><history><date date-type="received"><day>3</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>20</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-20 00:25:16.910"><day>20</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10620_2024_Article_8728.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Dietary fat malabsorption contributes to poor nutritional status in patients with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI). Prescribing gastric acid-reducing agents such as proton-pump inhibitors (PPI) as an adjunct to pancreatic enzyme replacement therapy (PERT) to improve dietary fat absorption has been accepted in clinical practice despite limited evidence.</p></sec><sec><title>Aims</title><p id="Par2">This was a pilot randomized, double-blind, placebo-controlled crossover trial of subjects aged 12 and older with CF and EPI assessed on placebo and omeprazole to determine if PPI improved the efficacy of PERT as indicated by measures of dietary fat absorption.</p></sec><sec><title>Methods</title><p id="Par3">Fat malabsorption via stool coefficient of fat absorption (CFA) and malabsorption blood test (MBT), gastrointestinal pH (wireless motility capsule [WMC]), and quality of life (QOL) were assessed after 14 days on both placebo or PPI (omeprazole).</p></sec><sec><title>Results</title><p id="Par4">Total 19 subjects enrolled, 13 were randomized, and 9 provided paired results on placebo and PPI. The 3 subject results for CFA were as follows: 1 increased, 1 decreased, and 1 was within the reference range in both tests for fat absorption. For 9 MBT subjects, 7 decreased and 2 increased fat absorption. For the 4 WMC studies, no change in transit times, nor in pH profiles were noted. No differences were seen in the domains of the two QOL questionnaires comparing placebo and PPI.</p></sec><sec><title>Conclusions</title><p id="Par5">These limited descriptive pilot study results in participants with CF and EPI on PERT evaluated by stool, blood, and QOL tests did not suggest improvement in fat absorption attributable to PPI.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cystic fibrosis</kwd><kwd>Proton-pump inhibitors</kwd><kwd>PERT</kwd><kwd>MBT</kwd><kwd>CFA</kwd><kwd>WMC</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM008562-23</award-id><principal-award-recipient><name name-style="western"><surname>Brownell</surname><given-names>Jefferson N.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011086</institution-id><institution>NASPGHAN Foundation</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100020218</institution-id><institution>Chiesi USA</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Dietary fat malabsorption contributes to poor nutritional status in patients with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI). Impaired pancreatic function has also been associated with increased gastric acidity, which results in gastroesophageal reflux, peptic ulcers, and decreased effectiveness of pancreatic enzyme replacement therapy (PERT) [<xref ref-type="bibr" rid="CR1">1</xref>]. The use of gastric acid suppression agents including histamine receptor antagonists (H2RA) and proton-pump inhibitors (PPI) is widespread in pediatric patients from preterm infants to young adults to treat many diagnoses including oral feeding intolerance, dyspepsia, gastroesophageal reflux, and functional abdominal pain [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. In pediatric and adult populations with EPI, adjunctive gastric acid suppression agents have been an established practice intended to improve efficacy of PERT [<xref ref-type="bibr" rid="CR4">4</xref>]. Specifically in CF, the use of PPI and H2RA with PERT to improve fat absorption has become accepted clinical practice despite limited clinical evidence [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. To date, no study has assessed the effect of gastric acid suppression on duodenal pH or dietary fatty acid absorption in the small intestine in participants with CF and EPI. Clarifying this relationship will provide information on how these common medications may affect nutritional and general health outcomes in this population.</p><p id="Par7">The most recent Cochrane review assessing acid suppression in patients with CF reports that single-center studies showed improvement in abdominal pain and some degree of variably measured fat malabsorption but did not provide data on lung function, quality of life, or survival; therefore, the authors offered no conclusion on whether these agents offered overall benefit in CF [<xref ref-type="bibr" rid="CR1">1</xref>]. Though ubiquitously used, PPI for any indication is not without risk [<xref ref-type="bibr" rid="CR8">8</xref>]. PPI use has been associated with an increased risk of asthma and decreased bone density in children and with liver cancer in the general population, though any causal relationship remains in question [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR12">12</xref>]. Acid suppression is also associated with increased risk of serious infection in neonates as well as young children; in the pediatric population with CF whose risk of infection is already elevated from that of the general pediatric population, this risk from acid suppression is almost certainly greater [<xref ref-type="bibr" rid="CR13">13</xref>]. Due to these risks as well as a lack of clarity about the risk of lifetime PPI use, gastric acid suppression agents should be used only in the presence of potential benefit [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par8">The aim of this study was to determine if daily PPI compared to placebo improved the efficacy of PERT as evidenced by changes in dietary fat malabsorption. The primary outcome was the efficacy of the standard dose of omeprazole 20 mg daily to improve dietary fat absorption in subjects with CF and EPI via measurement of the coefficient of fat absorption (CFA) in the stool. Other outcomes sought to determine changes in duodenal pH on and off acid suppression using a wireless motility capsule (WMC) and to characterize changes in plasma fatty acid absorption in the small intestine using the malabsorption blood test (MBT). GI symptoms and other quality of life (QOL) indicators were also assessed.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par9">This was a single-center pilot randomized, placebo-controlled, double-blinded crossover trial to determine the efficacy of acid suppression with a PPI in improving dietary fat malabsorption and other outcomes in subjects with CF and EPI. The trial was approved by the Children’s Hospital of Philadelphia (CHOP) Institutional Review Board and registered with clinicaltrials.gov (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03551691">NCT 03551691</ext-link>). All study activities were outpatient and conducted at the CHOP Center for Human Phenomic Science.</p><sec id="Sec3"><title>Study Subjects</title><p id="Par10">Subjects diagnosed with CF and EPI were eligible for inclusion in the study if they were ≥ 12 years of age at enrollment, had a fecal elastase of &lt; 200 µg/g stool indicating EPI, and in good pulmonary health with FEV1 &gt; 40% predicted. Subjects who were already receiving PPI or H2RA prior to the study were eligible if willing to discontinue the medication 14 days prior to study initiation. Subjects were excluded if they were either pregnant or breastfeeding, had another illness affecting nutritional status, using medication or had another diagnosis affecting dietary fat absorption, or allergy to soy or safflower products. Subject or parent/guardian informed consent and child assent when applicable was obtained prior to all study-related activities. After consent/assent was obtained, a stool sample was collected to confirm EPI via fecal elastase-1 (FE) via quantitative enzyme-linked immunosorbent assay (ARUP Laboratories, Salt Lake City, Utah).</p></sec><sec id="Sec4"><title>Randomization and Study Procedures</title><p id="Par11">Subjects were randomized by the University of Pennsylvania Investigational Drug Service to receive either omeprazole 20 mg daily or placebo for at least 14 days while maintaining their standard diet and PERT regimen (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). All other research personnel were blinded to the randomization throughout the study. After at least 14 days of study medication, subjects underwent the primary (CFA) and other outcome measures: MBT, Patient-Reported Outcomes Measurement Information Systems [PROMIS] questionnaires, Cystic Fibrosis Questionnaire-Revised [CFQ-R], WMC for gastric and duodenal pH assessment (&gt; 18 years of age), and questionnaires assessing adherence and adverse events via recall. Upon completion of study measures, subjects then underwent a 14-day wean and washout period before crossing over to the other treatment arm for 14 days. Study measures were completed at the end of a second treatment period (minimum 14 days, maximum 28 days), and subjects were weaned off the study medication and returned to usual care.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Protocol timeline. <italic toggle="yes">PPI</italic> proton-pump inhibitor, <italic toggle="yes">MBT</italic> malabsorption blood test, <italic toggle="yes">WMC</italic> wireless motility capsule</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="10620_2024_8728_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Clinical Data Collection</title><p id="Par12">Demographics and clinical data were collected by study staff. Anthropometrics were obtained in triplicate by the research staff according to standardized techniques, and the mean was used for analysis. Body mass index was calculated (kg/m<sup>2</sup>) from weight using a digital scale (Seca, Munich, Germany) and height using a stadiometer (Holtain, Crymych, United Kingdom).</p></sec><sec id="Sec6"><title>Measurement of Fat Malabsorption</title><p id="Par13">Subjects collected stool for 72 h at home for CFA (on and off PPI), and stool was assessed for total fat by nuclear magnetic resonance spectroscopy (Mayo Clinic Laboratories, Rochester, MN). The CFA was derived from the stool collection and 3-day dietary food records. Three-day average fat intake was analyzed by Nutrition Data System 2012 (NCC, University of Minnesota, Minneapolis, MN). CFA was calculated as grams of fat consumed per day minus grams of fat excreted per day, divided by total fat grams consumed.</p><p id="Par14">The MBT was performed at the same two timepoints on PPI and placebo to assess fatty acid absorption in the upper intestine [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR18">18</xref>]. A test meal containing pentadecanoic acid (PA), a 15-carbon free fatty acid, and triheptadecanoin (THA), a triglyceride containing three 17-carbon heptadecanoic fatty acids (HA) requiring hydrolysis by lipase for HA absorption, was administered in the morning after a 12-h fast. Blood samples were taken hourly over a nine-hour period following the test meal. Concentrations of plasma PA and HA were determined (CHOP, Clinical Laboratory). A noncompartmental analysis estimated the area under the curve (AUC) for PA and HA micromolar concentrations to facilitate comparison of relative absorption on PPI and placebo.</p></sec><sec id="Sec7"><title>Measurement of Gastric and Intestinal pH</title><p id="Par15">In subjects ≥ 18 years of age, gastric and intestinal pH was assessed with the WMC (SmartPill ®, Medtronic Corporation, Minneapolis, MN) at the same two timepoints described above. The WMC possesses sensors to measure pH, pressure, and temperature for approximately 72 h after administration. Anal exit was defined as an acute temperature drop and permanent loss of signal on the receiver. Data were extracted using GIMS software (Gastrointestinal Motility Software [GIMS™] Medtronic Corporation, Minneapolis MN). Available WMC data allowed the calculation of multiple values. The mean 1-min interval pH for stomach was calculated for 30 min prior to gastric emptying time (GET), defined as an abrupt rise in the pH by 3 or more units above the stomach pH. Similarly, small bowel mean 1-min pH increments for 30 min post GET was extracted [<xref ref-type="bibr" rid="CR19">19</xref>]. The colon mean 1-min pH intervals for 30 min were recorded prior to anal exit of WMC. Corresponding segments also had 5-min pH AUC calculated.</p></sec><sec id="Sec8"><title>Quality of Life Measurements</title><p id="Par16">The Cystic Fibrosis Questionnaire-Revised (CFQ-R, University of Miami, Miami, FL, adult format) was used to assess QOL after placebo and omeprazole treatment [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Subjects ≥ 14 years completed the PROMIS short forms for depression, mobility, pain behavior, social isolation, and GI symptoms including belly pain, constipation, diarrhea, gas and bloating, and reflux [<xref ref-type="bibr" rid="CR22">22</xref>]. Subjects also completed PROMIS-GI, which included eight symptom scales: reflux, disrupted swallowing, diarrhea, bowel incontinence, nausea and vomiting, constipation, belly pain, and gas, bloating, and flatulence.</p></sec><sec id="Sec9"><title>Statistical Analysis</title><p id="Par17">Descriptive statistics for CFA, duodenal pH, MBT, and other outcomes were calculated. The following was the statistical analysis plan for the study; however, the COVID-19 pandemic limited the number of subjects completing the protocol, and only exploratory statistical evaluations were appropriate due to the small final sample. Means and standard deviations were computed where able and applicable. Paired t tests or Wilcoxon sign rank tests were used to compare results for the total group on and off omeprazole treatment as appropriate. The primary outcome was the change in CFA between the measurements made on and off omeprazole. Exploratory outcomes included concurrent changes in fat absorption as measured by the MBT, changes in intestinal pH as measured by the WMC, and changes in QOL by PROMIS and CFQ-R. For the MBT outcomes, AUC from time zero to nine hours was calculated using the linear trapezoid method. PK parameters were compared for the total group comparing on and off omeprazole using paired t tests or Wilcoxon sign rank tests as appropriate, and between randomization groups at each time point using an unpaired t test or Mann–Whitney <italic toggle="yes">U</italic> rank sum test as appropriate. Ultimately, non-parametric Mann–Whitney <italic toggle="yes">t</italic> test or analysis of variance was used to evaluate the differences between placebo and PPI WMC studies using GraphPad Prism 9.4 (San Diego, CA).</p></sec></sec><sec id="Sec10"><title>Results</title><p id="Par18">A total of 19 subjects enrolled and 13 were randomized and provided test results included in this report. The other six subjects did not return for protocol tests after the randomization visit due to the impact of the COVID-19 pandemic, despite many efforts to accommodate health and scheduling concerns.</p><p id="Par19">Table <xref rid="Tab1" ref-type="table">1</xref> provides the baseline data on the 13 subjects for genotype, race, age, sex, and anthropometrics and results of all completed CFA and MBT. Three subjects completed the CFA with full results. One subject had increased stool fat loss and one had decreased stool fat loss when placebo and PPI were compared. The remaining subject’s CFA was within the reference range for both placebo and PPI.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Subject characteristics and outcomes at baseline and following active treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">ID</th><th align="left" rowspan="2" colspan="1">Genotype</th><th align="left" rowspan="2" colspan="1">Age</th><th align="left" rowspan="2" colspan="1">Race</th><th align="left" rowspan="2" colspan="1">Sex</th><th align="left" rowspan="2" colspan="1">Study drug</th><th align="left" colspan="6" rowspan="1">Baseline*</th><th align="left" colspan="1" rowspan="1">CFA</th><th align="left" colspan="2" rowspan="1">MBT</th></tr><tr><th align="left" colspan="2" rowspan="1">Weight (kg)</th><th align="left" colspan="1" rowspan="1">Height (cm)</th><th align="left" colspan="1" rowspan="1">WAZ</th><th align="left" colspan="1" rowspan="1">HAZ</th><th align="left" colspan="1" rowspan="1">BMIZ</th><th align="left" colspan="1" rowspan="1">%</th><th align="left" colspan="1" rowspan="1">HA AUC</th><th align="left" colspan="1" rowspan="1">HA % change</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">1</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">16</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">F</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1">61.4</td><td align="left" colspan="1" rowspan="1">148.1</td><td align="left" colspan="1" rowspan="1">0.7</td><td align="left" colspan="1" rowspan="1"> − 2.2</td><td align="left" colspan="1" rowspan="1">1.5</td><td align="left" colspan="1" rowspan="1">83</td><td align="left" colspan="1" rowspan="1">14.7</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">5.9</td><td align="left" colspan="1" rowspan="1"> − 59.9</td></tr><tr><td align="left" rowspan="2" colspan="1">2</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">28</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">M</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1">60.5</td><td align="left" colspan="1" rowspan="1">176.9</td><td align="left" colspan="1" rowspan="1"> − 1.0</td><td align="left" colspan="1" rowspan="1">0.0</td><td align="left" colspan="1" rowspan="1"> − 1.5</td><td align="left" colspan="1" rowspan="1">92</td><td align="left" colspan="1" rowspan="1">8.0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">96</td><td align="left" colspan="1" rowspan="1">5.5</td><td align="left" colspan="1" rowspan="1"> − 31.3</td></tr><tr><td align="left" rowspan="2" colspan="1">3</td><td align="left" rowspan="2" colspan="1">F508del, G542X</td><td char="." align="char" rowspan="2" colspan="1">16</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">M</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1">59.8</td><td align="left" colspan="1" rowspan="1">161.1</td><td align="left" colspan="1" rowspan="1"> − 0.1</td><td align="left" colspan="1" rowspan="1"> − 1.6</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">77</td><td align="left" colspan="1" rowspan="1">8.7</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">84</td><td align="left" colspan="1" rowspan="1">5.6</td><td align="left" colspan="1" rowspan="1"> − 35.6</td></tr><tr><td align="left" rowspan="2" colspan="1">4</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">19</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">F</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">5.1</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1">60.1</td><td align="left" colspan="1" rowspan="1">156.4</td><td align="left" colspan="1" rowspan="1">0.3</td><td align="left" colspan="1" rowspan="1"> − 1.1</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">83</td><td align="left" colspan="1" rowspan="1">4.8</td><td align="left" colspan="1" rowspan="1"> − 5.9</td></tr><tr><td align="left" rowspan="2" colspan="1">5</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">17</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">M</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">6.6</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1">78.2</td><td align="left" colspan="1" rowspan="1">180.8</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">0.8</td><td align="left" colspan="1" rowspan="1">99</td><td align="left" colspan="1" rowspan="1">8.9</td><td align="left" colspan="1" rowspan="1">34.8</td></tr><tr><td align="left" rowspan="2" colspan="1">6</td><td align="left" rowspan="2" colspan="1">G1551D, – 7 T/7 T</td><td char="." align="char" rowspan="2" colspan="1">18</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">F</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">11.5</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1">50.3</td><td align="left" colspan="1" rowspan="1">154.4</td><td align="left" colspan="1" rowspan="1"> − 0.8</td><td align="left" colspan="1" rowspan="1"> − 1.3</td><td align="left" colspan="1" rowspan="1"> − 0.1</td><td align="left" colspan="1" rowspan="1">89</td><td align="left" colspan="1" rowspan="1">9.3</td><td align="left" colspan="1" rowspan="1"> − 19.1</td></tr><tr><td align="left" rowspan="2" colspan="1">7</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">20</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">M</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">12.0</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1">60.4</td><td align="left" colspan="1" rowspan="1">165.8</td><td align="left" colspan="1" rowspan="1"> − 1.0</td><td align="left" colspan="1" rowspan="1"> − 1.5</td><td align="left" colspan="1" rowspan="1"> − 0.4</td><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">7.1</td><td align="left" colspan="1" rowspan="1"> − 40.8</td></tr><tr><td align="left" rowspan="2" colspan="1">8</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">23</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">M</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">6.4</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">11.1</td><td align="left" colspan="1" rowspan="1">73.4</td></tr><tr><td align="left" rowspan="2" colspan="1">9</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">23</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">F</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1">59.9</td><td align="left" colspan="1" rowspan="1">148.9</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1"> − 2.2</td><td align="left" colspan="1" rowspan="1">1.1</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">13.5</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">7.9</td><td align="left" colspan="1" rowspan="1"> − 41.5</td></tr><tr><td align="left" rowspan="2" colspan="1">10</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">14</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">F</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1">40.1</td><td align="left" colspan="1" rowspan="1">150.5</td><td align="left" colspan="1" rowspan="1"> − 1.2</td><td align="left" colspan="1" rowspan="1"> − 1.5</td><td align="left" colspan="1" rowspan="1"> − 0.6</td><td align="left" colspan="1" rowspan="1">–</td><td align="left" rowspan="2" colspan="2"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td></tr><tr><td align="left" rowspan="2" colspan="1">11</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">18</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">M</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1">74.6</td><td align="left" colspan="1" rowspan="1">179</td><td align="left" colspan="1" rowspan="1">0.6</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">7.8</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">12</td><td align="left" rowspan="2" colspan="1">F508del, F508del</td><td char="." align="char" rowspan="2" colspan="1">19</td><td align="left" rowspan="2" colspan="1">C</td><td align="left" rowspan="2" colspan="1">F</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="2" rowspan="1">–</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1">8.1</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">13</td><td align="left" rowspan="2" colspan="1">S549N, Q98X</td><td char="." align="char" rowspan="2" colspan="1">18</td><td align="left" rowspan="2" colspan="1">AA</td><td align="left" rowspan="2" colspan="1">F</td><td align="left" colspan="1" rowspan="1">Placebo</td><td align="left" colspan="2" rowspan="1">54.8</td><td align="left" colspan="1" rowspan="1">155.2</td><td align="left" colspan="1" rowspan="1"> − 0.2</td><td align="left" colspan="1" rowspan="1"> − 1.2</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">–</td><td align="left" rowspan="2" colspan="2"/></tr><tr><td align="left" colspan="1" rowspan="1">Active</td><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">–</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">C</italic> Caucasian, <italic toggle="yes">AA</italic> African–American, <italic toggle="yes">M</italic> male, <italic toggle="yes">F</italic> female, <italic toggle="yes">WAZ</italic> weight-for-age Z-score, <italic toggle="yes">HAZ</italic> height-for-age Z-score, <italic toggle="yes">BMIZ</italic> body mass index-for-age Z-score (BMIZ), <italic toggle="yes">CFA</italic> coefficient of fat absorption, <italic toggle="yes">MBT</italic> malabsorption blood test</p><p>*anthropometric measurements are baseline measures; alignment in the table indicate the study drug that participants were randomized to first</p><p>‘–’ in cells indicates measurement/test was not performed (e.g., not able to complete due to the COVID-19 pandemic) or the data were not usable (e.g., incomplete diet record to calculate CFA)</p></table-wrap-foot></table-wrap></p><p id="Par20">Nine subjects had full results for the MBT. Of these nine, seven (78%) demonstrated decreased plasma HA concentration while taking a PPI, with a mean decrease in HA AUC of 33.4% (range -5.9 to -59.9), indicating decreased duodenal fatty acid absorption. Two subjects had increased HA concentrations (+ 34.8, + 73.4), indicating an increase in fatty acid absorption on PPI relative to placebo.</p><p id="Par21">Four subjects completed both WMC evaluations, ultimately demonstrating that gastric transit time and small bowel transit time were not influenced by acid suppression, Fig. <xref rid="Fig2" ref-type="fig">2</xref>A. There was a decrease in colonic transit time when subjects were on PPI therapy, but this pattern did not reach statistical significance. No significant changes in gastric, intestinal, or colonic pH 30-min interval profiles were noted, Fig. <xref rid="Fig2" ref-type="fig">2</xref>B. There was an expected small decline in intestinal pH when subjects were on placebo compared to the PPI.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Measured gastrointestinal transit (<bold>a</bold>) and post-stomach small intestinal pH (<bold>b</bold>) profiles on and off treatment. <italic toggle="yes">CTT</italic> Colonic transit time, <italic toggle="yes">GET</italic> gastric emptying time, <italic toggle="yes">GTT</italic> gastric transit time, <italic toggle="yes">PPI</italic> proton-pump inhibitor, <italic toggle="yes">SBTT</italic> small bowel transit time, <italic toggle="yes">SLBTT</italic> small-large bowel transit time, <italic toggle="yes">WGTT</italic> whole gut transit time</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="10620_2024_8728_Fig2_HTML.jpg"/></fig></p><p id="Par22">Eleven subjects completed PROMIS questionnaires while on both placebo and PPI (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). This included seven adult and four pediatric subjects. In the adult subjects, no significant differences were seen in the QOL metrics nor the GI symptom profiles between treatments. Similarly, the eleven subjects who completed the CFQ-R (Fig. <xref rid="Fig4" ref-type="fig">4</xref>) had no significant changes in the domains between treatments. The digest domain trended toward improvement on PPI (<italic toggle="yes">p</italic> = 0.054).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>PROMIS and PROMIS-GI selected domains: 3<bold>a</bold> Reflux, 3<bold>b</bold> Belly Pain, 3<bold>c</bold> Gas and Bloating, 3<bold>d</bold> Constipation, 3<bold>e</bold> Adult Pain, and 3<bold>f</bold> Adult Depression. PROMIS measure domains are reported on a T-score, where 50 is the mean of the reference population. Higher numbers indicate more of the domain being measured. <italic toggle="yes">PROMIS</italic> Patient-reported outcomes measurement information system</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="10620_2024_8728_Fig3_HTML.jpg"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>CFQ-R selected domains: 3<bold>a</bold> Physical, 3<bold>b</bold> Emotion, 3<bold>c</bold> Eating, 3<bold>d</bold> Treatment Burden, 3<bold>e</bold> Respiratory, and 3<bold>f</bold> Digest. The CFQ-R is a disease-specific measure for patients with cystic fibrosis, with higher scores indicating better health-related quality of life in the domain being measured. <italic toggle="yes">CFQ-R</italic> Cystic fibrosis questionnaire–revised</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="10620_2024_8728_Fig4_HTML.jpg"/></fig></p><p id="Par23">No significant adverse events were reported in the study population, and subjects did not report any decreased adherence to study drug or PERT via recall questionnaire.</p></sec><sec id="Sec11"><title>Discussion</title><p id="Par24">Proton-pump inhibitors (PPIs) decrease gastric acid secretion from parietal cells by selectively and irreversibly inhibiting the H+/K+ ATPase. PPIs are pro-drugs that require gastric acid for activation, reacting covalently with cysteine on the luminal surface of the ATPase [<xref ref-type="bibr" rid="CR23">23</xref>]. Omeprazole, a commonly-used PPI, was patented in 1978 and FDA-approved for adults in 1989 with both prescription and over the counter preparations, in 2002 for children aged 2–16 years old, and in 2008 for children aged 1–2 years old. Label indications include treatment of gastroesophageal reflux disease, erosive esophagitis, eosinophilic esophagitis, gastric or duodenal ulcer, <italic toggle="yes">H. pylori</italic> eradication, and frequent heartburn [<xref ref-type="bibr" rid="CR24">24</xref>]. Off-label use in CF intended to enhance fat absorption with PERT is an accepted clinical practice despite limited evidence that PPI improves PERT effectiveness [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par25">Patients with CF and EPI have increased duodenal acidity due to impaired or absent pancreatic bicarbonate secretion. Intrinsic pancreatic enzymes and enteric-coated PERT both require the more basic pH typical of the duodenal environment to be activated (intrinsic enzymes) or dissolved and released (PERT) in a timely fashion for digestion of dietary macronutrients. An acidic small bowel milieu will not only impair enzymatic activity but also lead to bile salt precipitation, exacerbating fat malabsorption. Acid suppression has been hypothesized to facilitate fat absorption by raising the duodenal pH to increase lipase bioavailability and thus triglyceride hydrolysis, improving fatty acid absorption, and possibly supporting growth in children and healthy weight for adults. There is no prior evidence that PPI results in any changes in dietary fat absorption in CF or in healthy subjects.</p><p id="Par26">PPIs have been thought to be safe for short- and long-term use [<xref ref-type="bibr" rid="CR25">25</xref>]. The FDA package insert for omeprazole warns of an increased risk of inflammatory and malabsorptive states, including <italic toggle="yes">C. difficile</italic> diarrhea, acute interstitial nephritis, atrophic gastritis, systemic lupus erythematosus, hypomagnesemia, vitamin B<sub>12</sub> deficiency, iron deficiency, and bone fractures [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par27">Recent studies provide evidence for potential PPI risks in adults and children [<xref ref-type="bibr" rid="CR26">26</xref>]. Lassalle et al. found in a nationwide cohort study a higher rate of severe infections overall in infants through children nine years of age treated with a PPI compared H2RA or antacids. PPI use was associated with increased gastrointestinal, upper respiratory, and central nervous system infections, and the authors recommended judicious use in children [<xref ref-type="bibr" rid="CR27">27</xref>]. Increased risk of fracture in children exposed to early acid suppression was previously described in 2019 by Malchodi et al. and in 2020 by Wang et al. [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In the CF population, pulmonary exacerbation is of particular clinical importance, and McCrory et al. reported higher risk of pulmonary exacerbation in participants with CF taking PPI [<xref ref-type="bibr" rid="CR29">29</xref>]. Despite these data, acid suppression with PPI has increased over the past two decades, frequently in children. For example, a 2022 report demonstrated that PPIs were being prescribed in Scandinavia more frequently from 2007 to 2020 despite international guidelines recommending otherwise [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par28">Given the potential risks of PPI therapy as an adjunct to PERT in patients with CF and EPI, we designed this pilot study to evaluate the potential benefit. CFA results for the three subjects with placebo and PPI exposure were mixed: one subject had increased stool fat loss, one had decreased stool fat loss, and one subject remained within the reference range across both tests. Although PPI use in this study was anticipated to decrease fat malabsorption, prior work has demonstrated that PPI as an adjunct to PERT had no statistically significant effect on CFA [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par29">Of the nine subjects who completed the MBT, 78% had unexpectedly decreased plasma HA absorption with omeprazole, indicating decreased intestinal fatty acid absorption. While the intended effect of PPI is to suppress gastric acid secretion and increase the gastric pH and fatty acid absorption, other downstream effects may occur, changing absorption patterns of nutrients including magnesium and vitamin B<sub>12</sub> as well as altering enteral bacterial homeostasis [<xref ref-type="bibr" rid="CR32">32</xref>]. A well-described adverse effect of oral PPI is diarrhea, though the mechanism is not well understood and likely multifactorial. Subjects in this study did not report an increase in diarrheal symptoms. Whether the decrease in HA absorption in these participants was due to the changes in pH, a decrease in cofactors of HA absorption (i.e., bile salts), altered bacterial composition, or an as-yet-unidentified factor remains unclear. Previous studies utilizing the MBT in patients with CF and EPI detected changes in fat absorption with other intervention protocols including dosage and timing of PERT [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par30">In the four subjects who completed both WMC studies on placebo and PPI, there was no indication of significant changes in the transit or pH profiles across different regions of the intestine. Although a small increase in baseline pH profile was observed in the proximal small bowel on PPI, it did not reach statistical significance. Historical use of acid suppression in subjects with CF on PERT with no GERD symptoms was to improve luminal pH to facilitate earlier dissolution of enterically coated enzymes and improve digestion and nutritional assimilation of fat calories [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Our results question the need for acid suppression medications in CF care to improve dietary fat malabsorption when direct measurement of the gastric, small bowel, and duodenal pH showed no significant changes on or off PPI.</p><p id="Par31">QOL has rarely been investigated in prior studies of PPI use in subjects with CF, and the PROMIS symptom tool has not to our knowledge been evaluated [<xref ref-type="bibr" rid="CR35">35</xref>]. No significant differences were seen in the results with placebo and PPI in PROMIS domains of depression, mobility, pain behavior, and social isolation, nor were significant differences seen in the PROMIS-GI symptom profiles including belly pain, constipation, diarrhea, gas and bloating, and reflux. The digest domain approached statistical significance (<italic toggle="yes">p</italic> = 0.05). Lack of differences may be due to the small number of subjects studied here or due to the short amount of time that participants were treated with PPI. In non-CF adult studies, fewer than 50% of participants were satisfied with their response to PPI treatment when prescribed for symptoms of gastroesophageal reflux disease (regurgitation, heartburn) [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Perception of PPI non-response has been associated with psychological distress and lower QOL. In our study, an association with QOL was not seen with PPI non-response; however, the expectation in this study was that PPI may alter fat absorption, not symptoms of reflux. The CFQ-R has been used to report QOL symptoms with PPI. In one adult CF pilot randomized controlled double-blind trial of esomeprazole compared to placebo evaluating the effect of PPI on pulmonary exacerbations, QOL measured by CFQ-R showed no difference between placebo and PPI over 36 weeks [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par32">Our study results are limited by the small number of subjects who completed the outcome measurements both on PPI and placebo. The protocol complexity and COVID-19 disruption resulted in formal withdrawal from the study by some subjects, and for other subjects, an inability to complete the protocol within the extended study timeline. The two more novel tests, the MBT and WMC, were well-tolerated and provided meaningful information. They should be considered in the design of future clinical trials required to determine the clinical utility to improve fat absorption with adjunct therapy of PPI with PERT. Subjects were recruited from several CF Centers and there was significant interest in scientific and clinical question posed by this study from the CF teams, subjects, and their care providers, and this may support participation in future PPI and CF research.</p></sec><sec id="Sec12"><title>Conclusion</title><p id="Par33">Use of PPIs are common in children and adults with CF and EPI with the intent to increase PERT fat absorption efficacy and support healthy weight and fat-soluble vitamin and essential fatty acid status. Our limited descriptive results from participants with CF and EPI on PERT treated with PPI and placebo did not demonstrate improvement in fat absorption attributable to PPI via plasma or stool tests. The unexpected MBT results, arguably more specific than the CFA as a direct measure of fatty acid absorption, suggested that duodenal fat absorption may be impaired rather than enhanced by PPI in this setting. The similarly unexpected WMC pH results suggest that PPI use did not alter gastric, intestinal, or colonic pH. With these preliminary results showing no evidence of efficacy in the basic mechanism to improve outcomes in patients with CF and EPI, coupled with increasing evidence of risks of PPI medications in all clinical populations, further research is needed to justify continued use of these medications in this population.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>The authors would like to thank the teams at the Cystic Fibrosis Centers at the Children’s Hospital of Philadelphia, Hospital of the University of Pennsylvania, and Geisinger Medical Center for their referral of interested study subjects and support in study efforts.</p></ack><notes notes-type="author-contribution"><title>Author’s contribution</title><p>AT, JNB, and VAS are the guarantors and will ensure that questions related to any part of this work are appropriately investigated and resolved. VAS and JNB were responsible for study design; JNB, AT, BDK, and VAS participated in data acquisition. DP and DG were responsible for WMC data extraction and analysis. All authors (AEP, AT, JNB, BDK, VAS, DP, and DG) participated in data interpretation, drafted the manuscript, and were involved in critical manuscript revisions. All authors participated in final manuscript revisions and take responsibility for the integrity of the data and accuracy of the data analysis.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported in part by an Investigator Initiated Program award from Chiesi USA, Inc, NIH (UL1RR024134), NIH T32 GM008562-23 (JNB), and the NASPGHAN Foundation/Abbot Nutrition Training Grant (BDK).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par34">All authors disclose they have no conflicts of interest related to this project and manuscript. The funding sources had no role in study design, analysis, or drafting of the manuscript.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>SM</given-names></name><name name-style="western"><surname>Moore</surname><given-names>HS</given-names></name></person-group><article-title>Drug therapies for reducing gastric acidity in people with cystic fibrosis</article-title><source>Cochrane Database Syst Rev</source><year>2021</year><volume>4</volume><fpage>CD003424</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD003424.pub5</pub-id><pub-id pub-id-type="pmid">33905540</pub-id><pub-id pub-id-type="pmcid">PMC8079129</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ng SM, Moore HS. Drug therapies for reducing gastric acidity in people with cystic fibrosis. <italic toggle="yes">Cochrane Database Syst Rev</italic> 2021;4:CD003424. 10.1002/14651858.CD003424.pub5.<pub-id pub-id-type="pmid">33905540</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD003424.pub5</pub-id><pub-id pub-id-type="pmcid">PMC8079129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omari</surname><given-names>TI</given-names></name><name name-style="western"><surname>Haslam</surname><given-names>RR</given-names></name><name name-style="western"><surname>Lundborg</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2007</year><volume>44</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1097/01.mpg.0000252190.97545.07</pub-id><pub-id pub-id-type="pmid">17204951</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Omari TI, Haslam RR, Lundborg P et al. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. <italic toggle="yes">J Pediatr Gastroenterol Nutr</italic> 2007;44:41–44. 10.1097/01.mpg.0000252190.97545.07.<pub-id pub-id-type="pmid">17204951</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.mpg.0000252190.97545.07</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orel</surname><given-names>R</given-names></name><name name-style="western"><surname>Benninga</surname><given-names>MA</given-names></name><name name-style="western"><surname>Broekaert</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>Drugs in focus: proton-pump inhibitors</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2021</year><volume>72</volume><fpage>645</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000003063</pub-id><pub-id pub-id-type="pmid">33847286</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Orel R, Benninga MA, Broekaert IJ et al. Drugs in focus: proton-pump inhibitors. <italic toggle="yes">J Pediatr Gastroenterol Nutr</italic> 2021;72:645–653. 10.1097/MPG.0000000000003063.<pub-id pub-id-type="pmid">33847286</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPG.0000000000003063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiMagno</surname><given-names>EP</given-names></name></person-group><article-title>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2001</year><volume>15</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1053/bega.2001.0195</pub-id><pub-id pub-id-type="pmid">11403540</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">DiMagno EP. Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency. <italic toggle="yes">Best Pract Res Clin Gastroenterol</italic> 2001;15:477–486. 10.1053/bega.2001.0195.<pub-id pub-id-type="pmid">11403540</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/bega.2001.0195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borowitz</surname><given-names>DS</given-names></name><name name-style="western"><surname>Grand</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Durie</surname><given-names>PR</given-names></name></person-group><article-title>Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy</article-title><source>J Pediatr</source><year>1995</year><volume>127</volume><fpage>681</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/s0022-3476(95)70153-2</pub-id><pub-id pub-id-type="pmid">7472816</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. <italic toggle="yes">J Pediatr</italic> 1995;127:681–684. 10.1016/s0022-3476(95)70153-2.<pub-id pub-id-type="pmid">7472816</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-3476(95)70153-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruno</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rauws</surname><given-names>EA</given-names></name><name name-style="western"><surname>Hoek</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy</article-title><source>Dig Dis Sci</source><year>1994</year><volume>39</volume><fpage>988</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1007/BF02087549</pub-id><pub-id pub-id-type="pmid">8174440</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bruno MJ, Rauws EA, Hoek FJ et al. Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. <italic toggle="yes">Dig Dis Sci</italic> 1994;39:988–992. 10.1007/BF02087549.<pub-id pub-id-type="pmid">8174440</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02087549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marotta</surname><given-names>F</given-names></name><name name-style="western"><surname>O’Keefe</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Marks</surname><given-names>IN</given-names></name><etal/></person-group><article-title>Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating</article-title><source>Dig Dis Sci</source><year>1989</year><volume>34</volume><fpage>456</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1007/BF01536271</pub-id><pub-id pub-id-type="pmid">2563963</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Marotta F, O’Keefe SJ, Marks IN et al. Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating. <italic toggle="yes">Dig Dis Sci</italic> 1989;34:456–461. 10.1007/BF01536271.<pub-id pub-id-type="pmid">2563963</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01536271</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosen</surname><given-names>R</given-names></name><name name-style="western"><surname>Vandenplas</surname><given-names>Y</given-names></name><name name-style="western"><surname>Singendonk</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American society for pediatric gastroenterology, hepatology, and nutrition and the European society for pediatric gastroenterology, hepatology, and nutrition</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2018</year><volume>66</volume><fpage>516</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000001889</pub-id><pub-id pub-id-type="pmid">29470322</pub-id><pub-id pub-id-type="pmcid">PMC5958910</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Rosen R, Vandenplas Y, Singendonk M et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American society for pediatric gastroenterology, hepatology, and nutrition and the European society for pediatric gastroenterology, hepatology, and nutrition. <italic toggle="yes">J Pediatr Gastroenterol Nutr</italic> 2018;66:516–554. 10.1097/MPG.0000000000001889.<pub-id pub-id-type="pmid">29470322</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPG.0000000000001889</pub-id><pub-id pub-id-type="pmcid">PMC5958910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Wintzell</surname><given-names>V</given-names></name><name name-style="western"><surname>Ludvigsson</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Association between proton-pump inhibitor use and risk of asthma in children</article-title><source>JAMA Pediatr</source><year>2021</year><volume>175</volume><fpage>394</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2020.5710</pub-id><pub-id pub-id-type="pmid">33555324</pub-id><pub-id pub-id-type="pmcid">PMC7871209</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Wang Y-H, Wintzell V, Ludvigsson JF et al. Association between proton-pump inhibitor use and risk of asthma in children. <italic toggle="yes">JAMA Pediatr</italic> 2021;175:394–403. 10.1001/jamapediatrics.2020.5710.<pub-id pub-id-type="pmid">33555324</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapediatrics.2020.5710</pub-id><pub-id pub-id-type="pmcid">PMC7871209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Wintzell</surname><given-names>V</given-names></name><name name-style="western"><surname>Ludvigsson</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Association between proton-pump inhibitor use and risk of fracture in children</article-title><source>JAMA Pediatr</source><year>2020</year><volume>174</volume><fpage>543</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2020.0007</pub-id><pub-id pub-id-type="pmid">32176276</pub-id><pub-id pub-id-type="pmcid">PMC7076540</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wang Y-H, Wintzell V, Ludvigsson JF et al. Association between proton-pump inhibitor use and risk of fracture in children. <italic toggle="yes">JAMA Pediatr</italic> 2020;174:543–551. 10.1001/jamapediatrics.2020.0007.<pub-id pub-id-type="pmid">32176276</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapediatrics.2020.0007</pub-id><pub-id pub-id-type="pmcid">PMC7076540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedberg</surname><given-names>DE</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>K</given-names></name><name name-style="western"><surname>Denburg</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Use of proton-pump inhibitors is associated with fractures in young adults: a population-based study</article-title><source>Osteoporos Int</source><year>2015</year><volume>26</volume><fpage>2501</fpage><lpage>2507</lpage><pub-id pub-id-type="doi">10.1007/s00198-015-3168-0</pub-id><pub-id pub-id-type="pmid">25986385</pub-id><pub-id pub-id-type="pmcid">PMC4575851</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Freedberg DE, Haynes K, Denburg MR et al. Use of proton-pump inhibitors is associated with fractures in young adults: a population-based study. <italic toggle="yes">Osteoporos Int</italic> 2015;26:2501–2507. 10.1007/s00198-015-3168-0.<pub-id pub-id-type="pmid">25986385</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00198-015-3168-0</pub-id><pub-id pub-id-type="pmcid">PMC4575851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>KT</given-names></name><name name-style="western"><surname>McMenamin</surname><given-names>ÚC</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>B</given-names></name><etal/></person-group><article-title>Proton-pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies</article-title><source>Aliment Pharmacol Ther</source><year>2018</year><volume>48</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1111/apt.14796</pub-id><pub-id pub-id-type="pmid">29741272</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Tran KT, McMenamin ÚC, Hicks B et al. Proton-pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. <italic toggle="yes">Aliment Pharmacol Ther</italic> 2018;48:55–64. 10.1111/apt.14796.<pub-id pub-id-type="pmid">29741272</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.14796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><name name-style="western"><surname>Jeffries</surname><given-names>S</given-names></name><name name-style="western"><surname>Carr</surname><given-names>R</given-names></name></person-group><article-title>A review of histamine-2 receptor antagonist and proton-pump inhibitor therapy for gastroesophageal reflux disease in neonates and infants</article-title><source>Paediatr Drugs</source><year>2023</year><volume>25</volume><fpage>557</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1007/s40272-023-00580-z</pub-id><pub-id pub-id-type="pmid">37458926</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tan J, Jeffries S, Carr R. A review of histamine-2 receptor antagonist and proton-pump inhibitor therapy for gastroesophageal reflux disease in neonates and infants. <italic toggle="yes">Paediatr Drugs</italic> 2023;25:557–576. 10.1007/s40272-023-00580-z.<pub-id pub-id-type="pmid">37458926</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40272-023-00580-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedberg</surname><given-names>DE</given-names></name><name name-style="western"><surname>Kim</surname><given-names>LS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y-X</given-names></name></person-group><article-title>The risks and benefits of long-term use of proton-pump inhibitors: expert review and best practice advice from the American gastroenterological association</article-title><source>Gastroenterology</source><year>2017</year><volume>152</volume><fpage>706</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.01.031</pub-id><pub-id pub-id-type="pmid">28257716</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton-pump inhibitors: expert review and best practice advice from the American gastroenterological association. <italic toggle="yes">Gastroenterology</italic> 2017;152:706–715. 10.1053/j.gastro.2017.01.031.<pub-id pub-id-type="pmid">28257716</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2017.01.031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bashaw</surname><given-names>H</given-names></name><name name-style="western"><surname>Brownell</surname><given-names>JN</given-names></name><name name-style="western"><surname>Schall</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Measures of dietary fat and energy absorption in healthy adults</article-title><source>Pancreas</source><year>2020</year><volume>49</volume><fpage>845</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000001587</pub-id><pub-id pub-id-type="pmid">32590620</pub-id><pub-id pub-id-type="pmcid">PMC8335406</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Bashaw H, Brownell JN, Schall JI et al. Measures of dietary fat and energy absorption in healthy adults. <italic toggle="yes">Pancreas</italic> 2020;49:845–854. 10.1097/MPA.0000000000001587.<pub-id pub-id-type="pmid">32590620</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPA.0000000000001587</pub-id><pub-id pub-id-type="pmcid">PMC8335406</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brownell</surname><given-names>JN</given-names></name><name name-style="western"><surname>Schall</surname><given-names>JI</given-names></name><name name-style="western"><surname>Stallings</surname><given-names>VA</given-names></name></person-group><article-title>Pancreatic function in chronic pancreatitis: a cohort study comparing 3 methods of detecting fat malabsorption and the impact of short-term pancreatic enzyme replacement therapy</article-title><source>Pancreas</source><year>2019</year><volume>48</volume><fpage>1068</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1097/MPA.0000000000001381</pub-id><pub-id pub-id-type="pmid">31404029</pub-id><pub-id pub-id-type="pmcid">PMC7243202</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Brownell JN, Schall JI, Stallings VA. Pancreatic function in chronic pancreatitis: a cohort study comparing 3 methods of detecting fat malabsorption and the impact of short-term pancreatic enzyme replacement therapy. <italic toggle="yes">Pancreas</italic> 2019;48:1068–1078. 10.1097/MPA.0000000000001381.<pub-id pub-id-type="pmid">31404029</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPA.0000000000001381</pub-id><pub-id pub-id-type="pmcid">PMC7243202</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mascarenhas</surname><given-names>MR</given-names></name><name name-style="western"><surname>Mondick</surname><given-names>J</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Malabsorption blood test: assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency</article-title><source>J Clin Pharmacol</source><year>2015</year><volume>55</volume><fpage>854</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1002/jcph.484</pub-id><pub-id pub-id-type="pmid">25689042</pub-id><pub-id pub-id-type="pmcid">PMC4496318</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Mascarenhas MR, Mondick J, Barrett JS et al. Malabsorption blood test: assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency. <italic toggle="yes">J Clin Pharmacol</italic> 2015;55:854–865. 10.1002/jcph.484.<pub-id pub-id-type="pmid">25689042</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.484</pub-id><pub-id pub-id-type="pmcid">PMC4496318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stallings</surname><given-names>VA</given-names></name><name name-style="western"><surname>Mondick</surname><given-names>JT</given-names></name><name name-style="western"><surname>Schall</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis</article-title><source>Int J Clin Pharmacol Ther</source><year>2013</year><volume>51</volume><fpage>263</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.5414/CP201793</pub-id><pub-id pub-id-type="pmid">23357842</pub-id><pub-id pub-id-type="pmcid">PMC4350154</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Stallings VA, Mondick JT, Schall JI et al. Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis. <italic toggle="yes">Int J Clin Pharmacol Ther</italic> 2013;51:263–273. 10.5414/CP201793.<pub-id pub-id-type="pmid">23357842</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.5414/CP201793</pub-id><pub-id pub-id-type="pmcid">PMC4350154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gelfond</surname><given-names>D</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Semler</surname><given-names>J</given-names></name><etal/></person-group><article-title>Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule</article-title><source>Dig Dis Sci</source><year>2013</year><volume>58</volume><fpage>2275</fpage><lpage>2281</lpage><pub-id pub-id-type="doi">10.1007/s10620-012-2209-1</pub-id><pub-id pub-id-type="pmid">22592630</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gelfond D, Ma C, Semler J et al. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. <italic toggle="yes">Dig Dis Sci</italic> 2013;58:2275–2281. 10.1007/s10620-012-2209-1.<pub-id pub-id-type="pmid">22592630</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10620-012-2209-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modi</surname><given-names>AC</given-names></name><name name-style="western"><surname>Quittner</surname><given-names>AL</given-names></name></person-group><article-title>Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis</article-title><source>J Pediatr Psychol</source><year>2003</year><volume>28</volume><fpage>535</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1093/jpepsy/jsg044</pub-id><pub-id pub-id-type="pmid">14602844</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. <italic toggle="yes">J Pediatr Psychol</italic> 2003;28:535–545. 10.1093/jpepsy/jsg044.<pub-id pub-id-type="pmid">14602844</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jpepsy/jsg044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quittner</surname><given-names>AL</given-names></name><name name-style="western"><surname>Buu</surname><given-names>A</given-names></name><name name-style="western"><surname>Messer</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>2347</fpage><lpage>2354</lpage><pub-id pub-id-type="doi">10.1378/chest.128.4.2347</pub-id><pub-id pub-id-type="pmid">16236893</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Quittner AL, Buu A, Messer MA et al. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. <italic toggle="yes">Chest</italic> 2005;128:2347–2354. 10.1378/chest.128.4.2347.<pub-id pub-id-type="pmid">16236893</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.128.4.2347</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fries</surname><given-names>JF</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>B</given-names></name><name name-style="western"><surname>Cella</surname><given-names>D</given-names></name></person-group><article-title>The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes</article-title><source>Clin Exp Rheumatol</source><year>2005</year><volume>23</volume><fpage>S53</fpage><lpage>S57</lpage><pub-id pub-id-type="pmid">16273785</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Fries JF, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. <italic toggle="yes">Clin Exp Rheumatol</italic> 2005;23:S53–S57.<pub-id pub-id-type="pmid">16273785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of the proton-pump inhibitors</article-title><source>J Neurogastroenterol Motil</source><year>2013</year><volume>19</volume><fpage>25</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.5056/jnm.2013.19.1.25</pub-id><pub-id pub-id-type="pmid">23350044</pub-id><pub-id pub-id-type="pmcid">PMC3548122</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton-pump inhibitors. <italic toggle="yes">J Neurogastroenterol Motil</italic> 2013;19:25–35. 10.5056/jnm.2013.19.1.25.<pub-id pub-id-type="pmid">23350044</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.5056/jnm.2013.19.1.25</pub-id><pub-id pub-id-type="pmcid">PMC3548122</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Anon. Prilosec (omeprazole) [Package Insert] U.S. Food and Drug Administration Web site. 2012</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunasekaran</surname><given-names>TS</given-names></name><name name-style="western"><surname>Hassall</surname><given-names>EG</given-names></name></person-group><article-title>Efficacy and safety of omeprazole for severe gastroesophageal reflux in children</article-title><source>J Pediatr</source><year>1993</year><volume>123</volume><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/s0022-3476(05)81561-6</pub-id><pub-id pub-id-type="pmid">8320610</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. <italic toggle="yes">J Pediatr</italic> 1993;123:148–154. 10.1016/s0022-3476(05)81561-6.<pub-id pub-id-type="pmid">8320610</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-3476(05)81561-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berry</surname><given-names>JG</given-names></name><name name-style="western"><surname>Mansbach</surname><given-names>JM</given-names></name></person-group><article-title>Questionable safety of proton-pump inhibitor use in children</article-title><source>JAMA Pediatr</source><year>2023</year><volume>177</volume><fpage>1010</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2023.2906</pub-id><pub-id pub-id-type="pmid">37578788</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Berry JG, Mansbach JM. Questionable safety of proton-pump inhibitor use in children. <italic toggle="yes">JAMA Pediatr</italic> 2023;177:1010–1012. 10.1001/jamapediatrics.2023.2906.<pub-id pub-id-type="pmid">37578788</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapediatrics.2023.2906</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassalle</surname><given-names>M</given-names></name><name name-style="western"><surname>Zureik</surname><given-names>M</given-names></name><name name-style="western"><surname>Dray-Spira</surname><given-names>R</given-names></name></person-group><article-title>Proton-pump inhibitor use and risk of serious infections in young children</article-title><source>JAMA Pediatr</source><year>2023</year><volume>177</volume><fpage>1028</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2023.2900</pub-id><pub-id pub-id-type="pmid">37578761</pub-id><pub-id pub-id-type="pmcid">PMC10425862</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lassalle M, Zureik M, Dray-Spira R. Proton-pump inhibitor use and risk of serious infections in young children. <italic toggle="yes">JAMA Pediatr</italic> 2023;177:1028–1038. 10.1001/jamapediatrics.2023.2900.<pub-id pub-id-type="pmid">37578761</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapediatrics.2023.2900</pub-id><pub-id pub-id-type="pmcid">PMC10425862</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malchodi</surname><given-names>L</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>K</given-names></name><name name-style="western"><surname>Susi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Early acid suppression therapy exposure and fracture in young children</article-title><source>Pediatrics</source><year>2019</year><volume>144</volume><fpage>e20182625</fpage><pub-id pub-id-type="doi">10.1542/peds.2018-2625</pub-id><pub-id pub-id-type="pmid">31175146</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Malchodi L, Wagner K, Susi A et al. Early acid suppression therapy exposure and fracture in young children. <italic toggle="yes">Pediatrics</italic> 2019;144:e20182625. 10.1542/peds.2018-2625.<pub-id pub-id-type="pmid">31175146</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2018-2625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCrory</surname><given-names>BE</given-names></name><name name-style="western"><surname>Harper</surname><given-names>HN</given-names></name><name name-style="western"><surname>McPhail</surname><given-names>GL</given-names></name></person-group><article-title>Use and incidence of adverse effects of proton-pump inhibitors in patients with cystic fibrosis</article-title><source>Pharmacotherapy</source><year>2018</year><volume>38</volume><fpage>725</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1002/phar.2125</pub-id><pub-id pub-id-type="pmid">29800488</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">McCrory BE, Harper HN, McPhail GL. Use and incidence of adverse effects of proton-pump inhibitors in patients with cystic fibrosis. <italic toggle="yes">Pharmacotherapy</italic> 2018;38:725–729. 10.1002/phar.2125.<pub-id pub-id-type="pmid">29800488</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/phar.2125</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyamouri</surname><given-names>M</given-names></name><name name-style="western"><surname>Mårild</surname><given-names>K</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Proton-pump inhibitors for infants in three Scandinavian countries increased from 2007 to 2020 despite international recommendations</article-title><source>Acta Paediatr</source><year>2022</year><volume>111</volume><fpage>2222</fpage><lpage>2228</lpage><pub-id pub-id-type="doi">10.1111/apa.16491</pub-id><pub-id pub-id-type="pmid">35860963</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Lyamouri M, Mårild K, Nielsen RG et al. Proton-pump inhibitors for infants in three Scandinavian countries increased from 2007 to 2020 despite international recommendations. <italic toggle="yes">Acta Paediatr</italic> 2022;111:2222–2228. 10.1111/apa.16491.<pub-id pub-id-type="pmid">35860963</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apa.16491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sander-Struckmeier</surname><given-names>S</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>K</given-names></name><name name-style="western"><surname>Janssen-van Solingen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency</article-title><source>Pancreas</source><year>2013</year><volume>42</volume><fpage>983</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1097/MPA.0b013e31828784ef</pub-id><pub-id pub-id-type="pmid">23587850</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sander-Struckmeier S, Beckmann K, Janssen-van Solingen G et al. Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON®) in patients with pancreatic exocrine insufficiency. <italic toggle="yes">Pancreas</italic> 2013;42:983–989. 10.1097/MPA.0b013e31828784ef.<pub-id pub-id-type="pmid">23587850</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPA.0b013e31828784ef</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nehra</surname><given-names>AK</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>JA</given-names></name><name name-style="western"><surname>Loftus</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Proton-pump inhibitors: review of emerging concerns</article-title><source>Mayo Clin Proc</source><year>2018</year><volume>93</volume><fpage>240</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2017.10.022</pub-id><pub-id pub-id-type="pmid">29406201</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Nehra AK, Alexander JA, Loftus CG et al. Proton-pump inhibitors: review of emerging concerns. <italic toggle="yes">Mayo Clin Proc</italic> 2018;93:240–246. 10.1016/j.mayocp.2017.10.022.<pub-id pub-id-type="pmid">29406201</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocp.2017.10.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrone</surname><given-names>M</given-names></name><name name-style="western"><surname>Raimondo</surname><given-names>M</given-names></name><name name-style="western"><surname>Scolapio</surname><given-names>JS</given-names></name></person-group><article-title>Pancreatic enzyme pharmacotherapy</article-title><source>Pharmacotherapy</source><year>2007</year><volume>27</volume><fpage>910</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1592/phco.27.6.910</pub-id><pub-id pub-id-type="pmid">17542772</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. <italic toggle="yes">Pharmacotherapy</italic> 2007;27:910–920. 10.1592/phco.27.6.910.<pub-id pub-id-type="pmid">17542772</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1592/phco.27.6.910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraisinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Hochhaus</surname><given-names>G</given-names></name><name name-style="western"><surname>Stecenko</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations</article-title><source>J Clin Pharmacol</source><year>1994</year><volume>34</volume><fpage>158</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1002/j.1552-4604.1994.tb03981.x</pub-id><pub-id pub-id-type="pmid">8163716</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kraisinger M, Hochhaus G, Stecenko A et al. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. <italic toggle="yes">J Clin Pharmacol</italic> 1994;34:158–166. 10.1002/j.1552-4604.1994.tb03981.x.<pub-id pub-id-type="pmid">8163716</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/j.1552-4604.1994.tb03981.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadlapati</surname><given-names>R</given-names></name><name name-style="western"><surname>Tye</surname><given-names>M</given-names></name><name name-style="western"><surname>Keefer</surname><given-names>L</given-names></name><etal/></person-group><article-title>Psychosocial distress and quality of life impairment are associated with symptom severity in PPI non-responders with normal impedance-pH profiles</article-title><source>Am J Gastroenterol</source><year>2018</year><volume>113</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/ajg.2017.263</pub-id><pub-id pub-id-type="pmid">28895583</pub-id><pub-id pub-id-type="pmcid">PMC5772841</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Yadlapati R, Tye M, Keefer L et al. Psychosocial distress and quality of life impairment are associated with symptom severity in PPI non-responders with normal impedance-pH profiles. <italic toggle="yes">Am J Gastroenterol</italic> 2018;113:31–38. 10.1038/ajg.2017.263.<pub-id pub-id-type="pmid">28895583</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2017.263</pub-id><pub-id pub-id-type="pmcid">PMC5772841</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahrilas</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Denison</surname><given-names>H</given-names></name><etal/></person-group><article-title>Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease</article-title><source>Clin Gastroenterol Hepatol</source><year>2012</year><volume>10</volume><fpage>612</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2012.01.022</pub-id><pub-id pub-id-type="pmid">22343515</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kahrilas PJ, Jonsson A, Denison H et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. <italic toggle="yes">Clin Gastroenterol Hepatol</italic> 2012;10:612–619. 10.1016/j.cgh.2012.01.022.<pub-id pub-id-type="pmid">22343515</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2012.01.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canani</surname><given-names>RB</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>P</given-names></name><name name-style="western"><surname>Roggero</surname><given-names>P</given-names></name><etal/></person-group><article-title>Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><fpage>e817</fpage><lpage>e820</lpage><pub-id pub-id-type="doi">10.1542/peds.2005-1655</pub-id><pub-id pub-id-type="pmid">16651285</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Canani RB, Cirillo P, Roggero P et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. <italic toggle="yes">Pediatrics</italic> 2006;117:e817–e820. 10.1542/peds.2005-1655.<pub-id pub-id-type="pmid">16651285</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1542/peds.2005-1655</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article id="cpt3610" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">2002</journal-id><journal-id journal-id-type="pmc-domain">clpt</journal-id><journal-id journal-id-type="publisher-id">CPT</journal-id><journal-title-group><journal-title>Clinical Pharmacology and Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0009-9236</issn><issn pub-type="epub">1532-6535</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Clin Pharmacol Ther</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12087695</article-id><article-id pub-id-type="pmcid-ver">PMC12087695.1</article-id><article-id pub-id-type="pmcaid">12087695</article-id><article-id pub-id-type="pmcaiid">12087695</article-id><article-id pub-id-type="pmid">39982209</article-id><article-id pub-id-type="doi">10.1002/cpt.3610</article-id><article-id pub-id-type="publisher-id">CPT3610</article-id><article-id pub-id-type="other">2024-1454</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></subj-group></article-categories><title-group><article-title>A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil</article-title></title-group><contrib-group><contrib id="cpt3610-cr-0001" contrib-type="author"><name name-style="western"><surname>Aurinsalo</surname><given-names initials="L">Laura</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1915-6227</contrib-id><xref rid="cpt3610-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cpt3610-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cpt3610-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cpt3610-cr-0002" contrib-type="author"><name name-style="western"><surname>Lapatto‐Reiniluoto</surname><given-names initials="O">Outi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2463-1862</contrib-id><xref rid="cpt3610-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cpt3610-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cpt3610-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cpt3610-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cpt3610-cr-0003" contrib-type="author"><name name-style="western"><surname>Kurkela</surname><given-names initials="M">Mika</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4153-4143</contrib-id><xref rid="cpt3610-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cpt3610-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cpt3610-cr-0004" contrib-type="author"><name name-style="western"><surname>Neuvonen</surname><given-names initials="M">Mikko</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7627-1638</contrib-id><xref rid="cpt3610-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cpt3610-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cpt3610-cr-0005" contrib-type="author"><name name-style="western"><surname>Kiiski</surname><given-names initials="JI">Johanna I.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4089-7209</contrib-id><xref rid="cpt3610-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cpt3610-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cpt3610-cr-0006" contrib-type="author"><name name-style="western"><surname>Niemi</surname><given-names initials="M">Mikko</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4550-2189</contrib-id><xref rid="cpt3610-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cpt3610-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cpt3610-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cpt3610-cr-0007" contrib-type="author"><name name-style="western"><surname>Tornio</surname><given-names initials="A">Aleksi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5713-5692</contrib-id><xref rid="cpt3610-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="cpt3610-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="cpt3610-note-0001" ref-type="author-notes">
<sup>
<sup>†</sup>
</sup>
</xref></contrib><contrib id="cpt3610-cr-0008" contrib-type="author" corresp="yes"><name name-style="western"><surname>Backman</surname><given-names initials="JT">Janne T.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9577-2788</contrib-id><xref rid="cpt3610-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cpt3610-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cpt3610-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cpt3610-note-0001" ref-type="author-notes">
<sup>
<sup>†</sup>
</sup>
</xref><address><email>janne.backman@helsinki.fi</email></address></contrib></contrib-group><aff id="cpt3610-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Pharmacology</named-content>
<institution>University of Helsinki</institution>
<city>Helsinki</city>
<country country="FI">Finland</country>
</aff><aff id="cpt3610-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Individualized Drug Therapy Research Program, Faculty of Medicine</named-content>
<institution>University of Helsinki</institution>
<city>Helsinki</city>
<country country="FI">Finland</country>
</aff><aff id="cpt3610-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Pharmacology, HUS Diagnostic Center</named-content>
<institution>Helsinki University Hospital</institution>
<city>Helsinki</city>
<country country="FI">Finland</country>
</aff><aff id="cpt3610-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">HUS Pharmacy</named-content>
<institution>Helsinki University Hospital</institution>
<city>Helsinki</city>
<country country="FI">Finland</country>
</aff><aff id="cpt3610-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Integrative Physiology and Pharmacology, Institute of Biomedicine</named-content>
<institution>University of Turku</institution>
<city>Turku</city>
<country country="FI">Finland</country>
</aff><aff id="cpt3610-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Unit of Clinical Pharmacology</named-content>
<institution>Turku University Hospital</institution>
<city>Turku</city>
<country country="FI">Finland</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
Correspondence: Janne T. Backman (<email>janne.backman@helsinki.fi</email>)<break/>
</corresp><fn fn-type="equal" id="cpt3610-note-0001"><label>
<sup>†</sup>
</label><p>Equal contribution.</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>117</volume><issue seq="290">6</issue><issue-id pub-id-type="pmc-issue-id">488820</issue-id><issue-id pub-id-type="doi">10.1002/cpt.v117.6</issue-id><fpage>1732</fpage><lpage>1742</lpage><history><date date-type="received"><day>14</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>07</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>20</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-20 11:25:46.250"><day>20</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2025 The Author(s). <italic toggle="yes">Clinical Pharmacology &amp; Therapeutics</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CPT-117-1732.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CPT-117-1732.pdf"/><abstract><p>Clinical cocktails for cytochrome P450 (CYP) phenotyping lack a marker for CYP2C8. We aimed to combine the CYP2C8 index drug repaglinide with the Geneva cocktail (caffeine/CYP1A2, bupropion/CYP2B6, flurbiprofen/CYP2C9, omeprazole/CYP2C19, dextromethorphan/CYP2D6, and midazolam/CYP3A4). We also included endogenous organic anion transporting polypeptide (OATP) 1B1 and 1B3 biomarkers glycochenodeoxycholate 3‐O‐glucuronide and glycochenodeoxycholate 3‐sulfate, and investigated the CYP2C8 inhibition selectivity of clopidogrel and gemfibrozil with the full cocktail. In a five‐phase randomized cross‐over study, the following drugs were administered to 16 healthy volunteers: (i) repaglinide, (ii) the Geneva cocktail, (iii) repaglinide with the Geneva cocktail (full cocktail), (iv) clopidogrel followed by the full cocktail, and (v) gemfibrozil followed by the full cocktail. The Geneva cocktail increased repaglinide AUC<sub>0‐23h</sub> 1.22‐fold (90% confidence interval 1.04–1.44, <italic toggle="no">P</italic> = 0.033). The full cocktail accurately captured known inhibitory effects of clopidogrel on CYP2B6, CYP2C8, and CYP2C19 and that of gemfibrozil on CYP2C8. Gemfibrozil decreased the paraxanthine/caffeine AUC<sub>0‐12h</sub> ratio by 23% (14–31%, <italic toggle="no">P</italic> &lt; 0.01) and increased caffeine AUC<sub>0‐12h</sub> 1.20‐fold (1.03–1.40, <italic toggle="no">P</italic> = 0.036). Gemfibrozil increased the metabolite‐to‐index drug AUC<sub>0‐23h</sub> ratios of flurbiprofen, omeprazole, dextromethorphan, and midazolam 1.59‐fold (1.32–1.92), 1.47‐fold (1.34–1.61), 1.79‐fold (1.23–2.59), and 2.1‐fold (1.9–2.4), respectively, without affecting the index drug AUCs (<italic toggle="no">P</italic> &lt; 0.01). Gemfibrozil increased the AUC<sub>0‐4h</sub> of glycochenodeoxycholate 3‐O‐glucuronide 1.33‐fold (1.07–1.65, <italic toggle="no">P</italic> = 0.027). In conclusion, the combination of repaglinide, the Geneva cocktail and endogenous biomarkers for OATP1B1 and OATP1B3 yields a nine‐in‐one phenotyping tool. Apart from strong CYP2C8 inhibition, gemfibrozil weakly inhibits CYP1A2 and OATP1B1 and appears to impair the elimination of the metabolites of several CYP index drugs.</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Academy of Finland
</institution><institution-id institution-id-type="doi">10.13039/501100002341</institution-id></institution-wrap></funding-source><award-id>325667</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Sigrid Jusélius Foundation
</institution><institution-id institution-id-type="doi">10.13039/501100006306</institution-id></institution-wrap></funding-source><award-id>8037</award-id></award-group><award-group id="funding-0003"><funding-source>State Funding for University‐Level Health Research</funding-source><award-id>TYH2019300</award-id><award-id>TYH2021304</award-id></award-group><award-group id="funding-0004"><funding-source>Hospital District of Helsinki and Uusimaa, Finland</funding-source></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Finnish Medical Foundation
</institution><institution-id institution-id-type="doi">10.13039/100008723</institution-id></institution-wrap></funding-source><award-id>4697</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="11"/><word-count count="8000"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:19.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cpt3610-ntgp-0001"><fn id="cpt3610-note-0002"><p>This work has been presented in part in the 26th North American ISSX and 39th JSSX Meeting, Honolulu, Hawaii, USA, September 15–18, 2024.</p></fn></fn-group></notes></front><body id="cpt3610-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="cpt3610-blkfxd-0001" orientation="portrait"><caption><title>Study Highlights</title></caption><p>
<list list-type="simple" id="cpt3610-list-0001"><list-item id="cpt3610-li-0001"><p>
<bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
</p></list-item></list>
</p><p>Clinical cytochrome P450 (CYP) phenotyping cocktails lack an index of CYP2C8, an important drug‐metabolizing enzyme. Although clopidogrel and gemfibrozil are index inhibitors of CYP2C8, their selectivity has not been determined clinically. Gemfibrozil has been suspected to inhibit also organic anion transporting polypeptide (OATP) 1B1.
<list list-type="simple" id="cpt3610-list-0002"><list-item id="cpt3610-li-0002"><p>
<bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold>
</p></list-item></list>
</p><p>We validated a cocktail of seven major CYP enzymes and two transporter activities by combining the CYP2C8 index drug repaglinide with the Geneva cocktail and endogenous biomarkers for OATP1B1 and OATP1B3. The effects of clopidogrel and gemfibrozil on this full cocktail were investigated to determine their selectivity as CYP2C8 index inhibitors.
<list list-type="simple" id="cpt3610-list-0003"><list-item id="cpt3610-li-0003"><p>
<bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold>
</p></list-item></list>
</p><p>Repaglinide did not have relevant interactions with the Geneva cocktail. Established CYP inhibitory effects of clopidogrel and gemfibrozil were captured accurately with the full cocktail. The results documented weak inhibition of CYP1A2 and OATP1B1 by gemfibrozil. Unexpectedly, gemfibrozil increased 4′‐hydroxyflurbiprofen, 5′‐hydroxyomeprazole, dextrorphan, and 1′‐hydroxymidazolam concentrations without affecting parent drug variables. Gemfibrozil likely interferes with the elimination of these index metabolites and thus affects drug elimination pathways more than previously considered.
<list list-type="simple" id="cpt3610-list-0004"><list-item id="cpt3610-li-0004"><p>
<bold>HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?</bold>
</p></list-item></list>
</p><p>Repaglinide combined with the Geneva cocktail and endogenous biomarkers for OATP1B1 and OATP1B3 yields a phenotyping tool for simultaneous activity measurements of seven CYP enzymes and two transporters. Gemfibrozil is a more suitable CYP2C8 index inhibitor than clopidogrel as gemfibrozil is stronger and has no moderate/strong inhibitory effects on other CYPs. Yet, weak inhibition of CYP1A2 and OATP1B1 and apparent effects on uncharacterized “phase II” elimination mechanisms by gemfibrozil warrant caution in the interpretation of studies with gemfibrozil as a CYP2C8 index inhibitor.</p></boxed-text>
</p><p>Individual drug response is determined by genetics and epigenetics, diseases, and general physiological state, as well as various environmental factors, such as drug–drug interactions, diet, and other environmental exposures. To increase understanding of such interindividual variability and improve individualization of drug treatments, there is a need for methods to phenotype drug metabolism. Ultimately, such methods could be used to maximize the effectiveness of drug treatments and reduce adverse effects and costs.</p><p>Standalone drug–drug interaction studies utilizing sensitive index drugs are the gold‐standard for investigating a possible inhibitor or inducer of cytochrome P450 (CYP) enzymes.<xref rid="cpt3610-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> For profiling of drug metabolism, combinations of multiple index drugs for different CYP enzymes, called CYP cocktails, have proven useful. As activities of several CYP enzymes can be measured in one clinical trial, a more comprehensive view on drug metabolism is achieved, while efforts, costs, and invasiveness to study participants are reduced compared with studying each index drug separately. In addition to studying drug–drug interactions, index drug cocktails can be used to phenotype drug metabolism in clinical trials and patient care.<xref rid="cpt3610-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>Selective and sensitive clinical index drugs have been validated for all major CYP enzymes.<xref rid="cpt3610-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> However, it has been challenging to develop optimized index drug cocktails, for example, due to mutual interactions between index drugs, adverse effects caused by the cocktail or unfeasible sampling needed.<xref rid="cpt3610-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="cpt3610-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="cpt3610-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="cpt3610-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="cpt3610-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="cpt3610-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="cpt3610-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> In addition, CYP2C8 is not included in any of the published clinical phenotyping cocktails, such as the well‐validated Geneva cocktail, which lacks significant safety issues and includes index drugs for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A.<xref rid="cpt3610-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="cpt3610-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="cpt3610-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> CYP2C8 is of importance in the metabolism of multiple clinically used drugs such as daprodustat, desloratadine, enzalutamide, hydroxychloroquine, imatinib, montelukast, paclitaxel, and pioglitazone.<xref rid="cpt3610-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="cpt3610-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Overall, CYP2C8 is the most important CYP enzyme missing from clinical cocktails.</p><p>Our aim was to add the well‐established CYP2C8 index drug repaglinide to the Geneva cocktail and to test if its addition causes any mutual interaction with the index drugs (<bold>Table</bold>
<xref rid="cpt3610-tbl-0001" ref-type="table">
<bold>1</bold>
</xref>).<xref rid="cpt3610-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="cpt3610-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="cpt3610-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="cpt3610-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Repaglinide was chosen, because it has been extensively used, and because its short half‐life enables a short blood sampling period. We tested the effect of the moderate and strong CYP2C8 inhibitors clopidogrel and gemfibrozil<xref rid="cpt3610-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="cpt3610-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> on the full cocktail to characterize the selectivity of their CYP2C8 inhibitory effect and to further test the performance of repaglinide in this CYP cocktail. As both gemfibrozil and clopidogrel have been suggested to inhibit organic anion transporting polypeptides (OATP),<xref rid="cpt3610-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="cpt3610-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="cpt3610-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> endogenous biomarkers glycochenodeoxycholate 3‐O‐glucuronide (GCDCA‐3G) for OATP1B1 and glycochenodeoxycholate 3‐sulfate (GCDCA‐3S) for OATP1B3 were measured.<xref rid="cpt3610-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="cpt3610-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><table-wrap position="float" id="cpt3610-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Pretreatment and index drugs of a five‐phase randomized open‐label controlled crossover clinical trial with 16 healthy volunteers</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Study phase</th><th align="center" rowspan="1" colspan="1">Pretreatment</th><th align="center" rowspan="1" colspan="1">Index drugs</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">Repaglinide 0.05 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">Geneva cocktail<xref rid="cpt3610-note-0004" ref-type="table-fn">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">Geneva cocktail<xref rid="cpt3610-note-0004" ref-type="table-fn">a</xref> + repaglinide 0.05 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">IV</td><td align="left" rowspan="1" colspan="1">Clopidogrel 300 mg</td><td align="left" rowspan="1" colspan="1">Geneva cocktail<xref rid="cpt3610-note-0004" ref-type="table-fn">a</xref> + repaglinide 0.05 mg</td></tr><tr><td align="left" rowspan="1" colspan="1">V</td><td align="left" rowspan="1" colspan="1">Gemfibrozil 600 mg b.i.d for 3 days</td><td align="left" rowspan="1" colspan="1">Geneva cocktail<xref rid="cpt3610-note-0004" ref-type="table-fn">a</xref> + repaglinide 0.05 mg</td></tr></tbody></table><table-wrap-foot id="cpt3610-ntgp-0002"><fn id="cpt3610-note-0003"><p>Randomization was carried out using an electronic system by the Helsinki and Uusimaa Hospital District Pharmacy. All drugs were given orally as single doses if not otherwise indicated. Pretreatment drugs were administered at 8.00 <sc>am</sc> on study days (in phase V third day of gemfibrozil pretreatment) if not otherwise indicated and after that index drugs were given at 9.00 <sc>am</sc>.</p></fn><fn id="cpt3610-note-0004"><label>
<sup>a</sup>
</label><p>Geneva cocktail contains the following CYP enzyme index drugs: 50 mg caffeine (CYP1A2), 20 mg bupropion (CYP2B6), 10 mg flurbiprofen (CYP2C9), 10 mg omeprazole (CYP2C19), 10 mg dextromethorphan (CYP2D6) and 1 mg midazolam (CYP3A4).</p></fn></table-wrap-foot></table-wrap><sec sec-type="methods" id="cpt3610-sec-0003"><title>METHODS</title><sec id="cpt3610-sec-0004"><title>Study design</title><p>This open‐label cross‐over clinical trial included five study phases that each participant underwent in a randomized order (<bold>Table</bold>
<xref rid="cpt3610-tbl-0001" ref-type="table">
<bold>1</bold>
</xref>). There was at least 2‐week washout period between different study days. The pretreatment included placebo, clopidogrel (Plavix 300 mg, Sanofi‐Aventis, Paris, France), or gemfibrozil (Gevilon 600 mg, Pfizer Pharma GmbH, Berlin, Germany) depending on the study phase (<bold>Table</bold>
<xref rid="cpt3610-tbl-0001" ref-type="table">
<bold>1</bold>
</xref>). As for the index drugs, the Helsinki and Uusimaa Hospital District Pharmacy manufactured 0.05 mg repaglinide capsules, 20 mg bupropion capsules, and 10 mg flurbiprofen capsules from the following commercially available preparations: Repaglinide Krka 0.5 mg tablet (KRKA, Novo Mesto, Slovenia), Bupropion Hydrochloride tablet 100 mg (Heritage Pharmaceuticals Inc., Eatontown, NJ), and Cebutid 50 mg tablet (Almirall SA, Barcelona, Spain), respectively, with the addition of microcrystalline cellulose for repaglinide and bupropion capsules and lactose for flurbiprofen capsules. The other index drugs were administered as commercially available preparations: caffeine (exact half of Caffeine 100 mg tablet, University Pharmacy, Helsinki, Finland), omeprazole (gastro‐resistant Losec Mups 10 mg tablet, Astra Zeneca, Cambridge, UK), dextromethorphan (5.0 mL of Rometor Ratiopharm 2 mg/mL oral solution, Ratiopharm, Ulm, Germany), and midazolam (1.00 mL of Midazolam Accord 1 mg/mL solution, Accord Healthcare, Utrecht, the Netherlands).</p><p>On study days, venous blood samples from all participants were drawn from forearm vein cannulas before the administration of the pretreatment drugs and 5 minutes before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 23 hours after the administration of the index drugs for determination of index drug and metabolite concentrations. Additional venous blood samples for biomarker analyses were drawn before the administration of the pretreatment drugs and 5 minutes before and 3 hours after the administration of the index drugs. Standardized breakfast was served 1 hour, lunch 3 hours, and snacks 7 and 9 hours after the administration of index drugs. Blood glucose levels were monitored with CareSens Dual point‐of‐care blood glucose meter (i‐SENS Inc., Seoul, South Korea) at each venous blood sampling time point up to 12 hours after the administration of index drugs.</p><p>The use of grapefruit juice was prohibited from 1 week before and throughout the study. The participants were required to abstain from alcohol the day before the study day, on study day and the day after the study day during each study phase. The consumption of caffeine containing beverages was prohibited from 10 <sc>am</sc> on the day before the study day until 21.30 <sc>pm</sc> on the study day. Participants were required to fast overnight before the study days.</p></sec><sec id="cpt3610-sec-0005"><title>Study participants</title><p>Sixteen healthy volunteers were enrolled into this clinical trial after giving written informed consent. The participants did not take any continuous systemic medications, including hormonal contraception, were non‐smokers and had no clinically significant abnormalities in clinical examination or laboratory tests (hemoglobin, erythrocyte, leukocyte, and thrombocyte counts, liver function tests, creatinine, potassium, and sodium levels and blood glucose value). All female participants had a negative pregnancy test before each of the study phases. None of the participants had a higher blood pressure level than 145/90 mmHg or a history of abnormal bleeding.</p></sec><sec id="cpt3610-sec-0006"><title>Analytical methods</title><p>Prior to the analysis, the analytes were extracted from the plasma samples with simple protein precipitation. Plasma samples (50 μL) were mixed with acetonitrile solution (200 μL) containing internal standards. The samples were centrifugated and an aliquot of the supernatant was mixed with an equal volume of water before LC–MS analyses.</p><p>The analytical instrumentation, for measurement of the index drugs and their corresponding metabolites for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A and the pretreatment drug clopidogrel (<bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S1</bold>
</xref>), consisted of ExionLC liquid chromatography system coupled to the Sciex 6500 Qtrap ‐tandem mass spectrometry (AB Sciex, Toronto, ON, Canada). Analytes were separated on Atlantis T3 column (3 μm particle size, 2.1 × 100 mm, Waters, Milford, MA, USA), using a gradient elution of mobile phase consisting of 0.1% formic acid (A) and methanol (B). The flow rate was 0.3 mL/min, and the gradient program for the mobile phase B was from 20% to 90% over 7 minutes, wash at 90% 7–9.5 minutes, followed by balancing at 20% before next injection. The pretreatment drug gemfibrozil and metabolites gemfibrozil 1‐O‐β‐glucuronide, clopidogrel carboxylic acid, and clopidogrel acyl‐β‐D‐glucuronide were determined using a liquid chromatography system (Nexera X2, Shimadzu, Kyoto, Japan) coupled to an API 3000 tandem mass spectrometer (AB Sciex, Toronto, ON, Canada) (<bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S1</bold>
</xref>). The column and mobile phases were the same as above, and the gradient program for the mobile phase B was from 40% to 90% over 5 minutes, wash at 90% 5–7.3 minutes, followed by balancing at 40% before next injection. The quality control samples for each analyte at relevant concentrations were quantified with each batch of plasma samples. The precisions (coefficient of variation %) were below 11% and the accuracies ranged from 85% to 115%.</p><p>Plasma repaglinide, OATP1B1 biomarker GCDCA‐3G, OATP1B3 biomarker GCDCA‐3S, and CYP2D6 biomarker solanidine were analyzed using Sciex 5500 Qtrap and Sciex 6500 Qtrap LC–MS systems (AB Sciex, Toronto, ON, Canada) as previously described.<xref rid="cpt3610-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="cpt3610-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="cpt3610-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> The limit of quantification for repaglinide was 0.01 ng/mL. The between‐day precisions (CV%) for quality controls (0.1 and 2.0 ng/mL) were below 10% and accuracies were within ±10%. For GCDCA‐3G and GCDCA‐3S, the limit of quantification was 0.5 ng/mL and the between‐day precisions and accuracies were below 5% and ± 10% at relevant concentrations (10 and 200 ng/mL). For solanidine, the limit of quantification was 0.025 ng/mL and the between‐day precisions (CV%) and mean accuracies (%) were below 9% and within 5% at relevant concentrations (0.1, 0.5, and 10 ng/mL, <italic toggle="yes">n</italic> = 6).</p></sec><sec id="cpt3610-sec-0007"><title>Genotyping</title><p>An accredited clinical pharmacogenetic panel test was used.<xref rid="cpt3610-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Further details are found in <xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>Supplementary methods</bold>
</xref>.</p></sec><sec id="cpt3610-sec-0008"><title>Pharmacokinetics</title><p>Pharmacokinetic values, including peak plasma concentration (<italic toggle="yes">C</italic>
<sub>max</sub>), time to <italic toggle="yes">C</italic>
<sub>max</sub> (<italic toggle="yes">T</italic>
<sub>max</sub>), elimination half‐life (<italic toggle="yes">t</italic>
<sub>1/2</sub>), and area under the concentration–time curve up to 4, 12, and 23 hours and infinity (AUC<sub>0‐4h</sub>, AUC<sub>0‐12h</sub>, AUC<sub>0‐23h</sub>, and AUC<sub>0‐∞</sub> respectively) were calculated with Phoenix WinNonlin, Version 8.3 (Certara, Princeton, NJ) using standard non‐compartmental methods for the index drugs and their metabolites. Additionally, metabolic ratios (<italic toggle="yes">C</italic>
<sub>metabolite</sub>/<italic toggle="yes">C</italic>
<sub>index drug</sub>) at 2‐hour and 4‐hour timepoints and respective metabolite/index drug AUC<sub>0‐4h</sub>, AUC<sub>0‐12h</sub>, AUC<sub>0‐23h</sub>, and AUC<sub>0‐∞</sub> ratios were calculated. As the estimated part of the AUC<sub>0‐∞</sub> exceeded 10% for some index drugs and metabolites, AUC<sub>0‐23h</sub> was used as the main pharmacokinetic metric for the index drugs and metabolites. The only exception was the use of AUC<sub>0‐12h</sub> for caffeine and paraxanthine (caffeine consumption was allowed after collection of 12‐hour sample) (<bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>). For clopidogrel, gemfibrozil and their metabolites <italic toggle="yes">C</italic>
<sub>max</sub>, <italic toggle="yes">T</italic>
<sub>max</sub>, <italic toggle="yes">t</italic>
<sub>1/2</sub> and AUC<sub>0‐9h</sub> or AUC<sub>0‐24h</sub> values were calculated with Phoenix WinNonlin, Version 8.3 (Certara, Princeton, NJ) using standard non‐compartmental methods. As for biomarkers, AUC<sub>0‐3h</sub> values in phases I–III and AUC<sub>0‐4h</sub> values in phases III–V for GCDCA‐3G and GCDCA‐3S and AUC<sub>0‐4h</sub> values in phases III and V for M430, M444, and solanidine were calculated with trapezoidal rule in Excel (Microsoft, Redmond, WA). 0‐hour metabolic ratio and AUC<sub>0‐4h</sub> ratios were calculated for M430/solanidine and M444/solanidine.</p></sec><sec id="cpt3610-sec-0009"><title>Statistical analyses</title><p>The sample size of 16 participants was estimated to be sufficient to detect a 25% difference in the AUCs and AUC ratios of repaglinide and the Geneva cocktail index drugs between different study phases with a power of at least 80% (α level 5%). Individuals with poor metabolism or transport function phenotype were excluded from respective statistical comparisons. Additionally, to keep comparisons balanced, subjects lacking pharmacokinetic variable data in any study phase were excluded from the respective analyses. Prior to statistical analyses with IBM SPSS Statistics Version 29.0 for Windows (IBM Corporation, Armonk, NY), all pharmacokinetic variable values were logarithmically transformed. Pharmacokinetic variables except <italic toggle="yes">T</italic>
<sub>max</sub> were compared between different study phases by repeated‐measures analysis of variance with study phase as a within‐subjects factor. <italic toggle="yes">T</italic>
<sub>max</sub> values were compared with Wilcoxon signed‐rank test. Differences with <italic toggle="yes">P</italic> &lt; 0.05 after the Bonferroni correction were considered statistically significant. The data are presented as geometrical mean values or geometric mean ratios with geometric CV or 90% confidence intervals (CI) if not otherwise indicated.</p></sec><sec id="cpt3610-sec-0010"><title>Ethics statement</title><p>The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (record number HUS/1601/2021) and the Finnish Medicines Agency (EudraCT number 2020–003282‐19) gave approval for this study in August 2021 (conducted September 2021 to January 2022).</p></sec></sec><sec sec-type="results" id="cpt3610-sec-0011"><title>RESULTS</title><sec id="cpt3610-sec-0012"><title>Participants</title><p>All 16 healthy volunteers, eight females and eight males, completed all study phases. The mean age (± standard deviation) of study participants was 23 ± 3 years, mean height 1.75 ± 0.09 m, mean weight 68.6 ± 9.8 kg, and mean body mass index 22.3 ± 2.2 kg/m<sup>2</sup>. Genotypes of CYP enzymes and transporters are described in <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S3</bold>
</xref>.</p></sec><sec id="cpt3610-sec-0013"><title>Addition of repaglinide into the Geneva cocktail</title><p>The Geneva cocktail increased the AUC<sub>0‐23h</sub> of repaglinide 1.22‐fold (90% CI: 1.04–1.44, <italic toggle="yes">P</italic> = 0.033) compared with repaglinide alone but did not affect the <italic toggle="yes">C</italic>
<sub>max</sub>, <italic toggle="yes">T</italic>
<sub>max</sub> or <italic toggle="yes">t</italic>
<sub>1/2</sub> of repaglinide (<bold>Figure</bold>
<xref rid="cpt3610-fig-0001" ref-type="fig">
<bold>1a</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-tbl-0002" ref-type="table">
<bold>2</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>). The AUC<sub>0‐12h</sub> and AUC<sub>0‐23h</sub> values of the Geneva cocktail index drugs and their metabolites remained unaffected by the addition of repaglinide (<bold>Table</bold>
<xref rid="cpt3610-tbl-0002" ref-type="table">
<bold>2</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>).</p><fig position="float" fig-type="Figure" id="cpt3610-fig-0001" orientation="portrait"><label>Figure 1</label><caption><p>Repaglinide concentrations as geometric mean values ± 90% confidence intervals with and without the Geneva cocktail (<bold>a</bold>) and after clopidogrel pretreatment and gemfibrozil pretreatment compared with Geneva cocktail + repaglinide (<bold>b</bold>). Results are presented in two subfigures for clarity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CPT-117-1732-g002.jpg"/></fig><table-wrap position="float" id="cpt3610-tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>AUC<sub>0‐12h</sub> and AUC<sub>0‐23h</sub> values of index drugs and respective AUC ratios (AUC of CYP‐selective metabolite/AUC of index drug) in five study phases (I repaglinide, II Geneva cocktail, III Geneva cocktail + repaglinide (full cocktail), IV clopidogrel pretreatment followed by the full cocktail and V gemfibrozil pretreatment followed by the full cocktail) as geometric mean values (with geometric CV). Geometric mean ratios, GMR, (with 90% confidence intervals) compared with the respective control phase are indicated on the rows below each pharmacokinetic variable</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Repaglinide</th><th align="center" rowspan="1" colspan="1">Geneva cocktail</th><th align="center" rowspan="1" colspan="1">Geneva cocktail + repaglinide</th><th align="center" rowspan="1" colspan="1">Clopidogrel pretreatment</th><th align="center" rowspan="1" colspan="1">Gemfibrozil pretreatment</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">CYP1A2 (<italic toggle="yes">N</italic> = 16)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Caffeine AUC<sub>0‐12h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6,250 (34.7%)</td><td align="left" rowspan="1" colspan="1">6,270 (36.0%)</td><td align="left" rowspan="1" colspan="1">6,960 (34.0%)</td><td align="left" rowspan="1" colspan="1">7,540 (32.0%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.00 (0.86–1.17)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.11 (0.90–1.37)</td><td align="left" rowspan="1" colspan="1">1.20* (1.03–1.40)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Paraxanthine/caffeine AUC<sub>0‐12h</sub> ratio</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.54 (30.8%)</td><td align="left" rowspan="1" colspan="1">0.58 (23.4%)</td><td align="left" rowspan="1" colspan="1">0.57 (41.4%)</td><td align="left" rowspan="1" colspan="1">0.45 (34.3%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.08 (0.95–1.22)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.97 (0.82–1.16)</td><td align="left" rowspan="1" colspan="1">0.77** (0.69–0.86)</td></tr><tr><td align="left" colspan="6" rowspan="1">CYP2B6 (<italic toggle="yes">N</italic> = 15)<xref rid="cpt3610-note-0005" ref-type="table-fn">a</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bupropion AUC<sub>0‐23h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">76.5 (33.4%)</td><td align="left" rowspan="1" colspan="1">72.8 (29.6%)</td><td align="left" rowspan="1" colspan="1">87.6 (30.0%)</td><td align="left" rowspan="1" colspan="1">61.4 (31.2%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.95 (0.80–1.13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.20 (1.00–1.45)</td><td align="left" rowspan="1" colspan="1">0.84* (0.73–0.98)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">OH‐bupropion/bupropion AUC<sub>0‐23h</sub> ratio</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7.46 (41.1%)</td><td align="left" rowspan="1" colspan="1">7.91 (37.5%)</td><td align="left" rowspan="1" colspan="1">2.07 (32.0%)</td><td align="left" rowspan="1" colspan="1">9.52 (39.5%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.06 (0.83–1.35)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.26** (0.20–0.35)</td><td align="left" rowspan="1" colspan="1">1.20 (0.91–1.59)</td></tr><tr><td align="left" colspan="6" rowspan="1">CYP2C8 (<italic toggle="yes">N</italic> = 16)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Repaglinide AUC<sub>0‐23h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1">1.01 (53.7%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.23 (54.6%)</td><td align="left" rowspan="1" colspan="1">5.55 (42.0%)</td><td align="left" rowspan="1" colspan="1">9.21 (37.0%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.22* (1.04–1.44)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">4.51** (3.72–5.47)</td><td align="left" rowspan="1" colspan="1">7.49** (5.88–9.54)</td></tr><tr><td align="left" colspan="6" rowspan="1">CYP2C9 (<italic toggle="yes">N</italic> = 16)<xref rid="cpt3610-note-0006" ref-type="table-fn">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Flurbiprofen AUC<sub>0‐23h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5,550 (26.9%)</td><td align="left" rowspan="1" colspan="1">5,270 (24.0%)</td><td align="left" rowspan="1" colspan="1">5,720 (21.6%)</td><td align="left" rowspan="1" colspan="1">5,770 (27.0%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.95 (0.89–1.01)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.09 (0.99–1.19)</td><td align="left" rowspan="1" colspan="1">1.10 (0.97–1.24)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4′‐OH‐flurbiprofen/flurbiprofen AUC<sub>0‐23h</sub> ratio</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.040 (28.4%)</td><td align="left" rowspan="1" colspan="1">0.046 (40.5%)</td><td align="left" rowspan="1" colspan="1">0.042 (30.5%)</td><td align="left" rowspan="1" colspan="1">0.073 (29.8%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.13 (0.95–1.34)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.91 (0.80–1.03)</td><td align="left" rowspan="1" colspan="1">1.59** (1.32–1.92)</td></tr><tr><td align="left" colspan="6" rowspan="1">CYP2C19 (<italic toggle="yes">N</italic> = 15)<xref rid="cpt3610-note-0007" ref-type="table-fn">c</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Omeprazole AUC<sub>0‐23h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">177 (53.6%)</td><td align="left" rowspan="1" colspan="1">159 (64.1%)</td><td align="left" rowspan="1" colspan="1">214 (46.7%)</td><td align="left" rowspan="1" colspan="1">150 (62.8%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.90 (0.70–1.14)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.34* (1.09–1.66)</td><td align="left" rowspan="1" colspan="1">0.94 (0.70–1.27)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">5′‐OH‐omeprazole/omeprazole AUC<sub>0‐23h</sub> ratio</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.09 (39.4%)</td><td align="left" rowspan="1" colspan="1">1.15 (44.8%)</td><td align="left" rowspan="1" colspan="1">1.00 (42.5%)</td><td align="left" rowspan="1" colspan="1">1.69 (39.8%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.05 (0.95–1.17)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.87** (0.80–0.94)</td><td align="left" rowspan="1" colspan="1">1.47** (1.34–1.61)</td></tr><tr><td align="left" colspan="6" rowspan="1">CYP2D6 (<italic toggle="yes">N</italic> = 16)<xref rid="cpt3610-note-0008" ref-type="table-fn">d</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dextromethorphan AUC<sub>0‐23h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.90 (117%)</td><td align="left" rowspan="1" colspan="1">5.54 (95.6%)</td><td align="left" rowspan="1" colspan="1">6.01 (118%)</td><td align="left" rowspan="1" colspan="1">6.07 (125%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.13 (0.81–1.58)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.09 (0.72–1.64)</td><td align="left" rowspan="1" colspan="1">1.10 (0.72–1.68)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dextrorphan/dextromethorphan AUC<sub>0‐23h</sub> ratio</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.65 (94.0%)</td><td align="left" rowspan="1" colspan="1">1.64 (105%)</td><td align="left" rowspan="1" colspan="1">1.61 (113%)</td><td align="left" rowspan="1" colspan="1">2.93 (109%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.00 (0.80–1.24)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.98 (0.70–1.38)</td><td align="left" rowspan="1" colspan="1">1.79** (1.23–2.59)</td></tr><tr><td align="left" colspan="6" rowspan="1">CYP3A4 (<italic toggle="yes">N</italic> = 16)<xref rid="cpt3610-note-0009" ref-type="table-fn">e</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Midazolam AUC<sub>0‐23h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">9.89 (42.1%)</td><td align="left" rowspan="1" colspan="1">8.43 (40.0%)</td><td align="left" rowspan="1" colspan="1">11.3 (38.0%)</td><td align="left" rowspan="1" colspan="1">8.06 (41.7%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.85 (0.72–1.01)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.34** (1.17–1.53)</td><td align="left" rowspan="1" colspan="1">0.96 (0.82–1.11)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1′‐OH‐midazolam/midazolam AUC<sub>0‐23h</sub> ratio</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.36 (37.0%)</td><td align="left" rowspan="1" colspan="1">0.43 (38.2%)</td><td align="left" rowspan="1" colspan="1">0.45 (47.0%)</td><td align="left" rowspan="1" colspan="1">0.91 (42.6%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.20* (1.04–1.39)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.03 (0.88–1.20)</td><td align="left" rowspan="1" colspan="1">2.11** (1.87–2.38)</td></tr></tbody></table><table-wrap-foot id="cpt3610-ntgp-0003"><fn id="cpt3610-note-0005"><label>
<sup>a</sup>
</label><p>CYP2B6 phenotypes were the following: 1 rapid, 7 normal, 7 intermediate and 1 poor metabolizer, who was excluded from the statistical analyses regarding bupropion and hydroxybupropion.</p></fn><fn id="cpt3610-note-0006"><label>
<sup>b</sup>
</label><p>CYP2C9 phenotypes were the following: 10 normal and 6 intermediate metabolizers.</p></fn><fn id="cpt3610-note-0007"><label>
<sup>c</sup>
</label><p>CYP2C19 phenotypes were the following: 2 ultrarapid, 3 rapid, 5 normal and 6 intermediate metabolizers. One study participant was excluded due to delayed and erratic absorption of omeprazole in two study phases.</p></fn><fn id="cpt3610-note-0008"><label>
<sup>d</sup>
</label><p>CYP2D6 phenotypes were the following: 1 ultrarapid, 10 normal, and 5 intermediate metabolizers.</p></fn><fn id="cpt3610-note-0009"><label>
<sup>e</sup>
</label><p>CYP3A4 phenotypes were the following: 14 normal and 2 intermediate metabolizers.</p></fn><fn id="cpt3610-note-0010"><p>*<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cpt3610-sec-0014"><title>Effect of clopidogrel</title><p>Clopidogrel increased the AUC<sub>0‐23h</sub> and <italic toggle="yes">t</italic>
<sub>1/2</sub> of the CYP2C8 index substrate repaglinide 4.5‐fold (90% CI: 3.7–5.5, <italic toggle="yes">P</italic> &lt; 0.01) and 2.5‐fold (90% CI: 2.0–3.0, <italic toggle="yes">P</italic> &lt; 0.01), respectively (<bold>Figure</bold>
<xref rid="cpt3610-fig-0001" ref-type="fig">
<bold>1</bold>
<bold>b</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-tbl-0002" ref-type="table">
<bold>2</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>). After clopidogrel pretreatment, the hydroxybupropion/bupropion AUC<sub>0‐23h</sub> ratio (CYP2B6 index) was decreased by 74% compared with control (90% CI: 65–80%, <italic toggle="yes">P</italic> &lt; 0.01) (<bold>Figures</bold>
<xref rid="cpt3610-fig-0002" ref-type="fig">
<bold>2</bold>
</xref>
<bold>and</bold>
<xref rid="cpt3610-fig-0003" ref-type="fig">
<bold>3</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-tbl-0002" ref-type="table">
<bold>2</bold>
</xref>). While bupropion AUC<sub>0‐23h</sub> did not increase significantly, that of hydroxybupropion was decreased markedly by clopidogrel (<bold>Figure</bold>
<xref rid="cpt3610-fig-0003" ref-type="fig">
<bold>3</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>). The 5′‐hydroxyomeprazole/omeprazole AUC<sub>0‐23h</sub> ratio (CYP2C19 index) was decreased by 13% (90% CI: 6–20%, <italic toggle="yes">P</italic> &lt; 0.01) and omeprazole concentrations and AUCs slightly increased by clopidogrel (<bold>Figure</bold>
<xref rid="cpt3610-fig-0002" ref-type="fig">
<bold>2</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S4</bold>
</xref>). Also, the <italic toggle="yes">C</italic>
<sub>max</sub> and AUC<sub>0‐23h</sub> of the CYP3A4‐mediated metabolite of omeprazole, omeprazole sulfone, were increased by clopidogrel (<italic toggle="yes">P</italic> = 0.013 and <italic toggle="yes">P</italic> = 0.033, respectively) with no change in the omeprazole sulfone/omeprazole ratios (<bold>Tables</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>
<bold>and</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S4</bold>
</xref>).</p><fig position="float" fig-type="Figure" id="cpt3610-fig-0002" orientation="portrait"><label>Figure 2</label><caption><p>Individual AUC<sub>0‐12h</sub> and AUC<sub>0‐23h</sub> ratios of the Geneva cocktail index drugs in study phases with Geneva cocktail + repaglinide (full cocktail, control), clopidogrel pretreatment followed by the full cocktail and gemfibrozil pretreatment followed by the full cocktail represented with symbols for poor metabolizer (PM), intermediate metabolizer (IM), normal metabolizer (NM), rapid metabolizer (RM) and ultrarapid metabolizer (UM) CYP phenotypes. Geometric mean values ± 90% confidence intervals are expressed as horizontal lines with error bars. <italic toggle="yes">P</italic> &lt; 0.05 are considered statistically significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CPT-117-1732-g003.jpg"/></fig><fig position="float" fig-type="Figure" id="cpt3610-fig-0003" orientation="portrait"><label>Figure 3</label><caption><p>Concentrations of the Geneva cocktail index drugs and their metabolites for six CYP enzymes ((a) CYP1A2, (b) CYP2B6, (c) CYP2C9, (d) CYP2C19, (e) CYP2D6 and (f) CYP3A4) as geometric mean values ± 90% confidence intervals in study phases with Geneva cocktail + repaglinide (full cocktail), clopidogrel pretreatment followed by the full cocktail and gemfibrozil pretreatment followed by the full cocktail.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CPT-117-1732-g001.jpg"/></fig></sec><sec id="cpt3610-sec-0015"><title>Effect of gemfibrozil</title><p>Gemfibrozil increased the AUC<sub>0‐23h</sub> and <italic toggle="yes">t</italic>
<sub>1/2</sub> of repaglinide 7.5‐fold (90% CI: 5.9–9.5, <italic toggle="yes">P</italic> &lt; 0.01) and 3.0‐fold (90% CI: 2.5–3.6, <italic toggle="yes">P</italic> &lt; 0.01), respectively (<bold>Figure</bold>
<xref rid="cpt3610-fig-0001" ref-type="fig">
<bold>1</bold>
<bold>b</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-tbl-0002" ref-type="table">
<bold>2</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>). The paraxanthine/caffeine AUC<sub>0‐12h</sub> ratio (CYP1A2 index) was decreased by 23% (90% CI: 14–31%, <italic toggle="yes">P</italic> &lt; 0.01) by gemfibrozil, while caffeine AUC<sub>0‐12h</sub> was increased 1.20‐fold (1.03–1.40, <italic toggle="yes">P</italic> = 0.036) and <italic toggle="yes">t</italic>
<sub>1/2</sub> prolonged by 21% (8–35%, <italic toggle="yes">P</italic> &lt; 0.01). The 4′‐hydroxyflurbiprofen/flurbiprofen (CYP2C9 index), 5′‐hydroxyomeprazole/omeprazole (CYP2C19 index), dextrorphan/dextromethorphan (CYP2D6 index) and 1′‐hydroxymidazolam/midazolam (CYP3A4 index) AUC<sub>0‐23h</sub> ratios were increased by 1.59‐fold (90% CI: 1.32–1.92, <italic toggle="yes">P</italic> &lt; 0.01), 1.47‐fold (90% CI: 1.34–1.61, <italic toggle="yes">P</italic> &lt; 0.01), 1.79‐fold (90% CI: 1.23–2.59, <italic toggle="yes">P</italic> &lt; 0.01), and 2.1‐fold (90% CI: 1.9–2.4, <italic toggle="yes">P</italic> &lt; 0.01) by gemfibrozil, respectively (<bold>Figure</bold>
<xref rid="cpt3610-fig-0002" ref-type="fig">
<bold>2</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S4</bold>
</xref>). Similar effects were seen in the 2‐hour, 4‐hour, and AUC<sub>0‐4h</sub> metabolite/index drug ratios (<bold>Figure</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S1</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S4</bold>
</xref>). Of note, the AUC<sub>0‐23h</sub> values of 4′‐hydroxyflurbiprofen, 5′‐hydroxyomeprazole, dextrorphan, and 1′‐hydroxymidazolam were 1.75‐fold (90% CI: 1.45–2.11, <italic toggle="yes">P</italic> &lt; 0.01), 1.38‐fold (90% CI: 1.07–1.79, <italic toggle="yes">P</italic> = 0.031), 1.96‐fold (90% CI: 1.69–2.26, <italic toggle="yes">P</italic> &lt; 0.01), and 2.0‐fold (90% CI: 1.8–2.3, <italic toggle="yes">P</italic> &lt; 0.01) higher during the gemfibrozil phase than during the control phase, respectively, while the AUC<sub>0‐23h</sub> and <italic toggle="yes">t</italic>
<sub>1/2</sub> values of the respective index drugs remained unchanged (<bold>Figure</bold>
<xref rid="cpt3610-fig-0003" ref-type="fig">
<bold>3</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-tbl-0002" ref-type="table">
<bold>2</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>).</p></sec><sec id="cpt3610-sec-0016"><title>Pharmacokinetics of the pretreatment drugs</title><p>Clopidogrel and gemfibrozil concentrations are presented in <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S5</bold>
</xref> and <bold>Figure</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>.</p></sec><sec id="cpt3610-sec-0017"><title>Biomarkers</title><p>When repaglinide only and Geneva cocktail only study phases were compared with the full cocktail phase, no difference in AUC<sub>0‐3h</sub> of either GCDCA‐3G or GCDCA‐3S was found (<bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S6</bold>
</xref>). Clopidogrel did not change the C<sub>0</sub> or AUC<sub>0‐4h</sub> of the OATP1B1 biomarker GCDCA‐3G with statistical significance. On the other hand, gemfibrozil increased the C<sub>0</sub> of GCDCA‐3G 1.56‐fold (90% CI 1.15–2.10, <italic toggle="yes">P</italic> = 0.015) and AUC<sub>0‐4h</sub> 1.33‐fold (90% CI 1.07–1.65, <italic toggle="yes">P</italic> = 0.027) in individuals with either normal or decreased function phenotype of OATP1B1, whereas no effect was observed in individuals with the poor function phenotype of OATP1B1 (<bold>Table</bold>
<xref rid="cpt3610-tbl-0003" ref-type="table">
<bold>3</bold>
</xref>). Neither clopidogrel nor gemfibrozil affected the C<sub>0</sub> or AUC<sub>0‐4h</sub> of OATP1B3 biomarker GCDCA‐3S (<bold>Table</bold>
<xref rid="cpt3610-tbl-0003" ref-type="table">
<bold>3</bold>
</xref>). Gemfibrozil did not alter the CYP2D6‐dependent M430/solanidine and M444/solanidine metabolic ratios (<bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S7</bold>
</xref>).</p><table-wrap position="float" id="cpt3610-tbl-0003" content-type="Table" orientation="portrait"><label>Table 3</label><caption><p>C<sub>0</sub> concentrations and AUC<sub>0‐4h</sub> values (based on concentrations from pretreatment drug administration at 8.00 <sc>am</sc> to sampling timepoint at 12 <sc>am</sc> on study days) of the OATP1B1 and OATP1B3 biomarkers GCDCA‐3G and GCDCA‐3S, respectively, during control, clopidogrel, and gemfibrozil phases expressed as geometric mean values (with geometric CV). Geometric mean ratios (GMR), and their 90% confidence intervals, compared with the respective control phase are indicated on the rows below each variable</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Geneva cocktail + repaglinide</th><th align="center" rowspan="1" colspan="1">Clopidogrel pretreatment</th><th align="center" rowspan="1" colspan="1">Gemfibrozil pretreatment</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">OATP1B1 normal/decreased function (<italic toggle="yes">N</italic> = 13)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GCDCA‐3G C<sub>0</sub> (ng/mL)</td><td align="left" rowspan="1" colspan="1">22.9 (60.0%)</td><td align="left" rowspan="1" colspan="1">21.7 (81.7%)</td><td align="left" rowspan="1" colspan="1">35.7 (82.5%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.95 (0.71–1.25)</td><td align="left" rowspan="1" colspan="1">1.56 (1.15–2.10)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>‐value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&gt; 0.99</td><td align="left" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GCDCA‐3G AUC<sub>0‐4h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1">88.6 (51.3%)</td><td align="left" rowspan="1" colspan="1">77.5 (69.9%)</td><td align="left" rowspan="1" colspan="1">118 (65.4%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.87 (0.72–1.06)</td><td align="left" rowspan="1" colspan="1">1.33 (1.07–1.65)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>‐value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.32</td><td align="left" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" colspan="4" rowspan="1">OATP1B1 poor function (<italic toggle="yes">N</italic> = 3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GCDCA‐3G C<sub>0</sub> (ng/mL)</td><td align="left" rowspan="1" colspan="1">206 (73.8%)</td><td align="left" rowspan="1" colspan="1">238 (57.2%)</td><td align="left" rowspan="1" colspan="1">215 (79.1%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.16 (0.72–1.86)</td><td align="left" rowspan="1" colspan="1">1.04 (0.64–1.71)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>‐value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">&gt; 0.99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GCDCA‐3G AUC<sub>0‐4h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1">755 (48.4%)</td><td align="left" rowspan="1" colspan="1">791 (56.1%)</td><td align="left" rowspan="1" colspan="1">809 (75.4%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">1.05 (0.67–1.65)</td><td align="left" rowspan="1" colspan="1">1.07 (0.51–2.26)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>‐value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&gt; 0.99</td><td align="left" rowspan="1" colspan="1">&gt; 0.99</td></tr><tr><td align="left" colspan="4" rowspan="1">OATP1B3 (<italic toggle="yes">N</italic> = 16)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GCDCA‐3S C<sub>0</sub> (ng/mL)</td><td align="left" rowspan="1" colspan="1">50.8 (85.3%)</td><td align="left" rowspan="1" colspan="1">49.2 (69.3%)</td><td align="left" rowspan="1" colspan="1">65.5 (72.9%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.97 (0.72–1.30)</td><td align="left" rowspan="1" colspan="1">1.29 (0.91–1.83)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>‐value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&gt; 0.99</td><td align="left" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GCDCA‐3S AUC<sub>0‐4h</sub> (ng × h/mL)</td><td align="left" rowspan="1" colspan="1">190 (67.4%)</td><td align="left" rowspan="1" colspan="1">146 (61.8%)</td><td align="left" rowspan="1" colspan="1">212 (46.9%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">GMR</td><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">0.77 (0.59–1.00)</td><td align="left" rowspan="1" colspan="1">1.11 (0.83–1.49)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>‐value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.095</td><td align="left" rowspan="1" colspan="1">0.91</td></tr></tbody></table><table-wrap-foot id="cpt3610-ntgp-0004"><fn id="cpt3610-note-0011"><p>Values for GCDCA‐3G are expressed for two different OATP1B1 phenotype groups. <italic toggle="yes">P</italic> &lt; 0.05 is considered statistically significant.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cpt3610-sec-0018"><title>Safety</title><p>No adverse effects were reported during the study. Blood glucose levels were maintained &gt; 3.5 mmol/L in all participants throughout the study. Mean blood glucose values were lowest 4 hours after the index drug administration but remained above 4.0 mmol/L (<bold>Figure</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S3</bold>
</xref>). There was no need to serve additional carbohydrates to study participants.</p></sec></sec><sec sec-type="discussion" id="cpt3610-sec-0019"><title>DISCUSSION</title><p>The results of our clinical study showed that a small 0.05 mg dose of the CYP2C8 index drug repaglinide had no effect on the pharmacokinetics of the Geneva cocktail CYP index drugs and was safe even when given with CYP2C8 inhibitors. Moreover, despite a slight increase in repaglinide AUC<sub>0‐23h</sub> by the Geneva cocktail, the CYP2C8 inhibitors clopidogrel and gemfibrozil increased the AUC<sub>0‐23h</sub> of repaglinide 4.5‐fold and 7.5‐fold, when the full cocktail was used, that is, to an equal degree as in previous studies with the same inhibitor doses.<xref rid="cpt3610-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="cpt3610-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Also, the known inhibitory effect of clopidogrel on CYP2B6 was captured accurately. Additionally, the plasma levels of sensitive OATP1B1 and 1B3 biomarkers were not altered between the repaglinide only, Geneva cocktail only, and full cocktail alone phases. Moreover, the CYP and OATP1B1 phenotype findings were in a good agreement with the respective genotypes (<bold>Figure</bold>
<xref rid="cpt3610-fig-0002" ref-type="fig">
<bold>2</bold>
</xref>). Thus, the results indicate that the Geneva cocktail extended with a 0.05 mg dose of repaglinide can be used for simultaneous profiling of the activities of seven key CYP enzymes and two OATP1B biomarker activities. Slight inhibition of CYP1A2 and OATP1B1 and increase in the metabolic ratios of CYP2C9, CYP2C19, CYP2D6, and CYP3A4 were documented after gemfibrozil pretreatment.</p><p>Our study comprehensively profiled the effects of clopidogrel on CYP enzymes and OATP1B transporters. As expected,<xref rid="cpt3610-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="cpt3610-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="cpt3610-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> 300 mg clopidogrel caused a relatively strong effect on CYP2B6 indices, as hydroxybupropion/bupropion ratios decreased over 70%, which is in line with previous <italic toggle="yes">in vitro</italic> findings of mechanism‐based CYP2B6 inhibition by clopidogrel (<bold>Figure</bold>
<xref rid="cpt3610-fig-0003" ref-type="fig">
<bold>3</bold>
</xref>, <bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S4</bold>
</xref>). The United States Food and Drug Administration (US FDA) has classified 75 mg dose of clopidogrel as a weak CYP2B6 inhibitor. However, in our study, 300 mg of clopidogrel caused a 74% decline in hydroxybupropion/bupropion AUC<sub>0‐23h</sub> ratio indicating that a 300 mg clopidogrel dose could be used as a moderate CYP2B6 index inhibitor. In addition, clopidogrel slightly decreased the 5′‐hydroxyomeprazole/omeprazole AUC<sub>0‐23h</sub> ratio, consistent with weak inhibition of CYP2C19 by clopidogrel, in good agreement with two previous clinical studies and <italic toggle="yes">in vitro</italic> data describing CYP2C19 inhibition by clopidogrel.<xref rid="cpt3610-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="cpt3610-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="cpt3610-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Consequently, omeprazole metabolism shifted toward CYP3A4, whereby the <italic toggle="yes">C</italic>
<sub>max</sub> and AUC<sub>0‐23h</sub> of omeprazole sulfone were increased after clopidogrel pretreatment (<bold>Table</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>). Importantly, previous findings of lack of effect of clopidogrel on the pharmacokinetics of the sensitive OATP1B1 and CYP3A4 substrate simvastatin were corroborated as clopidogrel did not affect the metabolism of the sensitive CYP3A4 index drug midazolam or OATP1B biomarkers.<xref rid="cpt3610-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</p><p>An important secondary aim of this study was to profile the effects of gemfibrozil on CYP enzymes other than CYP2C8. Interestingly, gemfibrozil slightly reduced the paraxanthine/caffeine AUC<sub>0‐12h</sub> ratio and increased the <italic toggle="yes">t</italic>
<sub>1/2</sub> and AUC<sub>0‐12h</sub> of caffeine, consistent with weak CYP1A2 inhibition. Contrary to its 1‐O‐β‐glucuronide, gemfibrozil has been a weak CYP1A2 inhibitor <italic toggle="yes">in vitro</italic>.<xref rid="cpt3610-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="cpt3610-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Conversely, gemfibrozil increased the CYP2C9, CYP2C19, CYP2D6, and CYP3A4 index AUC<sub>0‐23h</sub> ratios by about 50–100%, which could at first sight be interpreted as weak/moderate enzyme induction. However, further evaluation contradicts this impression as the concentrations or elimination half‐lives of these four index drugs were not decreased, while the index metabolite concentrations were elevated. Such findings are not consistent with accelerated metabolic clearance of the index drug but could be well explained by decreased elimination rates of the index metabolites.</p><p>Apart from strong CYP2C8 inhibitory effects of gemfibrozil and its glucuronide, their most potent <italic toggle="yes">in vitro</italic> CYP inhibitory effect has been against CYP2C9, while CYP2D6 inhibition has been very weak.<xref rid="cpt3610-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="cpt3610-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> The present results are consistent with lack of any clinically meaningful CYP2C9 or CYP2D6 inhibition by gemfibrozil. Our results are equally in agreement with the limited and even contrasting effects of gemfibrozil on the pharmacokinetics of other CYP2C9 substrates, possibly explained by CYP2C8 inhibition and displacement from protein binding.<xref rid="cpt3610-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="cpt3610-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="cpt3610-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Although dextrorphan/dextromethorphan metabolic ratios were increased after gemfibrozil pretreatment in our study, CYP2D6 is not known to be inducible. Consistent with the lack of induction, the M430/solanidine and M444/solanidine metabolic ratios, sensitive markers of CYP2D6 were not increased by gemfibrozil. Solanidine metabolic ratios are a promising alternative for dextromethorphan as a CYP2D6 index, but they require a diet containing solanidine. Accordingly, it may be useful to monitor solanidine metabolic ratios in addition to dextromethorphan to verify the mechanisms of possible interactions as demonstrated here.</p><p>We hypothesize that the mechanisms for the elevated concentrations of the index metabolites 4′‐hydroxyflurbiprofen, 5′‐hydroxyomeprazole, dextrorphan, and 1′‐hydroxymidazolam after gemfibrozil pretreatment involve inhibition of their further metabolism or transporter‐mediated excretion by gemfibrozil. UDP‐glucuronosyltransferases (UGTs) are likely involved in the further metabolism of these four index metabolites since they are converted to glucuronides.<xref rid="cpt3610-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="cpt3610-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> In fact, UGT2B enzymes have been shown to metabolize 1′‐hydroxymidazolam and dextrorphan.<xref rid="cpt3610-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="cpt3610-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Interestingly, gemfibrozil can inhibit UGT‐mediated reactions <italic toggle="yes">in vitro</italic>.<xref rid="cpt3610-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="cpt3610-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="cpt3610-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Moreover, an interplay between UGT enzymes and CYP2C8 has been suggested to affect drug–drug interactions caused by gemfibrozil.<xref rid="cpt3610-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Accordingly, a potential explanation for the elevated index metabolite concentrations is impairment of their elimination by gemfibrozil either by direct inhibition of UGTs or by a complex hypothetical mechanism, where gemfibrozil inhibits a CYP2C8‐mediated elimination pathway of an unstable glucuronide metabolite, leading to accumulation of this glucuronide metabolite, which is then hydrolyzed back to the initial hydroxylated metabolite.<xref rid="cpt3610-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="cpt3610-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> However, as clopidogrel, a moderate CYP2C8 inhibitor, had no effect on the concentrations of these four index metabolites, this kind of a complex solely CYP2C8‐mediated mechanism can be excluded. Another possibility is that gemfibrozil impaired transporter‐mediated elimination of the index metabolites or their glucuronides; apart from N‐glucuronides, particularly acyl glucuronides can be unstable, and therefore, impairment of their elimination could lead to elevation of the respective aglycone metabolites. For example, gemfibrozil seems to inhibit OAT3 that can mediate tubular excretion of some glucuronide metabolites.<xref rid="cpt3610-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Nevertheless, further studies on the mechanisms of these novel gemfibrozil effects are required.</p><p>As gemfibrozil markedly increases the concentrations of OATP1B1 substrates like several statin acids and repaglinide,<xref rid="cpt3610-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="cpt3610-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> we evaluated its effects on OATP1B1 and OATP1B3. We chose GCDCA‐3G and GCDCA‐3S as OATP1B1 and OATP1B3 biomarkers, respectively, because they have shown high selectivity and sensitivity toward these transporters, and apart from slight diurnal variation in their concentrations, they seem to have no weaknesses compared with alternative biomarkers.<xref rid="cpt3610-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="cpt3610-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Inhibition of both OATP1B1 and OATP1B3 by gemfibrozil have been demonstrated <italic toggle="yes">in vitro</italic>.<xref rid="cpt3610-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="cpt3610-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Clinically, different <italic toggle="yes">SLCO1B1</italic> genotypes have affected the degree of change in repaglinide pharmacokinetics caused by gemfibrozil.<xref rid="cpt3610-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Accordingly, although alternative explanations exist for these interactions, gemfibrozil is thought to be a clinically significant OATP1B1 inhibitor.<xref rid="cpt3610-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> Based on our biomarker findings, gemfibrozil indeed slightly inhibits OATP1B1, but it does not affect OATP1B3 (<bold>Table</bold>
<xref rid="cpt3610-tbl-0003" ref-type="table">
<bold>3</bold>
</xref>). <italic toggle="yes">In vitro</italic>, gemfibrozil 1‐O‐β‐glucuronide is a stronger OATP1B1 inhibitor than parent gemfibrozil.<xref rid="cpt3610-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> As the GCDCA‐3G C<sub>0</sub> sample was taken 12 hours after the preceding gemfibrozil dose when residual gemfibrozil 1‐O‐β‐glucuronide concentrations were higher than gemfibrozil concentrations, our results may support the idea that OATP1B1 inhibition is mainly caused by gemfibrozil 1‐O‐β‐glucuronide (<bold>Figure</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2C,D</bold>
</xref>).</p><p>The advantages of our CYP activity phenotyping cocktail include oral administration of the index drugs, a clinically applicable venous blood sampling schedule, comprehensive inclusion of seven most important human drug‐metabolizing CYP enzymes, lack of significant drug–drug interactions between index drugs, and an excellent safety profile. In previous cocktails, common hindrances to clinical applicability have been caused by need to collect both blood and urine samples, mutual interactions between index drugs and adverse effects to study participants.<xref rid="cpt3610-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="cpt3610-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="cpt3610-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> In our study, a very low 0.05 mg dose of repaglinide was used and an hour later, breakfast was served to avoid hypoglycemia. With this procedure, no hypoglycemia was observed although repaglinide concentrations increased almost eightfold after gemfibrozil pretreatment. Repaglinide had no influence on the other index drugs and sensitively detected CYP2C8 inhibition. A disadvantage with the low dose was that repaglinide metabolite concentrations remained below the detection limit. Thus, CYP2C8 activity could only be assessed using repaglinide concentrations. The benefits of repaglinide are its sensitivity to CYP2C8 inhibition and its relatively short half‐life, allowing the detection of temporary changes in CYP2C8 activity.<xref rid="cpt3610-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="cpt3610-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> On the other hand, an important caveat with repaglinide is that it is also an OATP1B1 substrate.<xref rid="cpt3610-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Therefore, simultaneous use of a selective and sensitive biomarker of OATP1B1 activity, such as GCDCA‐3G, can be highly useful.<xref rid="cpt3610-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Similarities between the recently advocated novel CYP2C8 index drug daprodustat and repaglinide include short half‐life and likely transport by OATP1B1.<xref rid="cpt3610-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> However, repaglinide is currently more accessible (daprodustat has no marketing authorization in Europe) and affordable and the clinical significance of detected CYP2C8 inhibition is more easily estimated due to abundance of previously published clinical trials with varying degrees of CYP2C8 inhibition.<xref rid="cpt3610-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="cpt3610-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="cpt3610-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="cpt3610-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</p><p>The primary endpoint variables in CYP cocktail studies are typically either metabolic ratios at certain timepoints or AUC ratios.<xref rid="cpt3610-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="cpt3610-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="cpt3610-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="cpt3610-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="cpt3610-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="cpt3610-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="cpt3610-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> To reduce burden and increase the feasibility of a cocktail approach, limited sampling approaches are often used particularly in patient studies. For example, the 2‐hour metabolic ratio was the main phenotypic metric when the Geneva cocktail was used in a hospital study.<xref rid="cpt3610-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Importantly, the changes in CYP index metabolite concentrations after gemfibrozil pretreatment in our study demonstrate that interpretation based on a single timepoint metabolic ratio can lead to uncertain or even false conclusions. This emphasizes the superiority of a more detailed AUC‐based pharmacokinetic evaluation to get mechanistic insights and plan further studies accordingly. Based on our data (<bold>Tables</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S2</bold>
</xref>
<bold>and</bold>
<xref rid="cpt3610-supitem-0001" ref-type="supplementary-material">
<bold>S4</bold>
</xref>), AUC<sub>0‐4h</sub>‐based evaluation could be a sufficient compromise if a truncated sample collection protocol is needed.</p><p>In conclusion, repaglinide did not have relevant interactions with the Geneva cocktail index drugs. The generated full seven‐in‐one CYP cocktail with biomarkers for two OATP1B activities, as well as any truncated form of the cocktail, are feasible methods in drug–drug interaction trials and other clinical trials or even clinical use, when CYP activity profiling is needed. In our trial, the index drug and biomarker data showed that clopidogrel caused moderate CYP2B6 and CYP2C8 inhibition and weak CYP2C19 inhibition, while gemfibrozil caused strong CYP2C8 inhibition and weak CYP1A2 and OATP1B1 inhibition, as well as unexpected increases in several CYP index metabolite concentrations. Overall, gemfibrozil is superior to clopidogrel as a CYP2C8 index inhibitor in terms of inhibition strength and selectivity. The discovered nonselective effects of gemfibrozil are noteworthy and indicate that caution is warranted when evaluating test inhibitor effects on the common CYP index substrates used in the present cocktail.</p></sec><sec id="cpt3610-sec-0021"><title>FUNDING</title><p>This study was supported by grants from the Academy of Finland (Grant decision 325667, 2019), the Sigrid Jusélius Foundation (Grant number 8037; Helsinki, Finland), and by State Funding for University‐Level Health Research (TYH2019300 and TYH2021304); Hospital District of Helsinki and Uusimaa, Finland. Aurinsalo L received a personal grant from the Finnish Medical Foundation (Grant number: 4697, 2021; Helsinki, Finland).</p></sec><sec sec-type="COI-statement" id="cpt3610-sec-0022"><title>CONFLICT OF INTEREST</title><p>The authors declared no competing interests for this work.</p></sec><sec id="cpt3610-sec-0023"><title>Author contributions</title><p>L.A., M.Ni., A.T., and J.T.B. designed the research; L.A., O.L.‐R., M.K., M.Ne., J.I.K., and J.T.B. performed the research; L.A., A.T., and J.T.B. analyzed the data; L.A., M.K., M.Ne., M.Ni., A.T., and J.T.B. wrote the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cpt3610-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CPT-117-1732-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="cpt3610-sec-0020"><title>ACKNOWLEDGMENTS</title><p>The authors thank Meeri Alanappa, Katja Halme, and Laura Tervala for their skillful technical assistance. We also thank Youssef Daali and Caroline Samer from the Geneva University Hospital for sharing the formulation details of the Geneva cocktail with us.</p></ack><ref-list content-type="cited-references" id="cpt3610-bibl-0001"><ref id="cpt3610-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cpt3610-cit-0001">
<string-name name-style="western">
<surname>Tornio</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Filppula</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>
<article-title>Clinical studies on drug‐drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>105</volume>, <fpage>1345</fpage>–<lpage>1361</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30916389</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1435</pub-id><pub-id pub-id-type="pmcid">PMC6563007</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cpt3610-cit-0002">
<string-name name-style="western">
<surname>Lenoir</surname>, <given-names>C.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>109</volume>, <fpage>1668</fpage>–<lpage>1676</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33341941</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2146</pub-id><pub-id pub-id-type="pmcid">PMC8247903</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cpt3610-cit-0003">
<string-name name-style="western">
<surname>Ryu</surname>, <given-names>J.Y.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Development of the “Inje cocktail” for high‐throughput evaluation of five human cytochrome P450 isoforms in vivo</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>82</volume>, <fpage>531</fpage>–<lpage>540</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17392720</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100187</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cpt3610-cit-0004">
<string-name name-style="western">
<surname>Turpault</surname>, <given-names>S.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Pharmacokinetic assessment of a five‐probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A</article-title>. <source>Br. J. Clin. Pharmacol.</source>
<volume>68</volume>, <fpage>928</fpage>–<lpage>935</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">20002088</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2009.03548.x</pub-id><pub-id pub-id-type="pmcid">PMC2810805</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cpt3610-cit-0005">
<string-name name-style="western">
<surname>Bosilkovska</surname>, <given-names>M.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Evaluation of mutual drug‐drug interaction within Geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method</article-title>. <source>Basic Clin. Pharmacol. Toxicol.</source>
<volume>119</volume>, <fpage>284</fpage>–<lpage>290</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27009433</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcpt.12586</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cpt3610-cit-0006">
<string-name name-style="western">
<surname>Bosilkovska</surname>, <given-names>M.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Geneva cocktail for cytochrome p450 and P‐glycoprotein activity assessment using dried blood spots</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>96</volume>, <fpage>349</fpage>–<lpage>359</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24722393</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2014.83</pub-id><pub-id pub-id-type="pmcid">PMC4151019</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cpt3610-cit-0007">
<string-name name-style="western">
<surname>Donzelli</surname>, <given-names>M.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots</article-title>. <source>Clin. Pharmacokinet.</source>
<volume>53</volume>, <fpage>271</fpage>–<lpage>282</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24218006</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-013-0115-0</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cpt3610-cit-0008">
<string-name name-style="western">
<surname>Bosilkovska</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Magliocco</surname>, <given-names>G.</given-names>
</string-name>, <string-name name-style="western">
<surname>Desmeules</surname>, <given-names>J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Samer</surname>, <given-names>C.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Daali</surname>, <given-names>Y.</given-names>
</string-name>
<article-title>Interaction between fexofenadine and CYP phenotyping probe drugs in Geneva cocktail</article-title>. <source>J. Pers. Med.</source>
<volume>9</volume>, <fpage>45</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31581637</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm9040045</pub-id><pub-id pub-id-type="pmcid">PMC6963818</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cpt3610-cit-0009">
<string-name name-style="western">
<surname>Fuhr</surname>, <given-names>U.</given-names>
</string-name>, <string-name name-style="western">
<surname>Jetter</surname>, <given-names>A.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Kirchheiner</surname>, <given-names>J.</given-names>
</string-name>
<article-title>Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>81</volume>, <fpage>270</fpage>–<lpage>283</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17259951</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100050</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cpt3610-cit-0010">
<string-name name-style="western">
<surname>Rollason</surname>, <given-names>V.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Safety of the Geneva cocktail, a cytochrome P450 and P‐glycoprotein phenotyping cocktail, in healthy volunteers from three different geographic origins</article-title>. <source>Drug Saf.</source>
<volume>43</volume>, <fpage>1181</fpage>–<lpage>1189</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32851583</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-020-00983-8</pub-id><pub-id pub-id-type="pmcid">PMC7575470</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cpt3610-cit-0011">
<string-name name-style="western">
<surname>Paludetto</surname>, <given-names>M.N.</given-names>
</string-name>, <string-name name-style="western">
<surname>Kurkela</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Kahma</surname>, <given-names>H.</given-names>
</string-name>, <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>, <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Filppula</surname>, <given-names>A.M.</given-names>
</string-name>
<article-title>Hydroxychloroquine is metabolized by cytochrome P450 2D6, 3A4, and 2C8, and inhibits cytochrome P450 2D6, while its metabolites also inhibit cytochrome P450 3A in vitro</article-title>. <source>Drug Metab. Dispos.</source>
<volume>51</volume>, <fpage>293</fpage>–<lpage>305</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">36446607</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.122.001018</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cpt3610-cit-0012">
<string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>, <string-name name-style="western">
<surname>Filppula</surname>, <given-names>A.M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name>
<article-title>Role of cytochrome P450 2C8 in drug metabolism and interactions</article-title>. <source>Pharmacol. Rev.</source>
<volume>68</volume>, <fpage>168</fpage>–<lpage>241</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26721703</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pr.115.011411</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cpt3610-cit-0013">
<string-name name-style="western">
<surname>Tornio</surname>, <given-names>A.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Glucuronidation converts clopidogrel to a strong time‐dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug‐drug interactions</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>96</volume>, <fpage>498</fpage>–<lpage>507</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24971633</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2014.141</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cpt3610-cit-0014">
<string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name>
<article-title>Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide</article-title>. <source>Diabetologia</source>
<volume>46</volume>, <fpage>347</fpage>–<lpage>351</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12687332</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-003-1034-7</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cpt3610-cit-0015">
<string-name name-style="western">
<surname>Shitara</surname>, <given-names>Y.</given-names>
</string-name>, <string-name name-style="western">
<surname>Hirano</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Sato</surname>, <given-names>H.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Sugiyama</surname>, <given-names>Y.</given-names>
</string-name>
<article-title>Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)‐mediated hepatic uptake and CYP2C8‐mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug‐drug interaction between cerivastatin and gemfibrozil</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>311</volume>, <fpage>228</fpage>–<lpage>236</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15194707</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.104.068536</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cpt3610-cit-0016">
<string-name name-style="western">
<surname>Tornio</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>
<article-title>Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters</article-title>. <source>Expert Opin. Drug Metab. Toxicol.</source>
<volume>13</volume>, <fpage>83</fpage>–<lpage>95</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">27548563</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2016.1227791</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cpt3610-cit-0017">
<string-name name-style="western">
<surname>Tamraz</surname>, <given-names>B.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>OATP1B1‐related drug‐drug and drug‐gene interactions as potential risk factors for cerivastatin‐induced rhabdomyolysis</article-title>. <source>Pharmacogenet. Genomics</source>
<volume>23</volume>, <fpage>355</fpage>–<lpage>364</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23652407</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0b013e3283620c3b</pub-id><pub-id pub-id-type="pmcid">PMC3894639</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cpt3610-cit-0018">
<string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>M.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Identification of glycochenodeoxycholate 3‐O‐glucuronide and Glycodeoxycholate 3‐O‐glucuronide as highly sensitive and specific OATP1B1 biomarkers</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>109</volume>, <fpage>646</fpage>–<lpage>657</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">32961594</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2053</pub-id><pub-id pub-id-type="pmcid">PMC7983942</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cpt3610-cit-0019">
<string-name name-style="western">
<surname>Orozco</surname>, <given-names>C.C.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Characterization of bile acid sulfate conjugates as substrates of human organic anion transporting polypeptides</article-title>. <source>Mol. Pharm.</source>
<volume>20</volume>, <fpage>3020</fpage>–<lpage>3032</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37134201</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.3c00040</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cpt3610-cit-0020">
<string-name name-style="western">
<surname>Rago</surname>, <given-names>B.</given-names>
</string-name>, <string-name name-style="western">
<surname>Tierney</surname>, <given-names>B.</given-names>
</string-name>, <string-name name-style="western">
<surname>Rodrigues</surname>, <given-names>A.D.</given-names>
</string-name>, <string-name name-style="western">
<surname>Holliman</surname>, <given-names>C.L.H.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Ramanathan</surname>, <given-names>R.</given-names>
</string-name>
<article-title>A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers</article-title>. <source>Bioanalysis</source>
<volume>10</volume>, <fpage>645</fpage>–<lpage>657</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29749252</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/bio-2017-0274</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cpt3610-cit-0021">
<string-name name-style="western">
<surname>Kiiski</surname>, <given-names>J.I.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity</article-title>. <source>Hum. Genomics</source>
<volume>18</volume>, <fpage>11</fpage> (<year>2024</year>).<pub-id pub-id-type="pmid">38303026</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40246-024-00579-8</pub-id><pub-id pub-id-type="pmcid">PMC10835938</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cpt3610-cit-0022">
<string-name name-style="western">
<surname>Piha</surname>, <given-names>M.O.W.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Candesartan has no clinically meaningful effect on the plasma concentrations of cytochrome P450 2C8 substrate repaglinide in humans</article-title>. <source>Drug Metab. Dispos.</source>
<volume>52</volume>, <fpage>1388</fpage>–<lpage>1395</lpage> (<year>2024</year>).<pub-id pub-id-type="pmid">39486868</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.124.001798</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cpt3610-cit-0023">
<string-name name-style="western">
<surname>Litonius</surname>, <given-names>K.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Value of pharmacogenetic testing assessed with real‐world drug utilization and genotype data</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>117</volume>, <fpage>278</fpage>–<lpage>288</lpage> (<year>2025</year>).<pub-id pub-id-type="pmid">39365028</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.3458</pub-id><pub-id pub-id-type="pmcid">PMC11652815</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cpt3610-cit-0024">
<string-name name-style="western">
<surname>Richter</surname>, <given-names>T.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Potent mechanism‐based inhibition of human CYP2B6 by clopidogrel and ticlopidine</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>308</volume>, <fpage>189</fpage>–<lpage>197</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">14563790</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/jpet.103.056127</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cpt3610-cit-0025">
<string-name name-style="western">
<surname>Turpeinen</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Tolonen</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Uusitalo</surname>, <given-names>J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Jalonen</surname>, <given-names>J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Pelkonen</surname>, <given-names>O.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Laine</surname>, <given-names>K.</given-names>
</string-name>
<article-title>Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>77</volume>, <fpage>553</fpage>–<lpage>559</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15961986</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2005.02.010</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cpt3610-cit-0026">
<string-name name-style="western">
<surname>Kahma</surname>, <given-names>H.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>An automated cocktail method for in vitro assessment of direct and time‐dependent inhibition of nine major cytochrome P450 enzymes – application to establishing CYP2C8 inhibitor selectivity</article-title>. <source>Eur. J. Pharm. Sci.</source>
<volume>162</volume>, <elocation-id>105810</elocation-id> (<year>2021</year>).<pub-id pub-id-type="pmid">33753217</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2021.105810</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cpt3610-cit-0027">
<string-name name-style="western">
<surname>Ahmad</surname>, <given-names>L.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: a single dose study in healthy human volunteers</article-title>. <source>EXCLI J.</source>
<volume>16</volume>, <fpage>321</fpage>–<lpage>327</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28507476</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.17179/excli2016-658</pub-id><pub-id pub-id-type="pmcid">PMC5427475</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cpt3610-cit-0028">
<string-name name-style="western">
<surname>Chen</surname>, <given-names>B.L.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Clopidogrel inhibits CYP2C19‐dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms</article-title>. <source>J. Clin. Pharmacol.</source>
<volume>49</volume>, <fpage>574</fpage>–<lpage>581</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19398604</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270009333016</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cpt3610-cit-0029">
<string-name name-style="western">
<surname>Itkonen</surname>, <given-names>M.K.</given-names>
</string-name>, <string-name name-style="western">
<surname>Tornio</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>
<article-title>Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 substrate simvastatin</article-title>. <source>Drug Metab. Dispos.</source>
<volume>43</volume>, <fpage>1655</fpage>–<lpage>1660</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26329790</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.115.065938</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cpt3610-cit-0030">
<string-name name-style="western">
<surname>Wen</surname>, <given-names>X.</given-names>
</string-name>, <string-name name-style="western">
<surname>Wang</surname>, <given-names>J.S.</given-names>
</string-name>, <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>, <string-name name-style="western">
<surname>Kivisto</surname>, <given-names>K.T.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name>
<article-title>Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9</article-title>. <source>Drug Metab. Dispos.</source>
<volume>29</volume>, <fpage>1359</fpage>–<lpage>1361</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11602509</pub-id>
</mixed-citation></ref><ref id="cpt3610-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cpt3610-cit-0031">
<string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Kivisto</surname>, <given-names>K.T.</given-names>
</string-name>
<article-title>Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>70</volume>, <fpage>439</fpage>–<lpage>445</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11719730</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2001.119723</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cpt3610-cit-0032">
<string-name name-style="western">
<surname>Lilja</surname>, <given-names>J.J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name>
<article-title>Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects</article-title>. <source>Br. J. Clin. Pharmacol.</source>
<volume>59</volume>, <fpage>433</fpage>–<lpage>439</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15801938</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2004.02323.x</pub-id><pub-id pub-id-type="pmcid">PMC1884811</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cpt3610-cit-0033">
<string-name name-style="western">
<surname>Tornio</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>
<article-title>Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen</article-title>. <source>Eur. J. Clin. Pharmacol.</source>
<volume>63</volume>, <fpage>463</fpage>–<lpage>469</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17333159</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-007-0273-9</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cpt3610-cit-0034">
<string-name name-style="western">
<surname>Duthaler</surname>, <given-names>U.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>The activity of members of the UDP‐glucuronosyltransferase subfamilies UGT1A and UGT2B is impaired in patients with liver cirrhosis</article-title>. <source>Clin. Pharmacokinet.</source>
<volume>62</volume>, <fpage>1141</fpage>–<lpage>1155</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37328712</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-023-01261-3</pub-id><pub-id pub-id-type="pmcid">PMC10386950</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cpt3610-cit-0035">
<string-name name-style="western">
<surname>Rudesheim</surname>, <given-names>S.</given-names>
</string-name>, <string-name name-style="western">
<surname>Selzer</surname>, <given-names>D.</given-names>
</string-name>, <string-name name-style="western">
<surname>Fuhr</surname>, <given-names>U.</given-names>
</string-name>, <string-name name-style="western">
<surname>Schwab</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Lehr</surname>, <given-names>T.</given-names>
</string-name>
<article-title>Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups</article-title>. <source>CPT Pharmacometrics Syst. Pharmacol.</source>
<volume>11</volume>, <fpage>494</fpage>–<lpage>511</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35257505</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12776</pub-id><pub-id pub-id-type="pmcid">PMC9007601</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cpt3610-cit-0036">
<string-name name-style="western">
<surname>Seo</surname>, <given-names>K.A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Bae</surname>, <given-names>S.K.</given-names>
</string-name>, <string-name name-style="western">
<surname>Choi</surname>, <given-names>Y.K.</given-names>
</string-name>, <string-name name-style="western">
<surname>Choi</surname>, <given-names>C.S.</given-names>
</string-name>, <string-name name-style="western">
<surname>Liu</surname>, <given-names>K.H.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Shin</surname>, <given-names>J.G.</given-names>
</string-name>
<article-title>Metabolism of 1′‐ and 4‐hydroxymidazolam by glucuronide conjugation is largely mediated by UDP‐glucuronosyltransferases 1A4, 2B4, and 2B7</article-title>. <source>Drug Metab. Dispos.</source>
<volume>38</volume>, <fpage>2007</fpage>–<lpage>2013</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20713656</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.035295</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cpt3610-cit-0037">
<string-name name-style="western">
<surname>Prueksaritanont</surname>, <given-names>T.</given-names>
</string-name>, <string-name name-style="western">
<surname>Tang</surname>, <given-names>C.</given-names>
</string-name>, <string-name name-style="western">
<surname>Qiu</surname>, <given-names>Y.</given-names>
</string-name>, <string-name name-style="western">
<surname>Mu</surname>, <given-names>L.</given-names>
</string-name>, <string-name name-style="western">
<surname>Subramanian</surname>, <given-names>R.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Lin</surname>, <given-names>J.H.</given-names>
</string-name>
<article-title>Effects of fibrates on metabolism of statins in human hepatocytes</article-title>. <source>Drug Metab. Dispos.</source>
<volume>30</volume>, <fpage>1280</fpage>–<lpage>1287</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12386136</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.30.11.1280</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cpt3610-cit-0038">
<string-name name-style="western">
<surname>Kato</surname>, <given-names>Y.</given-names>
</string-name>, <string-name name-style="western">
<surname>Nakajima</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Oda</surname>, <given-names>S.</given-names>
</string-name>, <string-name name-style="western">
<surname>Fukami</surname>, <given-names>T.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Yokoi</surname>, <given-names>T.</given-names>
</string-name>
<article-title>Human UDP‐glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution</article-title>. <source>Drug Metab. Dispos.</source>
<volume>40</volume>, <fpage>240</fpage>–<lpage>248</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22028316</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.042150</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cpt3610-cit-0039">
<string-name name-style="western">
<surname>Gan</surname>, <given-names>J.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Repaglinide‐gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism</article-title>. <source>Br. J. Clin. Pharmacol.</source>
<volume>70</volume>, <fpage>870</fpage>–<lpage>880</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">21175442</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2010.03772.x</pub-id><pub-id pub-id-type="pmcid">PMC3014070</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cpt3610-cit-0040">
<string-name name-style="western">
<surname>Iga</surname>, <given-names>K.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Kiriyama</surname>, <given-names>A.</given-names>
</string-name>
<article-title>Interplay of UDP‐glucuronosyltransferase and CYP2C8 for CYP2C8 mediated drug oxidation and its impact on drug‐drug interaction produced by standardized CYP2C8 inhibitors, clopidogrel and gemfibrozil</article-title>. <source>Clin. Pharmacokinet.</source>
<volume>63</volume>, <fpage>43</fpage>–<lpage>56</lpage> (<year>2024</year>).<pub-id pub-id-type="pmid">37921907</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-023-01322-7</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cpt3610-cit-0041">
<string-name name-style="western">
<surname>Itkonen</surname>, <given-names>M.K.</given-names>
</string-name>, <string-name name-style="western">
<surname>Tornio</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>
<article-title>Clopidogrel and gemfibrozil strongly inhibit the CYP2C8‐dependent formation of 3‐Hydroxydesloratadine and increase desloratadine exposure in humans</article-title>. <source>Drug Metab. Dispos.</source>
<volume>47</volume>, <fpage>377</fpage>–<lpage>385</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30630815</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.118.084665</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cpt3610-cit-0042">
<string-name name-style="western">
<surname>Parkinson</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Kazmi</surname>, <given-names>F.</given-names>
</string-name>, <string-name name-style="western">
<surname>Buckley</surname>, <given-names>D.B.</given-names>
</string-name>, <string-name name-style="western">
<surname>Yerino</surname>, <given-names>P.</given-names>
</string-name>, <string-name name-style="western">
<surname>Ogilvie</surname>, <given-names>B.W.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Paris</surname>, <given-names>B.L.</given-names>
</string-name>
<article-title>System‐dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes</article-title>. <source>Drug Metab. Pharmacokinet.</source>
<volume>25</volume>, <fpage>16</fpage>–<lpage>27</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20208386</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2133/dmpk.25.16</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cpt3610-cit-0043">
<string-name name-style="western">
<surname>Watanabe</surname>, <given-names>T.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug‐drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments</article-title>. <source>Drug Metab. Dispos.</source>
<volume>39</volume>, <fpage>1031</fpage>–<lpage>1038</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21383204</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.036129</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cpt3610-cit-0044">
<string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>, <string-name name-style="western">
<surname>Kyrklund</surname>, <given-names>C.</given-names>
</string-name>, <string-name name-style="western">
<surname>Kivisto</surname>, <given-names>K.T.</given-names>
</string-name>, <string-name name-style="western">
<surname>Wang</surname>, <given-names>J.S.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name>
<article-title>Plasma concentrations of active simvastatin acid are increased by gemfibrozil</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>68</volume>, <fpage>122</fpage>–<lpage>129</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10976543</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.108507</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cpt3610-cit-0045">
<string-name name-style="western">
<surname>Ho</surname>, <given-names>R.H.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics</article-title>. <source>Gastroenterology</source>
<volume>130</volume>, <fpage>1793</fpage>–<lpage>1806</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16697742</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2006.02.034</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cpt3610-cit-0046">
<string-name name-style="western">
<surname>Kalliokoski</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>, <string-name name-style="western">
<surname>Kurkinen</surname>, <given-names>K.J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name>
<article-title>Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>84</volume>, <fpage>488</fpage>–<lpage>496</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">19238654</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.74</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cpt3610-cit-0047">
<string-name name-style="western">
<surname>Tornio</surname>, <given-names>A.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism‐based inhibition of CYP2C8 in vivo</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>84</volume>, <fpage>403</fpage>–<lpage>411</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18388877</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.34</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="cpt3610-cit-0048">
<string-name name-style="western">
<surname>Honkalammi</surname>, <given-names>J.</given-names>
</string-name>, <string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name>, <string-name name-style="western">
<surname>Neuvonen</surname>, <given-names>P.J.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Backman</surname>, <given-names>J.T.</given-names>
</string-name>
<article-title>Dose‐dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses</article-title>. <source>Drug Metab. Dispos.</source>
<volume>39</volume>, <fpage>1977</fpage>–<lpage>1986</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21778352</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.040931</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="cpt3610-cit-0049">
<string-name name-style="western">
<surname>Niemi</surname>, <given-names>M.</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>77</volume>, <fpage>468</fpage>–<lpage>478</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15961978</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2005.01.018</pub-id></mixed-citation></ref><ref id="cpt3610-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="cpt3610-cit-0050">
<string-name name-style="western">
<surname>Bi</surname>, <given-names>Y.A.</given-names>
</string-name>, <string-name name-style="western">
<surname>Jordan</surname>, <given-names>S.</given-names>
</string-name>, <string-name name-style="western">
<surname>King‐Ahmad</surname>, <given-names>A.</given-names>
</string-name>, <string-name name-style="western">
<surname>West</surname>, <given-names>M.A.</given-names>
</string-name> &amp; <string-name name-style="western">
<surname>Varma</surname>, <given-names>M.V.S.</given-names>
</string-name>
<article-title>Mechanistic determinants of Daprodustat drug‐drug interactions and pharmacokinetics in hepatic dysfunction and chronic kidney disease: significance of OATP1B‐CYP2C8 interplay</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>115</volume>, <fpage>1336</fpage>–<lpage>1345</lpage> (<year>2024</year>).<pub-id pub-id-type="pmid">38404228</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.3215</pub-id></mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Clinical pharmacology and therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0009-9236</issn><issn pub-type="epub">1532-6535</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10592245</article-id><article-id pub-id-type="pmcid-ver">PMC10592245.319</article-id><article-id pub-id-type="pmcaid">10592245</article-id><article-id pub-id-type="pmcaiid">10592245</article-id><article-id pub-id-type="manuscript-id">NIHMS1922281</article-id><article-id pub-id-type="pmid">37528442</article-id><article-id pub-id-type="doi">10.1002/cpt.3012</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1922281</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1922281</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Impact of <italic toggle="yes">CYP2C:TG</italic> haplotype on CYP2C19 substrates clearance <italic toggle="yes">in vivo</italic>, protein content and <italic toggle="yes">in vitro</italic> activity</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zubiaur</surname><given-names initials="P">Pablo</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soria-Chacartegui</surname><given-names initials="P">Paula</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boone</surname><given-names initials="EC">Erin C</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prasad</surname><given-names initials="B">Bhagwat</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dinh</surname><given-names initials="J">Jean</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="WY">Wendy Y</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zugbi</surname><given-names initials="S">Santiago</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rodríguez-Lopez</surname><given-names initials="A">Andrea</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>González-Iglesias</surname><given-names initials="E">Eva</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leeder</surname><given-names initials="JS">J. Steven</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abad-Santos</surname><given-names initials="F">Francisco</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gaedigk</surname><given-names initials="A">Andrea</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A5" ref-type="aff">5</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain.</aff><aff id="A2"><label>2</label>Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children’s Mercy Research Institute (CMRI), Kansas City, MO, United States.</aff><aff id="A3"><label>3</label>Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, United States.</aff><aff id="A4"><label>4</label>Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.</aff><aff id="A5"><label>5</label>School of Medicine, University of Missouri-Kansas City, Kansas City, MO, United States.</aff><aff id="A6"><label>6</label>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28006 Madrid, Spain.</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author contributions</p><p id="P2">P.Z. and A.G. wrote the manuscript. P.Z. and A.G. designed the research. P.Z., P.S-C., E.C.B., B.P., J.D., W.Y.W., S.Z., A.R-L. E.G-I., J.S.L., F.A-S., and A.G. performed the research. P.Z. analyzed the data. B.P., J.D., and J.S.L. contributed new reagents/analytical tools.</p></fn><corresp id="CR1"><label>*</label><bold>Correspondence:</bold> Pablo Zubiaur Precioso, <email>pablo.zubiaur@uam.es</email>, Clinical Pharmacology Department, 7th floor, Hospital Universitario de La Princesa, Madrid, Spain, +34 915202425, Andrea Gaedigk, <email>agaedigk@cmh.edu</email>; Children’s Mercy Kansas City, Division of Clinical Pharmacology, Toxicology &amp; Therapeutic Innovation, 2401 Gillham Rd, Kansas City, MO, United States, +1 816-731-7071</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>11</day><month>8</month><year>2023</year></pub-date><volume>114</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">447727</issue-id><fpage>1033</fpage><lpage>1042</lpage><pub-history><event event-type="nihms-submitted"><date><day>18</day><month>08</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>11</month><year>2024</year></date></event><event event-type="pmc-released-under-embargo"><date><day>24</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-18 01:25:15.900"><day>18</day><month>02</month><year>2026</year></date></event></pub-history><permissions><license><license-p>This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1922281.pdf"/><abstract id="ABS1"><p id="P3">A novel haplotype composed of two non-coding variants, <italic toggle="yes">CYP2C18</italic> <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000772.3">NM_000772.3</ext-link>:c.*31T (rs2860840) and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000772.2">NM_000772.2</ext-link>:c.819+2182G (rs11188059), referred to as <italic toggle="yes">“CYP2C:TG”,</italic> was recently associated with ultrarapid metabolism of various CYP2C19 substrates. As the underlying mechanism and clinical relevance of this effect remain uncertain, we analyzed existing <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> data to determine the magnitude of the <italic toggle="yes">CYP2C:TG</italic> haplotype effect. We assessed variability in pharmacokinetics of CYP2C19 substrates, including citalopram, sertraline, voriconazole, omeprazole, pantoprazole and rabeprazole in 222 healthy volunteers receiving one of these six drugs. We also determined its impact on CYP2C8, CYP2C9, CYP2C18 and CYP2C19 protein abundance in 135 human liver tissue samples, and on CYP2C18/CYP2C19 activity <italic toggle="yes">in vitro</italic> usin<italic toggle="yes">g N</italic>-desmethyl atomoxetine formation. No effects were observed according to <italic toggle="yes">CYP2C:TG</italic> haplotype or to <italic toggle="yes">CYP2C19*1</italic>+<italic toggle="yes">TG</italic> alleles (i.e., <italic toggle="yes">CYP2C19</italic> alleles containing the <italic toggle="yes">CYP2C:TG</italic> haplotype). In contrast, CYP2C19 intermediate (e.g., <italic toggle="yes">CYP2C19*1/*2</italic>) and poor metabolizers (e.g., <italic toggle="yes">CYP2C19*2/*2</italic>) showed significantly higher exposure <italic toggle="yes">in vivo</italic>, lower CYP2C19 protein abundance in human liver microsomes, and lower activity <italic toggle="yes">in vitro</italic> compared to normal, rapid (i.e., <italic toggle="yes">CYP2C19*1/*17</italic>), and ultrarapid metabolizers (i.e., <italic toggle="yes">CYP2C19*17/*17</italic>). Moreover, a tendency towards lower exposure was observed in ultrarapid metabolizers compared to rapid metabolizers and normal metabolizers. Furthermore, when the <italic toggle="yes">CYP2C19*17</italic> allele was present, CYP2C18 protein abundance was increased suggesting that genetic variation in <italic toggle="yes">CYP2C19</italic> may be relevant to the overall metabolism of certain drugs by regulating not only its expression levels, but also those of CYP2C18. Considering all available data, we conclude that there is insufficient evidence supporting clinical <italic toggle="yes">CYP2C:TG</italic> testing to inform drug therapy.</p></abstract><kwd-group><kwd><italic toggle="yes">CYP2C:TG</italic></kwd><kwd><italic toggle="yes">CYP2C18</italic></kwd><kwd><italic toggle="yes">CYP2C19</italic></kwd><kwd>drug exposure</kwd><kwd><italic toggle="yes">in vitro</italic> activity</kwd><kwd>protein abundance</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P4">Cytochrome P450 2C19 (CYP2C19) plays a principal role in the metabolism of many frequently prescribed medications. Genetic variation of <italic toggle="yes">CYP2C19</italic> contributes to the variability in drug metabolism and response and impacts drug safety and effectiveness. The Pharmacogene Variation Consortium (PharmVar)<sup><xref rid="R1" ref-type="bibr">1</xref></sup> defines allelic variation of pharmacogenes including <italic toggle="yes">CYP2C19.</italic> PharmVar-defined haplotypes are known as star alleles, which is a nomenclature system widely utilized by the community including the Pharmacogenomics Knowledgebase (PharmGKB)<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> and the Clinical Pharmacogenetics Implementation Consortium (CPIC)<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. CPIC has published several clinical guidelines for CYP2C19 substrates, including clopidogrel, proton pump inhibitors, voriconazole, serotonin selective reuptake inhibitors and tricyclic antidepressants<sup><xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R9" ref-type="bibr">9</xref></sup>. Based on the genotype-informed pharmacogenetic phenotype, therapeutic recommendations are issued. Although <italic toggle="yes">CYP2C19</italic> gene has been extensively characterized in the major population groups, novel variants within the gene may yet be discovered explaining some of the variability between patients.</p><p id="P5">Recently, Bråten <italic toggle="yes">et al.</italic> reported a novel <italic toggle="yes">CYP2C18</italic> haplotype (“<italic toggle="yes">CYP2C:TG”</italic>) which was associated with the ultrarapid metabolism of escitalopram to a similar extent as the well-characterized <italic toggle="yes">CYP2C19*17</italic> allele <sup><xref rid="R10" ref-type="bibr">10</xref></sup>. This new haplotype is informed by <italic toggle="yes">CYP2C18</italic> rs2860840 T (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000772.3">NM_000772.3</ext-link>:c.*31C<italic toggle="yes">&gt;</italic>T) and <italic toggle="yes">CYP2C18</italic> rs11188059 G (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_000772.2">NM_000772.2</ext-link>:c.819+2182G<italic toggle="yes">&gt;</italic>A) (<xref rid="F1" ref-type="fig">Figure 1</xref>); this <italic toggle="yes">CYP2C18</italic> haplotype was only found on <italic toggle="yes">CYP2C19*1</italic> alleles. Kee <italic toggle="yes">et al</italic>., 2022, confirmed that the <italic toggle="yes">CYP2C:TG</italic> haplotype occurs almost exclusively on <italic toggle="yes">CYP2C19*1</italic> alleles, but also on the nonfunctional <italic toggle="yes">CYP2C19*4</italic> allele<sup><xref rid="R11" ref-type="bibr">11</xref></sup>. Here, we refer to <italic toggle="yes">CYP2C19*1</italic> alleles that contain the <italic toggle="yes">CYP2C:TG</italic> haplotype as <italic toggle="yes">*1+TG</italic>, to discriminate these from <italic toggle="yes">CYP2C19*1</italic> alleles without this haplotype (i.e., have <italic toggle="yes">CYP2C:AT</italic> or <italic toggle="yes">GC</italic>) (<xref rid="F1" ref-type="fig">Figure 1</xref>). Moreover, Kee et al. found a higher prevalence of the <italic toggle="yes">CYP2C:TG</italic> haplotype but not <italic toggle="yes">CYP2C19*17</italic> in patients of gastroesophageal reflux disease (GERD) with therapeutic failure to omeprazole as compared with a healthy population control cohort. However, these differences were only observed for a subset of 39 patients with confirmed GERD and not in the general population of cases.</p><p id="P6">The underlying mechanism of how the <italic toggle="yes">CYP2C:TG</italic> haplotype increases the activity of <italic toggle="yes">CYP2C19*1</italic> alleles (<italic toggle="yes">*1+TG</italic>) remains unknown. The extent of increased activity conveyed by the <italic toggle="yes">CYP2C:TG</italic> haplotype and its clinical relevance remains uncertain and requires independent confirmation before considering its clinical utility. Although rs2860840 and rs11188059 are in <italic toggle="yes">CYP2C18</italic>, Bråten <italic toggle="yes">et al.</italic> dismissed the possibility of CYP2C18 playing a role in escitalopram metabolism. However, since CYP2C18 participates in the metabolism of several drugs generally considered CYP2C19 substrates<sup><xref rid="R12" ref-type="bibr">12</xref></sup> a contribution of this enzyme to the metabolism of escitalopram and other CYP2C19 substrates should not be disregarded<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. A recent editorial discussed possible mechanisms behind this association<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. Briefly, two different mechanisms were proposed: a) <italic toggle="yes">CYP2C18</italic> is expressed in the liver at low levels and supplements CYP2C19-related metabolic capacity, with this effect being dependent on <italic toggle="yes">CYP2C:TG</italic> haplotype b) the <italic toggle="yes">CYP2C:TG</italic> haplotype influences CYP2C19 expression levels thereby increasing activity through one or more yet unidentified regulatory mechanism(s).</p><p id="P7">The goal of this work was to investigate the contribution of the <italic toggle="yes">CYP2C:TG</italic> haplotype on CYP2C19 activity <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic>. We examined the impact of <italic toggle="yes">CYP2C18</italic> rs2860840 and rs11188059 genotypes and haplotypes and <italic toggle="yes">CYP2C19</italic> genotype and genotype-predicted phenotypes on the variability of systemic exposure of six CYP2C19 substrates (citalopram, sertraline, voriconazole, omeprazole, pantoprazole and rabeprazole). Furthermore, we assessed the impact of these variants on CYP2C8, CYP2C9, CYP2C18 and CYP2C19 protein abundance in human liver tissue and on <italic toggle="yes">N</italic>-desmethyl atomoxetine (NDA-ATX) formation <italic toggle="yes">in vitro</italic>, which is a measure of CYP2C18 and CYP2C19 activity. <italic toggle="yes">CYP2C18</italic> haplotype information was integrated with <italic toggle="yes">CYP2C19</italic> genotype to evaluate if this combination is a superior predictor of CYP2C19 activity.</p></sec><sec id="S2"><title>Materials and methods</title><sec id="S3"><title>Study participants, samples, and data sets</title><p id="P8">Pharmacokinetic data of 222 healthy volunteers participating in eight bioequivalence clinical trials investigating several drugs were available for this investigation: pantoprazole, n=60, EUDRA-CT: 2006–001162-17; omeprazole, n=31, 2010–024029-19; rabeprazole, n=35, 2007–002489-37 and 2007–002490-31; citalopram, n=21, EUDRA-CT: not registered, UECHUP code: CIT/02–5; sertraline, n=17, EUDRA-CT: not registered, UECHUP code: SER/02–1; and voriconazole, n=58. EUDRA-CT: 2014–001964-36 and 2014–005342-22. Several pharmacogenetic studies have been published using these data<sup><xref rid="R13" ref-type="bibr">13</xref>–<xref rid="R18" ref-type="bibr">18</xref></sup>. The clinical trials were conducted at the Clinical Trials Unit of Hospital Universitario de La Princesa (UECHUP), Madrid, Spain, according to Spanish and European legislation on research in humans and complied with Good Clinical Practice guidelines and the Declaration of Helsinki. Study protocols were approved by the Hospital’s Research Ethics Committee and the Spanish Drugs Agency (AEMPS). All volunteers gave written informed consent to participate in the bioequivalence clinical trial and in pharmacogenetic study. Drugs with the potential for any type of pharmacological interaction with the drug under investigation were strictly prohibited by the study protocol to avoid introducing confounding factors while demonstrating bioequivalence. Additionally, the consumption of alcohol, tobacco, as well as any other recreational or illegal drugs, were disallowed. A single oral dose (pantoprazole 40 mg, rabeprazole 20 mg, omeprazole 40 mg, citalopram 40 mg, sertraline 100 mg and voriconazole 200 mg) was administered; blood was collected at different time points (from predose to up to 72 h after dosing) for the quantification of plasma levels and DNA isolation for genotyping. Only the reference formulations data were used for this study. Drug exposure was assessed as the area under the time-concentration curve (AUC); the AUC from pre-dose and the last sample collection time (AUC<sub>t</sub>) was obtained by the trapezoidal method. The AUC from pre-dose to infinity (AUC<sub>0−∞</sub>) was determined by the sum of AUC<sub>t</sub> and extrapolated AUC between t and infinite (AUC<sub>t−∞</sub>, calculated by the C<sub>t</sub>/k ratio, where C<sub>t</sub> is the concentration at t and k is the elimination slope of the curve).</p><p id="P9">Liver tissue samples (n=135 pediatric, donor median age, 7 years; range, 0.01–18 years) were procured from the National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders at the University of Maryland (UMB, Baltimore, MD), the Liver Tissue Cell Distribution System (LCTD) at the University of Minnesota (Minneapolis, MN) and the University of Pittsburgh (Pittsburgh, PA). The use of these samples was approved and determined as nonhuman subject research by the Children’s Mercy Kansas City institutional review board. Additional information on these tissue samples has been previously published<sup><xref rid="R19" ref-type="bibr">19</xref>–<xref rid="R21" ref-type="bibr">21</xref></sup>.</p></sec><sec id="S4"><title>Genotyping</title><p id="P10">Volunteers participating in bioequivalence clinical trials and liver tissue samples were genotyped for <italic toggle="yes">CYP2C19*2, *3, *4, *17, CYP2C18</italic> rs2860840 and <italic toggle="yes">CYP2C18</italic> rs11188059. Detailed methods are provided in <xref rid="SD1" ref-type="supplementary-material">Supplemental Materials</xref>. <italic toggle="yes">CYP2C19</italic> star alleles were defined in accordance with those published by PharmVar<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. <italic toggle="yes">CYP2C19</italic> genotypes were translated into phenotype according to the CPIC/PharmGKB <italic toggle="yes">CYP2C19</italic> diplotype-phenotype table<sup><xref rid="R22" ref-type="bibr">22</xref></sup>.</p></sec><sec id="S5"><title>Proteomics and in vitro experiments</title><p id="P11">Protein abundance was measured by quantitative proteomics. Detailed methods are provided in the <xref rid="SD1" ref-type="supplementary-material">Supplemental Materials</xref>. <xref rid="SD1" ref-type="supplementary-material">Table S1</xref> summarizes the chromatographic conditions used to separate surrogate peptides of CYP2C19, CYP2C18, CYP2C9 and CYP2C8; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref> provides the Multiple Reaction Monitoring (MRM) parameters for MS/MS analysis of the surrogate peptides.</p><p id="P12">The formation of NDM-ATX after the incubation with atomoxetine 1, 3 and 10 μM was used in the current investigation as a biomarker of CYP2C18/19 activity (n=116). Dinh <italic toggle="yes">et al</italic>.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> demonstrated that heterologously expressed CYP2C18 and CYP2C19 have comparable rates of NDM-ATX formation, and therefore microsomal formation will be a function of the total CYP2C18+CYP2C19 content of individual samples. Sample preparation, incubations with ATX and UPLC-MS/MS analysis of metabolite formation are described in detail by Dinh <italic toggle="yes">et al.</italic><sup><xref rid="R23" ref-type="bibr">23</xref></sup>.</p></sec><sec id="S6"><title>Statistical analysis</title><p id="P13">To assess the impact of discrete variables on pantoprazole, rabeprazole, omeprazole, citalopram, sertraline, or voriconazole exposure, a normalized AUC (nAUC) variable was calculated. Individual AUC values were divided by the dose/weight (DW) ratio, yielding the AUC/DW variable, which was subsequently divided by the mean AUC/DW value within each clinical trial yielding the nAUC variable. The Shapiro–Wilk test was used to evaluate the normal distribution of dependent variables. Since AUC/DW and nAUC were not normally distributed, the nonparametric Kruskal–Wallis test was used for statistical inference. For the pairwise comparison of phenotypes or genotypes within the same variable, the Mann–Whitney U test was used. The statistical significance threshold was set at <italic toggle="yes">p</italic>&lt;0.05. The Bonferroni correction for multiple comparisons was applied to control for type-1 error. A similar approach was utilized to evaluate protein abundances and CYP2C18/CYP2C19 activity. Where the median was not informative due to the small sample size, mean data were provided, and parametric tests were used (after logarithmic transformation of the dependent variable and demonstrating its normal distribution). The IBM SPSS software version 28 was used for statistical analysis. The Statistics Kingdom software<sup><xref rid="R24" ref-type="bibr">24</xref></sup> was used to create the figures.</p></sec></sec><sec id="S7"><title>Results.</title><sec id="S8"><title>Pharmacokinetics of CYP2C19 substrates</title><p id="P14">Data from 222 healthy volunteers were available, n=109 females and n=113 males, with median ages (quartiles 1–3) of 23 (22–25) and 24 (21–25) years, respectively (<italic toggle="yes">p</italic>=0.684). Ethnicity was self-reported and predominantly European (n=216) followed by Latin-American (n=5); one individual reported one African parent, which was merged with the Latin-American group for statistical analysis (“other” ethnicity, n=6). The following median AUC/DWs were observed for the six investigated drugs: 1632.03 kg*ng/h*ml*mg for voriconazole, n=58; 2740.28 kg*ng/h*ml*mg for citalopram, n=21; 475.90 kg*ng/h*ml*mg for sertraline, n=17; 8267.99 kg*ng/h*ml*mg for pantoprazole, n=60; 2849.71 kg*ng/h*ml*mg for rabeprazole, n=35, and 2359.60 kg*ng/h*ml*mg for omeprazole, n=31; the differences in AUC/DW were statistically significant as they correspond to different drugs (<italic toggle="yes">p</italic>&lt;0.001). In contrast, nAUC values did not differ, confirming adequate normalization (<xref rid="SD1" ref-type="supplementary-material">Table S3</xref>).</p><p id="P15">Ethnicity and sex had no effect on nAUC (<xref rid="SD1" ref-type="supplementary-material">Table S3</xref>). <italic toggle="yes">CYP2C19</italic> genotype (without <italic toggle="yes">CYP2C18</italic> variants) and genotype-informed phenotype were significantly related to nAUC variability <xref rid="SD1" ref-type="supplementary-material">Table S3</xref>). A 39% statistically significant lower median nAUC was observed in rapid metabolizers (RMs) compared to intermediate metabolizers (IMs) (corrected <italic toggle="yes">p</italic>&lt;0.001), an 78% lower value compared to poor metabolizers (PMs) (corrected <italic toggle="yes">p</italic>=0.044), and a 10% lower value in normal metabolizers (NMs) compared to IMs (corrected <italic toggle="yes">p</italic>&lt;0.001). Similar differences were observed when comparing <italic toggle="yes">CYP2C19</italic> genotypes. In addition, ultrarapid metabolizers (UMs) (<italic toggle="yes">CYP2C19*17/*17</italic>) showed a 9% lower mean nAUC compared to RMs (<italic toggle="yes">CYP2C19*1/*17</italic>) and a 19% lower value compared to NMs (<italic toggle="yes">CYP2C19*1/*1</italic>). However, these differences did not reach statistical significance due to the low number of UMs (n=5). In contrast, the differences between UMs and PMs were large, i.e., UMs showed an 80% lower nAUC value compared to PMs, but due to the small sample size, only the level of nominal significance after nonparametric analysis was reached (<italic toggle="yes">p</italic>=0.011).</p><p id="P16"><italic toggle="yes">CYP2C18</italic> rs2860840 (c.*31C<italic toggle="yes">&gt;</italic>T) and rs11188059 (c.819+2182G<italic toggle="yes">&gt;</italic>A) were unrelated to nAUC (<xref rid="SD1" ref-type="supplementary-material">Table S3</xref>). Although <italic toggle="yes">CYP2C18</italic> genotype (i.e., the combination of rs2860840 and rs11188059) was nominally related to nAUC variability (<italic toggle="yes">p</italic>=0.033, <xref rid="SD1" ref-type="supplementary-material">Table S3</xref>), no differences were observed after Bonferroni correction for multiple comparisons. No association (including nominal significance, <italic toggle="yes">p</italic>=0.202) was observed according to <italic toggle="yes">CYP2C:TG</italic> haplotype (<xref rid="SD1" ref-type="supplementary-material">Table S3</xref>), nor when it was investigated together with <italic toggle="yes">CYP2C19</italic> genotype, i.e., the impact of the <italic toggle="yes">CYP2C19*1+TG</italic> allele (<xref rid="F2" ref-type="fig">Figure 2</xref>). No differences in the AUC/DW value according to the <italic toggle="yes">CYP2C:TG</italic> haplotype were observed either when analyzing the data of each clinical trial individually (<xref rid="SD1" ref-type="supplementary-material">Table S4</xref>). <xref rid="SD1" ref-type="supplementary-material">Table S5</xref> summarizes the pairwise comparisons of the interrogated genotypes and nAUC (corrected <italic toggle="yes">p</italic>=0.003). Expectedly, genotypes with one or two <italic toggle="yes">CYP2C19</italic> no function alleles were associated with higher nAUC, but no differences were found among <italic toggle="yes">CYP2C19*1</italic> alleles regardless of whether they had the <italic toggle="yes">CYP2C18 ‘TG’, ‘AT</italic>’ or ‘<italic toggle="yes">GC’</italic> haplotype nAUC was comparable for subjects having two <italic toggle="yes">CYP2C19*1</italic> alleles, two <italic toggle="yes">*1+TG</italic> alleles or were heterozygous for these. Likewise, there were no statistically significant differences when comparing <italic toggle="yes">CYP2C19*1/*17</italic> with <italic toggle="yes">*1+TG/*17</italic> or <italic toggle="yes">*17/*17</italic> with <italic toggle="yes">*1+TG/*1+TG.</italic> Healthy volunteers with the <italic toggle="yes">CYP2C19*17/*17</italic> genotype (n=5) showed a 20% lower nAUC compared to those with the <italic toggle="yes">*1/*17</italic> genotype (n=20) and a 23% lower value compared to <italic toggle="yes">*1/*1</italic> participants (n=33), but these differences were not statistically significant due to the relatively small sample size.</p></sec><sec id="S9"><title>Liver tissue protein abundance and <italic toggle="yes">CYP2C19</italic> activity</title><p id="P17">The study cohort comprised liver tissue samples of 47 females and 87 males, and one unknown sex (n=135) with median ages (quartile 1 and 3) of 7.34 (3.08–15.53) and 5.00 (0.56–13.42) years, respectively (<italic toggle="yes">p</italic>=0.255). Individuals were identified as European (n=64), African American (n=29), Hispanic (n=4) or Other (n=2) while no data were available for the remaining samples. European donors were significantly older than African American donors (7.71 years [2.25–15.00] vs 2.75 [0.37–8.04] years, corrected <italic toggle="yes">p</italic>=0.040). The majority of tissue samples (n=74) were obtained from the LCTD while n=61 were obtained from UMB. LCTD donors were significantly older than those obtained from UMB (8.00 years [4.00–14.00] vs 4.56 [0.38–13.93], <italic toggle="yes">p</italic>=0.013).</p><p id="P18">Median and first and third quartiles of CYP2C19, CYP2C18, CYP2C8 and CYP2C9 protein abundance are shown in <xref rid="SD1" ref-type="supplementary-material">Table S6</xref> which also provides CYP2C19 activity using NDA-ATX formation as a measure of CYP2C19 activity, according to <italic toggle="yes">CYP2C18</italic> genotype, <italic toggle="yes">CYP2C19</italic> genotype (with and without <italic toggle="yes">CYP2C18</italic> haplotypes) and CYP2C19 genotype-predicted phenotype. A trend between age and CYP2C18 protein content (R<sup>2</sup>=0.161), but CYP2C19, CYP2C9 and CYP2C8 protein content were unrelated to age. CYP2C19 protein abundance was significantly higher in UMB samples compared to those sourced from LCTD (<italic toggle="yes">p</italic>=0.019). Variability in CYP2C19 protein abundance was strongly related to <italic toggle="yes">CYP2C19</italic> genotype (without <italic toggle="yes">CYP2C18</italic> information) (<xref rid="F3" ref-type="fig">Figure 3a</xref>, <xref rid="SD1" ref-type="supplementary-material">Table S6</xref>). Expectedly, these differences were similar according to CYP2C19 phenotype (<xref rid="SD1" ref-type="supplementary-material">Table S6</xref>). No differences were observed according to <italic toggle="yes">CYP2C18</italic> variants or genotype (<xref rid="SD1" ref-type="supplementary-material">Table S6</xref>). When evaluating the impact of <italic toggle="yes">CYP2C19</italic> genotype including <italic toggle="yes">CYP2C18</italic> haplotype information, statistically significant differences were detected (<italic toggle="yes">p</italic>=0.002) (<xref rid="F3" ref-type="fig">Figure 3b</xref>). The pairwise comparison revealed significant differences between <italic toggle="yes">CYP2C19</italic>*<italic toggle="yes">1/*1</italic> and <italic toggle="yes">*2/*2</italic> and <italic toggle="yes">*2/*4</italic> genotypes (<italic toggle="yes">p</italic>=0.014); between <italic toggle="yes">*17/*17</italic> and <italic toggle="yes">*2/*2</italic> and <italic toggle="yes">*2/*4</italic> genotypes (<italic toggle="yes">p</italic>=0.018), and between <italic toggle="yes">*1/*1</italic> and <italic toggle="yes">*1/*2</italic> and <italic toggle="yes">*1/*35</italic> genotypes (<italic toggle="yes">p</italic>=0.047). That is, the differences observed were between samples with different <italic toggle="yes">CYP2C19</italic> genotype-informed phenotypes, while <italic toggle="yes">CYP2C19*1+TG</italic> alleles had no impact on CYP2C19 protein content (<xref rid="SD1" ref-type="supplementary-material">Table S7</xref>). Notably, the <italic toggle="yes">CYP2C19*2/*4</italic> sample had a <italic toggle="yes">CYP2C18 CG</italic>/<italic toggle="yes">TG</italic> genotype. We were unable to determine which <italic toggle="yes">CYP2C19</italic> star allele contained the <italic toggle="yes">CYP2C:TG</italic> haplotype, but based on Kee <italic toggle="yes">et al.</italic><sup><xref rid="R11" ref-type="bibr">11</xref></sup>, it is likely on the <italic toggle="yes">CYP2C19*4</italic> allele.</p><p id="P19">CYP2C18 protein abundance was significantly higher in the samples sourced from LCTD (corrected <italic toggle="yes">p</italic>&lt;0.001). Significant variability in CYP2C18 protein abundance was observed according to CYP2C19 phenotype (<italic toggle="yes">p</italic>=0.029) (<xref rid="F4" ref-type="fig">Figure 4</xref>); after the pairwise comparison and Bonferroni correction, no differences were observed. A similar trend was observed according to <italic toggle="yes">CYP2C19</italic> genotype (<italic toggle="yes">p</italic>=0.053) (<xref rid="SD1" ref-type="supplementary-material">Table S6</xref>). When analyzing CYP2C19+CYP2C18 protein abundance according to CYP2C19 phenotype, statistically significant differences were observed (p&lt;0.001, data not shown), which remained significant after pairwise comparison and multiple comparison correction (PM vs RM, NM, and UM: p=0.006, p=0.003 and p=0.002, respectively; IM vs RM, NM, and UM: p=0.046, p=0.017 and p=0.022, respectively). The same differences were observed for CYP2C19 genotype.</p><p id="P20">No differences in CYP2C8 and CYP2C9 protein abundance were observed according to any variable, except for CYP2C9 abundance in samples with <italic toggle="yes">CYP2C19*1/*2</italic> and <italic toggle="yes">*1/*35</italic> genotypes (IMs), which was lower than that observed for samples with the <italic toggle="yes">CYP2C19*1+TG</italic>/<italic toggle="yes">*17</italic> genotype (RMs) (corrected <italic toggle="yes">p</italic>=0.031) (<xref rid="SD1" ref-type="supplementary-material">Table S6</xref>).</p><p id="P21">Samples from LCTD exhibited higher formation rates of NDA-ATX compared to those from UMB (corrected <italic toggle="yes">p</italic>&lt;0.001) (<xref rid="SD1" ref-type="supplementary-material">Table S6</xref>). Significant variability in NDA-ATX formation rates was observed according to CYP2C19 phenotype (p=0.017) and <italic toggle="yes">CYP2C19</italic> genotype (p=0.034) after incubation with ATX 10 μM. The pairwise comparisons of subgroups revealed statistically significant differences between samples genotyped as <italic toggle="yes">CYP2C19*2/*2</italic> and <italic toggle="yes">*2/*4</italic> vs <italic toggle="yes">*1/*1</italic> (corrected p=0.014); vs <italic toggle="yes">*17/*17</italic> (corrected p=0.018) and between those genotyped as <italic toggle="yes">*1/*2</italic> and <italic toggle="yes">*1/*35</italic> vs <italic toggle="yes">*1/*1</italic> (corrected p=0.047). No differences were observed according to any other variable. Analyses were repeated with ATX 1 μM and 3 μM incubations and the same results were obtained (data not shown). Because liver tissue source was previously found to be a factor explaining variability<sup><xref rid="R25" ref-type="bibr">25</xref></sup>, analyses were repeated including only LCTD-sourced tissue samples to further evaluate whether the source of donors affects the results. Similar results were observed compared to the overall analysis, with <italic toggle="yes">p</italic> values increasing in general due to the reduction of the sample size (data not shown).</p></sec></sec><sec id="S10"><title>Discussion</title><p id="P22">Bråten <italic toggle="yes">et al.</italic><sup><xref rid="R10" ref-type="bibr">10</xref></sup> identified the <italic toggle="yes">CYP2C:TG</italic> haplotype by analyzing the GRCh37/hg19, Chr10:96442884–96522439 region in 24 patients with unexplained ultrarapid metabolism of escitalopram. This region includes <italic toggle="yes">CYP2C18</italic> and the <italic toggle="yes">CYP2C18-CYP2C1</italic>9 intergenic region (<xref rid="F1" ref-type="fig">Figure 1</xref>). A 2-fold higher frequency of <italic toggle="yes">CYP2C18</italic> rs2860840 and rs11188059 variants was found in these patients<sup><xref rid="R10" ref-type="bibr">10</xref></sup> compared to their respective frequencies in the 1000 Genomes Project. In their work, authors affirm that <italic toggle="yes">CYP2C:TG</italic> predicts CYP2C19 UM phenotype and dismiss CYP2C18 contributing to metabolism. Interestingly, carriers of the <italic toggle="yes">CYP2C:TG</italic> haplotype showed a higher prevalence of rs34117282 (an indel variant located in the <italic toggle="yes">CYP2C18-CYP2C1</italic>9 intergenic region), but this variant was not further pursued. Furthermore, the haplotype related to the ultrarapid metabolism of escitalopram was rs2860840 (T) and rs11188059 (G), i.e., <italic toggle="yes">CYP2C:TG</italic>, but not rs2860840 (T) and rs11188059 (A), i.e., <italic toggle="yes">CYP2C:TA</italic>. This is surprising since both alleles (T and A) were apparently more prevalent among the UM-like patients compared to the 1000 Genomes Project prevalence. Nonetheless, since the within <italic toggle="yes">CYP2C:TG</italic> haplotype variability was several-fold greater than the between haplotype variability reported by Bråten <italic toggle="yes">et al.</italic> (same as in this work), it is unlikely that the differences between the groups have a meaningful clinical impact.</p><p id="P23">Here, no associations were found between the <italic toggle="yes">CYP2C:TG</italic> haplotype or <italic toggle="yes">CYP2C19*1+TG</italic> alleles on the exposure of six CYP2C19 substrates, <italic toggle="yes">in vitro</italic> activity, or protein content on any of the four CYP2C proteins in human liver microsomes. Similarly, the <italic toggle="yes">CYP2C18</italic> variants had no effect on any dependent variable. In contrast, <italic toggle="yes">CYP2C19</italic> genotype, especially nonfunctional alleles, had a significant impact on drug exposure, <italic toggle="yes">in vitro</italic> protein abundance, and activity in liver microsomes, as expected according to published data<sup><xref rid="R26" ref-type="bibr">26</xref>–<xref rid="R28" ref-type="bibr">28</xref></sup>.</p><p id="P24"><italic toggle="yes">CYP2C19*17</italic> had no significant effect on drug exposure in this study either, although a tendency was observed. These results are consistent with Bråten <italic toggle="yes">et al.</italic><sup><xref rid="R10" ref-type="bibr">10</xref></sup>, who described a modest impact of <italic toggle="yes">CYP2C19*17</italic> while no function alleles had a considerable impact. For instance, patients with <italic toggle="yes">CYP2C19*17/*17</italic> and <italic toggle="yes">*1/*17</italic> genotypes essentially displayed identical dose-normalized concentrations of escitalopram (an image interpretation software was used to calculate concentration means and ranges<sup><xref rid="R29" ref-type="bibr">29</xref></sup>): <italic toggle="yes">*17/*17</italic>, 30 nM [7–140 nM] and <italic toggle="yes">*1/*17</italic>, 31 nM [7–173 nM]) which were slightly lower (17% and 14%, respectively) compared to those measured for <italic toggle="yes">*1/*1</italic> (36 nM [5–161 nM]). In contrast, when <italic toggle="yes">CYP2C19*1/*1</italic> patients were compared with<italic toggle="yes">*1/null</italic> and <italic toggle="yes">null/null</italic> genotypes (<italic toggle="yes">*1/null</italic>, 54 nM [14–190 nM]; <italic toggle="yes">null/null</italic>, 91 nM [34–184 nM]) drug exposure differed 1.5-fold and 2.5-fold, respectively. Patients with <italic toggle="yes">*1+TG/*1+TG</italic> and *<italic toggle="yes">1/*1+TG</italic> genotypes showed a 22% and 17% lower exposure (<italic toggle="yes">*1+TG/*1+TG</italic>, 28 nM [1–144 nM]; <italic toggle="yes">*1/*1+TG</italic>, 30 nM [4–121 nM]) compared to those with a <italic toggle="yes">*1/*1</italic> genotype (36 nM [5–161 nM]). However, all genotypes exhibited concentrations in the range of 34 and 110 nM, all within the same wide range. Therefore, considering the large within-genotype variability of at least 374%, the mean differences among <italic toggle="yes">*1+TG/*1+TG,</italic> *<italic toggle="yes">1/*1+TG</italic> and <italic toggle="yes">*1/*1</italic> appear negligible. In this case, statistical significance seems to be driven by the relatively large number of samples in the Bråten <italic toggle="yes">et al.</italic> study, which does, however, not necessarily translate into clinical relevance.</p><p id="P25">CYP2C19 phenotype was significantly related to CYP2C19 protein abundance (p&lt;0.001) and nominally to CYP2C18 protein abundance (p=0.029) in human liver microsomes. The combination of CYP2C18+CYP2C19 protein abundances was best predicted by CYP2C19 phenotype (compared to CYP2C19 or CYP2C18 individually), increasing the significance. CYP2C18 protein abundance ranges in UMs, RMs and IMs were not different, since CYP2C18 is present in some livers and absent in others. Many of the samples show extremely low or null abundance protein, therefore the lower value of the range is identical. However, four out of six CYP21C9 UMs showed high CYP2C18 levels, while in five of six PMs the protein was undetectable. This novel finding and its relevance regarding <italic toggle="yes">in vivo</italic> activity warrant further investigation. Additional research is warranted to determine the impact of <italic toggle="yes">CYP2C18</italic> genetic variation on the enzyme’s abundance in other tissues, such as the gastrointestinal track, gallbladder, etc.</p><p id="P26">Variants unique to the <italic toggle="yes">CYP2C19*17</italic> allele could also affect CYP2C18 protein expression; a concerted increase in CYP2C18 and CYP2C19 protein levels may contribute to the <italic toggle="yes">CYP2C19*17</italic> allele presenting with increased function. Genetic variability of <italic toggle="yes">CYP2C18</italic> has not been systematically explored, but considering that <italic toggle="yes">CYP2C8, CYP2C9</italic> and <italic toggle="yes">CYP2C19</italic> are all highly polymorphic, <italic toggle="yes">CYP2C18</italic> is likely also polymorphic, and its activity may widely range. CYP2C18 has been traditionally excluded from being studied due to Läpple <italic toggle="yes">et al.</italic> who reported 20 years ago that this protein is not expressed<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. More recent findings provide evidence to the contrary as discussed by Zubiaur &amp; Gaedigk<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. The proteomics data presented in this report further corroborates the presence of this enzyme in some livers while being absent in others. Taken together, it is plausible that CYP2C18 plays a role in the metabolism of some substrates which have traditionally been attributed to CYP2C19 in some patients. There is clearly a void of information regarding the contribution of CYP2C18 to drug metabolism. To close this knowledge gap, we call upon the scientific community to include this gene in their pharmacogenetics research.</p><p id="P27">Bråten <italic toggle="yes">et al.</italic> also published a study investigating the impact of the <italic toggle="yes">CYP2C:TG</italic> haplotype on sertraline exposure<sup><xref rid="R31" ref-type="bibr">31</xref></sup> concluding that “the <italic toggle="yes">CYP2C:TG</italic> haplotype status can prospectively be useful to clinicians in making more appropriate sertraline dosing decisions”. However, again, the within <italic toggle="yes">CYP2C:TG</italic> haplotype variability in serum concentrations was several-fold greater than the between haplotype variability. Furthermore, <italic toggle="yes">CYP2C19*1/*1</italic> patients (n=142) showed a mean serum concentration of 72.2 nM/100mg per day while those with <italic toggle="yes">*1/*1+TG</italic> (n=222) and <italic toggle="yes">1/*17</italic> (n=286) had concentrations of 71.6 nM/100mg and 59.5 nM/100mg, respectively, which appears to contrast their conclusion that this haplotype should be tested preemptively to guide dosing decisions.</p><p id="P28">Kee <italic toggle="yes">et al.,</italic> 2022<sup><xref rid="R11" ref-type="bibr">11</xref></sup> associated the <italic toggle="yes">CYP2C:TG</italic> haplotype with therapeutic failure to omeprazole in patients with GERD. However, this association was only found in a small subset of cases (n=39). Since <italic toggle="yes">CYP2C19*17</italic> is a well-known predictor of omeprazole therapeutic failure and the authors were unable to establish this association, their claims for <italic toggle="yes">CYP2C:TG</italic> are uncertain. Furthermore, a study describing the distribution of <italic toggle="yes">CYP2C</italic> haplotypes in Native American populations was published<sup><xref rid="R32" ref-type="bibr">32</xref></sup>, however, no functional data were available.</p><p id="P29">Finally, although <italic toggle="yes">CYP2C19*17/*17</italic> individuals are traditionally considered functionally different from <italic toggle="yes">*1/*17</italic> individuals (UMs vs. RMs), our data for CYP2C19 substrates suggest that differences in exposure are small and by far not as pronounced as those observed between NMs, IMs and PMs. Furthermore, recommendations in some CPIC guidelines do not differ for RMs and UMs (e.g., voriconazole<sup><xref rid="R6" ref-type="bibr">6</xref></sup> or sertraline<sup><xref rid="R9" ref-type="bibr">9</xref></sup>), reflecting the absence of literature supporting clinically meaningful differences among these two phenotype groups. In summary, no function alleles have a much greater impact on enzyme activity compared to <italic toggle="yes">CYP2C19*17</italic>. This opens the question of whether a RM phenotype classification is clinically useful or whether it should be merged into the NM group, as the Dutch Pharmacogenetics Working Group do<sup><xref rid="R33" ref-type="bibr">33</xref></sup>.</p><p id="P30">This work has several limitations and strengths. First, the sample size is small and arbitrary due to the availability of data. As this is an observational study, some associations may not be truly significant while others may have been missed because the methodology employed does not guarantee sufficient statistical power. However, a positive control was employed throughout (i.e., <italic toggle="yes">CYP2C19</italic> genotype or genotype-informed phenotype), and it was repeatedly related to the interrogated dependent variables (e.g., nAUC), thus it can be assumed that there is indeed sufficient statistical power to determine clinically relevant associations. Therefore, unobserved associations may not be interpreted as “not statistically significant”, but as probably “not clinically relevant”. Second, we used multiple pharmacokinetic data sets from clinical trials performed with high methodological rigor, avoiding important confounding factors that are present in patients (e.g., concomitant medications, smoking, etc.), correcting for weight and controlling for several possible confounder factors such as ethnicity. In the Bråten <italic toggle="yes">et al</italic> studies, authors evaluated pharmacokinetic data using a less rigorous methodology, based on point concentrations, without weight correction. Furthermore, the AUC is most informative when the pathway of interest is the sole/major clearance pathway, which is indeed the case for escitalopram but is problematic for citalopram (i.e., the decline in citalopram concentrations is a composite of CYP2C19 effects on the S enantiomer and CYP2D6 on the R-enantiomer) or for voriconazole which is also metabolized by CY3A4 and FMO3. Third, the origin of the liver tissue samples was heterogeneous. However, differences did not vary significantly depending on the origin of the samples.</p></sec><sec id="S11"><title>Conclusions</title><p id="P31">Consistent with the literature, CYP2C19 IM and PM metabolizer status impacted CYP2C19 drug exposure <italic toggle="yes">in vivo</italic>, protein abundance in human liver microsomes, and <italic toggle="yes">in vitro</italic> activity. In contrast, no effects were observed when C<italic toggle="yes">YP2C19*1</italic> alleles were stratified for the <italic toggle="yes">CYP2C:TG</italic> haplotype, i.e., <italic toggle="yes">CYP2C19*1</italic> alleles with ‘TG’ and those without. Considering all available data, we conclude that there is insufficient evidence supporting the clinical relevance of <italic toggle="yes">CYP2C:TG</italic> haplotype and its testing to inform drug therapy. Lastly, CYP2C18 should not be dismissed as it may contribute to the overall metabolism of some drugs.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>Supinfo</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS1922281-supplement-Supinfo.docx" id="d64e1277" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S12"><title>Acknowledgements</title><p id="P32">Authors are thankful to Aanchal Mehrotra and Michael Boberg, Department of Pharmaceutics, University of Washington for their help with the proteomics sample preparation.</p><sec id="S13"><title>Funding information:</title><p id="P33">Paula Soria-Chacartegui is financed by Universidad Autónoma de Madrid (FPI-UAM, 2021). P. Zubiaur is financed by Universidad Autónoma de Madrid, Margarita Salas contract, grants for the requalification of the Spanish university system. Andrea Rodríguez-Lopez and Eva González-Iglesias contracts are financed by Programa Investigo (NextGenerationEU funds of the ‎Recovery and Resilience Facility), fellowship numbers 2022-C23.I01.P03.S0020- 0000031 and 09-PIN1-00015.6/2022. Human liver tissue samples were obtained through the Liver Tissue Cell Distribution System, Minneapolis, MN and Pittsburgh, PA, which was funded by NIH Contract #HHSN276201200017C. The proteomics part of the work was supported by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) [Grant R01.HD081299].</p></sec></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P34"><bold>Conflict of interest statement:</bold> Francisco Abad-Santos. has been consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, FAES, Farmalíder, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva and Zambon. All other authors declared no competing interests for this work.</p></fn><fn id="FN3"><p id="P35">SUPPORTING INFORMATION</p><p id="P36">Supplementary information accompanies this paper on the <italic toggle="yes">Clinical Pharmacology &amp; Therapeutics</italic> website (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.cpt-journal.com/" ext-link-type="uri">www.cpt-journal.com</ext-link>).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Casey</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Whirl-Carrillo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>NA</given-names></name> &amp; <name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name>
<article-title>Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation</article-title>. <source>Clin Pharmacol Ther</source>
<volume>110</volume>, <fpage>542</fpage>–<lpage>545</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34091888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2321</pub-id><pub-id pub-id-type="pmcid">PMC8725060</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Whirl-Carrillo</surname><given-names>M</given-names></name>
<etal/>
<article-title>Pharmacogenomics Knowledge for Personalized Medicine</article-title>. <source>Clin Pharmacol Ther</source>
<volume>92</volume>, <fpage>414</fpage>–<lpage>417</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22992668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2012.96</pub-id><pub-id pub-id-type="pmcid">PMC3660037</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Whirl-Carrillo</surname><given-names>M</given-names></name>
<etal/>
<article-title>An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine</article-title>. <source>Clin Pharma and Therapeutics</source>
<volume>110</volume>, <fpage>563</fpage>–<lpage>572</lpage> (<year>2021</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2350</pub-id><pub-id pub-id-type="pmcid">PMC8457105</pub-id><pub-id pub-id-type="pmid">34216021</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Relling</surname><given-names>MV</given-names></name> &amp; <name name-style="western"><surname>Klein</surname><given-names>TE</given-names></name>
<article-title>CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network</article-title>. <source>Clin Pharmacol Ther</source>
<volume>89</volume>, <fpage>464</fpage>–<lpage>467</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21270786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2010.279</pub-id><pub-id pub-id-type="pmcid">PMC3098762</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hicks</surname><given-names>J</given-names></name>
<etal/>
<article-title>Clinical pharmacogenetics implementation consortium guideline (CPIC) for <italic toggle="yes">CYP2D6</italic> and <italic toggle="yes">CYP2C19</italic> genotypes and dosing of tricyclic antidepressants: 2016 update</article-title>. <source>Clin. Pharmacol. Ther</source>. <volume>102</volume>, <fpage>37</fpage>–<lpage>44</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">27997040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.597</pub-id><pub-id pub-id-type="pmcid">PMC5478479</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Moriyama</surname><given-names>B</given-names></name>
<etal/>
<article-title>Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for <italic toggle="yes">CYP2C19</italic> and Voriconazole Therapy</article-title>. <source>Clin. Pharmacol. Ther</source>. <volume>102</volume>, <fpage>45</fpage>–<lpage>51</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">27981572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.583</pub-id><pub-id pub-id-type="pmcid">PMC5474211</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lima</surname><given-names>JJ</given-names></name>
<etal/>
<article-title>Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <italic toggle="yes">CYP2C19</italic> and Proton Pump Inhibitor Dosing</article-title>. <source>Clin. Pharmacol. Ther</source>. <volume>109</volume>, <fpage>1417</fpage>–<lpage>1423</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">32770672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2015</pub-id><pub-id pub-id-type="pmcid">PMC7868475</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lee</surname><given-names>CR</given-names></name>
<etal/>
<article-title>Clinical Pharmacogenetics Implementation Consortium Guideline for <italic toggle="yes">CYP2C19</italic> Genotype and Clopidogrel Therapy: 2022 Update</article-title>. <source>Clin Pharma and Therapeutics</source>
<fpage>cpt.2526</fpage> (<year>2022</year>).doi:<pub-id pub-id-type="doi">10.1002/cpt.2526</pub-id><pub-id pub-id-type="pmcid">PMC9287492</pub-id><pub-id pub-id-type="pmid">35034351</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bousman</surname><given-names>CA</given-names></name>
<etal/>
<article-title>Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants</article-title>. <source>Clin Pharmacol Ther</source> (<year>2023</year>).doi:<pub-id pub-id-type="doi">10.1002/cpt.2903</pub-id><pub-id pub-id-type="pmcid">PMC10564324</pub-id><pub-id pub-id-type="pmid">37032427</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bråten</surname><given-names>LS</given-names></name>
<etal/>
<article-title>A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram</article-title>. <source>Clin Pharma and Therapeutics</source>
<volume>110</volume>, <fpage>786</fpage>–<lpage>793</lpage> (<year>2021</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2233</pub-id><pub-id pub-id-type="pmid">33759177</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kee</surname><given-names>PS</given-names></name>
<etal/>
<article-title>Omeprazole Treatment Failure in Gastroesophageal Reflux Disease and Genetic Variation at the CYP2C Locus</article-title>. <source>Front. Genet</source>. <volume>13</volume>, <fpage>869160</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35664313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.869160</pub-id><pub-id pub-id-type="pmcid">PMC9160307</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zubiaur</surname><given-names>P</given-names></name> &amp; <name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name>
<article-title>CYP2C18: the orphan in the CYP2C family</article-title>. <source>Pharmacogenomics</source>
<volume>23</volume>, <fpage>913</fpage>–<lpage>916</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36331025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/pgs-2022-0142</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dapía</surname><given-names>I</given-names></name>
<etal/>
<article-title>Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population</article-title>. <source>Int J Antimicrob Agents</source>
<volume>54</volume>, <fpage>463</fpage>–<lpage>470</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31279853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2019.06.026</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zubiaur</surname><given-names>P</given-names></name>
<etal/>
<article-title>Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling</article-title>. <source>Clin Pharmacokinet</source>
<volume>60</volume>, <fpage>261</fpage>–<lpage>270</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">32939689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-020-00941-8</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Saiz-Rodríguez</surname><given-names>M</given-names></name>
<etal/>
<article-title>Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers</article-title>. <source>Basic Clin Pharmacol Toxicol</source>
<volume>122</volume>, <fpage>501</fpage>–<lpage>511</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29136336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcpt.12938</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Saiz-Rodríguez</surname><given-names>M</given-names></name>
<etal/>
<article-title>Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants</article-title>. <source>Basic Clin Pharmacol Toxicol</source>
<volume>123</volume>, <fpage>474</fpage>–<lpage>485</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29723928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcpt.13031</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Román</surname><given-names>M</given-names></name>
<etal/>
<article-title>Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole</article-title>. <source>Pharmacogenomics</source>
<volume>15</volume>, <fpage>1893</fpage>–<lpage>1901</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25495411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/pgs.14.141</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ochoa</surname><given-names>D</given-names></name>
<etal/>
<article-title>Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole</article-title>. <source>BMC Pharmacol Toxicol</source>
<volume>21</volume>, <fpage>54</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32711578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40360-020-00433-2</pub-id><pub-id pub-id-type="pmcid">PMC7382816</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bhatt</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pearce</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name> &amp; <name name-style="western"><surname>Prasad</surname><given-names>B</given-names></name>
<article-title>Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver</article-title>. <source>Drug Metab Dispos</source>
<volume>45</volume>, <fpage>1044</fpage>–<lpage>1048</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28607029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.117.076463</pub-id><pub-id pub-id-type="pmcid">PMC5563927</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dinh</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Pearce</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Van Haandel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name> &amp; <name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name>
<article-title>Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children</article-title>. <source>Drug Metab Dispos</source>
<volume>44</volume>, <fpage>1070</fpage>–<lpage>1079</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27052878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.116.069518</pub-id><pub-id pub-id-type="pmcid">PMC4931890</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name>
<etal/>
<article-title>Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver</article-title>. <source>Drug Metab Dispos</source>
<volume>50</volume>, <fpage>24</fpage>–<lpage>32</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">34686522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.121.000623</pub-id><pub-id pub-id-type="pmcid">PMC8969199</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="webpage"><source>PharmGKB &amp; CPIC Gene-specific Information Tables for CYP2C19</source>. <comment>at</comment> &lt;<comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pharmgkb.org/page/cyp2c19RefMaterials" ext-link-type="uri">https://www.pharmgkb.org/page/cyp2c19RefMaterials</ext-link></comment>&gt;</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dinh</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Pearce</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Van Haandel</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name> &amp; <name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name>
<article-title>Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children</article-title>. <source>Drug Metabolism and Disposition</source>
<volume>44</volume>, <fpage>1070</fpage>–<lpage>1079</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27052878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.116.069518</pub-id><pub-id pub-id-type="pmcid">PMC4931890</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="webpage"><source>Statistics Kingdom Statistics Kingdom</source>. (<year>2023</year>).<comment>at</comment> &lt;<comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.statskingdom.com" ext-link-type="uri">http://www.statskingdom.com</ext-link></comment>&gt;.</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stancil</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Nolte</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Pearce</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Staggs</surname><given-names>VS</given-names></name> &amp; <name name-style="western"><surname>Leeder</surname><given-names>JS</given-names></name>
<article-title>The Impact of Age and Genetics on Naltrexone Biotransformation</article-title>. <source>Drug Metab Dispos</source>
<volume>50</volume>, <fpage>168</fpage>–<lpage>173</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">34728519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.121.000646</pub-id><pub-id pub-id-type="pmcid">PMC9621334</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Steere</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>JAR</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>SD</given-names></name> &amp; <name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name>
<article-title>Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model</article-title>. <source>Drug Metab Dispos</source>
<volume>43</volume>, <fpage>870</fpage>–<lpage>883</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25845826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.114.061523</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name>
<etal/>
<article-title>The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro</article-title>. <source>IDR</source> Volume <volume>11</volume>, <fpage>2129</fpage>–<lpage>2135</lpage> (<year>2018</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IDR.S179078</pub-id><pub-id pub-id-type="pmcid">PMC6219421</pub-id><pub-id pub-id-type="pmid">30464555</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hiratsuka</surname><given-names>M</given-names></name>
<article-title>Genetic Polymorphisms and <italic toggle="yes">in Vitro</italic> Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants</article-title>. <source>Biological &amp; Pharmaceutical Bulletin</source>
<volume>39</volume>, <fpage>1748</fpage>–<lpage>1759</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27803446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/bpb.b16-00605</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="webpage"><name name-style="western"><surname>Rohatgi</surname><given-names>A</given-names></name>
<source>WebPlotDigitizer v4.6</source>. (<year>2023</year>).<comment>at</comment> &lt;<comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.automeris.io/wpd/" ext-link-type="uri">https://apps.automeris.io/wpd/</ext-link></comment>&gt;</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Läpple</surname><given-names>F</given-names></name>
<etal/>
<article-title>Differential expression and function of CYP2C isoforms in human intestine and liver</article-title>. <source>Pharmacogenetics</source>
<volume>13</volume>, <fpage>565</fpage>–<lpage>575</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12972955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00008571-200309000-00005</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bråten</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jukic</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Molden</surname><given-names>E</given-names></name> &amp; <name name-style="western"><surname>Kringen</surname><given-names>MK</given-names></name>
<article-title>Impact of the novel <italic toggle="yes">CYP2C:TG</italic> haplotype and <italic toggle="yes">CYP2B6</italic> variants on sertraline exposure in a large patient population</article-title>. <source>Clinical Translational Sci</source>
<volume>15</volume>, <fpage>2135</fpage>–<lpage>2145</lpage> (<year>2022</year>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13347</pub-id><pub-id pub-id-type="pmcid">PMC9468554</pub-id><pub-id pub-id-type="pmid">35668575</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fernandes</surname><given-names>VC</given-names></name>, <name name-style="western"><surname>Pretti</surname><given-names>MAM</given-names></name>, <name name-style="western"><surname>Tsuneto</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>Petzl-Erler</surname><given-names>ML</given-names></name> &amp; <name name-style="western"><surname>Suarez-Kurtz</surname><given-names>G</given-names></name>
<article-title>Distribution of a novel CYP2C haplotype in Native American populations</article-title>. <source>Front. Genet</source>. <volume>14</volume>, <fpage>1114742</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37025454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2023.1114742</pub-id><pub-id pub-id-type="pmcid">PMC10071019</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="webpage"><source>KNMP Pharmacogenetics Working Group General background text Pharmacogenetics - CYP2C19</source>. (<year>2016</year>).<comment>at</comment> &lt;<comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://api.pharmgkb.org/v1/download/file/attachment/CYP2C19.pdf" ext-link-type="uri">https://api.pharmgkb.org/v1/download/file/attachment/CYP2C19.pdf</ext-link></comment>&gt;</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><title>Overview of the <italic toggle="yes">CYP2C</italic> gene locus (a) and <italic toggle="yes">CYP2C:TG</italic> haplotype and its linkage with <italic toggle="yes">CYP2C19</italic> star alleles</title><p id="P37"><bold>(b).</bold> Boxes represent exons and arrows indicate whether the gene is encoded on the positive or negative stand. The size of each gene is provided in kilobase pairs (kb); “CYP2C:TG” haplotype refers to the combination of the following genotypes: T at CYP2C18 c.*31C&gt;T (rs2860840) and G at c.819+2182G&gt;A (rs11188059).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1922281-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><title>Normalized AUC according to <italic toggle="yes">CYP2C19</italic> genotype and including <italic toggle="yes">CYP2C:TG</italic> haplotype information.</title><p id="P38"><italic toggle="yes">CYP2C19*1+TG</italic> refers to <italic toggle="yes">CYP2C19*1</italic> alleles with the <italic toggle="yes">CYP2C:TG</italic> haplotype. <italic toggle="yes">CYP2C:TG</italic> haplotype refers to the combination of T at <italic toggle="yes">CYP2C18</italic> c.*31C&gt;T (rs2860840) and G at c.819+2182G&gt;A (rs11188059). <italic toggle="yes">CYP2C19*1</italic> alleles with <italic toggle="yes">CYP2C18 AT</italic> or <italic toggle="yes">GC</italic> haplotypes are referred as <italic toggle="yes">CYP2C19*1.</italic> Statistical inference values are shown in <xref rid="SD1" ref-type="supplementary-material">Table S5</xref>. Genotypes colored in dark blue correspond to CYP2C19 ultrarapid metabolizers (UMs); light blue denote rapid (RMs), green normal (NMs), yellow intermediate (IMs) and red poor metabolizers (PMs). Points represent real values of nAUC. Box borders and the central line represent quartiles 1, 2 and 3. The whiskers represent the maximum and minimum values outside the q1-q3-range</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1922281-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><title>CYP2C19 protein abundance (pmol/mg microsomal protein) according to <italic toggle="yes">CYP2C19</italic> genotype (a) and <italic toggle="yes">CYP2C19</italic> genotype including <italic toggle="yes">CYP2C:TG</italic> haplotype information (b).</title><p id="P39"><italic toggle="yes">CYP2C19</italic> genotype does not comprise <italic toggle="yes">CYP2C18</italic> variants in panel a); <italic toggle="yes">CYP2C19*1</italic> includes <italic toggle="yes">CYP2C19*1+TG</italic> alleles and <italic toggle="yes">*1</italic> alleles with <italic toggle="yes">CYP2C18 AT</italic> or <italic toggle="yes">GC</italic> haplotypes. In panel b), <italic toggle="yes">CYP2C19*1+TG</italic> refers to <italic toggle="yes">CYP2C19*1</italic> alleles with the <italic toggle="yes">CYP2C:TG</italic> haplotype; <italic toggle="yes">CYP2C:TG</italic> haplotype refers to the combination of T at <italic toggle="yes">CYP2C18</italic> c.*31C&gt;T (rs2860840) and G at c.819+2182G&gt;A (rs11188059); <italic toggle="yes">CYP2C19*1</italic> alleles with <italic toggle="yes">CYP2C18 AT</italic> or <italic toggle="yes">GC</italic> haplotypes are referred as <italic toggle="yes">CYP2C19*1.</italic> Statistical inference values are shown in <xref rid="SD1" ref-type="supplementary-material">Table S7</xref>. Genotypes colored in dark blue correspond to CYP2C19 ultrarapid metabolizers (UMs); light blue denotes rapid (RMs), green normal (NMs), yellow intermediate (IMs) and red poor metabolizers (PMs). Outliers were excluded from the plot according to the Tukey fences technique. Points represent real values of nAUC. Box borders and the central line represent quartiles 1, 2 and 3. The whiskers represent the maximum and minimum values outside the q1-q3-range</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1922281-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4</label><caption><title>CYP2C18 protein abundance (pmol/mg microsomal protein) according to CYP2C19 phenotype.</title><p id="P40"><italic toggle="yes">CYP2C19</italic> genotype does not comprise <italic toggle="yes">CYP2C18</italic> variants. Statistical inference values are shown in <xref rid="SD1" ref-type="supplementary-material">Table S6</xref>. Outliers are excluded from the plot according to the Tukey fences technique. Points represent real values of nAUC. Box borders and the central line represent quartiles 1, 2 and 3. The whiskers represent the maximum and minimum values outside the q1-q3-range</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1922281-f0004.jpg"/></fig><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Study Highlights</title></caption><sec id="S14"><title>What is the current knowledge on the topic?</title><p id="P41">The <italic toggle="yes">“CYP2C:TG”</italic> haplotype was recently identified and related to the ultrarapid metabolism of CYP2C19 substrates. However, the underlying mechanism behind this effect and its clinical relevance remain uncertain.</p></sec><sec id="S15"><title>What question did this study address?</title><p id="P42">We evaluated the impact of the <italic toggle="yes">CYP2C:TG</italic> haplotype on the pharmacokinetic variability of six CYP2C19 substrates (citalopram, sertraline, voriconazole, omeprazole, pantoprazole and rabeprazole), CYP2C18, CYP2C19, CYP2C8 and CYP2C9 protein abundance in human liver samples and CYP2C18/CYP2C19 activity <italic toggle="yes">in vitro.</italic></p></sec><sec id="S16"><title>What does this study add to our knowledge?</title><p id="P43"><italic toggle="yes">CYP2C19</italic> genotype was related to drug exposure <italic toggle="yes">in vivo,</italic> CYP2C19 protein abundance, and activity in human liver tissue. We were unable, however, to confirm an association between the <italic toggle="yes">CYP2C:TG</italic> haplotype (i.e., <italic toggle="yes">CYP2C19*1+TG</italic> alleles) and increased CYP2C19 activity. Increased levels of CYP2C18 protein were detected in liver samples with one or two <italic toggle="yes">CYP2C19*17</italic> alleles, suggesting a possible intricate interplay between CYP2C19 and CYP2C18 expression levels and activity.</p></sec><sec id="S17"><title>How might this change clinical pharmacology or translational science?</title><p id="P44">There is insufficient evidence supporting the clinical relevance of <italic toggle="yes">CYP2C:TG</italic> haplotype and its testing to inform drug therapy. The contribution of variable CYP2C18 expression levels and genetic variation in its gene may not be fully recognized and warrants further investigation.</p></sec></boxed-text></floats-group></article><article article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacokinet</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Clinical Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0312-5963</issn><issn pub-type="epub">1179-1926</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11052790</article-id><article-id pub-id-type="pmcid-ver">PMC11052790.1</article-id><article-id pub-id-type="pmcaid">11052790</article-id><article-id pub-id-type="pmcaiid">11052790</article-id><article-id pub-id-type="pmid">38393578</article-id><article-id pub-id-type="doi">10.1007/s40262-024-01350-x</article-id><article-id pub-id-type="publisher-id">1350</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Rohr</surname><given-names initials="BS">Brit S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0004-8636-7993</contrib-id><name name-style="western"><surname>Krohmer</surname><given-names initials="E">Evelyn</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8583-7181</contrib-id><name name-style="western"><surname>Foerster</surname><given-names initials="KI">Kathrin I.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2190-1698</contrib-id><name name-style="western"><surname>Burhenne</surname><given-names initials="J">Jürgen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5876-7322</contrib-id><name name-style="western"><surname>Schulz</surname><given-names initials="M">Martin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8743-5194</contrib-id><name name-style="western"><surname>Blank</surname><given-names initials="A">Antje</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1783-133X</contrib-id><name name-style="western"><surname>Mikus</surname><given-names initials="G">Gerd</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0672-6876</contrib-id><name name-style="western"><surname>Haefeli</surname><given-names initials="WE">Walter E.</given-names></name><address><email>walter.emil.haefeli@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.5253.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0328 4908</institution-id><institution>Department of Clinical Pharmacology and Pharmacoepidemiology, </institution><institution>University of Heidelberg, Medical Faculty of Heidelberg, Heidelberg University Hospital, </institution></institution-wrap>Im Neuenheimer Feld 410, 69120 Heidelberg, Germany </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/046ak2485</institution-id><institution-id institution-id-type="GRID">grid.14095.39</institution-id><institution-id institution-id-type="ISNI">0000 0000 9116 4836</institution-id><institution>Drug Commission of German Pharmacists and Institute of Pharmacy, </institution><institution>Freie Universität Berlin, </institution></institution-wrap>Berlin, Germany </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>2</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>63</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">461182</issue-id><fpage>469</fpage><lpage>481</lpage><history><date date-type="accepted"><day>29</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>02</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-28 00:25:14.580"><day>28</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2024</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40262_2024_Article_1350.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">We investigated the effect of a 5-day low-dose ritonavir therapy, as it is used in the treatment of COVID-19 with nirmatrelvir/ritonavir, on the pharmacokinetics of three factor Xa inhibitors (FXaI). Concurrently, the time course of the activities of the cytochromes P450 (CYP) 3A4, 2C19, and 2D6 was assessed.</p></sec><sec><title>Methods</title><p id="Par2">In an open-label, fixed sequence clinical trial, the effect and duration of a 5-day oral ritonavir (100 mg twice daily) treatment on the pharmacokinetics of three oral microdosed FXaI (rivaroxaban 25 µg, apixaban 25 µg, and edoxaban 50 µg) and microdosed probe drugs (midazolam 25 µg, yohimbine 50 µg, and omeprazole 100 µg) was evaluated in eight healthy volunteers. The plasma concentrations of all drugs were quantified using validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) methods and pharmacokinetics were analysed using non-compartmental analyses.</p></sec><sec><title>Results</title><p id="Par3">Ritonavir increased the exposure of apixaban, edoxaban, and rivaroxaban, but to a different extent the observed area under the plasma concentration–time curve (geometric mean ratio 1.29, 1.46, and 1.87, respectively). A strong CYP3A4 inhibition (geometric mean ratio &gt; 10), a moderate CYP2C19 induction 2 days after ritonavir (0.64), and no alteration of CYP2D6 were observed. A CYP3A4 recovery half-life of 2.3 days was determined.</p></sec><sec><title>Conclusion</title><p id="Par4">This trial with three microdosed FXaI suggests that at most the rivaroxaban dose should be reduced during short-term ritonavir, and only in patients receiving high maintenance doses. Thorough time series analyses demonstrated differential effects on three different drug-metabolising enzymes over time with immediate profound inhibition of CYP3A4 and only slow recovery after discontinuation.</p></sec><sec><title>Clinical Trial Registration</title><p id="Par5">EudraCT number: 2021-006643-39.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40262-024-01350-x.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010441</institution-id><institution>Medizinischen Fakultät Heidelberg, Universität Heidelberg</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Universitätsklinikum Heidelberg (8914)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer Nature Switzerland AG 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Key Points</title><p id="Par6">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">The effect of short-term low-dose ritonavir on the pharmacokinetics of factor Xa inhibitors (FXaI) is not well studied and the time course of interaction with major cytochrome P450 (CYP) pathways has not been described in detail.</td></tr><tr><td align="left" colspan="1" rowspan="1">We simultaneously quantified the effect of 5 days of ritonavir 100 mg twice daily on three microdosed oral FXaI and concurrently assessed the time course of CYP3A4, CYP2C19, and CYP2D6 activity during ritonavir and for 4 days after discontinuation.</td></tr><tr><td align="left" colspan="1" rowspan="1">Of the three FXaI, only rivaroxaban exposure increased relevantly during ritonavir treatment while apixaban and edoxaban exposures were only mildly increased.</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir inhibited CYP3A4 rapidly and profoundly and the recovery of its activity was delayed. CYP2C19 was mildly and transiently induced at the end of treatment, while CYP2D6 activity was unchanged throughout the observation period.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec2"><title>Introduction</title><p id="Par7">The COVID-19 pandemic affects people worldwide and can lead to hospitalization and death. Nirmatrelvir-ritonavir (Paxlovid<sup>®</sup>) has been available through an Emergency Use Authorization (EUA) since early 2022 and was approved by the US Food and Drug Administration (FDA) in May 2023 for the treatment of mild to moderate COVID-19 in adults at high risk for progression to severe COVID-19 and within 5 days of symptom onset. This therapy consists of a low dose (100 mg) of ritonavir taken orally every 12 h for 5 days, which inhibits the metabolism of nirmatrelvir, reducing its clearance (CL) and increasing its bioavailability [<xref ref-type="bibr" rid="CR1">1</xref>]. This short-term use for only 5 days is new for ritonavir, as ritonavir-boosted treatments for HIV patients are chronic and therefore drug–drug interaction (DDI) studies usually examine the effects of long-term use. Ritonavir is a potent mechanism-based inhibitor of cytochrome P450 (CYP) 3A with inhibitory and time-dependent inductive effects on numerous other CYPs and drug transporters such as p-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion-transporting polypeptides (OATP) [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. Using a 300-mg twice-daily (bid) schedule, potent CYP3A inhibition of ritonavir over time was already demonstrated during 9 days of treatment [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par8">Nirmatrelvir/ritonavir therapy is indicated for patients at high-risk for severe COVID-19 courses, who frequently take other drugs such as factor Xa inhibitors (FXaI). Infection with SARS-CoV-2 seems additionally associated with an increased risk of thrombotic events [<xref ref-type="bibr" rid="CR9">9</xref>]. All three available FXaI are substrates of P-gp and BCRP but their clearance pathways differ, with edoxaban being mostly excreted unchanged [<xref ref-type="bibr" rid="CR10">10</xref>], apixaban being metabolized mainly by CYP3A with a minor contribution from other CYP isozymes [<xref ref-type="bibr" rid="CR11">11</xref>], and rivaroxaban being metabolized mainly by CYP2J2 and CYP3A [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. Therefore, DDIs are known and expected for strong CYP3A and P-gp inhibitors and are associated with increased haemorrhagic risk [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. However, there are limited data on coadministration with ritonavir showing a 2.5-fold exposure increase in rivaroxaban in healthy volunteers after 6 days of high-dose (600 mg bid) ritonavir therapy [<xref ref-type="bibr" rid="CR17">17</xref>], as well as case reports of increased plasma concentrations and/or bleeding risk of FXaI with concomitant ritonavir-boosted therapy [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]. The manufacturer does not recommend the use of nirmatrelvir/ritonavir with rivaroxaban, while there is no statement for apixaban and edoxaban [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par9">Therefore, we aimed to assess the influence of shorter and much lower standard boosting doses of ritonavir, as recommended for COVID-19 treatment (100 mg ritonavir bid for 5 days), on the pharmacokinetics of FXaI to quantify the magnitude of these DDI. We administered FXaI microdoses, which are predictive of their therapeutic doses [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], and evaluated all three FXaI simultaneously.</p><p id="Par10">In the absence of mechanistic studies on the time course of the interaction of short-term ritonavir with other major CYPs, we also examined the effects on CYP2D6 and CYP2C19 activities over time. Therefore, the pharmacokinetics of the established microdosed CYP probe drugs midazolam [<xref ref-type="bibr" rid="CR8">8</xref>], yohimbine [<xref ref-type="bibr" rid="CR27">27</xref>], and omeprazole [<xref ref-type="bibr" rid="CR28">28</xref>] were studied daily during ritonavir intake and for another 4 days after stopping ritonavir.</p></sec><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Trial Design</title><p id="Par11">This phase I trial was conducted as a single-centre, open-label, fixed sequence clinical trial. Ritonavir was administered orally as 100-mg tablets (Norvir<sup>®</sup> 100-mg film-coated tablets, Abbvie, Ludwigshafen, Germany) bid for 5 days. Before ritonavir administration (baseline day) and on the last day of ritonavir intake, the participants received a microdosed cocktail of FXaI (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) consisting of apixaban 25 µg (Eliquis<sup>®</sup>, Bristol-Myers Squibb, Munich, Germany), edoxaban 50 µg (Lixiana<sup>®</sup>, Daiichi Sankyo Europe, Munich, Germany), and rivaroxaban 25 µg (Xarelto<sup>®</sup>, Bayer, Leverkusen, Germany) [<xref ref-type="bibr" rid="CR25">25</xref>]. The oral stock solutions of edoxaban (30 µg/mL), rivaroxaban (25 µg/mL), and apixaban (25 µg/mL) were prepared by the Pharmacy of Heidelberg University Hospital in compliance with GMP guidelines according to the pharmaceutical development protocols approved by the competent authority (BfArM, Bonn, Germany).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Eight healthy volunteers received oral ritonavir 100 mg (blue boxes) twice daily from day 1 to 5. At baseline and on day 5, a microdosed cocktail consisting of apixaban 25 µg, edoxaban 50 µg, and rivaroxaban 25 µg was administered (µFXaI, orange boxes). Additionally, at each visit, a cocktail of CYP probe drugs (green boxes) consisting of midazolam 10 µg (at baseline 30 µg), yohimbine 50 µg, and omeprazole 100 µg together with sodium hydrogen carbonate (50 mL 10 min before and 100 mL simultaneously) was administered. Blood samples (red arrows) for the analyses of FXaI concentration were taken before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 23, and 24 h after drug administration at baseline and on day 5. On other study visits, blood samplings were taken over a period of 4 h (before, 0.5, 1, 1.5, 2, 2.5, 3, and 4 h post dose). Urine was collected for 24 h at baseline and on day 5. <italic toggle="yes">CYP</italic> cytochrome P450, <italic toggle="yes">FXaI</italic> factor Xa inhibitor</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40262_2024_1350_Fig1_HTML.jpg"/></fig></p><p id="Par12">To monitor the different CYP isozyme activities, midazolam (Dormicum<sup>®</sup>; 5 mg/5 mL solutions for infusion; Roche, Grenzach-Wyhlen, Germany; 30 µg at baseline and 10 µg at all other administration times), yohimbine 50 µg (Yohimbinum hydrochloricum D4<sup>®</sup> tablets, DHU-Arzneimittel GmbH, Karlsruhe, Germany), and omeprazole 100 µg (OMEP<sup>®</sup> 40 mg power for solution for infusion; Hexal, Holzkirchen, Germany) were administered as oral solutions together with the FXaI cocktail before ritonavir was initiated, every day with the intake of ritonavir, and 2 and 4 days after stopping ritonavir. To buffer gastric acid and prevent degradation of the uncoated omeprazole, sodium hydrogen carbonate (4.2% w/v) was administered 10 min before (50 mL equivalent to 25 mmol) and simultaneously (100 mL equivalent to 50 mmol) with the 100-µg uncoated omeprazole dose as used previously [<xref ref-type="bibr" rid="CR28">28</xref>]. Microdoses were always prepared immediately before administration and were administered with ritonavir always in the same sequence (first the FXaI, followed by yohimbine, midazolam, and omeprazole) within 1 min.</p></sec><sec id="Sec5"><title>Trial Population</title><p id="Par13">We enrolled volunteers who were in good physical and mental health and had no clinically relevant findings in medical history, physical examination, electrocardiogram, and routine laboratory analyses including renal and liver function. Not enrolled were pregnant or lactating women, participants with known intolerance or contraindication to any component of the trial medication, a history of anaphylactic shock, or participants of an interventional clinical trial within 30 days before inclusion. The use of medicines (except iodine and levothyroxine), cannabis, or citrus fruits (including grapefruit) was not allowed during the trial, and enrolment in the study was allowed at the earliest 5 half-lives (for inhibitors) or 2 weeks (for inductors) after discontinuation of the previously taken medicines. Alcohol and smoking were not allowed on study days. All participants used highly effective contraceptive methods (intrauterine devices, intrauterine hormone-releasing systems, vasectomized partner, or sexual abstinence for female volunteers and condom or sexual abstinence for men) during the trial and for a further 2 weeks after the last medication intake.</p></sec><sec id="Sec6"><title>Trial Conduct</title><p id="Par14">The trial was conducted at the Clinical Research Centre of the Department of Clinical Pharmacology and Pharmacoepidemiology (KliPS), Heidelberg University Hospital, which is certified according to DIN EN ISO 9001:2015. Participants arrived fasting (for at least 8 h) and remained fasting for a further 4 h after taking all microdoses simultaneously. Blood samples for the analyses of FXaI concentration were drawn before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 23, and 24 h after drug administration on the first day (baseline) and at the fifth day of ritonavir intake (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). On days with FXaI intake, the entire 24-h urine was collected. Blood samples for analyses of yohimbine, omeprazole, and ritonavir were taken before and 0.5, 1, 1.5, 2, 2.5, 3, and 4 h on every day of ritonavir intake and on days 2 and 4 after discontinuation of ritonavir. Additional ritonavir plasma samples were taken 6, 8, 23, and 24 h after dosing on baseline and on day 5. Midazolam plasma samples were taken before and 2, 2.5, 3, and 4 h after drug administration on each study day.</p><p id="Par15">All samples were collected in lithium-heparin tubes and centrifuged for 10 min at 20 °C and 2500<italic toggle="yes">g</italic> within 30 min. Urine aliquots and separated plasma aliquots were stored at − 20 °C until analysis.</p></sec><sec id="Sec7"><title>Quantification of Factor Xa Inhibitors and Probe Drugs</title><p id="Par16">The concentrations of FXaI, midazolam, yohimbine, and omeprazole with 5’-hydroxy omeprazole were quantified by ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC–MS/MS) according to published assays [<xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR32">32</xref>] with a lower limit of quantification (LLOQ) of 1 pg/mL for midazolam and yohimbine and 5 pg/mL for omeprazole, 5′-hydroxy omeprazole, and the FXaI. Ritonavir plasma concentrations were quantified by high-performance LC–MS/MS with a LLOQ of 10 ng/mL [<xref ref-type="bibr" rid="CR2">2</xref>]. Urine samples were diluted 1:10 with blank human plasma for analyses of FXaI concentrations [<xref ref-type="bibr" rid="CR33">33</xref>]. Accuracy and precision values were always ≤ ± 15% and all assays complied with the relevant guidelines for the validation of bioanalytical methods of the European Medicines Agency and the US Food and Drug Administration [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="Sec8"><title>Calculations and Statistical Analysis</title><p id="Par17">The sample size was determined using the interaction data from a previous trial (EudraCT 2017-004453) [<xref ref-type="bibr" rid="CR36">36</xref>] investigating the effect of ketoconazole on FXaI, which was assumed to be comparable to ritonavir. A sample size of 3 (apixaban and rivaroxaban) and 5 (edoxaban) was calculated to detect the observed area under the plasma concentration–time curve (AUC) extrapolated to infinity (AUC<sub>inf</sub>) ratio of 1.68 ± 0.36 for apixaban, 2.28 ± 1.10 for edoxaban, and 2.37 ± 0.53 for rivaroxaban with a power of 0.8 and an α error of 5%. Using these data, a two-sided paired t-test with a sample size of <italic toggle="yes">N</italic> = 8 (log-transformed AUC<sub>inf</sub>) would allow to detect a 20% change of exposure (i.e., an AUC<sub>inf</sub> ratio of 1.20) for apixaban, rivaroxaban, and edoxaban with a power of 80% and an α error of 5%.</p><p id="Par18">The standard non-compartmental pharmacokinetic parameters of each FXaI were calculated using Phoenix™ WinNonlin Software 8.3.5 (Certara, Princeton, NJ, USA). The calculated parameters included maximum plasma concentration (<italic toggle="yes">C</italic><sub>max</sub>), time to <italic toggle="yes">C</italic><sub>max</sub> (<italic toggle="yes">t</italic><sub>max</sub>), AUC<sub>inf</sub>, AUC from 0 to 24 h (AUC<sub>0–24</sub>), 0 to 4 h (AUC<sub>0–4</sub>, omeprazole, yohimbine), and 2 to 4 h (AUC<sub>2–4</sub>, midazolam), apparent volume of distribution at steady-state (<italic toggle="yes">V</italic><sub>z</sub>/<italic toggle="yes">F</italic>), apparent oral clearance (CL/<italic toggle="yes">F</italic>), terminal elimination half-life (<italic toggle="yes">t</italic><sub>½</sub>), renal clearance (CL<sub>renal</sub>), expressed as the amount excreted unchanged in urine over 24 h divided by AUC<sub>0–24</sub>, and non-renal clearance (CL<sub>nonrenal</sub>) as the difference between CL/F and renal clearance. The AUC was calculated using a mixed log-linear trapezoidal model.</p><p id="Par19">To determine the effect of ritonavir on CYP3A activity, the estimated midazolam partial metabolic clearance (eCL<sub>met</sub>) was calculated using the data of a limited sampling methodology [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Due to the prolonged midazolam elimination half-life with coadministration of ritonavir, midazolam concentrations above the LLOQ were observed in predose samples from the second day of ritonavir intake until 4 days after ritonavir discontinuation, which was taken into account as follows: the residual AUC was calculated using the predose concentration and the current half-life in the interval 2–4 h of the individual visit and then subtracted accordingly. The CYP3A4 recovery half-life was calculated as described previously [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par20">The effect of ritonavir on CYP2C19 and CYP2D6 activity was determined using AUC<sub>0–4</sub> and <italic toggle="yes">C</italic><sub>max</sub> of yohimbine and omeprazole. The exposure of ritonavir was determined using AUC<sub>0–4</sub> after dose 1, 3, 5, 7, and 9, and after discontinuation.</p><p id="Par21">Data are reported as geometric means with 95% confidence intervals (CIs) except <italic toggle="yes">t</italic><sub>max</sub>, which is reported as median with range. To test for differences of each FXaI separately between baseline and ritonavir, the geometric mean ratios (GMRs) and their 90% CIs were calculated. The default no-effect boundary of point estimates is 0.8–1.25 and when 90% CIs for systemic exposure (AUC) ratios are entirely within the equivalence range of 0.85–1.25, according to the standard practice of the FDA, it is concluded that no clinically relevant interaction is present. For other FXaI PK parameters, a ratio paired <italic toggle="yes">t</italic>-test (two-tailed) was performed to compare day 5 of ritonavir intake with baseline.</p><p id="Par22">To account for the multiple occasions of assessing midazolam, yohimbine, and omeprazole exposure, repeated-measure one-way ANOVA of logarithmic transformed data with correction for multiple testing (Dunnett’s multiple comparisons test) was performed to test for differences to baseline.</p><p id="Par23">All statistics were performed with Prism 9.0.0 (GraphPad Software, La Jolla, CA, USA). A <italic toggle="yes">p</italic> value &lt;0.05 was considered significant.</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par24">Nine healthy volunteers were included in the study. One participant dropped out on the last day of ritonavir intake due to an unrelated COVID-19 infection. Therefore, eight participants (7 females) with a median age of 25.5 years (range 21–58) and a body mass index of 24.2 kg/m<sup>2</sup> (range 18.0–28.1) completed the study.</p><sec id="Sec10"><title>Factor Xa Inhibitors</title><p id="Par25">Over the observation period, all plasma concentrations were above the LLOQ, except for the 23- and 24-h edoxaban concentrations in two and the 24-h edoxaban concentration in three participants. The 24-h urine collection from one participant was excluded from analyses due to suspected incomplete urine collection on day 5.</p><p id="Par26">Coadministration of ritonavir 100 mg bid for 5 days increased plasma concentrations of all three FXaI (Fig. <xref rid="Fig2" ref-type="fig">2</xref>; Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). The individual increase in AUC<sub>0–24</sub> for apixaban and edoxaban was heterogeneous: three participants had an AUC<sub>0–24</sub> ratio of 0.8–1.2 versus two and three participants, respectively, with AUC<sub>0–24</sub> increases of 2–2.3 (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). The largest and consistent change was observed for rivaroxaban. A slightly but significantly prolonged <italic toggle="yes">t</italic><sub>½</sub> (from 5.14 h to 6.57 h) and a significantly reduced CL<sub>renal</sub> (from 49.4 to 34.8 mL/min) were observed for rivaroxaban but not for the other two FXaI. The volume of distribution was significantly reduced for edoxaban and rivaroxaban but not for apixaban.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Geometric mean plasma concentration–time curves (± 95% confidence intervals) after oral administration of apixaban 25 µg, edoxaban 50 µg, and rivaroxaban 25 µg alone (baseline; red symbols and line) and at day 5 of ritonavir therapy (blue symbols and line) in 8 healthy volunteers. <italic toggle="yes">bid</italic> twice daily</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40262_2024_1350_Fig2_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Pharmacokinetic parameters of apixaban, rivaroxaban (both 25 µg), and edoxaban (50 µg) after a single oral dose before ritonavir and on the fifth day of ritonavir (100 mg bid) in 8 healthy volunteers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Apixaban</th><th align="left" colspan="2" rowspan="1">Edoxaban</th><th align="left" colspan="2" rowspan="1">Rivaroxaban</th></tr><tr><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">Ritonavir day 5</th><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">Ritonavir day 5</th><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">Ritonavir day 5</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1"><italic toggle="yes">C</italic><sub>max</sub> [pg/mL]</td><td align="left" colspan="1" rowspan="1">671</td><td align="left" colspan="1" rowspan="1">906</td><td align="left" colspan="1" rowspan="1">125</td><td align="left" colspan="1" rowspan="1">212*</td><td align="left" colspan="1" rowspan="1">891</td><td align="left" colspan="1" rowspan="1">1130*</td></tr><tr><td align="left" colspan="1" rowspan="1">556–810</td><td align="left" colspan="1" rowspan="1">747–1099</td><td align="left" colspan="1" rowspan="1">111–140</td><td align="left" colspan="1" rowspan="1">167–269</td><td align="left" colspan="1" rowspan="1">727–1093</td><td align="left" colspan="1" rowspan="1">916–1395</td></tr><tr><td align="left" rowspan="2" colspan="1"><italic toggle="yes">t</italic><sub>max</sub><sup>a</sup> [min]</td><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">60</td></tr><tr><td align="left" colspan="1" rowspan="1">60–240</td><td align="left" colspan="1" rowspan="1">30–150</td><td align="left" colspan="1" rowspan="1">30–240</td><td align="left" colspan="1" rowspan="1">30–150</td><td align="left" colspan="1" rowspan="1">30–60</td><td align="left" colspan="1" rowspan="1">30–120</td></tr><tr><td align="left" rowspan="2" colspan="1">AUC<sub>0–24</sub> [pg/mL⋅h]</td><td align="left" colspan="1" rowspan="1">6230</td><td align="left" colspan="1" rowspan="1">8074</td><td align="left" colspan="1" rowspan="1">1028</td><td align="left" colspan="1" rowspan="1">1522*</td><td align="left" colspan="1" rowspan="1">3574</td><td align="left" colspan="1" rowspan="1">6700*</td></tr><tr><td align="left" colspan="1" rowspan="1">5360–7241</td><td align="left" colspan="1" rowspan="1">6592–9889</td><td align="left" colspan="1" rowspan="1">809.3–1305</td><td align="left" colspan="1" rowspan="1">1269–1826</td><td align="left" colspan="1" rowspan="1">2835–4506</td><td align="left" colspan="1" rowspan="1">4848–9258</td></tr><tr><td align="left" rowspan="2" colspan="1">CL/<italic toggle="yes">F</italic> [mL/min]</td><td align="left" colspan="1" rowspan="1">66.9</td><td align="left" colspan="1" rowspan="1">51.6</td><td align="left" colspan="1" rowspan="1">811</td><td align="left" colspan="1" rowspan="1">548*</td><td align="left" colspan="1" rowspan="1">117</td><td align="left" colspan="1" rowspan="1">62.2*</td></tr><tr><td align="left" colspan="1" rowspan="1">57.5–77.7</td><td align="left" colspan="1" rowspan="1">42.13–63.1</td><td align="left" colspan="1" rowspan="1">639–1030</td><td align="left" colspan="1" rowspan="1">456–657</td><td align="left" colspan="1" rowspan="1">92.5–147</td><td align="left" colspan="1" rowspan="1">45.1–85.9</td></tr><tr><td align="left" rowspan="2" colspan="1">CL<sub>renal</sub><sup>b</sup> [mL/min]</td><td align="left" colspan="1" rowspan="1">13.1</td><td align="left" colspan="1" rowspan="1">11.6</td><td align="left" colspan="1" rowspan="1">165</td><td align="left" colspan="1" rowspan="1">143</td><td align="left" colspan="1" rowspan="1">49.4</td><td align="left" colspan="1" rowspan="1">34.8*</td></tr><tr><td align="left" colspan="1" rowspan="1">10.3–16.7</td><td align="left" colspan="1" rowspan="1">9.27–14.4</td><td align="left" colspan="1" rowspan="1">141–193</td><td align="left" colspan="1" rowspan="1">116–177</td><td align="left" colspan="1" rowspan="1">36.2–67.4</td><td align="left" colspan="1" rowspan="1">23.7–51.3</td></tr><tr><td align="left" rowspan="2" colspan="1">CL<sub>nonrenal</sub><sup>b</sup> [mL/min]</td><td align="left" colspan="1" rowspan="1">53.9</td><td align="left" colspan="1" rowspan="1">40.7</td><td align="left" colspan="1" rowspan="1">629</td><td align="left" colspan="1" rowspan="1">407*</td><td align="left" colspan="1" rowspan="1">70.4</td><td align="left" colspan="1" rowspan="1">30.9*</td></tr><tr><td align="left" colspan="1" rowspan="1">42.7–68.1</td><td align="left" colspan="1" rowspan="1">30.4–54.6</td><td align="left" colspan="1" rowspan="1">453–873</td><td align="left" colspan="1" rowspan="1">453–873</td><td align="left" colspan="1" rowspan="1">54.5–90.9</td><td align="left" colspan="1" rowspan="1">21.4–44.0</td></tr><tr><td align="left" rowspan="2" colspan="1">Ae<sup>b</sup> [% of dose]</td><td align="left" colspan="1" rowspan="1">17.7</td><td align="left" colspan="1" rowspan="1">16.5</td><td align="left" colspan="1" rowspan="1">19.6</td><td align="left" colspan="1" rowspan="1">24.8</td><td align="left" colspan="1" rowspan="1">40.0</td><td align="left" colspan="1" rowspan="1">48.8</td></tr><tr><td align="left" colspan="1" rowspan="1">12.7–24.6</td><td align="left" colspan="1" rowspan="1">10.52–26.0</td><td align="left" colspan="1" rowspan="1">14.9–25.7</td><td align="left" colspan="1" rowspan="1">19.8–31.1</td><td align="left" colspan="1" rowspan="1">35.3–45.2</td><td align="left" colspan="1" rowspan="1">40.3–59.2</td></tr><tr><td align="left" rowspan="2" colspan="1"><italic toggle="yes">V</italic><sub>z</sub>/<italic toggle="yes">F</italic> [L]</td><td align="left" colspan="1" rowspan="1">38.5</td><td align="left" colspan="1" rowspan="1">30.2</td><td align="left" colspan="1" rowspan="1">368</td><td align="left" colspan="1" rowspan="1">248*</td><td align="left" colspan="1" rowspan="1">51.9</td><td align="left" colspan="1" rowspan="1">35.4*</td></tr><tr><td align="left" colspan="1" rowspan="1">30.6–48.4</td><td align="left" colspan="1" rowspan="1">27.6–33.0</td><td align="left" colspan="1" rowspan="1">300–450</td><td align="left" colspan="1" rowspan="1">205–299</td><td align="left" colspan="1" rowspan="1">39.2–68.6</td><td align="left" colspan="1" rowspan="1">27.2–46.0</td></tr><tr><td align="left" rowspan="2" colspan="1"><italic toggle="yes">t</italic><sub>½</sub> [h]</td><td align="left" colspan="1" rowspan="1">6.65</td><td align="left" colspan="1" rowspan="1">6.76</td><td align="left" colspan="1" rowspan="1">5.24</td><td align="left" colspan="1" rowspan="1">5.23</td><td align="left" colspan="1" rowspan="1">5.14</td><td align="left" colspan="1" rowspan="1">6.57*</td></tr><tr><td align="left" colspan="1" rowspan="1">5.33–8.30</td><td align="left" colspan="1" rowspan="1">5.64–8.10</td><td align="left" colspan="1" rowspan="1">3.76–7.30</td><td align="left" colspan="1" rowspan="1">4.44–6.15</td><td align="left" colspan="1" rowspan="1">4.47–5.91</td><td align="left" colspan="1" rowspan="1">5.02–8.61</td></tr></tbody></table><table-wrap-foot><p>Data are expressed as geometric mean and 95% confidence interval, except <sup>a</sup>median and range; <sup>b</sup><italic toggle="yes">n</italic> = 7</p><p><italic toggle="yes">Ae</italic> amount excreted in urine as parent drug, <italic toggle="yes">AUC</italic><sub><italic toggle="yes">0–24</italic></sub> area under the concentration–time curve from 0 to 24 h, <italic toggle="yes">CL/F</italic> apparent oral clearance, <italic toggle="yes">CL</italic><sub><italic toggle="yes">nonrenal</italic></sub> non-renal clearance, <italic toggle="yes">CL</italic><sub><italic toggle="yes">renal</italic></sub> renal clearance, <italic toggle="yes">C</italic><sub><italic toggle="yes">max</italic></sub> peak concentration, <italic toggle="yes">t</italic><sub><italic toggle="yes">max</italic></sub> time to C<sub>max</sub>, <italic toggle="yes">t</italic><sub><italic toggle="yes">½</italic></sub> terminal elimination half-life, <italic toggle="yes">V</italic><sub><italic toggle="yes">z</italic></sub><italic toggle="yes">/F</italic> apparent volume of distribution</p><p>*<italic toggle="yes">p</italic> &lt; 0.05 vs baseline</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Geometric mean ratios (GMR) of apixaban, rivaroxaban (both 25 µg), and edoxaban (50 µg) as single oral doses before ritonavir and on the fifth day of ritonavir (100 mg bid) in 8 healthy volunteers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Apixaban</th><th align="left" colspan="2" rowspan="1">Edoxaban</th><th align="left" colspan="2" rowspan="1">Rivaroxaban</th></tr><tr><th align="left" colspan="1" rowspan="1">GMR</th><th align="left" colspan="1" rowspan="1">90% confidence interval</th><th align="left" colspan="1" rowspan="1">GMR</th><th align="left" colspan="1" rowspan="1">90% confidence interval</th><th align="left" colspan="1" rowspan="1">GMR</th><th align="left" colspan="1" rowspan="1">90% confidence interval</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0–24</sub></td><td char="." align="char" colspan="1" rowspan="1">1.29</td><td char="–" align="char" colspan="1" rowspan="1">1.04–1.61</td><td char="." align="char" colspan="1" rowspan="1">1.46*</td><td char="–" align="char" colspan="1" rowspan="1">1.23–1.73</td><td char="." align="char" colspan="1" rowspan="1">1.87*</td><td char="–" align="char" colspan="1" rowspan="1">1.54–2.28</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">C</italic><sub>max</sub></td><td char="." align="char" colspan="1" rowspan="1">1.35</td><td char="–" align="char" colspan="1" rowspan="1">1.05–1.74</td><td char="." align="char" colspan="1" rowspan="1">1.69*</td><td char="–" align="char" colspan="1" rowspan="1">1.34–2.14</td><td char="." align="char" colspan="1" rowspan="1">1.27*</td><td char="–" align="char" colspan="1" rowspan="1">1.11–1.45</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">AUC</italic><sub><italic toggle="yes">0–24h</italic></sub> area under the concentration–time curve from 0 to 24 h, <italic toggle="yes">C</italic><sub><italic toggle="yes">max</italic></sub> peak concentration</p></table-wrap-foot></table-wrap><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Individual AUC<sub>0–24</sub> changes of apixaban, edoxaban, and rivaroxaban and geometric population mean (with 95% confidence interval) of 8 healthy volunteers after oral administration of apixaban 25 µg, edoxaban 50 µg, and rivaroxaban 25 µg alone and during low-dose ritonavir for 5 days. <italic toggle="yes">AUC</italic><sub><italic toggle="yes">0–24</italic></sub> area under the plasma concentration–time curve from 0 to 24 h</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="40262_2024_1350_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>CYP Probe Drugs</title><sec id="Sec12"><title>Midazolam</title><p id="Par27">Ritonavir profoundly reduced the CL<sub>met</sub> of midazolam (Table <xref rid="Tab3" ref-type="table">3</xref>) and already after the first intake of ritonavir 100 mg, midazolam AUC<sub>2–4</sub> increased 5.1-fold. From day 2 to day 5 of ritonavir treatment, the AUC<sub>2–4</sub> of midazolam continued to increase to 11.1–15.5 times baseline values and recovered only slowly after ritonavir discontinuation, with AUC<sub>2–4</sub> values still 10.2-fold and 2.9-fold higher 2 and 4 days after ritonavir discontinuation, respectively (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). The estimated CYP3A4 recovery half-life was 2.30 ± 0.89 days.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Pharmacokinetics of midazolam, yohimbine, and omeprazole before, during, and after treatment with ritonavir 100 mg bid in 8 healthy volunteers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="1" rowspan="1">Before ritonavir</th><th align="left" colspan="5" rowspan="1">Oral ritonavir 100 mg bid</th><th align="left" colspan="2" rowspan="1">After ritonavir</th></tr><tr><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">Day 1</th><th align="left" colspan="1" rowspan="1">Day 2</th><th align="left" colspan="1" rowspan="1">Day 3</th><th align="left" colspan="1" rowspan="1">Day 4</th><th align="left" colspan="1" rowspan="1">Day 5</th><th align="left" colspan="1" rowspan="1">Day 7</th><th align="left" colspan="1" rowspan="1">Day 9</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1"><bold>Midazolam</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>2–4</sub> [pg/mL⋅h]</td><td align="left" colspan="1" rowspan="1"><p>14.3</p><p>10.2–20.0</p></td><td align="left" colspan="1" rowspan="1"><p>72.9*</p><p>46.9–114</p></td><td align="left" colspan="1" rowspan="1"><p>222*</p><p>192–256</p></td><td align="left" colspan="1" rowspan="1"><p>211*</p><p>175–256</p></td><td align="left" colspan="1" rowspan="1"><p>187*</p><p>159–221</p></td><td align="left" colspan="1" rowspan="1"><p>158*</p><p>130–192</p></td><td align="left" colspan="1" rowspan="1"><p>147*</p><p>121–178</p></td><td align="left" colspan="1" rowspan="1"><p>41.7*</p><p>28.3–61.3</p></td></tr><tr><td align="left" colspan="1" rowspan="1">GMR AUC<sub>2–4</sub></td><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1"><p>5.10</p><p>3.76–6.92</p></td><td align="left" colspan="1" rowspan="1"><p>15.5</p><p>11.2–21.4</p></td><td align="left" colspan="1" rowspan="1"><p>14.8</p><p>10.5–20.8</p></td><td align="left" colspan="1" rowspan="1"><p>13.1</p><p>9.30–18.4</p></td><td align="left" colspan="1" rowspan="1"><p>11.1</p><p>7.72–15.8</p></td><td align="left" colspan="1" rowspan="1"><p>10.2</p><p>7.60–13.8</p></td><td align="left" colspan="1" rowspan="1"><p>2.91</p><p>1.99–4.27</p></td></tr><tr><td align="left" colspan="1" rowspan="1">eCL<sub>met</sub> [mL/min]</td><td align="left" colspan="1" rowspan="1"><p>1291</p><p>923–1805</p></td><td align="left" colspan="1" rowspan="1"><p>253*</p><p>163–394</p></td><td align="left" colspan="1" rowspan="1"><p>83.3*</p><p>72.3–96.0</p></td><td align="left" colspan="1" rowspan="1"><p>87.4*</p><p>72.2–106</p></td><td align="left" colspan="1" rowspan="1"><p>98.5*</p><p>83.4–116</p></td><td align="left" colspan="1" rowspan="1"><p>117*</p><p>96.1–142</p></td><td align="left" colspan="1" rowspan="1"><p>126*</p><p>104–153</p></td><td align="left" colspan="1" rowspan="1"><p>443*</p><p>301–653</p></td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Omeprazole</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0–4</sub> [pg/mL⋅h]</td><td align="left" colspan="1" rowspan="1"><p>1942</p><p>1242–3037</p></td><td align="left" colspan="1" rowspan="1"><p>2053</p><p>1302–3236</p></td><td align="left" colspan="1" rowspan="1"><p>2389</p><p>1456–3921</p></td><td align="left" colspan="1" rowspan="1"><p>1909</p><p>1116–3266</p></td><td align="left" colspan="1" rowspan="1"><p>1603</p><p>864–2973</p></td><td align="left" colspan="1" rowspan="1"><p>1583</p><p>951–2636</p></td><td align="left" colspan="1" rowspan="1"><p>1234*</p><p>753–2021</p></td><td align="left" colspan="1" rowspan="1"><p>1287</p><p>748–2214</p></td></tr><tr><td align="left" colspan="1" rowspan="1">GMR AUC<sub>0–4</sub></td><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1"><p>1.06</p><p>0.87–1.29</p></td><td align="left" colspan="1" rowspan="1"><p>1.23</p><p>1.02–1.49</p></td><td align="left" colspan="1" rowspan="1"><p>0.98</p><p>0.76–1.28</p></td><td align="left" colspan="1" rowspan="1"><p>0.83</p><p>0.60–1.13</p></td><td align="left" colspan="1" rowspan="1"><p>0.82</p><p>0.65–1.02</p></td><td align="left" colspan="1" rowspan="1"><p>0.64</p><p>0.51–0.79</p></td><td align="left" colspan="1" rowspan="1"><p>0.66</p><p>0.51–0.86</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Molar AUC ratio [% of 5-OH-omeprazole]</td><td align="left" colspan="1" rowspan="1"><p>121</p><p>82.2–179</p></td><td align="left" colspan="1" rowspan="1"><p>122</p><p>78.2–189</p></td><td align="left" colspan="1" rowspan="1"><p>120</p><p>76.7–187</p></td><td align="left" colspan="1" rowspan="1"><p>101</p><p>61.2–166</p></td><td align="left" colspan="1" rowspan="1"><p>90.3*</p><p>55.7–147</p></td><td align="left" colspan="1" rowspan="1"><p>82.3*</p><p>52.6–129</p></td><td align="left" colspan="1" rowspan="1"><p>72.0*</p><p>45.3–115</p></td><td align="left" colspan="1" rowspan="1"><p>83.6*</p><p>53.0–132</p></td></tr><tr><td align="left" colspan="9" rowspan="1"><bold>Yohimbine</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">AUC<sub>0–4</sub> [pg/mL⋅h]</td><td align="left" colspan="1" rowspan="1"><p>135</p><p>61.4–295</p></td><td align="left" colspan="1" rowspan="1"><p>162</p><p>71.9–366</p></td><td align="left" colspan="1" rowspan="1"><p>165</p><p>66.3–412</p></td><td align="left" colspan="1" rowspan="1"><p>212</p><p>92.8–484</p></td><td align="left" colspan="1" rowspan="1"><p>200</p><p>83.8–478</p></td><td align="left" colspan="1" rowspan="1"><p>201</p><p>83.4–485</p></td><td align="left" colspan="1" rowspan="1"><p>165</p><p>74.1–367</p></td><td align="left" colspan="1" rowspan="1"><p>175</p><p>74.5–413</p></td></tr><tr><td align="left" colspan="1" rowspan="1">GMR AUC<sub>0–4</sub></td><td align="left" colspan="1" rowspan="1">–</td><td align="left" colspan="1" rowspan="1"><p>1.20</p><p>0.88–1.66</p></td><td align="left" colspan="1" rowspan="1"><p>1.23</p><p>0.90–1.68</p></td><td align="left" colspan="1" rowspan="1"><p>1.57</p><p>1.20–2.07</p></td><td align="left" colspan="1" rowspan="1"><p>1.49</p><p>1.13–1.96</p></td><td align="left" colspan="1" rowspan="1"><p>1.49</p><p>1.12–1.99</p></td><td align="left" colspan="1" rowspan="1"><p>1.22</p><p>0.94–1.59</p></td><td align="left" colspan="1" rowspan="1"><p>1.3</p><p>0.90–1.89</p></td></tr></tbody></table><table-wrap-foot><p>Data are expressed as geometric mean values with 95% confidence intervals and, in case of GMR, with 90% confidence intervals. Molar AUC ratio: the molar AUC ratio of omeprazole is expressed as a percentage of 5-OH-omeprazole; it is calculated as the AUC<sub>0–4</sub> of omeprazole (nmol/L⋅h) divided by the AUC<sub>0–4</sub> of 5-hydroxy omeprazole (nmol/L⋅h) and multiplied by 100</p><p><italic toggle="yes">AUC</italic><sub><italic toggle="yes">0–4</italic></sub> area under the concentration–time curve from 0 to 4 h, <italic toggle="yes">AUC</italic><sub><italic toggle="yes">2–4</italic></sub> area under the concentration–time curve from 2 to 4 h, <italic toggle="yes">eCL</italic><sub><italic toggle="yes">met</italic></sub> estimated midazolam partial metabolic clearance, <italic toggle="yes">GMR</italic> geometric mean ratio.</p><p>*<italic toggle="yes">p</italic> &lt; 0.05 vs baseline</p></table-wrap-foot></table-wrap><fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Time course of the estimated geometric mean metabolic clearance (CL<sub>met</sub>, with 95% confidence interval) of midazolam in 8 healthy volunteers before (baseline) and during ritonavir therapy (100 mg twice daily, days 1–5; light blue box) as well as 2 and 4 days after ritonavir discontinuation (day 7 and 9, respectively)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="40262_2024_1350_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Omeprazole and Yohimbine</title><p id="Par28">The baseline pharmacokinetics of yohimbine and omeprazole are shown in Table <xref rid="Tab3" ref-type="table">3</xref>. During ritonavir, omeprazole pharmacokinetics were unchanged but after ritonavir discontinuation, the AUC<sub>0–4</sub> was decreased by approximately 35% and the AUC<sub>0–4</sub> ratio also decreased (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). The molar AUC<sub>0–4</sub> ratio of omeprazole and 5-OH-omeprazole decreased from baseline during ritonavir treatment and was significantly reduced on days 4 and 5 (32%), and remained significantly reduced afterwards (Table <xref rid="Tab3" ref-type="table">3</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Geometric means of the omeprazole AUC<sub>0–4</sub> and 5-OH-omeprazole AUC<sub>0–4</sub> of a 100-µg omeprazole dose (with 95% confidence intervals) before (baseline) and during ritonavir (100 mg bid) for 5 days (light blue box), as well as 2 and 4 days after ritonavir discontinuation (day 7 and 9, respectively). ns: <italic toggle="yes">p</italic> &gt; 0.05. <italic toggle="yes">AUC</italic><sub><italic toggle="yes">0–4</italic></sub> area under the concentration–time curve from 0 to 4 h, <italic toggle="yes">bid</italic> twice daily</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="40262_2024_1350_Fig5_HTML.jpg"/></fig></p><p id="Par29">Ritonavir gradually, but not significantly, increased yohimbine AUC<sub>0–4</sub> to a GMR of approximately 1.5; this effect was short-lived and 2 days after ritonavir discontinuation, CYP2D6 activity had returned to baseline activity (Table <xref rid="Tab3" ref-type="table">3</xref>; Fig. <xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Geometric means of AUC<sub>0–4</sub> of a 50-µg yohimbine dose (with 95% confidence intervals) before (baseline) and during ritonavir (100 mg bid) for 5 days (light blue box), as well as 2 and 4 days after ritonavir discontinuation (day 7 and 9, respectively). ns: <italic toggle="yes">p</italic> &gt; 0.05. <italic toggle="yes">AUC</italic><sub><italic toggle="yes">0–4</italic></sub> area under the concentration–time curve from 0 to 4 h, <italic toggle="yes">bid</italic> twice daily</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="40262_2024_1350_Fig6_HTML.jpg"/></fig></p></sec></sec><sec id="Sec14"><title>Ritonavir</title><p id="Par30">The AUC<sub>0–4</sub> of ritonavir was 906 ng/mL⋅h (95% CI 543–1512) and <italic toggle="yes">C</italic><sub>max</sub> was 373 ng/mL (95% CI 244–572) after intake of the first dose. Exposure and <italic toggle="yes">C</italic><sub>max</sub> were similar on the remaining 4 days, ranging between 4593–5331 ng/mL⋅h and 1776–2107 ng/mL, respectively (Fig. <xref rid="Fig7" ref-type="fig">7</xref>). Two days after the last ritonavir dose, concentrations were close to or below the LLOQ.<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Ritonavir plasma concentration–time curves during 5 days of ritonavir therapy (100 mg twice daily; light blue box) and 2 days after discontinuation (day 7) in 8 healthy volunteers. <italic toggle="yes">LLOQ</italic> lower limit of quantification</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="40262_2024_1350_Fig7_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>Safety Data</title><p id="Par31">Overall, the study medication was well tolerated. Twenty adverse events (5 considered related to study drug) were observed in six participants with most adverse events occurring on baseline day, that is, before ritonavir administration (Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>, see electronic supplementary material [ESM]), and all were transient. One adverse event (presyncope) was moderate and one (syncope) was severe and both occurred as an immediate consequence of unsuccessful venepunctures; all other adverse events were mild. The most common adverse event was headache on the first study day without ritonavir therapy (5 out of 8 participants affected). A relationship was considered unlikely, as only microdosed substances were administered on this day and headaches only occurred in one participant after repeated administration on the fifth day of ritonavir intake.</p></sec></sec><sec id="Sec16"><title>Discussion</title><sec id="Sec17"><title>Interaction of Low-Dose Ritonavir With Factor Xa Inhibitors</title><p id="Par32">Treatment with ritonavir 100 mg bid for 5 days increased the AUC<sub>0–24</sub> of all currently marketed FXaI but with different magnitude and likely little clinical relevance in the absence of other clearance impairment (e.g., renal dysfunction) [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR42">42</xref>]. The largest increase was observed with rivaroxaban but this change was below the order of magnitude that usually prompts dose reductions (factor 2). Unless very high doses are administered, as required in the initial treatment of major embolic events [<xref ref-type="bibr" rid="CR43">43</xref>], dose reductions should be individually planned and it should also be considered that COVID-19 can trigger a prothrombotic state and at least prophylactic anticoagulation is generally recommended [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par33">The differences in the magnitude of interaction between the different FXaI are not fully elucidated. They are certainly influenced by the different effects of ritonavir on the diverse clearance mechanisms involved, and similar differences have also been observed in a series of patients receiving these FXaI together with protease inhibitors boosted with ritonavir 100 mg bid [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]. In these earlier case series and in our study, the interaction was most pronounced with rivaroxaban, the FXaI with the largest bioavailability (and complete bioavailability at low doses [<xref ref-type="bibr" rid="CR45">45</xref>]), indicating that the exposure change was not caused by a change in bioavailability but rather a reduction of systemic drug clearance, which is also reflected in a prolongation of the elimination <italic toggle="yes">t</italic><sub>½</sub>. Other than with other FXaI, these clearance changes were partly due to reduced renal excretion, likely reflecting combined inhibition of efflux transporters (P-gp and BCRP) and of the organic anion transporter 3 (OAT3, SLC22A8), which plays a major role in the renal elimination of rivaroxaban [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. In our study with low ritonavir doses, the effect was smaller than the interaction observed with very high doses of ritonavir (600 mg bid), where a 2.5-fold increase in AUC and an even more extensive reduction of CL<sub>renal</sub> were observed [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. These data therefore suggest that boosting doses of ritonavir do not completely inhibit renal efflux transporters while they are likely high enough to inhibit CYP3A4 (and possibly CYP2J2 [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]) as efficiently as higher doses [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par34">In contrast, there was only a minor DDI with apixaban, which is in agreement with the minimal interaction with potent CYP3A inhibitors such as voriconazole [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] and the limited suspected contribution of efflux transporters [<xref ref-type="bibr" rid="CR49">49</xref>] or OAT3 [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par35">Ritonavir also increased edoxaban exposure but, in contrast to rivaroxaban, CL<sub>renal</sub> and <italic toggle="yes">t</italic><sub>½</sub> were not altered, suggesting an increase in bioavailability as a result of intestinal inhibition of efflux transporters. This is consistent with other DDI studies and physiology-based pharmacokinetic modelling, which suggested a role of intestinal P-gp (and possibly BCRP) in edoxaban bioavailability [<xref ref-type="bibr" rid="CR50">50</xref>–<xref ref-type="bibr" rid="CR52">52</xref>]. It also agrees well with the effect size observed with the P-gp substrate dabigatran etexilate when it was administered with the same dose of ritonavir [<xref ref-type="bibr" rid="CR53">53</xref>]. In addition, ritonavir also inhibits carboxylesterase 1 (CES1) in vitro [<xref ref-type="bibr" rid="CR54">54</xref>], suggesting that concurrent inhibition of this minor pathway [<xref ref-type="bibr" rid="CR10">10</xref>] could additionally be involved. The different influence of ritonavir on the urinary excretion of FXaI could be due to the fact that edoxaban and apixaban are not substrates of OAT3 and therefore the activity of the downstream renal P-gp is less important for their urinary excretion [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p></sec><sec id="Sec18"><title>CYP Probe Drugs</title><p id="Par36">Our trial generated activity data of relevant drug metabolising CYPs over the time course of ritonavir treatment (5 days) and after its discontinuation. As expected [<xref ref-type="bibr" rid="CR2">2</xref>], already after the first ritonavir dose, the CYP3A4 clearance profoundly decreased, indicating strong inhibition. This is in line with the dose–CYP3A4 inhibition relationship established in vivo, which estimated that the ritonavir dose inhibiting CYP3A4 by 50% (ED<sub>50</sub>) was very low (3.4 mg) [<xref ref-type="bibr" rid="CR2">2</xref>]. After ritonavir discontinuation, the CYP3A activity recovered slowly with a half-life of 2.3 days. On day 4 after ritonavir discontinuation, CYP3A activity was still reduced while no ritonavir was detectable in plasma, which suggests prolonged mechanism-based inactivation of CYP3A4. Based on these data, the full recovery of CYP3A4 activity is estimated to take 10–12 days after a 5-day treatment course with ritonavir 100 mg bid.</p><p id="Par37">Regarding the effect of ritonavir on CYP2D6 activity, no significant changes of the probe drug yohimbine were observed. In contrast, using desipramine as an index substrate for CYP2D6, ritonavir (100 mg bid) caused a modest inhibitory effect on CYP2D6 activity in extensive metabolizers [<xref ref-type="bibr" rid="CR55">55</xref>]. However, the dextromethorphan/dextrorphan metabolic ratio as another indicator for CYP2D6 activity was not altered. Thus, these findings with microdosed yohimbine as a sensitive CYP2D6 probe drug [<xref ref-type="bibr" rid="CR27">27</xref>] confirm that no clinically relevant alteration of CYP2D6 enzyme activity during the course of a 5-day treatment with ritonavir 100 mg bid occurs.</p><p id="Par38">Ritonavir had a small induction effect on CYP2C19 activity leading to slightly decreased omeprazole exposure on day 5 of ritonavir treatment, which was also reflected in corresponding changes in the molar AUC ratio of omeprazole and 5-hydroxy omeprazole. This inducing effect is time-dependent as it is more pronounced after a 10-day ritonavir (100 mg bid) treatment [<xref ref-type="bibr" rid="CR56">56</xref>]. CYP2C19 induction is also dose-dependent as reported with other CYP2C19 substrates; as an example, after 20 days of ritonavir (100 mg bid) treatment, voriconazole exposure was decreased by 33% [<xref ref-type="bibr" rid="CR57">57</xref>] or 39% [<xref ref-type="bibr" rid="CR58">58</xref>], which is only a small effect, probably attenuated by the autoinhibition of voriconazole [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. However, higher doses of ritonavir 400 mg bid for 20 days decreased voriconazole AUC by 83% [<xref ref-type="bibr" rid="CR58">58</xref>]. Although short-term ritonavir treatment with low doses induces CYP2C19 activity, this effect is short lasting and likely does not require any dose adaptation of CYP2C19 substrates.</p></sec><sec id="Sec19"><title>Limitations</title><p id="Par39">The following limitations merit discussion. First, we only assessed the effect on the last day of the 5-day ritonavir treatment, which was expected to be the day with the maximum possible change in short-course low-dose therapies with ritonavir. Due to its short duration, this trial was not suitable to assess the potential inducing properties of ritonavir and its results should only be extrapolated to longer treatment regimens with caution. In addition, no transporter probe drugs were tested, so the time course of transporter inhibition is still not well characterized. Second, patients may differ from healthy volunteers in many ways. In patients, comorbidities such as renal impairment can potentiate apparently minor DDI [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] and it will always be critical to consider all relevant clearance pathways when determining appropriate individualized treatment plans for FXaI. Third, coadministration of the probe drugs with sodium hydrogen carbonate to buffer gastric acid could potentially influence their pharmacokinetics. However, the baseline pharmacokinetics agree well with prior studies using microdosed FXaI [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], suggesting that buffering did not alter the pharmacokinetics of the three microdosed FXaI. This is in line with the absence of clinically relevant DDI of therapeutic FXaI doses with acid lowering drugs such as famotidine, ranitidine, or omeprazole [<xref ref-type="bibr" rid="CR61">61</xref>–<xref ref-type="bibr" rid="CR64">64</xref>]. In addition, the clearance values and relative contribution of renal excretion compare well with those reported for regular doses of FXaI in healthy volunteers [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR65">65</xref>], suggesting that microdoses adequately reflect the pharmacokinetics of regular doses and are therefore suitable for DDI studies.</p></sec></sec><sec id="Sec20"><title>Conclusion</title><p id="Par40">We have successfully evaluated the effect of a 5-day treatment regimen with low doses of ritonavir (100 mg bid) on the pharmacokinetics of three FXaI in healthy volunteers (Fig. <xref rid="Fig8" ref-type="fig">8</xref>) and found that the clearance of all FXaI decreased with potential clinical relevance only for rivaroxaban, where a dose reduction by a factor of 0.5 might be considered if therapeutic rivaroxaban doses are administered. Concurrently, we also monitored the daily activity changes of three important CYPs over the 5-day treatment and 2 days and 4 days after discontinuation of ritonavir and found that CYP2D6 activity was not significantly altered, while CYP2C19 was mildly induced and CYP3A was profoundly inhibited.<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Radar chart of oral clearance changes induced by 5 days of low-dose ritonavir therapy (100 mg twice daily) in 8 healthy volunteers. The percentage clearance compared with baseline, which is set at 100%, is shown for the different study days. The area of bioequivalence is highlighted in green, the risk area where dose adjustments may be required is highlighted in red</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="40262_2024_1350_Fig8_HTML.jpg"/></fig></p></sec><sec sec-type="supplementary-material"><sec id="Sec21"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2024_1350_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 46 KB)</p></caption></media></supplementary-material></p></sec></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank Marina Weißenborn and Theresa Terstegen for monitoring the study, all lab technicians for their support in the sample analyses, and the clinical team of the trial centre for their contribution to the trial conduct.</p></ack><notes><title>Declarations</title><notes id="FPar2" notes-type="funding"><title>Funding</title><p id="Par41">Open Access funding enabled and organized by Projekt DEAL. This trial was funded by the Department’s internal resources. No medical writing support was used.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par42">Walter E. Haefeli received grants for clinical trials, travel support, and lecture fees from Daiichi Sankyo, the manufacturer of edoxaban, not related to this work. All other authors have no conflicts of interest to declare.</p></notes><notes id="FPar4"><title>Availability of data and material</title><p id="Par43">The collected and analysed data can be made available upon reasonable request. Part of the data was presented at the 19th World Congress of Clinical Pharmacology, Glasgow, and therefore published as an abstract [<xref ref-type="bibr" rid="CR66">66</xref>].</p></notes><notes id="FPar5"><title>Ethical approval and informed consent</title><p id="Par44">The trial protocol (EudraCT 2021-006634-39) was approved by the competent authority (BfArM, Bonn, Germany) and the responsible Ethics Committee of the Medical Faculty of Heidelberg University. All procedures performed in studies involving human participants were in accordance with Good Clinical Practice (ICH-GCP) guidelines, all pertinent German laws, and the ethical standards specified in the applicable version of the declaration of Helsinki. All volunteers gave their written informed consent prior to any study procedures.</p></notes><notes id="FPar6"><title>Trial registration</title><p id="Par45">The trial was registered at the European Union Drug Regulating Authorities for Clinical Trials (EudraCT-No. 2021-006643-39) and at German Clinical Trial Register with ID DRKS00027838.</p></notes><notes id="FPar7" notes-type="author-contribution"><title>Author contributions</title><p id="Par46">WEH and GM proposed the research topic. BSR, AB, EK, WEH, and GM developed the trial protocol. BSR was the responsible study physician and executed the trial. KIF and JB analysed the samples. BSR and GM performed the trial analysis and the statistics. BSR wrote the first draft of the manuscript. All authors discussed and interpreted the results and contributed to the manuscript.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>YN</given-names></name></person-group><article-title>Nirmatrelvir plus ritonavir: first approval</article-title><source>Drugs</source><year>2022</year><volume>82</volume><issue>5</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1007/s40265-022-01692-5</pub-id><pub-id pub-id-type="pmid">35305258</pub-id><pub-id pub-id-type="pmcid">PMC8933659</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eichbaum</surname><given-names>C</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name></person-group><article-title>Concentration effect relationship of CYP3A inhibition by ritonavir in humans</article-title><source>Eur J Clin Pharmacol</source><year>2013</year><volume>69</volume><issue>10</issue><fpage>1795</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1007/s00228-013-1530-8</pub-id><pub-id pub-id-type="pmid">23748748</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeldin</surname><given-names>RK</given-names></name><name name-style="western"><surname>Petruschke</surname><given-names>RA</given-names></name></person-group><article-title>Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients</article-title><source>J Antimicrob Chemother</source><year>2004</year><volume>53</volume><issue>1</issue><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh029</pub-id><pub-id pub-id-type="pmid">14657084</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foisy</surname><given-names>MM</given-names></name><name name-style="western"><surname>Yakiwchuk</surname><given-names>EM</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>CA</given-names></name></person-group><article-title>Induction effects of ritonavir: implications for drug interactions</article-title><source>Ann Pharmacother</source><year>2008</year><volume>42</volume><issue>7</issue><fpage>1048</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1345/aph.1K615</pub-id><pub-id pub-id-type="pmid">18577765</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kis</surname><given-names>O</given-names></name><name name-style="western"><surname>Robillard</surname><given-names>K</given-names></name><name name-style="western"><surname>Chan</surname><given-names>GN</given-names></name><name name-style="western"><surname>Bendayan</surname><given-names>R</given-names></name></person-group><article-title>The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters</article-title><source>Trends Pharmacol Sci</source><year>2010</year><volume>31</volume><issue>1</issue><fpage>22</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2009.10.001</pub-id><pub-id pub-id-type="pmid">20004485</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermeer</surname><given-names>LM</given-names></name><name name-style="western"><surname>Isringhausen</surname><given-names>CD</given-names></name><name name-style="western"><surname>Ogilvie</surname><given-names>BW</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>DB</given-names></name></person-group><article-title>Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters</article-title><source>Drug Metab Dispos</source><year>2016</year><volume>44</volume><issue>3</issue><fpage>453</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1124/dmd.115.067744</pub-id><pub-id pub-id-type="pmid">26668209</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loos</surname><given-names>NHC</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>AH</given-names></name></person-group><article-title>The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>17</issue><fpage>9866</fpage><pub-id pub-id-type="doi">10.3390/ijms23179866</pub-id><pub-id pub-id-type="pmid">36077262</pub-id><pub-id pub-id-type="pmcid">PMC9456214</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katzenmaier</surname><given-names>S</given-names></name><name name-style="western"><surname>Markert</surname><given-names>C</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>KD</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name></person-group><article-title>Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy</article-title><source>Clin Pharmacol Ther</source><year>2011</year><volume>90</volume><issue>5</issue><fpage>666</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/clpt.2011.164</pub-id><pub-id pub-id-type="pmid">21937987</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>MAM</given-names></name><name name-style="western"><surname>Spinler</surname><given-names>SA</given-names></name></person-group><article-title>COVID-19 and thrombosis: from bench to bedside</article-title><source>Trends Cardiovasc Med</source><year>2021</year><volume>31</volume><issue>3</issue><fpage>143</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2020.12.004</pub-id><pub-id pub-id-type="pmid">33338635</pub-id><pub-id pub-id-type="pmcid">PMC7836332</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bathala</surname><given-names>MS</given-names></name><name name-style="western"><surname>Masumoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Oguma</surname><given-names>T</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Lowrie</surname><given-names>C</given-names></name><name name-style="western"><surname>Mendell</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans</article-title><source>Drug Metab Dispos</source><year>2012</year><volume>40</volume><issue>12</issue><fpage>2250</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1124/dmd.112.046888</pub-id><pub-id pub-id-type="pmid">22936313</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Raghavan</surname><given-names>N</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Frost</surname><given-names>CE</given-names></name><etal/></person-group><article-title>In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies</article-title><source>Drug Metab Dispos</source><year>2010</year><volume>38</volume><issue>3</issue><fpage>448</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1124/dmd.109.029694</pub-id><pub-id pub-id-type="pmid">19940026</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinz</surname><given-names>C</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>T</given-names></name><name name-style="western"><surname>Kubitza</surname><given-names>D</given-names></name><name name-style="western"><surname>Mueck</surname><given-names>W</given-names></name><name name-style="western"><surname>Lang</surname><given-names>D</given-names></name></person-group><article-title>Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans</article-title><source>Drug Metab Dispos</source><year>2009</year><volume>37</volume><issue>5</issue><fpage>1056</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.025569</pub-id><pub-id pub-id-type="pmid">19196845</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueck</surname><given-names>W</given-names></name><name name-style="western"><surname>Schwers</surname><given-names>S</given-names></name><name name-style="western"><surname>Stampfuss</surname><given-names>J</given-names></name></person-group><article-title>Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring</article-title><source>Thromb J</source><year>2013</year><volume>11</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/1477-9560-11-10</pub-id><pub-id pub-id-type="pmid">23809871</pub-id><pub-id pub-id-type="pmcid">PMC3726366</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Dong</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant</article-title><source>Cardiovasc Drugs Ther</source><year>2022</year><volume>36</volume><issue>1</issue><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1007/s10557-020-07129-z</pub-id><pub-id pub-id-type="pmid">33411110</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruff</surname><given-names>CT</given-names></name><name name-style="western"><surname>Giugliano</surname><given-names>RP</given-names></name><name name-style="western"><surname>Braunwald</surname><given-names>E</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>DA</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kuder</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9984</issue><fpage>2288</fpage><lpage>2295</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(14)61943-7</pub-id><pub-id pub-id-type="pmid">25769361</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herink</surname><given-names>MC</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>YF</given-names></name><name name-style="western"><surname>Williams</surname><given-names>CD</given-names></name><name name-style="western"><surname>DeLoughery</surname><given-names>TG</given-names></name></person-group><article-title>Clinical management of pharmacokinetic drug interactions with direct oral anticoagulants (DOACs)</article-title><source>Drugs</source><year>2019</year><volume>79</volume><issue>15</issue><fpage>1625</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1007/s40265-019-01183-0</pub-id><pub-id pub-id-type="pmid">31440911</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueck</surname><given-names>W</given-names></name><name name-style="western"><surname>Kubitza</surname><given-names>D</given-names></name><name name-style="western"><surname>Becka</surname><given-names>M</given-names></name></person-group><article-title>Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects</article-title><source>Br J Clin Pharmacol</source><year>2013</year><volume>76</volume><issue>3</issue><fpage>455</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1111/bcp.12075</pub-id><pub-id pub-id-type="pmid">23305158</pub-id><pub-id pub-id-type="pmcid">PMC3769672</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Testa</surname><given-names>S</given-names></name><name name-style="western"><surname>Prandoni</surname><given-names>P</given-names></name><name name-style="western"><surname>Paoletti</surname><given-names>O</given-names></name><name name-style="western"><surname>Morandini</surname><given-names>R</given-names></name><name name-style="western"><surname>Tala</surname><given-names>M</given-names></name><name name-style="western"><surname>Dellanoce</surname><given-names>C</given-names></name><etal/></person-group><article-title>Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience</article-title><source>J Thromb Haemost</source><year>2020</year><volume>18</volume><issue>6</issue><fpage>1320</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1111/jth.14871</pub-id><pub-id pub-id-type="pmid">32329231</pub-id><pub-id pub-id-type="pmcid">PMC7264501</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lomakina</surname><given-names>V</given-names></name><name name-style="western"><surname>Sozio</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Tekle</surname><given-names>J</given-names></name></person-group><article-title>Use of apixaban in atrial fibrillation with ritonavir-boosted antiretroviral therapy: a case report</article-title><source>J Pharm Pract</source><year>2022</year><volume>36</volume><issue>3</issue><fpage>728</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1177/08971900221074938</pub-id><pub-id pub-id-type="pmid">35138967</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nisly</surname><given-names>SA</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>BN</given-names></name></person-group><article-title>Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: a case for apixaban</article-title><source>Int J STD AIDS</source><year>2019</year><volume>30</volume><issue>7</issue><fpage>718</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1177/0956462419832099</pub-id><pub-id pub-id-type="pmid">30975070</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corallo</surname><given-names>CE</given-names></name><name name-style="western"><surname>Grannell</surname><given-names>L</given-names></name><name name-style="western"><surname>Tran</surname><given-names>H</given-names></name></person-group><article-title>Postoperative bleeding after administration of a single dose of rivaroxaban to a patient receiving antiretroviral therapy</article-title><source>Drug Saf Case Rep.</source><year>2015</year><volume>2</volume><issue>1</issue><fpage>11</fpage><pub-id pub-id-type="doi">10.1007/s40800-015-0014-4</pub-id><pub-id pub-id-type="pmid">27747723</pub-id><pub-id pub-id-type="pmcid">PMC5005638</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kuriakose</surname><given-names>SS</given-names></name><name name-style="western"><surname>Monroe</surname><given-names>A</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>M</given-names></name><name name-style="western"><surname>Pau</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Utilization of direct oral anticoagulants in people living with human immunodeficiency virus: observational data from the District of Columbia cohort</article-title><source>Clin Infect Dis</source><year>2020</year><volume>71</volume><issue>10</issue><fpage>e604</fpage><lpage>e613</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa284</pub-id><pub-id pub-id-type="pmid">32179901</pub-id><pub-id pub-id-type="pmcid">PMC7744993</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakatos</surname><given-names>B</given-names></name><name name-style="western"><surname>Stoeckle</surname><given-names>M</given-names></name><name name-style="western"><surname>Elzi</surname><given-names>L</given-names></name><name name-style="western"><surname>Battegay</surname><given-names>M</given-names></name><name name-style="western"><surname>Marzolini</surname><given-names>C</given-names></name></person-group><article-title>Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus</article-title><source>Swiss Med Wkly</source><year>2014</year><volume>22</volume><issue>144</issue><fpage>w13906</fpage><pub-id pub-id-type="doi">10.4414/smw.2014.13906</pub-id><pub-id pub-id-type="pmid">24452338</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">European Medicines Agency. Summary of product characteristics Paxlovid. 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf">https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf</ext-link>. Accessed 18 Sept 2023.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>KI</given-names></name><name name-style="western"><surname>Schaumaeker</surname><given-names>M</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>ML</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name></person-group><article-title>Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs</article-title><source>Br J Clin Pharmacol</source><year>2020</year><volume>86</volume><issue>8</issue><fpage>1632</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1111/bcp.14277</pub-id><pub-id pub-id-type="pmid">32159869</pub-id><pub-id pub-id-type="pmcid">PMC7373712</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenard</surname><given-names>A</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>SA</given-names></name><name name-style="western"><surname>Stoll</surname><given-names>F</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>KI</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><etal/></person-group><article-title>Effect of clarithromycin, a strong CYP3A and P-glycoprotein inhibitor, on the pharmacokinetics of edoxaban in healthy volunteers and the evaluation of the drug interaction with other oral factor Xa inhibitors by a microdose cocktail approach</article-title><source>Cardiovasc Drugs Ther</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s10557-023-07443-2</pub-id><pub-id pub-id-type="pmid">36870039</pub-id><pub-id pub-id-type="pmcid">PMC11266212</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vay</surname><given-names>M</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A</given-names></name><name name-style="western"><surname>Skopp</surname><given-names>G</given-names></name><name name-style="western"><surname>Rose</surname><given-names>P</given-names></name><name name-style="western"><surname>Tzvetkov</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial</article-title><source>Clin Pharmacokinet</source><year>2020</year><volume>59</volume><issue>7</issue><fpage>927</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00862-6</pub-id><pub-id pub-id-type="pmid">32060866</pub-id><pub-id pub-id-type="pmcid">PMC7329762</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elbe</surname><given-names>A</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>KI</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A</given-names></name><name name-style="western"><surname>Rose</surname><given-names>P</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans</article-title><source>Eur J Clin Pharmacol</source><year>2022</year><volume>78</volume><issue>6</issue><fpage>975</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1007/s00228-022-03304-3</pub-id><pub-id pub-id-type="pmid">35238961</pub-id><pub-id pub-id-type="pmcid">PMC9107402</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foerster</surname><given-names>KI</given-names></name><name name-style="western"><surname>Huppertz</surname><given-names>A</given-names></name><name name-style="western"><surname>Muller</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Rizos</surname><given-names>T</given-names></name><name name-style="western"><surname>Tilemann</surname><given-names>L</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy</article-title><source>J Pharm Biomed Anal</source><year>2018</year><volume>30</volume><issue>148</issue><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2017.10.011</pub-id><pub-id pub-id-type="pmid">29055248</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Halama</surname><given-names>B</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>M</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>KD</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>N</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><etal/></person-group><article-title>Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry</article-title><source>Anal Bioanal Chem</source><year>2012</year><volume>402</volume><issue>7</issue><fpage>2439</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1007/s00216-011-5675-y</pub-id><pub-id pub-id-type="pmid">22252655</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vay</surname><given-names>M</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>M</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name></person-group><article-title>Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range</article-title><source>Bioanalysis</source><year>2019</year><volume>11</volume><issue>16</issue><fpage>1459</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.4155/bio-2019-0129</pub-id><pub-id pub-id-type="pmid">31411489</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoudi</surname><given-names>M</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>KI</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name></person-group><article-title>Application of microdosed intravenous omeprazole to determine hepatic CYP2C19 activity</article-title><source>J Clin Pharmacol</source><year>2021</year><volume>61</volume><issue>6</issue><fpage>789</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1002/jcph.1789</pub-id><pub-id pub-id-type="pmid">33236774</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>KI</given-names></name><name name-style="western"><surname>Schaumaeker</surname><given-names>M</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>M-L</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name></person-group><article-title>Microdosed cocktail of three oral factor Xa inhibitors to evaluate drug-drug interactions with potential perpetrator drugs</article-title><source>Clin Pharmacokinet</source><year>2019</year><volume>58</volume><issue>9</issue><fpage>1155</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1007/s40262-019-00749-1</pub-id><pub-id pub-id-type="pmid">30828771</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Food and Drug Administration. Bioanalytical method validation guidance for industry. 2018. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf">https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf</ext-link>. Accessed 18 Sept 2023.</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">European Medical Agency. Guideline on bioanalytical method validation. 2012. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf</ext-link>. Accessed 18 Sept 2023.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohr</surname><given-names>BS</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>KI</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Mahmoudi</surname><given-names>M</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Perpetrator characteristics of azole antifungal drugs on three oral factor Xa inhibitors administered as a microdosed cocktail</article-title><source>Clin Pharmacokinet</source><year>2022</year><volume>61</volume><issue>1</issue><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1007/s40262-021-01051-9</pub-id><pub-id pub-id-type="pmid">34273071</pub-id><pub-id pub-id-type="pmcid">PMC8761715</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katzenmaier</surname><given-names>S</given-names></name><name name-style="western"><surname>Markert</surname><given-names>C</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name></person-group><article-title>Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam</article-title><source>Eur J Clin Pharmacol</source><year>2010</year><volume>66</volume><issue>11</issue><fpage>1137</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1007/s00228-010-0878-2</pub-id><pub-id pub-id-type="pmid">20680253</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halama</surname><given-names>B</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>N</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name></person-group><article-title>A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions</article-title><source>Clin Pharmacol Ther</source><year>2013</year><volume>93</volume><issue>6</issue><fpage>564</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/clpt.2013.27</pub-id><pub-id pub-id-type="pmid">23511711</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breithaupt</surname><given-names>MH</given-names></name><name name-style="western"><surname>Krohmer</surname><given-names>E</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>L</given-names></name><name name-style="western"><surname>Körner</surname><given-names>E</given-names></name><name name-style="western"><surname>Hoppe-Tichy</surname><given-names>T</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><etal/></person-group><article-title>Time course of CYP3A activity during and after metamizole (dipyrone) in healthy volunteers</article-title><source>Br J Clin Pharmacol</source><year>2023</year><volume>89</volume><issue>8</issue><fpage>2458</fpage><lpage>2464</lpage><pub-id pub-id-type="doi">10.1111/bcp.15720</pub-id><pub-id pub-id-type="pmid">36946257</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chan</surname><given-names>ECY</given-names></name></person-group><article-title>Physiologically-based pharmacokinetic modeling-guided dose management of oral anticoagulants when initiating nirmatrelvir/ritonavir (Paxlovid) for COVID-19 treatment</article-title><source>Clin Pharmacol Ther</source><year>2022</year><volume>112</volume><issue>4</issue><fpage>803</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1002/cpt.2687</pub-id><pub-id pub-id-type="pmid">35712802</pub-id><pub-id pub-id-type="pmcid">PMC9349724</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Coboeken</surname><given-names>K</given-names></name><name name-style="western"><surname>Kapsa</surname><given-names>S</given-names></name><name name-style="western"><surname>Thelen</surname><given-names>K</given-names></name><name name-style="western"><surname>Mundhenke</surname><given-names>M</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>K</given-names></name><etal/></person-group><article-title>Applications of physiologically based pharmacokinetic modeling of rivaroxaban-renal and hepatic impairment and drug–drug interaction potential</article-title><source>J Clin Pharmacol</source><year>2021</year><volume>61</volume><issue>5</issue><fpage>656</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1002/jcph.1784</pub-id><pub-id pub-id-type="pmid">33205449</pub-id><pub-id pub-id-type="pmcid">PMC8048900</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanigan</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>JM</given-names></name></person-group><article-title>Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2022</year><volume>18</volume><issue>3</issue><fpage>189</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1080/17425255.2022.2074397</pub-id><pub-id pub-id-type="pmid">35543017</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">European Medicines Agency. Summary of product characteristics Xarelto<sup>®</sup>. 2018. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto">https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto</ext-link>. Accessed 18 Sept 2023.</mixed-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spyropoulos</surname><given-names>AC</given-names></name><name name-style="western"><surname>Levy</surname><given-names>JH</given-names></name><name name-style="western"><surname>Ageno</surname><given-names>W</given-names></name><name name-style="western"><surname>Connors</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Iba</surname><given-names>T</given-names></name><etal/></person-group><article-title>Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19</article-title><source>J Thromb Haemost</source><year>2020</year><volume>18</volume><issue>8</issue><fpage>1859</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1111/jth.14929</pub-id><pub-id pub-id-type="pmid">32459046</pub-id><pub-id pub-id-type="pmcid">PMC7283841</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stampfuss</surname><given-names>J</given-names></name><name name-style="western"><surname>Kubitza</surname><given-names>D</given-names></name><name name-style="western"><surname>Becka</surname><given-names>M</given-names></name><name name-style="western"><surname>Mueck</surname><given-names>W</given-names></name></person-group><article-title>The effect of food on the absorption and pharmacokinetics of rivaroxaban</article-title><source>Int J Clin Pharmacol Ther</source><year>2013</year><volume>51</volume><issue>7</issue><fpage>549</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.5414/cp201812</pub-id><pub-id pub-id-type="pmid">23458226</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheong</surname><given-names>EJY</given-names></name><name name-style="western"><surname>Teo</surname><given-names>DWX</given-names></name><name name-style="western"><surname>Chua</surname><given-names>DXY</given-names></name><name name-style="western"><surname>Chan</surname><given-names>ECY</given-names></name></person-group><article-title>Systematic development and verification of a physiologically based pharmacokinetic model of rivaroxaban</article-title><source>Drug Metab Dispos</source><year>2019</year><volume>47</volume><issue>11</issue><fpage>1291</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1124/dmd.119.086918</pub-id><pub-id pub-id-type="pmid">31506301</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuruya</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>T</given-names></name><name name-style="western"><surname>Komori</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>N</given-names></name><name name-style="western"><surname>Kito</surname><given-names>T</given-names></name><etal/></person-group><article-title>Different involvement of OAT in renal disposition of oral anticoagulants rivaroxaban, dabigatran, and apixaban</article-title><source>J Pharm Sci</source><year>2017</year><volume>106</volume><issue>9</issue><fpage>2524</fpage><lpage>2534</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.04.044</pub-id><pub-id pub-id-type="pmid">28456731</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaspera</surname><given-names>R</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Sahele</surname><given-names>T</given-names></name><name name-style="western"><surname>Collier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kharasch</surname><given-names>ED</given-names></name><name name-style="western"><surname>Unadkat</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo</article-title><source>Biochem Pharmacol</source><year>2014</year><volume>91</volume><issue>1</issue><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2014.06.020</pub-id><pub-id pub-id-type="pmid">24973543</pub-id><pub-id pub-id-type="pmcid">PMC4169885</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sodhi</surname><given-names>JK</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name></person-group><article-title>Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition</article-title><source>Pharm Res</source><year>2020</year><volume>37</volume><issue>10</issue><fpage>208</fpage><pub-id pub-id-type="doi">10.1007/s11095-020-02927-4</pub-id><pub-id pub-id-type="pmid">32996065</pub-id><pub-id pub-id-type="pmcid">PMC7936879</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parasrampuria</surname><given-names>DA</given-names></name><name name-style="western"><surname>Truitt</surname><given-names>KE</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><issue>6</issue><fpage>641</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0342-7</pub-id><pub-id pub-id-type="pmid">26620048</pub-id><pub-id pub-id-type="pmcid">PMC4875962</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikkaichi</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshigae</surname><given-names>Y</given-names></name><name name-style="western"><surname>Masumoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Imaoka</surname><given-names>T</given-names></name><name name-style="western"><surname>Rozehnal</surname><given-names>V</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition</article-title><source>Drug Metab Dispos</source><year>2014</year><volume>42</volume><issue>4</issue><fpage>520</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1124/dmd.113.054866</pub-id><pub-id pub-id-type="pmid">24459178</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Mikkaichi</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshigae</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okudaira</surname><given-names>N</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model</article-title><source>Int J Pharm</source><year>2021</year><volume>15</volume><issue>597</issue><fpage>120349</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120349</pub-id><pub-id pub-id-type="pmid">33545293</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>DS</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>T</given-names></name><name name-style="western"><surname>Ginman</surname><given-names>K</given-names></name><name name-style="western"><surname>Salageanu</surname><given-names>J</given-names></name><name name-style="western"><surname>LaBadie</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants</article-title><source>Br J Clin Pharmacol</source><year>2023</year><volume>89</volume><issue>11</issue><fpage>3352</fpage><lpage>3363</lpage><pub-id pub-id-type="doi">10.1111/bcp.15835</pub-id><pub-id pub-id-type="pmid">37354048</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhoades</surname><given-names>JA</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>YK</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Appel</surname><given-names>DI</given-names></name><name name-style="western"><surname>Peloquin</surname><given-names>CA</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>JS</given-names></name></person-group><article-title>Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions</article-title><source>Pharm Res</source><year>2012</year><volume>29</volume><issue>4</issue><fpage>972</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1007/s11095-011-0637-9</pub-id><pub-id pub-id-type="pmid">22161308</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aarnoutse</surname><given-names>RE</given-names></name><name name-style="western"><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>PP</given-names></name><name name-style="western"><surname>Touw</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Wieling</surname><given-names>J</given-names></name><name name-style="western"><surname>Hekster</surname><given-names>YA</given-names></name><etal/></person-group><article-title>Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers</article-title><source>Clin Pharmacol Ther</source><year>2005</year><volume>78</volume><issue>6</issue><fpage>664</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2005.09.001</pub-id><pub-id pub-id-type="pmid">16338282</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>RF</given-names></name><name name-style="western"><surname>Gaver</surname><given-names>VE</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>KB</given-names></name><name name-style="western"><surname>Rezk</surname><given-names>NL</given-names></name><name name-style="western"><surname>Baxter-Meheux</surname><given-names>F</given-names></name><name name-style="western"><surname>Blake</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers</article-title><source>J Acquir Immune Defic Syndr</source><year>2006</year><volume>42</volume><issue>1</issue><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1097/01.qai.0000219774.20174.64</pub-id><pub-id pub-id-type="pmid">16639344</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Bruggemann</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Uy</surname><given-names>J</given-names></name><name name-style="western"><surname>Colbers</surname><given-names>A</given-names></name><name name-style="western"><surname>Hruska</surname><given-names>MW</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E</given-names></name><etal/></person-group><article-title>CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir-boosted atazanavir in healthy subjects</article-title><source>J Clin Pharmacol</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1002/jcph.798</pub-id><pub-id pub-id-type="pmid">27432796</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Foster</surname><given-names>G</given-names></name><name name-style="western"><surname>Gandelman</surname><given-names>K</given-names></name><name name-style="western"><surname>LaBadie</surname><given-names>RR</given-names></name><name name-style="western"><surname>Allison</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects</article-title><source>Antimicrob Agents Chemother</source><year>2007</year><volume>51</volume><issue>10</issue><fpage>3617</fpage><lpage>3626</lpage><pub-id pub-id-type="doi">10.1128/aac.00526-07</pub-id><pub-id pub-id-type="pmid">17646413</pub-id><pub-id pub-id-type="pmcid">PMC2043278</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohmann</surname><given-names>N</given-names></name><name name-style="western"><surname>Kocheise</surname><given-names>F</given-names></name><name name-style="western"><surname>Carls</surname><given-names>A</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><issue>12</issue><fpage>1535</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1007/s40262-016-0416-1</pub-id><pub-id pub-id-type="pmid">27236320</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohmann</surname><given-names>N</given-names></name><name name-style="western"><surname>Kreuter</surname><given-names>R</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics</article-title><source>Br J Clin Pharmacol</source><year>2017</year><volume>83</volume><issue>9</issue><fpage>1954</fpage><lpage>1965</lpage><pub-id pub-id-type="doi">10.1111/bcp.13297</pub-id><pub-id pub-id-type="pmid">28370390</pub-id><pub-id pub-id-type="pmcid">PMC5555860</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upreti</surname><given-names>VV</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Byon</surname><given-names>W</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>RA</given-names></name><name name-style="western"><surname>Pursley</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor</article-title><source>Clin Pharmacol</source><year>2013</year><volume>5</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2147/cpaa.S41999</pub-id><pub-id pub-id-type="pmid">23637566</pub-id><pub-id pub-id-type="pmcid">PMC3637032</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kubitza</surname><given-names>D</given-names></name><name name-style="western"><surname>Becka</surname><given-names>M</given-names></name><name name-style="western"><surname>Zuehlsdorf</surname><given-names>M</given-names></name><name name-style="western"><surname>Mueck</surname><given-names>W</given-names></name></person-group><article-title>Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects</article-title><source>J Clin Pharmacol</source><year>2006</year><volume>46</volume><issue>5</issue><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1177/0091270006286904</pub-id><pub-id pub-id-type="pmid">16638738</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>KT</given-names></name><name name-style="western"><surname>Plotnikov</surname><given-names>AN</given-names></name><name name-style="western"><surname>Thyssen</surname><given-names>A</given-names></name><name name-style="western"><surname>Vaccaro</surname><given-names>N</given-names></name><name name-style="western"><surname>Ariyawansa</surname><given-names>J</given-names></name><name name-style="western"><surname>Burton</surname><given-names>PB</given-names></name></person-group><article-title>Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban</article-title><source>J Cardiovasc Pharmacol</source><year>2011</year><volume>58</volume><issue>6</issue><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1097/FJC.0b013e31822f6c2b</pub-id><pub-id pub-id-type="pmid">21822144</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Mendell J, Lasseter K, Shi M. Effect of esomeprazole on edoxaban pharmacokinetics and pharmacodynamics when administered orally as tablet and as solution. Europace. 2011;13(Suppl 3). (<bold>Abstract P1052</bold>).</mixed-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J</given-names></name><name name-style="western"><surname>Noveck</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M</given-names></name></person-group><article-title>Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination</article-title><source>J Cardiovasc Pharmacol</source><year>2012</year><volume>60</volume><issue>4</issue><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1097/FJC.0b013e31826265b6</pub-id><pub-id pub-id-type="pmid">23064240</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohr</surname><given-names>BS</given-names></name><name name-style="western"><surname>Krohmer</surname><given-names>E</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>KI</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>M</given-names></name><name name-style="western"><surname>Blank</surname><given-names>A</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>WE</given-names></name></person-group><article-title>Factor Xa inhibitors exposure increases by five-day, low-dose ritonavir therapy</article-title><source>Br J Pharmacol</source><year>2023</year><volume>180</volume><issue>Suppl 1</issue><fpage>214</fpage><pub-id pub-id-type="doi">10.1111/bph.16106</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>